A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003
Phase: PHASE3
Conditions: Short Bowel Syndrome
Sponsor: Shire

CLINICAL STUDY PROTOCOL 
 
 
NCT Number:   
NCT02949362 
 
Study Title:  
A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy 
Study of Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who 
Completed TED-C13-003 
 
Study Number:  
SHP633-303 
 
 
Protocol Version and Date:  
 
Original Protocol:  
11 May 2016 
Amendment 1:  
22 Nov 2016 
Amendment 1.1: 
09 Jan 2017 
Amendment 2:  
17 Mar 2017 
Amendment 3:  
16 May 2018 
Amendment 4:   
01 Oct 2019 
 

PROTOCOL: SHP633-303
TITLE:
A Retrospective and Prospective, Open-label, Long-term Safety and 
Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED-C13-003
DRUG:
Teduglutide
IND:
IND# 058213
EUDRACT NO.:
2016-000863-17
SPONSOR:
Shire Human Genetic Therapies, Inc.
300 Shire Way, Lexington, MA 02421 USA
PROTOCOL 
HISTORY:
Original Protocol: 11 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only

Shire 
CONFIDENTIAL 
Protocol SHP633-303 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Shire) Approval 
"-· "''"" ... " ........ ·-·-···· 
Date: 
Page2 
11 May2016 
Signature: 
··········-··················· 
, MD PhD 
..... -···
_ ..... . 
 Clinical Medicine 
. Global Clinical Development 
Investigator's Aclmowledgement 
I have read this protocol for Shire Study SHP633-303. 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-C13-003 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
For non-commercial use only

Shire
CONFIDENTIAL
Page 3
Protocol SHP633-303
11 May 2016
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required by Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e-mail address can be found on the form 
(sent under separate cover). A copy of this form must also be sent to the contract research 
organization Shire Medical Monitor by fax or e-mail using the details below.
, MD PhD
Email: 
Fax: 
For protocol- or safety-related issues during normal business hours (9 am to 5 pm Eastern 
Standard Time), the investigator must contact the Shire Medical Monitor:
, MD PhD, 
 Clinical Medicine
Phone: 
Mobile: 
Email: 
Fax: 
For protocol- or safety-related issues outside of normal business hours, the investigator 
must contact Quintiles Medical Support:
, MD, 
Phone: 
 (medical emergencies – United States)
Phone: 
 (medical emergencies – Global)
Email: 
r
on-commercial use only

Shire
CONFIDENTIAL
Page 4
Protocol SHP633-303
11 May 2016
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints to Shire within 
24 hours. This includes any instances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint
E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire (USA) 
For non-commercial use only

Shire
CONFIDENTIAL
Page 5
Protocol SHP633-303
11 May 2016
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
EMERGENCY CONTACT INFORMATION................................................................................3
PRODUCT QUALITY COMPLAINTS..........................................................................................4
LIST OF TABLES.........................................................................................................................10
LIST OF FIGURES .......................................................................................................................10
LIST OF APPENDICES................................................................................................................10
ABBREVIATIONS .......................................................................................................................11
STUDY SYNOPSIS ......................................................................................................................13
STUDY SCHEDULES..................................................................................................................19
1
BACKGROUND INFORMATION.......................................................................................25
1.1
Indication and Current Treatment Options...............................................................25
1.2
Product Background.................................................................................................25
2
STUDY OBJECTIVES AND PURPOSE ..............................................................................27
2.1
Rationale for the Study.............................................................................................27
2.2
Study Objectives ......................................................................................................27
2.2.1
Primary Objectives.................................................................................................27
2.2.2
Secondary Objectives.............................................................................................27
3
STUDY DESIGN ...................................................................................................................28
3.1
Study Design and Flow Chart ..................................................................................28
3.1.1
Informed Consent/Assent and Eligibility...............................................................29
3.1.2
Retrospective Data Collection ...............................................................................29
3.1.3
Prospective Data Collection and Treatment ..........................................................30
3.2
Duration and Study Completion Definition .............................................................31
4
STUDY POPULATION.........................................................................................................32
4.1
Study Inclusion Eligibility Criteria ..........................................................................32
4.2
Study Exclusion Eligibility Criteria .........................................................................32
4.3
Teduglutide Eligibility Criteria ................................................................................32
4.4
Teduglutide Treatment Inclusion Criteria................................................................32
4.5
Teduglutide Treatment Exclusion Criteria...............................................................33
4.6
Follow-up Period Escape Criteria ............................................................................34
4.7
Reproductive Potential .............................................................................................34
4.7.1
Female Contraception............................................................................................34
4.8
Discontinuation of Subjects .....................................................................................35
4.8.1
Teduglutide Discontinuation..................................................................................35
4.8.2
Study Withdrawal ..................................................................................................35
4.8.3
Reasons for Discontinuation..................................................................................35
For non-commercial use only

Shire
CONFIDENTIAL
Page 6
Protocol SHP633-303
11 May 2016
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit ..................36
5
CONCOMITANT TREATMENT..........................................................................................37
5.1
Concomitant Medications and GI Procedures..........................................................37
5.1.1
Permitted Treatment...............................................................................................37
5.1.2
Prohibited Treatment .............................................................................................37
6
INVESTIGATIONAL PRODUCT ........................................................................................38
6.1
Identity of Investigational Product...........................................................................38
6.1.1
Blinding the Treatment Assignment......................................................................38
6.2
Administration of Investigational Product(s)...........................................................38
6.2.1
Interactive Response Technology (IRT) for Investigational Product 
Management...........................................................................................................38
6.2.2
Allocation of Subjects to Treatment ......................................................................38
6.2.3
Dosing....................................................................................................................38
6.2.4
Unblinding the Treatment Assignment..................................................................39
6.3
Labeling, Packaging, Storage, and Handling ...........................................................39
6.3.1
Labeling .................................................................................................................39
6.3.2
Packaging...............................................................................................................39
6.3.3
Storage ...................................................................................................................39
6.4
Drug Accountability.................................................................................................40
6.5
Subject Compliance..................................................................................................41
7
STUDY PROCEDURES........................................................................................................42
7.1
Study Schedule.........................................................................................................42
7.1.1
Retrospective Data Collection ...............................................................................42
7.1.2
Screening................................................................................................................43
7.1.3
Visits for Subjects Not Receiving Teduglutide .....................................................43
7.1.4
Visits for Subjects Receiving Teduglutide Treatment...........................................44
7.1.4.1
Pretreatment Visit...................................................................................44
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24).....................................45
7.1.4.3
Site Visits during Teduglutide Treatment Period...................................45
7.1.4.4
Phone Visits............................................................................................46
7.1.5
Teduglutide Follow-up Period...............................................................................46
7.1.5.1
CxW28 ...................................................................................................46
7.1.5.2
Study Completion/Early Termination Visit (EOS/ET Visit) .................47
7.2
Study Evaluations and Procedures ...........................................................................47
7.2.1
Retrospective Data Collection ...............................................................................47
7.2.1.1
Growth (Height, Weight, and Head Circumference) .............................47
7.2.1.2
Prior Teduglutide Treatment Prescribed ................................................47
7.2.1.3
Parenteral Support Prescribed ................................................................47
For non-commercial use only

Shire
CONFIDENTIAL
Page 7
Protocol SHP633-303
11 May 2016
7.2.1.4
Adverse Events.......................................................................................48
7.2.2
Prospective Data Collection...................................................................................48
7.2.2.1
Demographics, Medical History, and SBS History................................48
7.2.2.2
Physical Examination.............................................................................48
7.2.2.3
Vital Signs, Body Weight, Height, Head Circumference and Body 
Mass Index (BMI) ..................................................................................48
7.2.2.4
Clinical Laboratory Tests.......................................................................49
7.2.2.5
Serum Sampling.....................................................................................51
7.2.2.6
Pregnancy Testing..................................................................................51
7.2.2.7
Antibody Testing....................................................................................51
7.2.2.8
Volume of Blood....................................................................................51
7.2.2.9
Gastrointestinal-specific Testing............................................................52
7.2.2.10
Health-related Quality of Life Assessments...........................................54
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................56
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................56
8.1.1
Severity Categorization..........................................................................................57
8.1.2
Relationship Categorization...................................................................................57
8.1.3
Outcome Categorization ........................................................................................58
8.1.4
Symptoms of the Disease under Study ..................................................................58
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)..................................................................................................58
8.1.6
Pregnancy...............................................................................................................59
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)..................................................................................................59
8.2
Serious Adverse Event Procedures ..........................................................................60
8.2.1
Reference Safety Information................................................................................60
8.2.2
Reporting Procedures.............................................................................................60
8.2.3
Serious Adverse Event Definition .........................................................................61
8.2.4
Serious Adverse Event Collection Time Frame.....................................................61
8.2.5
Serious Adverse Event Onset and Resolution Dates .............................................62
8.2.6
Fatal Outcome........................................................................................................62
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting................................................................................................................62
8.3
Adverse Events of Special Interest...........................................................................62
8.4
Dose Interruption and Permanent Discontinuation (Prospective Period of 
Observation Only)....................................................................................................63
8.4.1
Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only).........................................63
For non-commercial use only

Shire
CONFIDENTIAL
Page 8
Protocol SHP633-303
11 May 2016
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury (Prospective 
Period of Observation Only)..................................................................................65
8.5
Early Termination of the Clinical Study (Prospective Period of Observation 
Only).........................................................................................................................66
9
DATA MANAGEMENT AND STATISTICAL METHODS...............................................67
9.1
Data Collection.........................................................................................................67
9.2
Clinical Data Management.......................................................................................67
9.3
Statistical Analysis Process......................................................................................67
9.4
Planned Interim Analysis, and Data Monitoring Committee...................................67
9.5
Sample Size Calculation and Power Considerations................................................68
9.6
Study Population ......................................................................................................68
9.7
Efficacy Analyses.....................................................................................................68
9.7.1
Efficacy Endpoints.................................................................................................68
9.8
Safety Analyses........................................................................................................68
9.8.1
Safety Endpoints....................................................................................................68
9.9
Other Analyses .........................................................................................................70
9.9.1
Health-related Quality of Life Analyses................................................................70
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES...........................................71
10.1
Sponsor’s Responsibilities .......................................................................................71
10.1.1 Good Clinical Practice Compliance.......................................................................71
10.1.2 Indemnity/Liability and Insurance.........................................................................71
10.1.3 Public Posting of Study Information......................................................................71
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees........................71
10.1.5 Study Suspension, Termination, and Completion..................................................72
10.2
Investigator’s Responsibilities .................................................................................72
10.2.1 Good Clinical Practice Compliance.......................................................................72
10.2.2 Protocol Adherence and Investigator Agreement..................................................72
10.2.3 Documentation and Retention of Records.............................................................73
10.2.3.1
Case Report Forms.................................................................................73
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents..............................................................................................73
10.2.3.3
Audit/Inspection.....................................................................................73
10.2.3.4
Financial Disclosure...............................................................................74
10.3
Ethical Considerations..............................................................................................74
10.3.1 Informed Consent...................................................................................................74
10.3.2 Institutional Review Board or Ethics Committee..................................................74
10.4
Privacy and Confidentiality......................................................................................75
10.5
Study Results / Publication Policy ...........................................................................76
For non-commercial use only

Shire
CONFIDENTIAL
Page 9
Protocol SHP633-303
11 May 2016
11 REFERENCES .......................................................................................................................77
12 APPENDICES ........................................................................................................................78
For non-commercial use only

Shire
CONFIDENTIAL
Page 10
Protocol SHP633-303
11 May 2016
LIST OF TABLES
Table 1-1:
Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................19
Table 1-2:
Schedule of Events for Screening and End of Study or Early 
Termination ...................................................................................................20
Table 1-3:
Schedule of Events for No Teduglutide Treatment Period ...........................21
Table 1-4:
Schedule of Events for Teduglutide Treatment Period .................................22
Table 5-1: 
Prohibited Treatment.....................................................................................37
Table 7-1:
List of Laboratory Tests ................................................................................50
Table 7-2:
Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................52
Table 7-3:
Developmentally Appropriate PedsQL™Generic Core Scales .....................55
Table 8-1:
CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only) ................................64
LIST OF FIGURES
Figure 3-1:
Study Design Flow Chart ..............................................................................31
LIST OF APPENDICES
Appendix 1
Guidelines for Nutritional Support Management During the Study .............79
For non-commercial use only

Shire
CONFIDENTIAL
Page 11
Protocol SHP633-303
11 May 2016
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
-HCG
beta-human chorionic gonadotropin
BMI
body mass index
CRA
clinical research associate
CRO
contract research organization
CSR
clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
drug-induced livery injury
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase 4
EC
ethics committee
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EN
enteral nutrition
EOS
end of study
EOT
end of treatment
ET
early termination
EU
European Union
FDA
Food and Drug Administration
FOBT
fecal occult blood test
FOCBP
female of child-bearing potential
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide 1
GLP-2
glucagon-like peptide 2
HIPAA
Health Insurance Portability and Accountability Act
ICF
informed consent form
ICH
International Conference on Harmonization
IGF-1
insulin-like growth factor 1
IRB
institutional review board
IRT
interactive response technology
IV
intravenous
IWRS
interactive web-based response system
MedDRA
Medical Dictionary for Regulatory Activities
NCI
National Cancer Institute
NDA
new drug application
For non-commercial use only

Shire
CONFIDENTIAL
Page 12
Protocol SHP633-303
11 May 2016
NTT
no-teduglutide treatment
PDA
patent ductus arteriosus
PedsQL
Pediatric Quality of Life Inventory
PS
parenteral support
PT/INR
prothrombin time/international normalized ratio
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SBS
short bowel syndrome
SC
subcutaneous
SOC
standard of care
t1/2
elimination half-life
TESAE
treatment-emergent serious adverse event
UK
United Kingdom
ULN
upper limit of normal
US
United States
WHO-DD
World Health Organization-Drug Dictionary
For non-commercial use only

Shire
CONFIDENTIAL
Page 13
Protocol SHP633-303
11 May 2016
STUDY SYNOPSIS
Protocol number: SHP633-303
Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of 
Teduglutide in Pediatric Patients with Short Bowel Syndrome Who Completed TED-C13-003
Number of subjects (total and for each treatment arm):
Approximately 40 subjects who completed the TED-C13-003 study, including subjects in the standard of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED-C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the United States (US) and the United Kingdom (UK) will participate in 
this extension study.
Study period (planned):
October 2016-September 2019
Clinical phase:
3 Extension
Objectives:
Primary: To evaluate the long-term safety and tolerability of teduglutide treatment in pediatric subjects with short 
bowel syndrome (SBS) who completed TED-C13-003.
Secondary: To evaluate long-term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED-C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED-C13-003 study. In addition to 
evaluating the long-term safety and durability of efficacy after 12 weeks of treatment in TED-C13-003, this 
extension study will evaluate the need for additional teduglutide treatment in these subjects, and will allow for the 
first-time treatment of teduglutide-naïve subjects who participated in the standard of care (SOC) treatment arm in 
TED-C13-003.
Investigational product, dose, and mode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED-C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of specific 
safety and efficacy measures that were completed in the course of the subject’s standard medical care between the 
date of the TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if applicable, 
informed assent) is signed for this study. In addition to this retrospective data collection, prospective study 
assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only

Shire
CONFIDENTIAL
Page 14
Protocol SHP633-303
11 May 2016
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1. For subjects that only consent to 
retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were completed in the course 
of the subject’s standard medical care between the date of the TED-C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth [height, head circumference (up to 36 months of age), weight]

End dates for adverse events (AEs) ongoing at the time of TED-013-003

Nonserious treatment-related adverse events (AEs)

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1-2. These 
procedures include but are not limited to, collection of demographics, medical history, and short bowel syndrome 
history. Prescription parenteral support requirements will be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit, for collection of actual parenteral support (PS)
volume and hours per day, and actual enteral nutrition (EN) volume per day (Section 7.2.2.9). Diary data for 
PN/intravenous (IV) volume will be collected for at least 2 weeks after the ICF (and if applicable, the informed 
assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no-teduglutide treatment [NTT] period), will be seen every 
12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for PN/IV volume will be 
collected for at least 2 weeks prior to any NTT visit. The first NTT visit will occur approximately 12 weeks after the 
screening visit. At any point after screening, including during an NTT period, subjects who meet ≥1 teduglutide 
treatment inclusion criteria, may proceed immediately to the pretreatment visit if the investigator, subject, and parent 
or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4-week follow-up (no treatment) period (Figure 3-1). During 
the 28-week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the TED treatment period, between Weeks 1-24, and weekly 
during the follow-up period, between Weeks 24 and 28.
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 weeks. To maintain 
consistency across centers, all attempts should be made to follow the nutritional support adjustment guidelines 
(developed with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 1).
For non-commercial use only

Shire
CONFIDENTIAL
Page 15
Protocol SHP633-303
11 May 2016
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured every 12 weeks, but 
subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. Eligible subjects 
will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy assessments at 
Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after adjustments in 
PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide at Week 24 
and enter a 4-week follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey lines). If 
an escape criterion is met during the follow-up period, subjects may proceed directly to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet all of the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.
Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, informed 
assent) to participate in the study before completing any study-related procedures.
2.
Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
3.
Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria, and none of the 
teduglutide treatment exclusion criteria, are met. In addition, the investigator and the subject (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria:
1.
Subject is teduglutide-naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by the investigator. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of baseline 
prior to the event.
2.
Subject was previously treated with teduglutide and at least 1 of the following criteria is satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b.
Decreased PS requirement during prior teduglutide treatment, followed by cessation of 
improvement after teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 16
Protocol SHP633-303
11 May 2016
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition following teduglutide discontinuation
d.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.
Body weight <10 kg at the pretreatment visit
2.
Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.
History of cancer in the previous 5 years except surgically curative skin cancers
4.
Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections ≤10 
cm, and endoscopic procedures are allowed.
5.
Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6.
Clinically significant intestinal stricture or obstruction
7.
Clinically significant, active or recurrent pancreatic or biliary disease
8.
Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b.
Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9.
Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects who 
had undergone ventricular or atrial septal defect repair, or patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine or Omegaven) within 
3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the pretreatment visit 
and for the duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) (not 
including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, within 1 month 
preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior to the 
pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related 
compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16. Pregnant or lactating female subjects
17. Sexually active female subjects of child-bearing potential unwilling to use approved contraception during 
teduglutide treatment and for 30 days after the treatment period
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the subject at any 
undue risk, prevents completion of the study, or interferes with analysis of the study results
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow-up period may be interrupted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.
Increasing PS requirements following teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 17
Protocol SHP633-303
11 May 2016
2.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated enteral 
nutrition following teduglutide discontinuation
3.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake 
following teduglutide discontinuation
4.
Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvement in the study:
A subject will be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple 28-week treatment cycles. The study will continue for at least 1 year, and until each 
subject has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately 3 years. A subject will be considered as having completed the study if the subject has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.

Planned duration of retrospective data collection: variable

Planned duration of no-teduglutide treatment periods: variable, depending on disease course

Planned duration of the teduglutide pretreatment visit: 1-21 days

Planned teduglutide treatment cycle duration: 28 weeks. Each cycle consists of 24 weeks of 
teduglutide treatment followed by a 4-week follow-up period (no treatment)
Endpoints and statistical analysis:

The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
The following efficacy endpoints will be analyzed relative to the baseline of the prospective study period, the 
baseline of each teduglutide treatment cycle, and the baseline of the core study, as applicable, at the following time 
points: 1) 12-week intervals during the retrospective observation period, 2) the end of each prospective teduglutide 
treatment period (Week 24/end of treatment [EOT]), and 3) each prospective study visit. The derivations of the 
weekly PS volume and baselines will be described in the study statistical analysis plan (SAP) in detail.

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
Health Economics and Outcomes Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals (Weeks 
12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), relative to the 
baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an additional 
baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:
o
Food and drink limits
o
Diarrhea
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study period:

Adverse events, including those pertaining to GI symptoms

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output
For non-commercial use only

Shire
CONFIDENTIAL
Page 18
Protocol SHP633-303
11 May 2016

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy 
and as needed
The following safety endpoints will be analyzed from the end of the core study (Week 16/EOS) to the beginning of 
the prospective study period:

All adverse events related to teduglutide

All SAEs

All Adverse Events of Special Interest (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study (TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compiled for classification of 
qualitative safety data.
Sample Size Justification
As this is an extension study, the maximum number of subjects will be determined by enrollment in 
TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 19
Protocol SHP633-303
11 May 2016
STUDY SCHEDULES
Table 1-1: Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment
Note
Informed consent/assent
Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study-
related procedures, including retrospective data collection.
Study eligibility
Weight
The last representative value for weight during each 12-week interval 
throughout the retrospective data collection period will be captured.
Height and head circumference
The last representative value for height during each 12-week interval 
throughout the retrospective data collection period will be captured. Head 
circumference should be provided for subjects 36 months of age and younger 
at the time the data were collected, if available.
Prior teduglutide treatment
Collect all available teduglutide prescription start and stop dates and 
corresponding dose levels (mg/kg/day) that were prescribed or planned as part 
of an investigator-initiated trial during the retrospective data collection period.
Parenteral support (PS) 
prescribed
The last stable, representative PS prescription during each 12-week interval 
throughout the retrospective period and at the beginning and end of any 
teduglutide treatment will be collected. Data collected should include weekly 
prescribed volume, calories, average hours per day, and days per week of 
prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED-013-003
Teduglutide-related AEs
Teduglutide-related AEs must be deemed by the investigator to be related to 
teduglutide treatment.
AEs of special interest
Serious adverse events (SAEs)
Note: Retrospective data is defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED-C13-003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Twelve-week intervals of data will be 
collected starting 12 weeks from each subject’s TED-013-003 EOS visit. All available retrospective data should be captured in 
the corresponding CRFs. Failure to collect data because data are unavailable will not be considered a protocol deviation. For 
subjects who consent only to retrospective data collection, only assessments in this table (Table 1-1) will be completed.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
For non-commercial use only

Shire
CONFIDENTIAL
Page 20
Protocol SHP633-303
11 May 2016
Table 1-2: Schedule of Events for Screening and End of Study or Early Termination
Screening
End of Study or Early 
Termination
Visit Type
Site
Site
Informed consent/assent
X
Study eligibility
X
Demographics, medical history, SBS historya
X
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriab
X
Adverse events
X
X
Concomitant medications and GI proceduresc
X
X
Physical examination and vital signs, including weight
X
X
Height and head circumferenced
X
X
Review intake and output diariese
X
X
Record PS and EN prescriptions, and adjust as neededf
X
X
Safety laboratory testsg
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-Scales
X
Antibodies to teduglutideh
X
Fecal occult blood testingi
(X)
Colonoscopyj
(X)
Pregnancy testingk
(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EN=enteral nutrition; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
a If the subject has any changes to the SBS history that had been collected at the baseline of the TED-C13-003 study, then the 
updated SBS history will be collected.
b Subjects who meet ≥1 teduglutide treatment inclusion criteria may proceed to the pre-treatment visit if the investigator, subject, 
and parent or legal guardian agrees to proceed with teduglutide therapy. (Table 1-4).
c Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
d Head circumference will be measured in subjects 36 months of age and younger.
e Intake diaries will be dispensed at the screening visit. The intake diaries should be completed daily for a minimum of 2 weeks at 
screening and for the 2 weeks preceding each clinic visit.
f Parenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after 
review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment provided 
in Appendix 1.
g Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. For pediatric subjects in diapers, urine specimen collection should be attempted as part of the safety labs, 
but lack of urinalysis will not constitute a protocol deviation.
h Required for all teduglutide-exposed subjects.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 48-60 
weeks at a minimum.
j The need for colonoscopy in response to a positive FOBT result during a no-teduglutide treatment period is at the discretion of 
the investigator, but all teduglutide-exposed subjects will undergo colonoscopy after they have received the equivalent of 2 
treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide will undergo colonoscopy 
at 5 year intervals or more often as needed. See Section 7.2.2.9 for details.
k Pregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 21
Protocol SHP633-303
11 May 2016
Table 1-3: Schedule of Events for No Teduglutide Treatment Period
Visit Number
NTx
Visit Type
Site
Visit Frequency
Every 12 weeks
Window (days)
±7
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriaa
X
Adverse events
X
Concomitant medications and GI proceduresb
X
Physical examination and vital signs, including weight
X
Height and head circumferencec
X
Review intake and output diariesd 
X
Record PS and EN prescriptions, and adjust as needede
X
Safety laboratory testsf
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-Scales
X
Antibodies to teduglutideg
(X)
Fecal occult blood testingh
Annually
Colonoscopyi
(X)
Serum samplej
Every 24 weeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EN=enteral nutrition; PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
a Subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed to the pre-treatment visit if the investigator, subject, 
and parent or legal guardian agree to proceed with teduglutide therapy (Table 1-4).
b Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
c Head circumference will be measured in subjects 36 months of age and younger.
d Intake diaries will collect actual PS volume and hours per day, and actual EN volume per day, completed daily during the 
2 weeks preceding each clinic visit (Section 7.2.2.9). Urine and stool output should be recorded in the output diary over a 48-hour 
period of PS and EN stability before every clinic visit (see Section 7.2.2.9 for more detail).
e Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix 1.
f Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. For pediatric subjects in diapers, urine specimen collection should be attempted as part of the safety labs, 
but lack of urinalysis will not constitute a protocol deviation.
g Subjects who have been treated previously and test positive/specific for teduglutide antibodies should have follow-up samples 
collected every 12 weeks during the study until a negative result is obtained.
h Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
i The need for colonoscopy in response to a positive fecal occult blood test during a no-teduglutide treatment period is at the 
discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy after they have received the 
equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive teduglutide will undergo 
colonoscopy at 5-year intervals or more often as needed. See Section 7.2.2.9 for details.
j Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 22
Protocol SHP633-303
11 May 2016
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Px
Cx
D1
Cx
W1
Cx
W2
Phone contact is required approximately 1 week after PS adjustment
Cx
W4
Phone contact is required approximately 1 week after PS adjustment
Cx 
W6
Phone contact is required approximately 1 week after PS adjustment
Cx 
W9
Phone contact is required approximately 1 week after PS adjustment
Cx 
W12
Phone contact is required approximately 1 week after PS adjustment
Cx 
W16
Phone contact is required approximately 1 week after PS adjustment
Cx 
W20
Phone contact is required approximately 1 week after PS adjustment
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28
EOS/ET
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phonea
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window (days)
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteria
X
Xb
Dispense intake 
and output 
diaries
X
X
X
X
X
X
X
X
X
X
X
Xc
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant 
medications and 
GI
proceduresd
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examination and 
vital signs, 
including weight
X
X
X
X
X
X
X
X
X
X
X
X
Height and head 
circumferencee
X
X
X
X
Review intake 
and output 
diariesf
X
X
X
X
X
X
X
X
X
X
X
X
Record PS and 
EN Rx, and 
adjust as neededg
X
X
X
X
X
X
X
X
X
X
X
X
X
Safety laboratory 
testsh
Xh
X
X
X
X
X
X
X
X
X
X
(X)
X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms 
Module Sub-
X
X
X
For non-commercial use only

Shire
CONFIDENTIAL
Page 23
Protocol SHP633-303
11 May 2016
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Scales
Antibodies to 
teduglutidei
X
X
X
X
Fecal occult 
blood testingj
X
X
X
Colonoscopyk
(X)
(X)
(X)
Pregnancy 
testingl
X
X
X
X
X
X
X
X
X
Serum samplem
X
X
Evaluate escape 
criterian
X
X
Dispense study 
drugo
X
X
X
X
X
X
X
X
X
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EN=enteral nutrition; eCRFs=electronic case report forms; EOF=end of follow-up; EOS=end of study; EOT=end of treatment; ET=early termination; FOBT=fecal occult blood 
test; FOCBP=females of child-bearing potential; FU=follow-up; GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin 
time/international normalized ratio; SBS=short bowel syndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
a Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria).
b Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
c CxW28 only.
d Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and associated pathology results.
e Head circumference will be measured in subjects 36 months of age and younger.
f Intake diaries will collect actual PS volume and hours per day, and actual EN volume per day. Two weeks of intake diary data are required before drug is administered at CxD1.
Diaries should be completed daily from CxD1 up to CxW6 visit during teduglutide treatment. After CxW6 visit, diaries should be completed daily for a minimum of 2 weeks
immediately prior to each study visit during teduglutide treatment (Section 7.2.2.9). During the 24-week teduglutide treatment period, the intake diary will also be completed for 1 
week following PS adjustment, and daily during the 4-week follow-up period. Urine and stool output should be recorded in the output diary over a 48-hour period of PS and EN 
stability before every clinic visit, and within 1 week of implementing a change in the PS prescription (see Section 7.2.2.9 for more detail).
g Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment 
provided in Appendix 1.
h Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed by a central laboratory. Clinical chemistry and 
urinalysis must also be performed within approximately 5-7 days of any adjustment to the PS prescription. Safety labs performed between clinic visits may be performed locally. 
Unscheduled lab results will not be captured in the eCRFs. If abnormal results are considered an adverse event, an AE form will be completed. Collect PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug-induced liver injury signal is observed. For pediatric subjects in diapers, urine specimen collection should be attempted as 
part of the safety labs, but lack of urinalysis will not constitute a protocol deviation.
iSamples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
jFecal occult blood test should be performed on teduglutide-exposed subjects on an annual basis.
For non-commercial use only

Shire
CONFIDENTIAL
Page 24
Protocol SHP633-303
11 May 2016
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
k The teduglutide-naïve subjects age 12 and older will undergo colonoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any age with newly 
positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy prior to receiving teduglutide. 
If newly positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment cycle (CxW24/EOT), colonoscopy will 
be performed. The need for colonoscopy in response to positive FOBT results at CxW12 is at the discretion of the investigator. Teduglutide-exposed subjects who have received 
the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy. See Section 7.2.2.9 for details.
l A serum pregnancy test is performed on all females of child-bearing potential (FOCBP) at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all 
other visits according to the study schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.
n If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF.
For non-commercial use only

Shire
CONFIDENTIAL
Page 25
Protocol SHP633-303
11 May 2016
1
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options
Short bowel syndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. It is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with SBS (Khan et al. 
2015; Wales et al. 2004). Unlike the adult population, the majority of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy. 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
by 12 months of age, and an additional 10% wean off PS by 24 months of age. After this time, 
linear intestinal growth slows. About 60% of pediatric subjects with SBS are able to become 
independent of PS within 5 years of the initial diagnosis (Khan et al. 2015). Nevertheless, despite 
optimal medical management, many pediatric subjects remain dependent on PS. Complications 
of long-term PS include liver disease, catheter-related blood stream infections, central 
line-associated venous thrombosis and dwindling central venous access. Sepsis is the leading 
cause of death in these patients and quality of life is poor (Squires et al. 2012). Accelerating the 
adaptive process and achieving enteral autonomy is an urgent goal for all patients with SBS who 
are dependent on PS (Khan et al. 2015; Squires et al. 2012).
Intestinal adaptation is driven by hormonal cues in response to nutrient malabsorption (Drucker 
and Yusta 2014). Chief among these is hormones glucagon-like peptide 2 (GLP-2), which is 
secreted from L-type enteroendocrine cells that reside in the intestinal epithelium in the ileum 
and colon. Resection of these regions impairs the adaptive response by limiting endogenous 
production of GLP-2.
1.2
Product Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP-2 that regulates 
the functional and structural integrity of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33-amino acid peptide that differs from native GLP-2 in the substitution of 
glycine for alanine at the second position at the N-terminus. As a result, teduglutide demonstrates 
resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and therefore maintains a longer 
elimination half-life (t1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t1/2 of approximately 7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and crypt depth in the intestinal 
epithelium, thereby increasing the absorptive surface area of the intestines (Tappenden et al. 
2013; Thymann et al. 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (REVESTIVE™) on 30 
August 2012 and a New Drug Application (NDA) for teduglutide (GATTEX®) was approved by 
the United States (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide is not currently 
approved for use in pediatric subjects.
For non-commercial use only

Shire
CONFIDENTIAL
Page 26
Protocol SHP633-303
11 May 2016
1.3 Clinical Studies with Teduglutide in Pediatric subjects
One Phase 3 study, TED-C13-003, was completed in pediatric SBS subjects in the US and 
United Kingdom (UK). In this study, teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1-17. Thirty-seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for 12 weeks. Five additional pediatric subjects were enrolled in an 
observational standard of care (SOC) cohort. There were clear dose-dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day doses compared to SOC and the 0.0125
mg/kg/day dose. In the 0.025 mg/kg/day cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in 1 subject, and a reduction of 
3.94 hours per day infusion time. In the 0.05 mg/kg/day cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day infusion time. Teduglutide was generally safe and well 
tolerated by pediatric subjects in all dosing cohorts. There were no deaths during the study and 
no treatment-emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study were due to adverse events (AEs).
TED-C14-006 is an ongoing study which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a 2-week minimum 
screening period, a 24-week treatment period, and a 4-week follow-up period. During the 
screening period, subjects will choose into which arm to enroll. During the 24-week treatment 
period, subjects in the SOC treatment arm will receive standard medical therapy for SBS; while 
those in the teduglutide treatment arm will receive daily subcutaneous (SC) injections of 
teduglutide (study drug) in addition to standard medical therapy. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double-blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day of teduglutide administered subcutaneously for 
24 weeks.
Always refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy and safety of teduglutide (SHP633).
For non-commercial use only

Shire
CONFIDENTIAL
Page 27
Protocol SHP633-303
11 May 2016
2
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to 
evaluate the safety and efficacy of teduglutide in pediatric subjects with SBS who completed the 
TED-C13-003 study. In addition to evaluating the long-term safety and durability of efficacy 
after 12 weeks of treatment in TED-C13-003, this extension study will evaluate the need for 
additional teduglutide treatment in these subjects, and will allow for the first-time treatment of 
teduglutide-naïve subjects who participated in the SOC treatment arm in TED-C13-003.
2.2
Study Objectives
2.2.1
Primary Objectives
The primary objective of the study is to evaluate the long-term safety and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED-C13-003.
2.2.2
Secondary Objectives
The secondary objective of this study is to evaluate the long-term efficacy of teduglutide 
treatment in pediatric subjects with SBS who completed TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 28
Protocol SHP633-303
11 May 2016
3
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects who completed the TED-C13-003 study (the core 
study). At the time of entry into the TED-C13-003 study, subjects were less than 18 years of age, 
were dependent on parenteral nutrition to provide at least 30% of their caloric or fluid needs, and 
had not been able to significantly reduce PS for at least 3 months prior to enrollment. During the 
core study, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day, 0.025 mg/kg/day, or 0.05 mg/kg/day dose cohort based on the timing of their 
enrollment in the study. The cohorts were filled in a sequential manner.
Approximately 40 subjects who completed the core study are expected to enroll in this extension 
study. Subjects who previously received teduglutide during the core study, as well as subjects 
who were in the SOC treatment group, may be eligible to receive teduglutide treatment in this 
extension study. To be eligible for treatment with teduglutide in this extension study, subjects 
must meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Rechallenge
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. 
At any point during an NTT period, subjects who meet ≥1 teduglutide treatment inclusion
criteria may proceed directly to the pretreatment visit if the investigator, subject, and parent or 
legal guardian agrees to proceed with teduglutide therapy.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long-term follow-up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analysis suggested that pediatric patients, ages 1-17 years-old, are likely to require the same 
dose as used in adults, namely 0.05 mg/kg/day (Mouksassi et al. 2009). In this extension study to 
TED-C13-003, repeat doses of teduglutide 0.05 mg/kg/day will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU at a dose of 0.05 mg/kg SC 
once daily. The completed 12-week pediatric study (TED-C13-003) demonstrated that 
teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was associated with a favorable 
benefit/risk profile. In addition, population pharmacokinetic modeling and simulations were 
conducted to determine the effective dose to be used in pediatric subjects using data from 8 adult 
clinical studies including adult Phase 1 studies and Phases 2/3 studies as well as the pediatric 
(core) study (TED-C13-003) and suggested that the dose in pediatric subjects is likely to be same 
as the dose in adults (O'Keefe et al. 2006).
For non-commercial use only

Shire
CONFIDENTIAL
Page 29
Protocol SHP633-303
11 May 2016
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED-C14-006 study, 
consisting of 24 weeks of teduglutide treatment, followed by a 4-week follow-up period. The 
follow-up period is a mechanism to evaluate whether continued teduglutide is needed. If a 
subject deteriorates during the follow-up period, the subject may be evaluated immediately for 
additional teduglutide treatment. Subjects who clinically deteriorate or stop improving at any 
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED-C13-003 and TED-C14-006, to ensure sufficient safety monitoring and 
weaning of PS. During the NTT period, visits occur every 12 weeks, a frequency that is 
consistent with standard medical practices.
Measures and Parameters
To evaluate efficacy and safety from the time subjects completed the core study to the time they 
enter this extension study, retrospective data collection is planned for this study. The 
retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. In addition to this retrospective data 
collection, prospective study assessments of safety and efficacy will be completed as a part of 
this study.
3.1.1
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be 
completed before any other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study; however subjects may 
consent to retrospective data collection only. Subjects may not consent to the prospective data 
collection only. After informed consent/assent is obtained, study eligibility will be assessed for 
all subjects.
3.1.2
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1. For subjects 
that only consent to retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study. Retrospective data collection may begin any time after informed consent/assent is 
obtained for this study. The following data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth [height, head circumference (up to 36 months of age), weight]

End dates for adverse events (AEs) ongoing at the time of TED-013-003
For non-commercial use only

Shire
CONFIDENTIAL
Page 30
Protocol SHP633-303
11 May 2016

Nonserious treatment-related adverse events (AEs)

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
3.1.3
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, medical 
history, and short bowel syndrome history. Prescription parenteral support requirements will be 
collected at screening. Additionally, intake diaries will be dispensed at the screening visit, for 
collection of actual PS volume and hours per day, and actual enteral nutrition (EN) volume per 
day (Section 7.2.2.9). Diary data for PN/IV volume will be collected for at least 2 weeks after the 
ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen every 12 weeks 
for safety, PS requirements, and quality of life. Diary data for PN/IV volume will be collected 
for at least 2 weeks prior to any NTT visit. The first NTT visit will occur approximately 
12 weeks after the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed immediately to the 
pretreatment visit if the investigator, subject, and parent or legal guardian agrees to proceed with 
teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28-week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily, followed by a 
4-week follow-up (no treatment) period (Figure 3-1). During the 28-week cycle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the TED treatment period, between Weeks 1-24, and 
weekly during the follow-up period, between Weeks 24 and 28.
At all site visits and telephone contacts, safety will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality of life assessments will be made approximately every 
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation (Appendix 1).
Rationale: Measures of long-term safety will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
by reduction in PS and improvement in pediatric quality of life measures (Pediatric Quality of 
Life Inventory [PedsQL], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pivotal Phase 3 adult 
clinical trials and the completed Phase 3 pediatric study (TED-C13-003), and will be used as an 
endpoint in this extension study. In previous clinical studies, a reduction of this magnitude was 
associated with a reduction in the number of days per week of PS, and increases in enteral 
intake. Reduction in volume and time of PS due to improved enteral absorption may provide a 
For non-commercial use only

Shire
CONFIDENTIAL
Page 31
Protocol SHP633-303
11 May 2016
pediatric subject with opportunities for more age-appropriate activities including oral 
rehabilitation. Quality of life assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI-specific screening tests, 
including fecal occult blood testing and colonoscopy, which are commonly part of the routine 
care of these subjects, will be performed to ensure safety. This study captures long-term safety 
data on polyps and other colonic mucosal changes in teduglutide-exposed subjects using the 
surveillance strategy proposed in Section 7.2.2.9.
Figure 3-1:
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured every 12 weeks, but subjects 
may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. Eligible subjects will enter 
a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy assessments at Weeks 1, 2, 
4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after adjustments in PS during the 
intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide at Week 24 and enter a 4-week 
follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey lines). If an escape criterion is 
met during the follow-up period, subjects may proceed directly to another pretreatment visit.
3.2
Duration and Study Completion Definition
A subject will be considered enrolled in the study once the subject has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility 
Criteria. The study will continue for at least 1 year, and until each subject has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
3 years. The study will be completed in approximately 40 months. A subject will be considered 
as having completed the study if the subject has not withdrawn early from the study for any 
reason prior to completing the EOS visit.
The study completion date is defined as the date the final subject, across all sites, completes their 
final protocol-defined assessment. Please note that this includes the follow-up visit or contact 
(last safety contact), whichever is later. The study completion date will be used to ascertain 
timing for study results posting and reporting.
For non-commercial use only

Shire
CONFIDENTIAL
Page 32
Protocol SHP633-303
11 May 2016
4
STUDY POPULATION
Each subject and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any study-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility does not impact study eligibility.
4.1
Study Inclusion Eligibility Criteria
The subject will not be considered eligible for the study without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing any 
study-related procedures. 
2. Subject completed the TED-C13-003 study (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully adhere to study requirements as 
defined in this protocol.
4.2
Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study.
4.3
Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria
and none of the teduglutide treatment exclusion criteria are met. In addition, the investigator and 
the subject (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.4
Teduglutide Treatment Inclusion Criteria
1. Subject is teduglutide-naïve, receiving PS, and unable to significantly reduce PS or 
advance enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 
3 months prior to and during the teduglutide pretreatment visit, as assessed by the 
investigator. Transient instability for events such as interruption of central access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2. Subject was previously treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b. Decreased PS requirement during prior teduglutide treatment, followed by 
cessation of improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite 
maximal tolerated enteral nutrition following teduglutide discontinuation
d. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid 
and electrolyte intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 33
Protocol SHP633-303
11 May 2016
4.5
Teduglutide Treatment Exclusion Criteria
1. Body weight <10 kg at the pretreatment visit
2. Unresected GI polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3. History of cancer in the previous 5 years except surgically curative skin cancers
4. Serial transverse enteroplasty or other major intestinal surgery within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5. Intestinal or other major surgery planned or scheduled to occur during the 28-week 
cycle
6. Clinically significant intestinal stricture or obstruction
7. Clinically significant, active or recurrent pancreatic or biliary disease
8. Active, severe, or unstable, clinically significant hepatic impairment or injury, 
including the following laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9. Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) 
below 50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the 
exception of subjects who had undergone ventricular or atrial septal defect repair, or 
patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine or 
Omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is 
longer, prior to the pretreatment visit and for the duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 
(GLP-2) (not including teduglutide), insulin-like growth factor-1 (IGF-1), or growth 
hormone, within 1 month preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months 
prior to the pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, 
closely-related compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
17. Sexually active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 days after the treatment period 
For non-commercial use only

Shire
CONFIDENTIAL
Page 34
Protocol SHP633-303
11 May 2016
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts 
the subject at any undue risk, prevents completion of the study, or interferes with 
analysis of the study results
4.6
Follow-up Period Escape Criteria
At the discretion of the investigator, the follow-up period may be interrupted and the subject may 
proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1. Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal 
tolerated enteral nutrition following teduglutide discontinuation
3. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and 
electrolyte intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
4.7
Reproductive Potential
4.7.1
Female Contraception
To be eligible for treatment with teduglutide, sexually active females of child-bearing potential 
must use an acceptable form of contraception throughout the study period and for 30 days 
following the last dose of investigational product. If hormonal contraceptives are used, they 
should be administered according to the package insert. Females of child-bearing potential who 
are not currently sexually active must agree to use acceptable contraception, as defined below, if 
they become sexually active during the period of the study and 30 days following the last dose of 
investigational product. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects
should be either:

Premenarchal and either Tanner Stage 1 or less than age 9 years, or

Females of child-bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin (-HCG) pregnancy test at the teduglutide pretreatment visit. Females of 
child-bearing potential must agree to abstain from sexual activity that could result in 
pregnancy or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:

Abstinence

Intrauterine devices plus condoms

Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)

Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 days prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually active during the study, they should use 1 of the other acceptable methods noted 
above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
For non-commercial use only

Shire
CONFIDENTIAL
Page 35
Protocol SHP633-303
11 May 2016
4.8
Discontinuation of Subjects 
4.8.1
Teduglutide Discontinuation
If the investigational product is discontinued prematurely during a teduglutide treatment cycle, 
regardless of the reason, the evaluations listed for the EOT visit are to be performed as 
completely as possible. After the appropriate EOT assessments are performed, a subject may 
remain in the study. A subject who remains in the study would enter an NTT period and could be 
evaluated for subsequent teduglutide treatment eligibility according to the study schedules. 
Comments (spontaneous or elicited) or complaints made by the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.3. The investigator is encouraged to discuss withdrawal of a subject 
from investigational product with the medical monitor, when possible.
4.8.2
Study Withdrawal
At any time during the study, the investigator or sponsor may withdraw a subject, or a subject 
may withdraw from the study, for any reason, without prejudice to their future medical care by 
the physician or at the institution.
If a subject withdraws from the study during a teduglutide cycle, the evaluations listed for the 
EOT visit are to be performed as completely as possible. Whenever possible, the subject will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contacted 
weekly by phone during the interim period between EOT and ET for safety follow-up.
If a subject withdraws from the study during a NTT period, the evaluations listed for the ET visit 
are to be performed as completely as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3
Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study must 
be determined by the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than 1 reason, each reason should be documented in the source 
document, and the most clinically relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:

Adverse event

Protocol deviation

Lack of efficacy

Physician decision

Withdrawal by subject

Lost to follow-up

Pregnancy (Discontinuation of treatment only)

Death

Other
For non-commercial use only

Shire
CONFIDENTIAL
Page 36
Protocol SHP633-303
11 May 2016
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations, and return any unused investigational product.
For non-commercial use only

Shire
CONFIDENTIAL
Page 37
Protocol SHP633-303
11 May 2016
5
CONCOMITANT TREATMENT
5.1
Concomitant Medications and GI Procedures
Concomitant treatment will be collected for the prospective period only and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this
study. Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medication changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may increase absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, COUMADIN®, 
psychotropics, metronidazole, and digoxin). Accordingly, due consideration should be given to 
modifying concomitant medication regimens. Down-titration of concomitant medications should 
be considered when drugs, especially those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.1
Permitted Treatment
Standard medical therapy for SBS should be continued.
5.1.2
Prohibited Treatment
The mechanism of action of teduglutide may increase enteral absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, COUMADIN, 
psychotropics, metronidazole, digoxin), so consideration should be given to modifying 
concomitant enteral medication regimens. Down-titration of concomitant enteral medications 
should be considered when drugs, especially those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy
Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon-like peptide-2 (not-including teduglutide)
Any
Glucagon-like peptide-1 analog or human growth hormone
1 month
Octreotide or dipeptidyl peptidase 4 inhibitors
3 months
Biological therapy (eg, antitumor necrosis factor)
6 months
For non-commercial use only

Shire
CONFIDENTIAL
Page 38
Protocol SHP633-303
11 May 2016
6
INVESTIGATIONAL PRODUCT
6.1
Identity of Investigational Product
The test product is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L-histidine, mannitol, monobasic sodium 
phosphate monohydrate, and dibasic sodium phosphate as excipients. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.1
Blinding the Treatment Assignment
Not applicable for this open-label study.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology (IRT) for Investigational Product 
Management
An interactive web-based response system (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory management and supply ordering, investigational product expiration tracking and 
management, and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The IWRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.2
Allocation of Subjects to Treatment
This is an open-label study. Subjects will retain their assigned subject number from the 
TED-C13-003 study. Assessment of need for teduglutide treatment should be guided by the 
teduglutide treatment inclusion criteria. If the investigator, subject, and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit (Table 1-4).
6.2.3
Dosing
If teduglutide treatment eligibility is established at the pretreatment visit and again, confirmed at 
the Cycle Day 1 visit, the subject will start a teduglutide treatment period, consisting of 24 weeks 
of teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based 
on body weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered by SC injection once daily (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than 3 hours 
later.
For non-commercial use only

Shire
CONFIDENTIAL
Page 39
Protocol SHP633-303
11 May 2016
The subject should be dosed at approximately the same time each day. Consecutive doses should 
be separated by at least 12 hours. Each day, the injection site should be rotated.
The first SC injection in teduglutide-naïve subjects should be administered under the supervision 
of the investigator or designee and the subject observed for hypersensitivity reactions for at least 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the Instructions for Use. 
Following each 24-week teduglutide treatment period, subjects will enter a 4-week follow-up 
period. During the follow-up, the investigator will assess the subject via weekly telephone visits. 
At any time during the follow-up period, if escape criteria are met, the subject may proceed 
directly to another Pretreatment visit to assess treatment eligibility for another cycle 
(Section 4.6). Following the completion of the 4-week follow-up, the subject will continue in the 
study off teduglutide. Additional 28-week cycles may be repeated if treatment eligibility is 
established each time. 
6.2.4
Unblinding the Treatment Assignment
Not applicable for this open-label study.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification will be applied to the investigational 
product(s) container.
The study drug will be packaged, labeled, and shipped to the study site by the sponsor or 
designee. Kits containing 7 vials of study drug will be supplied and these will be labeled in 
accordance with applicable regulatory requirements. Sterile water for injection syringes will be 
provided separately and will be labeled in accordance with the applicable regulatory 
requirements.
All study drug used in this study will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2
Packaging
Teduglutide will be provided in a 3 mL sterile, single-use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL) will be provided in a prefilled syringe.
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the sponsor.
6.3.3
Storage
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Limited responsibility may be delegated to the pharmacy or 
member of the study team, but this delegation must be documented.
Study drug must be kept in a locked area with access restricted to specific study personnel. Study 
drug will be stored refrigerated at a temperature between 2-8°C (35.6-46.4°F) until dispensed to 
For non-commercial use only

Shire
CONFIDENTIAL
Page 40
Protocol SHP633-303
11 May 2016
a subject. Once dispensed to a subject, the study drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2-25°C, or 35.6-77°F). Parent/legal guardian 
will be instructed to keep the subject’s study drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study drug may be refrigerated.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed by the pharmacy or nominated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed number of subjects. The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. The 
investigator is to keep a current record of the inventory and dispensation of all clinical supplies. 
This record will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any discrepancy or deficiency will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any unauthorized situation.
The investigator has overall responsibility for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study protocol. All dispensed 
study medication will be documented in the eCRFs and/or other investigational product record 
For non-commercial use only

Shire
CONFIDENTIAL
Page 41
Protocol SHP633-303
11 May 2016
(eg, investigation product accountability form). The investigator is responsible for assuring the 
retrieval of all study supplies from subjects.
All used and unused study drug vials must be returned by the subjects and/or parent/guardian, 
and will be retained at the site. All original containers, whether empty or containing study drug 
will be returned to the pharmacy. Returned study drugs will NOT be relabeled or reassigned for 
use by other subjects. Contents of the study drug containers will not be combined. All used and 
unused vials must be returned to the distribution center according to the sponsor’s instruction. 
No vial/kit may be destroyed on site without approval by the sponsor.
Please see the Pharmacy Manual for additional information.
6.5
Subject Compliance
Subjects will be instructed to bring their unused investigational product and empty/used 
investigational product packaging to every visit. Drug accountability will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper-evident sealed container (eg, bottles, trays, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 42
Protocol SHP633-303
11 May 2016
7
STUDY PROCEDURES
7.1
Study Schedule
Detailed study procedures and assessments to be performed for subjects throughout the study are 
outlined in the Schedule of Assessments (Table 1-1, Table 1-2, Table 1-3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing any study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject (Table 1-1).
7.1.1
Retrospective Data Collection
Retrospective data is defined as specific safety and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. Twelve-week intervals of data will be 
collected starting 12 weeks from each subject’s TED-013-003 EOS visit. All available 
retrospective data should be captured in the corresponding CRFs. Failure to collect data because 
data are unavailable will not be considered a protocol deviation. For subjects who consent only 
to retrospective data collection, only assessments in this table (Table 1-1) will be completed. The 
following data will be collected for the retrospective portion of the study:

Informed consent, and informed assent (if applicable)

Study eligibility is determined.
o
A screen failure is a subject who has given informed consent and failed to meet 
the study inclusion eligibility criteria. Subjects cannot be rescreened once they 
have been designated as a screen failure.

Prior teduglutide use (as prescribed)
o
Collect all available teduglutide prescription start and stop dates, and 
corresponding dose levels (mg/kg/day), that were prescribed or planned as part of 
an investigator-initiated trial during the retrospective data collection period.

Parenteral support (as prescribed)
o
The last stable, representative PS prescription during each 12-week interval 
throughout the retrospective period and at the beginning and end of any 
teduglutide treatment will be collected. Data collected should include weekly 
prescribed volume, calories, average hours per day, and days per week of 
prescribed PS.

Growth (height, head circumference, and weight)
o
The last representative value for height, during each 12-week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and younger at the time the data 
were collected, if available.
For non-commercial use only

Shire
CONFIDENTIAL
Page 43
Protocol SHP633-303
11 May 2016

Adverse events
o
All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study. The details of data collection and safety reporting for these events 
can be found in Section 8.
o
End dates for AEs ongoing at the end of TED-C13-003 will be collected.
7.1.2
Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:

Informed consent, and informed assent (if applicable)

Study eligibility is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study inclusion eligibility criteria. Subjects cannot be 
rescreened once they have been designated as a screen failure.

Demographics, medical history, and SBS history

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS and EN prescriptions, and adjust as needed
The first visit after screening (either a no-teduglutide treatment visit or a pretreatment visit), 
must occur within 12 weeks of screening.
7.1.3
Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide-treatment cycle, subjects will be followed every 
12 weeks for safety and efficacy assessments. No-teduglutide treatment visits are numbered 
sequentially (NT1, NT2, etc.), even if interrupted by the treatment cycles. Assessments will be 
performed as outlined in Table 1-3 and described below.

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries
For non-commercial use only

Shire
CONFIDENTIAL
Page 44
Protocol SHP633-303
11 May 2016

Record PS and enteral nutrition (EN) prescriptions, and adjust as needed

Safety laboratory tests (ie, clinical chemistry, hematology, and urinalysis)

PedsQL Generic Core Scale/PedsQL Family Impact Module/ PedsQL Gastrointestinal 
Symptoms Module Sub-Scales

Antibodies to teduglutide, if and when required

Fecal occult blood testing, as indicated (see Section 7.2.2.9)

Colonoscopy, as indicated (see Section 7.2.2.9)

Serum sample, as indicated
Teduglutide treatment may be considered at any time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may proceed to the pretreatment visit to determine eligibility. 
The pretreatment visit must occur within 12 weeks of a given NTT visit.
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
7.1.4.1
Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may proceed to the pretreatment visit after the subject collects 
2 weeks of intake diary data. Similarly, subjects who meet escape criteria during the teduglutide 
follow-up period may proceed to the pretreatment visit after the subject collects 2 weeks of 
intake diary data.
A subject must also have 2 weeks of intake diary data collected, prior to the first dose 
administration (CxD1) during any teduglutide treatment cycle. In general, pretreatment 
assessments may occur over a period of up to 21 days. The teduglutide pretreatment visit (Px) 
assessments and procedures will be performed in Table 1-4 and as described below:

Evaluate teduglutide eligibility (treatment inclusion/exclusion criteria)

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Fecal occult blood testing

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy as indicated

Physical examination and vital signs, including weight

Height and head circumference

Record PS and EN prescriptions, and adjust as needed.

Safety laboratory tests
(In addition to clinical chemistry, hematology, and urinalysis, labs at this visit include 
prothrombin time [PT] international normalized ratio [INR]. Subsequent prothrombin 
time/international normalized ratio (PT/INR) measurement is only required to evaluate 
for suspected drug-induced liver injury [DILI]).
For non-commercial use only

Shire
CONFIDENTIAL
Page 45
Protocol SHP633-303
11 May 2016

Pregnancy testing (serum)

Serum sample
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24)
The open-label teduglutide treatment period will comprise 24 weeks, during which all 
assessments and procedures listed for Visits CxD1-CxW24 in Table 1-4 shall be completed. 
Cycles are numbered sequentially, such that the first visit of the first cycle is C1D1, and the first 
visit of the second cycle is C2D1, etc. Visit windows are calculated relative to the date of first 
investigational product administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1-4 and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.

Confirm teduglutide eligibility

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS and EN prescriptions, and adjust as needed

Safety laboratory tests

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing (urine)

Dispense study drug
7.1.4.3
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cycle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Record PS and EN prescriptions, and adjust as needed

Safety laboratory tests

Urine pregnancy testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, 
CxW24)
For non-commercial use only

Shire
CONFIDENTIAL
Page 46
Protocol SHP633-303
11 May 2016

Study drug dispensation (except for CxW24)

Adverse events, concomitant medications and concomitant GI procedures
In addition, at CxW12 and CxW24 Visits ONLY, the following procedures will be performed:

Height and head circumference

Antibodies to teduglutide

Fecal occult blood testing (FOBT)

GI-specific testing, including colonoscopy or sigmoidoscopy as indicated

Quality of life measurements
At CxW24 ONLY, a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
7.1.4.4
Phone Visits
Phone visits are required approximately 1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-4 and described 
below:

Review intake and output diaries

Safety laboratory tests (clinical chemistry and urinalysis)

Record PS and EN prescriptions, and adjust as needed

Obtain AEs, concomitant medications, and concomitant GI procedures

Evaluate escape criteria
7.1.5
Teduglutide Follow-up Period
The safety follow-up period for this protocol is 4 weeks (Weeks 25-28 of the cycle). Phone visits 
will occur on cycle Weeks 25, 26, and 27 for all subjects. Phone visit assessments and 
procedures at Weeks 25-27 will be the same as for telephone visits performed during the 
teduglutide treatment period. In addition, subjects will be evaluated for follow-up period escape 
criteria. If escape criteria are met at any time during the follow-up period, the subject may 
proceed directly to another pretreatment visit at the investigator’s discretion.
7.1.5.1
CxW28
At Cycle Week 28 (CxW28), subjects will return to the study site. In addition to the assessments 
performed at Weeks 25-27, the following procedures will be performed at CxW28 only:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Antibodies to teduglutide

Pregnancy testing (urine)

Evaluate escape criteria
For non-commercial use only

Shire
CONFIDENTIAL
Page 47
Protocol SHP633-303
11 May 2016
7.1.5.2
Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study site for the end of study/early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-2 and as 
described here. If a subject discontinues the study prematurely, the assessments for the EOS/ET 
visit are to be performed as completely as possible.

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS and EN prescriptions, and adjust as needed

Safety laboratory tests

Fecal occult blood testing, as indicated

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy, as 
indicated

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing, as needed
7.2
Study Evaluations and Procedures
7.2.1
Retrospective Data Collection
Retrospective data are being collected to evaluate the safety, tolerability, and efficacy of 
teduglutide during the interval between a subject's completion of the TED-C13-003 study and the 
date the ICF (and if applicable, assent) is signed for the SHP633-303 study.
7.2.1.1
Growth (Height, Weight, and Head Circumference)
Retrospective body height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z-score, weight z-score, body mass index (BMI), and BMI z-score will be calculated by 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the SAP.
7.2.1.2
Prior Teduglutide Treatment Prescribed
Retrospective teduglutide prescription start and stop dates and dose levels will be recorded on the 
appropriate eCRF page, if available, using data from prescriptions filled during the retrospective 
data collection period.
7.2.1.3
Parenteral Support Prescribed
Retrospective parenteral support entries consist of 1 prescription per 12-week interval during the 
retrospective period. The prescription should include start and stop dates, and corresponding 
volumes, of prescribed PS, excluding transient instability/interruption(s) for events such as 
For non-commercial use only

Shire
CONFIDENTIAL
Page 48
Protocol SHP633-303
11 May 2016
central line access issues, sepsis, or acute illness. If the subject has multiple PS prescriptions in a 
12-week interval, the latest stable prescription from the interval should be used. Prescription data 
will be recorded in the eCRF.
7.2.1.4
Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESIs) and all serious adverse events (SAEs) regardless of causal attribution to teduglutide, that 
occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safety reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED-C13-003 will be collected.
7.2.2
Prospective Data Collection
Prospective data are data that are being collected for the purpose of establishing subject baselines 
and completing the treatment-related assessments (including the evaluation of eligibility for 
teduglutide treatment) of SHP633-303.
7.2.2.1
Demographics, Medical History, and SBS History
Demographics, medical history, and SBS history will be obtained at screening. Medical history 
for purposes of this extension study will consist of the following:

Events that occurred during the period between completion of TED-C13-003 and 
informed consent/assent to SHP633-303 with the exception of:  nonserious AEs 
related to teduglutide treatment, and all adverse events of special interest (AESIs) and 
all serious adverse events, regardless of causality attribution to teduglutide. 
This medical history information will supplement the medical history information collected at 
the start of the TED-C13-003 core study. If the subject has any changes to the SBS history since 
the baseline visit of the TED-C13-003 study, that information (updated SBS history) will be 
collected.
7.2.2.2
Physical Examination
Physical examinations will be performed according to the study schedules. Any new clinically 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF.
7.2.2.3
Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body temperature 
(°C/°F). Blood pressure should be determined by cuff (using the same method, the same arm, 
and in the same position throughout the study).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each study visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z-score, weight z-score, BMI, and BMI z-score will be 
calculated by the sponsor using the site-provided height and weight data collected at each site 
visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 49
Protocol SHP633-303
11 May 2016
New clinically significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.2.4
Clinical Laboratory Tests
Safety laboratory tests to be performed at site visits consist of clinical chemistry, hematology, 
and urinalysis and will be performed as outlined in the study plan (Table 1-2, Table 1-3, and 
Table 1-4). Scheduled laboratory testing will be processed by a central lab. All laboratory assays 
will be performed according to the central laboratory’s normal procedures. Reference ranges are 
to be supplied by the laboratory. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Abnormal clinical laboratory values, which are unexpected or not 
explained by the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safety labs within approximately 
5-7 days after a PS adjustment. Safety labs performed after PS adjustment and between site visits 
will consist of clinical chemistry and urinalysis and may be processed by the central laboratory 
or a local laboratory. Local lab results will not be entered in the eCRFs; however, if the local lab 
results indicate any new clinically significant changes, they must be reported as an adverse event 
(see Section 8.1). For pediatric subjects in diapers, urine specimen collection should be 
attempted as part of the safety labs, but lack of urinalysis will not constitute a protocol deviation.
New clinically significant labs should be reported as AEs.
The following clinical laboratory assessments will be performed according to the study 
schedules:
For non-commercial use only

Shire
CONFIDENTIAL
Page 50
Protocol SHP633-303
11 May 2016
Table 7-1: List of Laboratory Tests 
Hematology:

Hematocrit 

Hemoglobin 

Platelet count

Red blood cell count 

Red blood cell morphology, if needed

White blood cell count with differential
Coagulation:
Prothrombin time/International normalized ratio 
Urinalysis: 

Blood

Glucose

Leucocytes

Microscopic analysis

pH and osmolality

Protein

Sodium

Specific gravity

Pregnancy tests (females of childbearing 
potential):
o
Serum β-HCG (screening)
o
Urine β-HCG (all other visits)
Biochemistry:

Albumin 

Alkaline phosphatase 

Alanine aminotransferase 

Amylase

Aspartate aminotransferase 

Bicarbonate

Bilirubin (total and indirect)

Blood urea nitrogen 

Calcium (total)

Chloride

Cholesterol

C-reactive protein 

Creatinine

Estimated Glomerular Filtration Rate 

(Schwartz formula)

Gamma-glutamyl transferase 

Glucose

Lipase

Magnesium

Phosphorus

Potassium 

Sodium 

Triglycerides

Uric acid
For non-commercial use only

Shire
CONFIDENTIAL
Page 51
Protocol SHP633-303
11 May 2016
7.2.2.5
Serum Sampling
Serum samples will be collected and stored for future analysis at the following times:

During teduglutide treatment period: at the pretreatment and CxW24 (EOT) visits

During NTT: Approximately every 24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and any specialty laboratories will be 
blinded to the subject’s identity. The sample and/or extracted material will otherwise be stored 
for up to 15 years from the end of the study after which time it will be destroyed. Upon written 
request, subjects will be permitted to withdraw their sample from the analysis and have their 
sample and/or extracted material destroyed. Any results already generated from the samples will 
not be removed from any analyses that have already been performed.
7.2.2.6
Pregnancy Testing
A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy tests will be administered at all other visits according to the study schedules, or if 
pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the 
study.
7.2.2.7
Antibody Testing
Blood samples will be drawn for the analysis of positive/specific antibodies to teduglutide 
according to the Schedule of Assessments (Table 1-2, Table 1-3, and Table 1-4). Blood samples 
for antibodies may be drawn from a central line or from peripheral access. The sample drawn on 
CxD1 must be drawn prior to administration of the first dose of teduglutide. Once the subject has 
started teduglutide treatment, samples must be drawn at least 14 hours after dosing. Subjects who 
test positive/specific for antibodies to teduglutide will also be tested for neutralizing antibody. 
Subjects who have been previously treated with teduglutide, and who test positive/specific for 
antibodies to teduglutide, will have follow-up blood draws for positive/specific antibodies to 
teduglutide every 12 weeks while on study until a negative result is obtained.
7.2.2.8
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study. The volumes of blood to be drawn from each subject will vary depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annually are shown 
in the following table.
For non-commercial use only

Shire
CONFIDENTIAL
Page 52
Protocol SHP633-303
11 May 2016
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
Assessment
Sample 
Volume (mL)
No. Samples per two 28-week 
Teduglutide Cycles
Total 
Volume (mL)
Subjects Receiving Teduglutide Treatment 
Safety
Biochemistry and -hCGa
2.5
24
60
Hematology
2
24
48
Coagulation Parameters
1
2
2
Antibodies
2
8
16
Serum storage samples
3
4
12
Total mL per 2, 28-week Treatment Cycles (Approximate Annual Volume):
138
Subjects Not Receiving Teduglutide Treatmentb
Assessment
Sample 
Volume (mL)
No. Samples per 4 NTT Visits
Total 
Volume (mL)
Safety
Biochemistry
2.5
4
10
Hematology
2
4
8
Serum storage samples
3
2
6
Total mL per 4 “No Teduglutide Treatment” Visits 48-week period:
24
β-hCG=beta-human chorionic gonadotropin; NTT=no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
b Subjects not receiving TED treatment, but who were exposed to it previously and tested positive for anti-TED antibodies will 
require blood samples for antibody testing every 12 weeks until they test negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by the manufacturer or laboratory 
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they require the same type of tube, the assessments should be combined. Blood 
volume estimates do not include safety labs performed after PS adjustment, and anti-teduglutide 
antibody testing during no-teduglutide treatment.
7.2.2.9
Gastrointestinal-specific Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week 24 of the teduglutide cycle. During NTT periods, FOBT must be performed on 
teduglutide-exposed subjects (subjects who have received teduglutide any time in the past and 
are therefore not teduglutide-naïve) on a roughly annual basis (approximately every 48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY
Teduglutide-naïve subjects age 12 and older will undergo colonoscopy at the pretreatment visit if 
one has not been performed within 1 year.
Subjects of any age with newly positive FOBT results at the pretreatment visit for which a 
readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy prior 
to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause 
cannot be identified) are obtained at the end of a teduglutide treatment cycle (CxW24/EOT), 
colonoscopy will be performed. The need for colonoscopy in response to positive FOBTs at any 
For non-commercial use only

Shire
CONFIDENTIAL
Page 53
Protocol SHP633-303
11 May 2016
other point during the study, or to reevaluate persistently positive FOBTs is at the discretion of 
the investigator.
Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks 
of study drug exposure) will undergo colonoscopy. While receiving additional teduglutide 
treatment, subjects will undergo colonoscopy at 5 year intervals or more often as needed.
Upper endoscopy may be performed along with any colonoscopy at the investigator’s discretion. 
If a polyp is found, adherence to current polyp follow-up guidelines is recommended. Subjects 
with unresected GI polyps, polyposis conditions, premalignant change or malignancy in the GI 
tract will be excluded from teduglutide treatment.
NUTRITIONAL SUPPORT
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hydration 
status, and safety laboratory results. Intake and output diaries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 1.
INTAKE DIARY
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS and enteral nutrition 
(formula) sections of the intake diary 2 weeks prior to ALL scheduled prospective site visits. 
During the 24-week teduglutide treatment period, the intake diary will also be completed for 1 
week following PS adjustments. The intake diary will also be completed daily during the 4-week 
follow-up period. The following data will be captured in the intake diaries:

Parenteral support volume and infusion duration

Enteral nutrition (formula) volume

Site personnel will determine the actual PS and EN daily calories based on diary 
entries
OUTPUT DIARY
Urine and stool output should be recorded in the output diary over a 48-hour period of PS and 
EN stability before every clinic visit; in addition, output should be recorded for subjects that are 
in a teduglutide treatment cycle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:

Toilet-trained subjects (who do not wear diapers)

Measure and record all urine output in mL or cc. The subject or parent/legal guardian
will perform dipstick specific gravity tests on the first urine produced after the daily 
infusions of PS.
Nontoilet-trained subjects (who wear diapers)

Measure and record the weight of all urine-only diapers. Urine volume will be 
calculated using the following formula: 1 g (scale weight) = 1 mL or 1 cc
For non-commercial use only

Shire
CONFIDENTIAL
Page 54
Protocol SHP633-303
11 May 2016
At the discretion of the investigator, the parent or legal guardian may be asked to collect the first 
void after the daily PS infusion to measure specific gravity.
Stool data (includes diapers with mixed urine and stool):

Toilet-trained subjects (who do not wear diapers)
o
Record the occurrence of each bowel movement and score the stool consistency 
using the Bristol Stool Form Scale (see Output diary)

Nontoilet-trained subjects (who wear diapers)
o
Record the weight of diapers containing stool (including diapers with mixed urine 
and stool) as stool output and score the stool consistency using the Bristol Stool 
Form Scale (see Output diary). Stool volume will be calculated using the formula: 
1 g (scale weight)=1 mL or 1 cc
All ostomy output volume should be recorded. Ostomy output will not be scored using the 
Bristol scale.
All diaries will be reviewed by the investigator or their designee at each clinic and telephone 
contact to assess clinical status and opportunity for PS reduction and advance in feeds.
7.2.2.10
Health-related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes less than 4 minutes to 
complete. The scales include self-reports for pediatric subjects and adolescents aged 5 to 
18 years and proxy-reports from parents of pediatric subjects aged 2 to 18 years.
Field trials have shown that the internal consistency reliability of the PedsQL was excellent, with 
alphas for the generic core scales in both self- and proxy-report greater than the 0.70 standard, 
and alphas for the full 23-item scale approaching 0.90 for self- and proxy-report. Missing data 
were minimal. Item response distributions were across the full scale range, with no floor effects, 
and minimal ceiling effects.
The validity of the PedsQL Generic Core Scales was demonstrated through known group 
comparisons, and correlations with other measures of disease burden. The PedsQL self- and 
proxy-report distinguished between pediatric subjects with and without a chronic health 
condition, and within the group of pediatric subjects with a chronic condition, between those 
who did or did not have an overnight hospital visit in the last 12 months. Further, both child 
self-report and parent proxy-report correlated significantly with the number of days the child was 
too ill to pursue normal activities, needed someone to care for him or her, missed school in the 
last month, the number of days the parent missed from work in the last month, and parent-report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (PEDSQL™), ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health-related quality of life (HRQoL) 
in pediatric subjects and adolescents (2-18 years of age). The developmentally appropriate 
PedsQL Generic Core Scale will be completed by either the parent or legal guardian and subject 
as indicated in Table 7-3 at the time points as outlined in Table 1-2, Table 1-3, and Table 1-4.
For non-commercial use only

Shire
CONFIDENTIAL
Page 55
Protocol SHP633-303
11 May 2016
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report
Completed by
Parent Report for Toddlers (ages 2-4)
Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Young Pediatric subjects 
(ages 5-7)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Pediatric subjects (ages 
8-12)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Teens (ages 13-18)
Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2-4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8-12), and Teens (ages 13-18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Family Impact Module is a parent-report multidimensional instrument that will be 
completed by the parent or legal guardian, as outlined in Table 1-2, Table 1-3, and Table 1-4.
The PedsQL Family Impact Module is a specific module of the PedsQL that is used to measure 
the impact of pediatric chronic health conditions on parents and the family (Varni et al. 2004). 
The 36-item PedsQL Family Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry (5 items). Two additional scales measure parent-
reported family functioning as follows: 1) Daily Activities (3 items), and 2) Family Relationships 
(5 items). The PedsQL Family Impact Module should take the parent or legal guardian 
approximately 5-10 minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Gastrointestinal Symptom Module is a disease-specific 58-item module, comprised 
of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Symptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink Limits (6 items) and Diarrhea (7 items) were identified as 
clinically relevant and appropriate for the symptoms experienced in this pediatric study 
population, and therefore, are the only scales used in this study. The scales will be completed by 
either the parent or legal guardian and subject as indicated in Table 7-3 at the time points 
outlined in Table 1-2, Table 1-3, and Table 1-4.
For non-commercial use only

Shire
CONFIDENTIAL
Page 56
Protocol SHP633-303
11 May 2016
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD OF OBSERVATION
For the retrospective data collection period (the EOS visit of the core study until signing the ICF 
[and informed assent, if applicable] for SHP633-303), investigators will be asked if they are 
aware of any nonserious AEs possibly related to teduglutide that occurred during this time and 
any AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during this time. 
The following guidance is given for defining a treatment-related event:

The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.

The event cannot be explained by the subject’s medical condition, other therapies, or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this 
study.
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow-up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the study, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of symptoms should be 
recorded. If a diagnosis has not been made, then each symptom should be listed individually. All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. Closure indicates that an outcome is reached, stabilization achieved 
(the investigator does not expect any further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
For non-commercial use only

Shire
CONFIDENTIAL
Page 57
Protocol SHP633-303
11 May 2016
8.1.1
Severity Categorization
The severity of all AEs must be recorded during the course of the event including the start and 
stop dates for each change in severity. An event that changes in severity should be captured as a 
new event. Worsening of pre-treatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
Note that the severity of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) grading criteria (Table 8-1).
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause-and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
The following additional guidance may be helpful:
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
For non-commercial use only

Shire
CONFIDENTIAL
Page 58
Protocol SHP633-303
11 May 2016
Term
Relationship Definition
Not Related
The event can be readily explained by other factors such as the 
subject’s underlying medical condition, concomitant therapy, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled physical examinations must 
be reported as AEs if the investigator considers the finding to be a clinically significant change 
from the baseline.
8.1.3
Outcome Categorization
The outcome of all AEs must be recorded during the course of the study in the eCRF. Outcomes 
are as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae

Recovering/Resolving

Unknown
8.1.4
Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the disease and are part of the efficacy 
data to be collected in the study; however, significant worsening of the symptoms should be 
recorded as an AE.
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory or vital sign can represent an AE if the change is 
clinically relevant or if, during the study, a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an already abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study, further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
For non-commercial use only

Shire
CONFIDENTIAL
Page 59
Protocol SHP633-303
11 May 2016
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign is clinically significant and 
therefore represents an AE.
8.1.6
Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core study until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633-303 study until the defined follow-up 
period stated in Section 7.1.5.
Any report of pregnancy for any female study participant must be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy Report Form. A copy of the Shire 
Investigational and Marketed Products Pregnancy Report Form (and any applicable follow-up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency contact information section of the protocol. In the event a subject becomes pregnant 
after signing the ICF (and, if applicable, assent), teduglutide administration must be discontinued 
immediately.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. For pregnancy reports during the prospective period of observation, it is 
the responsibility of the investigator to obtain this information within 30 calendar days after the 
initial notification and approximately 30 calendar days post partum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633-303), the initial notification date will be the date the pregnancy is recorded for this 
study and outcome and infant condition information may be collected anytime post partum.
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire Clinical Study Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required by the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Nonserious AEs as required by the Protocol as well as the Shire Investigational and Marketed 
Products Pregnancy Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy onset date.
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
For non-commercial use only

Shire
CONFIDENTIAL
Page 60
Protocol SHP633-303
11 May 2016
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may be detrimental to the individual and/or society

Misuse – Intentional use of investigational product other than as directed or indicated 
at any dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed by the protocol)

Overdose – Administration of a dose greater than the allocated dose of the study 
medication or at a frequency greater than the dosing interval specified by the protocol

Medication Error – An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not considered 
reportable as medication errors

Medication errors should be collected/reported for all products under 
investigation

The administration and/or use of an expired investigational product should be 
considered as a reportable medication error
All investigational product provided to pediatric subjects should be supervised by the 
parent/legally-authorized representative/caregiver.
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference for safety information for this study is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
8.2.2
Reporting Procedures
All initial and follow-up SAE reports for SAEs experienced during the prospective period of 
observation must be reported by the investigator to the Shire Global Pharmacovigilance and Risk 
Management Department and the Shire Medical Monitor within 24 hours of the first awareness 
of the event. Note: The 24-hour reporting requirement for SAEs does not apply to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by the investigator to the Shire Global 
Pharmacovigilance and Risk Management Department and the Shire Medical Monitor within 24 
hours of the first awareness of the event even if the event does not fulfill seriousness criterion.
The investigator must complete, sign, and date the Shire Clinical Study Adverse Event Form for 
SAEs and Nonserious AEs as Required by Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e-mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy of the completed Shire Clinical 
For non-commercial use only

Shire
CONFIDENTIAL
Page 61
Protocol SHP633-303
11 May 2016
Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as Required 
by Protocol (and any applicable follow-up reports) must also be sent to the Shire Medical 
Monitor or designee using the details specified in the emergency contact information section of 
the protocol.
8.2.3
Serious Adverse Event Definition
A SAE is any untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 

Results in death

Is life-threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it was more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospitalization for an elective or previously scheduled surgery that meet(s) serious 
criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity

Is a congenital abnormality/birth defect

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency or 
drug abuse.
8.2.4
Serious Adverse Event Collection Time Frame
For the prospective period of observation, all SAEs (regardless of relationship to study drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow-up period stated in Section 7.1.5, and must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department and the Shire Medical Monitor within 24 
hours of the first awareness of the event. First awareness for SAEs collected during the 
retrospective observation period will be the date the event is recorded for this study.
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within 24 hours of the first awareness of 
the event.
For non-commercial use only

Shire
CONFIDENTIAL
Page 62
Protocol SHP633-303
11 May 2016
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notifying the 
relevant regulatory authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notifying active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
8.3
Adverse Events of Special Interest
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
the investigator to the sponsor is required.
The AEs of special interest that require expedited regulatory reporting include the following:

Growth of pre-existing polyps of the colon

Benign neoplasia of the GI tract including the hepatobiliary system

Tumor-promoting ability (eg, benign and/or malignant neoplasia of any kind, not 
limited to those of the GI or hepatobiliary system)
For non-commercial use only

Shire
CONFIDENTIAL
Page 63
Protocol SHP633-303
11 May 2016
For AESIs experienced during the prospective period of observation, the sponsor must be 
informed within 24 hours of first awareness as per the SAE notification instructions described in 
Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4
Dose Interruption and Permanent Discontinuation (Prospective Period of 
Observation Only)
Sections 8.4 and 8.5 apply only to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contacting the sponsor/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may include but are 
not limited to hospitalization, incidents of certain AEs, SAEs considered to be related to the 
study drug, a lapse in investigational product delivery, etc.
Study drug must be discontinued if any of the following events occur:

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to be 
related to study drug. This does not include anti-teduglutide antibodies, mild injection 
site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.

An AE listed in (Table 8-1) that is of NCI CTCAE severity Grade 3 or 4 and 
considered to be related to study drug administration

Confirmed drug-induced liver injury (DILI) related to teduglutide (see Section 8.4.2)
8.4.1
Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only)
The investigational product may be discontinued if the subject has an AE listed in Table 8-1 that 
is of severity ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor as soon as possible. Teduglutide administration must be discontinued if the AE 
is considered related to the investigational product. The length of the dose interruption, and 
whether teduglutide administration resumes or is permanently discontinued, depends on the 
clinical situation.
Investigators and the data monitoring committee (DMC) should be guided by the descriptions of 
Grade 3 and 4 events, as they relate to known and possible risks associated with the 
administration of teduglutide.
For non-commercial use only

Shire
CONFIDENTIAL
Page 64
Protocol SHP633-303
11 May 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events
Grade 3 Description
Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps
Severe or medically significant but not 
immediately life threatening; 
hospitalization or prolongation of 
existing hospitalization indicated; 
disabling; limiting self-care activities of 
daily living
Life-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction
Hospitalization indicated; elective 
operative intervention indicated; limiting 
self-care activities of daily living; 
disabling
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis
Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation
Not Applicable
Life-threatening consequences; urgent 
intervention indicated
Gallbladder obstruction
Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospitalization indicated; nonemergent 
operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection
Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicated
Life-threatening consequences; urgent 
intervention indicated
Adverse Events
Grade 3 Description
Grade 4 Description
Alkaline Phosphatase 
increased
>5.0 to 20.0x ULN
>20.0x ULN
Blood bilirubin increased
>3.0 to 10.0x ULN
>10.0x ULN
Bile duct stenosis
Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis
Severe pain; vomiting; medical 
intervention indicated (eg, analgesia, 
nutritional support)
Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis
Severely altered gastrointestinal function; 
tube feeding or hospitalization indicated; 
elective operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Pancreas infection
Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicated
Life-threatening consequences; urgent 
intervention indicated
For non-commercial use only

Shire
CONFIDENTIAL
Page 65
Protocol SHP633-303
11 May 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events
Grade 3 Description
Grade 4 Description
Serum amylase increaseda
>2.0 to 5.0x ULN
>5.0x ULN
Lipase increaseda
>2.0 to 5.0x ULN
>5.0x ULN
Cardiovascular Disease
Heart failure
Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicated
Life-threatening consequences; urgent 
intervention indicated (eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, 14 June 2010
ULN=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may need to be interrupted if the subject has 
clinical and laboratory evidence of potential DILI, in the absence of an alternative explanation, 
as identified by the following criteria:

ALT or AST >8x ULN

ALT or AST >5x ULN and >2x baseline value for more than 2 weeks

(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)

ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
All laboratory values suggestive of potentially new DILI should be repeated and verified within 
3 days. International normalized ratio should be measured with this set of verification laboratory 
assessments and an inquiry should be made as to the presence of clinical symptoms consistent 
with new liver injury. The subject should be followed closely to determine the trajectory of the 
laboratory abnormalities and to evaluate the cause of liver injury. This evaluation may include, 
as clinically indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cytomegalovirus IgM, 
Epstein-Barr virus antibody panel), hepatobiliary obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti-actin, or anti-liver kidney microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permanently discontinued if DILI is confirmed and deemed 
related to study drug.
For non-commercial use only

Shire
CONFIDENTIAL
Page 66
Protocol SHP633-303
11 May 2016
8.5
Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may recommend stopping the study if:

≥2 subjects develop the same event listed in Table 8-1 of severity CTCAE Grade 3
or

1 subject develops an event listed in Table 8-1 of severity CTCAE Grade 4 which is 
attributable to investigational product or is not reasonably related to the underlying 
disease process
For non-commercial use only

Shire
CONFIDENTIAL
Page 67
Protocol SHP633-303
11 May 2016
9
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
in the eCRF. A study monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safety follow up assessments 
(conducted after EOS) are not required to be collected.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality control and data validation procedures are applied to ensure the validity and 
accuracy of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed 
using SAS® (SAS Institute, Cary, NC, USA) version 9.3 or higher.
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4
Planned Interim Analysis, and Data Monitoring Committee
An interim analysis is planned when 6 months of safety data have been collected.
A DMC will be involved in the management of this study. The DMC members will review the 
data approximately every 3 months during the study treatment period (date of the first subject’s 
first dose to date of the last subject’s last dose). The DMC review will include all cumulative 
safety data (ie, AEs, laboratory assessments, physical examinations, etc.) from study assessments 
through each cutoff period. Further details regarding the DMC can be found in the DMC charter, 
which will be available prior to the administration of investigational product. 
The DMC for this study will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
The DMC will be an external, independent board comprised of physicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory in nature. The DMC will be governed by a 
Charter agreed to by members of the Board and the sponsor. Members of the Board may not be 
study investigators or be employed at the same institution as a study investigator, individuals 
employed by the sponsor, independent contractors hired by the sponsor, or members of 
For non-commercial use only

Shire
CONFIDENTIAL
Page 68
Protocol SHP633-303
11 May 2016
regulatory agencies. The DMC may make recommendations to the sponsor regarding study
aspects including stopping, modifying or continuing the study; however, the sponsor will have 
the final responsibility to determine whether the study should be modified or temporarily or 
permanently stopped.
9.5
Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects will be determined by enrollment 
in TED-C13-003.
9.6
Study Population
The safety population includes all enrolled subjects in the study. The safety population will be 
used for both safety and efficacy analyses.
9.7
Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1
Efficacy Endpoints
The following efficacy endpoints will be analyzed relative to the baseline of the prospective 
study period, the baseline of each teduglutide treatment cycle, and the baseline of the core study, 
as applicable, at the following time points: 1) 12-week intervals during the retrospective 
observation period, 2) the end of each prospective teduglutide treatment period (Week 24/EOT), 
and 3) each prospective study visit. The derivations of the weekly PS volume and baselines will 
be described in the study SAP in detail.

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
9.8
Safety Analyses
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safety data as well as for the difference from baseline, if applicable. Frequency 
counts will be compiled for classification of qualitative safety data.
9.8.1
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study 
period:

Adverse events, including those pertaining to GI symptoms
For non-commercial use only

Shire
CONFIDENTIAL
Page 69
Protocol SHP633-303
11 May 2016

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing including fetal occult blood testing and colonoscopy 
or sigmoidoscopy, as needed
The following safety endpoints will be analyzed from the end of the core study (Week 16/EOS) 
to the beginning of the prospective study period:

All treatment-related AEs

All SAEs

All AESIs (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study 
(TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
body mass index
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by System Organ Class and by preferred term. Serious adverse events will be further 
summarized by severity and relationship to investigational product. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization-Drug 
Dictionary (WHO-DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history (including 
surgical/procedural history) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by system organ class and preferred term. 
For clinical laboratory tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive specific or neutralizing 
antibodies to teduglutide will be used to summarize the presence of antibodies. 
Additional safety parameters and measures will include change in body weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z-score, BMI, and BMI z-score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 70
Protocol SHP633-303
11 May 2016
9.9
Other Analyses
9.9.1
Health-related Quality of Life Analyses
Health economics and outcomes research endpoints will be analyzed at approximately 12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study period. The beginning of 
each treatment cycle (CxD1) will be an additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:

Food and drink limits

Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 71
Protocol SHP633-303
11 May 2016
10
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH Good Clinical Practice (GCP) Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO as necessary. 
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
For non-commercial use only

Shire
CONFIDENTIAL
Page 72
Protocol SHP633-303
11 May 2016
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an EOS declaration to the relevant competent authority as required by 
Article 10 (c) of Directive 2001/20/EC.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by the signed and dated signature of the 
principal investigator (single-site study) or coordinating principal investigator (multicenter 
study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH 
Guidance E3 (1995). 
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by international regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
For non-commercial use only

Shire
CONFIDENTIAL
Page 73
Protocol SHP633-303
11 May 2016
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly into the 
eCRF.
Electronic case report forms should be approved by the investigator per study specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory reports, and histology and 
pathology reports.
All key data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the eCRF 
entries against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory authorities, or the IRB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X-rays etc.). Nonstudy site personnel will not 
disclose any personal information or personal medical information.
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA, 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Agency) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory authorities), the 
European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory 
For non-commercial use only

Shire
CONFIDENTIAL
Page 74
Protocol SHP633-303
11 May 2016
Agency, other regulatory authorities, the sponsor or its representatives, and the IRB/EC for each 
site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, where 
applicable, from all study subjects prior to any study-related procedures including screening 
assessments. All consent and assent documentation must be in accordance with applicable 
regulations and GCP. Each subject or the subject’s legally-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully executed signature pages) must be given to the subject or the 
subject’s legally-authorized representative, as applicable. This document may require translation 
into the local language. Signed consent forms must remain in each subject’s study file and must 
be available for verification at any time.
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legally-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study subject.
The principal investigator provides the sponsor with a copy of the consent form, and assent form 
where applicable, which was reviewed by the IRB/EC and which received their favorable 
opinion/approval. A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study unless it is agreed to 
and documented (abiding by regulatory guidelines and national provisions) prior to study start 
that another party (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally, if the IRB/EC requires modification of the sample subject information and 
consent document provided by the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 75
Protocol SHP633-303
11 May 2016
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity as defined by HIPAA must provide documentation of 
this fact to the sponsor (or designee).
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representatives 
review their medical records and data collected during the study. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP633; national or local regulatory authorities; and the IRBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subject).
The results of studies – containing subjects’ unique identifying number, relevant medical 
records, and possibly initials and dates of birth – will be recorded. They may be transferred to, 
and used in, other countries which may not afford the same level of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities.
For non-commercial use only

Shire
CONFIDENTIAL
Page 76
Protocol SHP633-303
11 May 2016
10.5
Study Results / Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the 
publication steering committee is to act as a noncommercial body that advises or decides on 
dissemination of scientific study data in accordance with the scope of this policy.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any rights to authorship of 
publications.
For non-commercial use only

Shire
CONFIDENTIAL
Page 77
Protocol SHP633-303
11 May 2016
11
REFERENCES
Drucker, D. J. & Yusta, B. 2014. Physiology and pharmacology of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 
2015. Predictors of Enteral Autonomy in Children with Intestinal Failure: A Multicenter 
Cohort Study. J Pediatr, 167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like 
peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol 
Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy, K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs-Lasky, M. & Belle, S. H. 
2012. Natural history of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin 
Gastroenterol, 47, 602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon-like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr 
Gastroenterol Nutr, 58, 694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL 
Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes,
2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg,
39, 690-5.
For non-commercial use only

Shire
CONFIDENTIAL
Page 78
Protocol SHP633-303
11 May 2016
12
APPENDICES
For non-commercial use only

Shire
CONFIDENTIAL
Page 79
Protocol SHP633-303
11 May 2016
APPENDIX 1
GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 

Growth trajectory, including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)

Other clinical evaluations

Normal serum electrolytes

Stable blood urea nitrogen /creatinine levels

Decrease in stool frequency or volume, including mixed output

Stool consistency (ie, Bristol Stool Scale)

Urine specific gravity

General consideration to possible clinical deterioration in SBS

Inability to maintain weight and growth velocity

Diarrhea (≥10 bowel movements per day, ≥80 mL/kg/day from an ostomy, or 
≥75 mL/kg/day mixed output)

Colic/vomiting frequency increased

Electrolyte changes or imbalance

Skin breakdown 

Adjustments should be based on the actual nutritional support in volume and calories 
the subject infuses. Subjects should remain compliant with the nutritional support 
prescription in volume and calories during the study.

Nutritional support constituents may be adjusted at the discretion of the investigator.

During the 48-hour Intake/Output measurement period prior to the subject’s scheduled 
visit, no further changes to the prescribed nutritional support should be made.

If there is a change in EN or other food or fluid intake, the investigator should consider 
this when adjusting the PS/EN support in volume and calories.
For non-commercial use only

Shire
CONFIDENTIAL
Page 80
Protocol SHP633-303
11 May 2016
Figure A-1
Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 81
Protocol SHP633-303
11 May 2016
Figure A-2
Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 82
Protocol SHP633-303
11 May 2016
Figure A-3
Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only

300 Shire Way 
Lexington 
MA 
02421 
USA 
www.shire.com 
MEMORANDUM 
To: 
Cc: 
From: 
Investigator 
Study Coordinator 
, MD, PhD 
 
Global Clinical Development 
Date: 
25 Aug 2016 
 
 
Global Clinical Operations 
Re: 
Protocol SHP633-303 - Protocol Administrative Change Memo #1 
This memorandum clarifies administrative changes made to protocol SHP633-303 dated 11 May 2016. 
The change and rationale are reflected below: 
Change: Remove the collection of all actual and prescribed enteral nutrition data 
Sections finpacted by change: Synopsis; Table 1-2; Table 1-3; Table 1-4; Section 3.1.3; Section 7.1.2; 
Section 7.1.3; Section 7.1.4.1; Section 7.1.4.2; Section 7.1.4.3; Section 7.1.4.4; Section 7.1.5.2; 
Section 7.2.2.9 
Rationale: To reduce the burden on the subjects and investigators. Enteral nutrition data is not required, 
as the efficacy endpoints are limited to parenteral support parameters. 
Change: Remove the collection of urine sodium and urine osmolality 
Sections impacted by change: Synopsis; Table 1-2; Table 1-3; Table 1-4; Table 7-1; Section 7.1.3; 
Section 7.1 .4.1; Section 7.1 .4.2; Section 7.1 .4.3; Section 7.1 .4.4; Section 7.1.5.2; Section 9.8.1 
Rationale: To reduce the burden on subjects and investigators. These tests are not needed to monitor 
hydration status. 
This administrative change does not impact the ccnduct of the study. This change will be documented in a 
subsequent amendment to the protocol. In the meantime, please· submit this memo to your IRB notifying 
them of this change and file this memo in your study file records. Please incorporate these changes once 
you have IRB approvaL 
If you have further questions, please do not hesitate to contact your Quintiles CRA or Shire directly. 
Thank you, 
 
Global Clinical Development 
cc: SHP633-303 CTMF Main Study File 
 
 
Global Clinical Operations 
For non-commercial use only

PROTOCOL: SHP633-303
TITLE:
A Retrospective and Prospective, Open-label, Long-term Safety and 
Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED-C13-003
DRUG:
Teduglutide
IND:
IND# 058213
EUDRACT NO.:
2016-000863-17
SPONSOR:
Shire Human Genetic Therapies, Inc.
300 Shire Way, Lexington, MA 02421 USA
PROTOCOL 
HISTORY:
Amendment 1: 22 Nov 2016
Original Protocol: 11 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only

Page2 
Version 2 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Shire) Approval 
Signature: 
, 
 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
Date: 
 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-003 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
Shire
CONFIDENTIAL
Page 2
Protocol SHP633-303
Version 2 / 22 Nov 2016
For non-commercial use only

Shire
CONFIDENTIAL
Page 3
Protocol SHP633-303
Version 2 / 22 Nov 2016
SUMMARY OF CHANGES FROM PREVIOUS VERSION
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Title of the Shire medical monitor has been changed to Medical Director 
for clarity.
Protocol Signature Page
Emergency Contact Information
Clarification has been made that during the no-teduglutide treatment
period, visits will take place approximately every 12 weeks.
Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3-1
The study design flow chart has been edited for clarity.
Synopsis
Figure 3-1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.
Synopsis
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.2, 7.1.3, 7.1.4.1, 
7.1.4.2, 7.1.6, 7.2.2.11, 7.2.2.12
Exclusion criterion 11 has been revised to add Smoflipid as other
experimental drugs that are allowed prior and during the study. Like 
glutamine and Omegaven, Smoflipid is not expected to interfere with the 
assessments of safety and efficacy of teduglutide and many subjects may 
already be receiving the treatments off-label as part of standard medical 
therapy.  
Synopsis
Section 4.5
Exclusion criterion 12 and prohibited treatment have been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to 3 months for consistency with other teduglutide studies.
Synopsis
Section 4.5
Table 5-1
Retrospective data collection has been removed from the duration of the 
study for clarity.
Synopsis
Language in efficacy and safety endpoints has been clarified.
Synopsis
Sections 9.7.1, 9.8.1
Instructions on recording retrospective data for teduglutide and PS usage, 
and growth parameters have been refined.
Table 1-1
Sections 7.1.1, 7.2.1.2, 7.2.1.3
Completion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.
Table 1-2, Table 1-3, Table 1-4
Sections 7.1.2, 7.1.4.1, 7.1.4.2,  
7.1.6, 7.2.2.12
The requirement for urine specimen collection has been revised so that a
lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects wearing diapers).
Table 1-2, Table 1-3, Table 1-4
Section 7.2.2.5
Clarification has been made that the first no-teduglutide treatment visit 
after the screening visit will occur within 2 to 12 weeks of the screening 
(formerly within 12 weeks of screening). 
Synopsis
Table 1-3
Sections 3.1.3, 7.1.2
Windows have been clarified for visits during the no-teduglutide and 
teduglutide treatment periods.
Table 1-3, Table 1-4
Section 7.1.3
For non-commercial use only

Shire
CONFIDENTIAL
Page 4
Protocol SHP633-303
Version 2 / 22 Nov 2016
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. By definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise
considered negative.
Table 1-3
Sections 7.2.2.8, 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol.
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.3, 7.2.2.10
Removal of former footnote j on fecal occult blood test for clarity.
Table 1-4
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit. 
Table 1-4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects with 
SBS has been clarified, and text on intestinal adaptation has been refined.
Section 1.1
Status of current teduglutide approvals for use has been updated.
Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced with ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency with other 
studies.
Synopsis
Sections 3.1, 3.1.3
Evaluations to be performed when a subject discontinues teduglutide or
when withdraws from the study have been clarified.
Sections 4.8.1, 4.8.2
Withdrawal by parent/guardian has been added as reason for 
discontinuation.
Section 4.8.3
COUMADIN has been changed to warfarin for clarity.
Sections 5.1, 5.1.2
Clarification has been made on handling of study drug, which is for 
single use only and should be used within 3 hours following 
reconstitution.  
Section 6.3.3
The investigator or designee may now dispense the unused study drug 
vials to the same subject if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study drug
has been clarified.
Section 6.4
Paragraph on the purpose of prospective data collection has been deleted 
for clarity.
Section 7.2.2
Clarification has been made on the collection of medical history and SBS 
history.
Synopsis
Sections 3.1.3, 7.1.2, 7.2.2.1
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. 
Section 7.2.2.3
Clarification has been made that local laboratory results are not required 
to be entered in the eCRFs. (formerly Section 7.2.2.4)
Section 7.2.2.5
Collection of urine sodium and urine osmolality has been removed.
Section 7.2.2.5
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow-up period escape 
criterion. (formerly Section 7.2.2.5)
Section 7.2.2.6
Nutritional support and diaries (formerly in Section 7.2.2.9) have been 
Sections 7.2.2.11, 7.2.2.12
For non-commercial use only

Shire
CONFIDENTIAL
Page 5
Protocol SHP633-303
Version 2 / 22 Nov 2016
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
moved under separate sections (Sections 7.2.2.11 and 7.2.2.12,
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be reviewed at each clinic and telephone 
visit.
Performance of dipstick specific gravity tests by the subject at home on 
the first urine produced after the daily infusions of PS has been removed. 
It is now at the discretion of the investigator for all subjects, not just 
those in diapers. This change is to align with standard medical practice.
Section 7.2.2.12
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related) to teduglutide need 
to be reported. No changes to the protocol were made for the reporting of 
all AEs of special interest or any serious adverse events, regardless of 
relationship to teduglutide, that occurred during the retrospective period.
Section 8.1
The timeframe for collecting and reporting AESIs and SAEs occurring 
during the retrospective period of the study has been clarified.
Sections 8.2.2, 8.2.4, 8.3
Minor clarifications have been made to the language on dose 
interruption.
Sections 8.4, 8.4.1
Unscheduled safety follow up assessments (including visits conducted 
after EOS) are not to be recorded. However, clarification has been made 
that they are to be collected where requested.
Section 9.1
Clarification has been made that the interim analysis will be conducted
on all retrospective data, and other interim analyses may also be 
conducted if needed.
Section 9.4
The protocol now refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.
Section 9.4
Minor corrections have been made to the guidelines for nutritional 
support management during the study.
Appendix 2
See Appendix 1 for protocol history, including all amendments.
For non-commercial use only

Shire
CONFIDENTIAL
Page 6
Protocol SHP633-303
Version 2 / 22 Nov 2016
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required by Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e-mail address can be found on the form 
(sent under separate cover). A copy of this form must also be sent to the Shire Medical Monitor 
by fax or e-mail using the details below.
, MD PhD
Email: 
Fax:
For protocol- or safety-related issues during normal business hours (9 am to 5 pm Eastern 
Standard Time), the investigator must contact the Shire Medical Monitor:
, MD PhD, 
Phone: 
Mobile: 
Email: 
Fax: 
For protocol- or safety-related issues outside of normal business hours, the investigator 
must contact Quintiles Medical Support:
, MD, 
Phone: 
 (medical emergencies – United States)
Phone: 
 (medical emergencies – Global)
Email: 
r 
n-commercial use only

Shire
CONFIDENTIAL
Page 7
Protocol SHP633-303
Version 2 / 22 Nov 2016
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints to Shire within 
24 hours. This includes any instances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint
E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire (USA) 
For non-commercial use only

Shire
CONFIDENTIAL
Page 8
Protocol SHP633-303
Version 2 / 22 Nov 2016
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSION........................................................3
EMERGENCY CONTACT INFORMATION................................................................................6
PRODUCT QUALITY COMPLAINTS..........................................................................................7
LIST OF TABLES.........................................................................................................................13
LIST OF FIGURES .......................................................................................................................13
LIST OF APPENDICES................................................................................................................13
ABBREVIATIONS .......................................................................................................................14
STUDY SYNOPSIS ......................................................................................................................16
STUDY SCHEDULES..................................................................................................................22
1
BACKGROUND INFORMATION.......................................................................................28
1.1
Indication and Current Treatment Options...............................................................28
1.2
Product Background.................................................................................................28
2
STUDY OBJECTIVES AND PURPOSE ..............................................................................30
2.1
Rationale for the Study.............................................................................................30
2.2
Study Objectives ......................................................................................................30
2.2.1
Primary Objectives.................................................................................................30
2.2.2
Secondary Objectives.............................................................................................30
3
STUDY DESIGN ...................................................................................................................31
3.1
Study Design and Flow Chart ..................................................................................31
3.1.1
Informed Consent/Assent and Eligibility...............................................................32
3.1.2
Retrospective Data Collection ...............................................................................32
3.1.3
Prospective Data Collection and Treatment ..........................................................33
3.2
Duration and Study Completion Definition .............................................................34
4
STUDY POPULATION.........................................................................................................36
4.1
Study Inclusion Eligibility Criteria ..........................................................................36
4.2
Study Exclusion Eligibility Criteria .........................................................................36
4.3
Teduglutide Eligibility Criteria ................................................................................36
4.4
Teduglutide Treatment Inclusion Criteria................................................................36
4.5
Teduglutide Treatment Exclusion Criteria...............................................................37
4.6
Follow-up Period Escape Criteria ............................................................................38
4.7
Reproductive Potential .............................................................................................38
4.7.1
Female Contraception............................................................................................38
4.8
Discontinuation of Subjects .....................................................................................39
4.8.1
Teduglutide Discontinuation..................................................................................39
4.8.2
Study Withdrawal ..................................................................................................39
For non-commercial use only

Shire
CONFIDENTIAL
Page 9
Protocol SHP633-303
Version 2 / 22 Nov 2016
4.8.3
Reasons for Discontinuation..................................................................................39
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit ..................40
5
CONCOMITANT TREATMENT..........................................................................................41
5.1
Concomitant Medications and GI Procedures..........................................................41
5.1.1
Permitted Treatment...............................................................................................41
5.1.2
Prohibited Treatment .............................................................................................41
6
INVESTIGATIONAL PRODUCT ........................................................................................42
6.1
Identity of Investigational Product...........................................................................42
6.1.1
Blinding the Treatment Assignment......................................................................42
6.2
Administration of Investigational Product(s)...........................................................42
6.2.1
Interactive Response Technology for Investigational Product Management ........42
6.2.2
Allocation of Subjects to Treatment ......................................................................42
6.2.3
Dosing....................................................................................................................42
6.2.4
Unblinding the Treatment Assignment..................................................................43
6.3
Labeling, Packaging, Storage, and Handling ...........................................................43
6.3.1
Labeling .................................................................................................................43
6.3.2
Packaging...............................................................................................................43
6.3.3
Storage and Handling.............................................................................................44
6.4
Drug Accountability.................................................................................................44
6.5
Subject Compliance..................................................................................................45
7
STUDY PROCEDURES........................................................................................................46
7.1
Study Schedule.........................................................................................................46
7.1.1
Retrospective Data Collection ...............................................................................46
7.1.2
Screening................................................................................................................47
7.1.3
Visits for Subjects Not Receiving Teduglutide .....................................................48
7.1.4
Visits for Subjects Receiving Teduglutide Treatment...........................................48
7.1.4.1
Pretreatment Visit...................................................................................48
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24).....................................49
7.1.5
Teduglutide Follow-up Period...............................................................................51
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit).................................51
7.2
Study Evaluations and Procedures ...........................................................................52
7.2.1
Retrospective Data Collection ...............................................................................52
7.2.1.1
Growth (Height, Weight, and Head Circumference) .............................52
7.2.1.2
Prior Teduglutide Treatment Prescribed ................................................52
7.2.1.3
Parenteral Support Prescribed ................................................................52
7.2.1.4
Adverse Events.......................................................................................53
7.2.2
Prospective Data Collection...................................................................................53
7.2.2.1
Demographics, Medical History, and SBS History................................53
For non-commercial use only

Shire
CONFIDENTIAL
Page 10
Protocol SHP633-303
Version 2 / 22 Nov 2016
7.2.2.2
Physical Examination.............................................................................53
7.2.2.3
Adverse Event Collection.......................................................................53
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body 
Mass Index (BMI) ..................................................................................53
7.2.2.5
Clinical Laboratory Tests.......................................................................54
7.2.2.6
Serum Sampling.....................................................................................56
7.2.2.7
Pregnancy Testing..................................................................................56
7.2.2.8
Antibody Testing....................................................................................56
7.2.2.9
Volume of Blood....................................................................................56
7.2.2.10
Gastrointestinal-specific Testing............................................................57
7.2.2.11
Nutritional Support.................................................................................58
7.2.2.12
Diaries ....................................................................................................58
7.2.2.13
Health-related Quality of Life Assessments...........................................59
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................62
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................62
8.1.1
Severity Categorization..........................................................................................63
8.1.2
Relationship Categorization...................................................................................63
8.1.3
Outcome Categorization ........................................................................................64
8.1.4
Symptoms of the Disease under Study ..................................................................64
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)..................................................................................................64
8.1.6
Pregnancy...............................................................................................................65
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)..................................................................................................66
8.2
Serious Adverse Event Procedures ..........................................................................66
8.2.1
Reference Safety Information................................................................................66
8.2.2
Reporting Procedures.............................................................................................67
8.2.3
Serious Adverse Event Definition .........................................................................67
8.2.4
Serious Adverse Event Collection Time Frame.....................................................68
8.2.5
Serious Adverse Event Onset and Resolution Dates .............................................68
8.2.6
Fatal Outcome........................................................................................................68
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting................................................................................................................69
8.3
Adverse Events of Special Interest...........................................................................69
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only).........................................................................................................................69
8.4.1
Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only).........................................70
For non-commercial use only

Shire
CONFIDENTIAL
Page 11
Protocol SHP633-303
Version 2 / 22 Nov 2016
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury (Prospective 
Period of Observation Only)..................................................................................72
8.5
Early Termination of the Clinical Study (Prospective Period of Observation 
Only).........................................................................................................................73
9
DATA MANAGEMENT AND STATISTICAL METHODS...............................................74
9.1
Data Collection.........................................................................................................74
9.2
Clinical Data Management.......................................................................................74
9.3
Statistical Analysis Process......................................................................................74
9.4
Planned Interim Analysis, and Data Monitoring Committee...................................74
9.5
Sample Size Calculation and Power Considerations................................................75
9.6
Study Population ......................................................................................................75
9.7
Efficacy Analyses.....................................................................................................75
9.7.1
Efficacy Endpoints.................................................................................................75
9.8
Safety Analyses........................................................................................................75
9.8.1
Safety Endpoints....................................................................................................76
9.9
Other Analyses .........................................................................................................77
9.9.1
Health-related Quality of Life Analyses................................................................77
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES...........................................78
10.1
Sponsor’s Responsibilities .......................................................................................78
10.1.1 Good Clinical Practice Compliance.......................................................................78
10.1.2 Indemnity/Liability and Insurance.........................................................................78
10.1.3 Public Posting of Study Information......................................................................78
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees........................78
10.1.5 Study Suspension, Termination, and Completion..................................................79
10.2
Investigator’s Responsibilities .................................................................................79
10.2.1 Good Clinical Practice Compliance.......................................................................79
10.2.2 Protocol Adherence and Investigator Agreement..................................................79
10.2.3 Documentation and Retention of Records.............................................................80
10.2.3.1
Case Report Forms.................................................................................80
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents..............................................................................................80
10.2.3.3
Audit/Inspection.....................................................................................81
10.2.3.4
Financial Disclosure...............................................................................81
10.3
Ethical Considerations..............................................................................................81
10.3.1 Informed Consent...................................................................................................81
10.3.2 Institutional Review Board or Ethics Committee..................................................82
10.4
Privacy and Confidentiality......................................................................................82
10.5
Study Results / Publication Policy ...........................................................................83
For non-commercial use only

Shire
CONFIDENTIAL
Page 12
Protocol SHP633-303
Version 2 / 22 Nov 2016
11 REFERENCES .......................................................................................................................85
12 APPENDICES ........................................................................................................................86
For non-commercial use only

Shire
CONFIDENTIAL
Page 13
Protocol SHP633-303
Version 2 / 22 Nov 2016
LIST OF TABLES
Table 1-1:
Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................22
Table 1-2:
Schedule of Events for Screening and End of Study or Early 
Termination ...................................................................................................23
Table 1-3:
Schedule of Events for No Teduglutide Treatment Period ...........................24
Table 1-4:
Schedule of Events for Teduglutide Treatment Period .................................25
Table 5-1: 
Prohibited Treatment.....................................................................................41
Table 7-1:
List of Laboratory Tests ................................................................................55
Table 7-2:
Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................57
Table 7-3:
Developmentally Appropriate PedsQL™Generic Core Scales .....................60
Table 8-1:
CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only) ................................71
LIST OF FIGURES
Figure 3-1:
Study Design Flow Chart ..............................................................................34
LIST OF APPENDICES
Appendix 1
Protocol History.............................................................................................87
Appendix 2
Guidelines for Nutritional Support Management During the Study .............88
For non-commercial use only

Shire
CONFIDENTIAL
Page 14
Protocol SHP633-303
Version 2 / 22 Nov 2016
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
-HCG
beta-human chorionic gonadotropin
BMI
body mass index
CRA
clinical research associate
CRO
contract research organization
CSR
clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
drug-induced livery injury
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase 4
EC
ethics committee
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EN
enteral nutrition
EOS
end of study
EOT
end of treatment
ET
early termination
EU
European Union
FDA
Food and Drug Administration
FOBT
fecal occult blood test
FOCBP
female of child-bearing potential
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide 1
GLP-2
glucagon-like peptide 2
HIPAA
Health Insurance Portability and Accountability Act
ICF
informed consent form
ICH
International Conference on Harmonization
IGF-1
insulin-like growth factor 1
IRB
institutional review board
IV
intravenous
For non-commercial use only

Shire
CONFIDENTIAL
Page 15
Protocol SHP633-303
Version 2 / 22 Nov 2016
IWRS
interactive web-based response system
MedDRA
Medical Dictionary for Regulatory Activities
NCI
National Cancer Institute
NDA
new drug application
NTT
no-teduglutide treatment
PDA
patent ductus arteriosus
PedsQL
Pediatric Quality of Life Inventory
PS
parenteral support
PT/INR
prothrombin time/international normalized ratio
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SBS
short bowel syndrome
SC
subcutaneous
SOC
standard of care
t1/2
elimination half-life
TESAE
treatment-emergent serious adverse event
UK
United Kingdom
ULN
upper limit of normal
US
United States
WHO-DD
World Health Organization-Drug Dictionary
For non-commercial use only

Shire
CONFIDENTIAL
Page 16
Protocol SHP633-303
Version 2 / 22 Nov 2016
STUDY SYNOPSIS
Protocol number: SHP633-303
Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003
Number of subjects (total and for each treatment arm):
Approximately 40 subjects who completed the TED-C13-003 study, including subjects in the standard of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED-C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the United States (US) and the United Kingdom (UK) will participate in 
this extension study.
Study period (planned):
October 2016-September 2019
Clinical phase:
3 Extension
Objectives:
Primary: To evaluate the long-term safety and tolerability of teduglutide treatment in pediatric subjects with short 
bowel syndrome (SBS) who completed TED-C13-003.
Secondary: To evaluate long-term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED-C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED-C13-003 study. In addition to 
evaluating the long-term safety and durability of efficacy after 12 weeks of treatment in TED-C13-003, this 
extension study will evaluate the need for additional teduglutide treatment in these subjects, and will allow for the 
first-time treatment of teduglutide-naïve subjects who participated in the standard of care (SOC) treatment arm in 
TED-C13-003.
Investigational product, dose, and mode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED-C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of 
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
between the date of the TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only

Shire
CONFIDENTIAL
Page 17
Protocol SHP633-303
Version 2 / 22 Nov 2016
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and Section 7.1.1. For subjects 
that only consent to retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were completed in the course 
of the subject’s standard medical care between the date of the TED-C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after
informed consent/assent is obtained for this study. The following retrospective data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide treatment

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1-2. These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. Prescription parenteral support requirements will be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS)
volume and hours per day (Section 7.2.2.12). Diary data for PS volume will be collected for at least 2 weeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no-teduglutide treatment [NTT] period), will be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed immediately to the pretreatment visit if 
the investigator, subject, and parent or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4-week follow-up (no treatment) period (Figure 3-1). During 
the 28-week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 weeks. To maintain 
consistency across centers, all attempts should be made to follow the nutritional support adjustment guidelines 
(developed with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only

Shire
CONFIDENTIAL
Page 18
Protocol SHP633-303
Version 2 / 22 Nov 2016
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 
1 week after adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects 
discontinue teduglutide at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be 
performed weekly (solid grey lines). If an escape criterion is met during the follow-up period, subjects may proceed directly 
to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet all of the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.
Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study-related procedures.
2.
Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
3.
Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria, and none of the 
teduglutide treatment exclusion criteria, are met. In addition, the investigator and the subject (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria:
1.
Subject is teduglutide-naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by the investigator. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.
Subject was previously treated with teduglutide and at least 1 of the following criteria is satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b.
Decreased PS requirement during prior teduglutide treatment, followed by cessation of 
improvement after teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 19
Protocol SHP633-303
Version 2 / 22 Nov 2016
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition following teduglutide discontinuation
d.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.
Body weight <10 kg at the pretreatment visit
2.
Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.
History of cancer in the previous 5 years except surgically curative skin cancers
4.
Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10 cm, and endoscopic procedures are allowed.
5.
Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6.
Clinically significant intestinal stricture or obstruction
7.
Clinically significant, active or recurrent pancreatic or biliary disease
8.
Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b.
Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9.
Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects 
who had undergone ventricular or atrial septal defect repair, or patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, or 
Smoflipid) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the 
pretreatment visit and for the duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) (not 
including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, within 3 months
preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior to the 
pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related 
compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16. Pregnant or lactating female subjects
17. Sexually active female subjects of child-bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the subject at any 
undue risk, prevents completion of the study, or interferes with analysis of the study results
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow-up period may be interrupted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.
Increasing PS requirements following teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 20
Protocol SHP633-303
Version 2 / 22 Nov 2016
2.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated enteral 
nutrition following teduglutide discontinuation
3.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake 
following teduglutide discontinuation
4.
Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvement in the study:
A subject will be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple 28-week treatment cycles. The study will continue for at least 1 year, and until each 
subject has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately 3 years. A subject will be considered as having completed the study if the subject has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.

Planned duration of no-teduglutide treatment periods: variable, depending on disease course

Planned duration of the teduglutide pretreatment visit: 1-21 days

Planned teduglutide treatment cycle duration: 28 weeks. Each cycle consists of 24 weeks of 
teduglutide treatment followed by a 4-week follow-up period (no treatment)
Endpoints and statistical analysis:

The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
Health Economics and Outcomes Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an 
additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:
o
Food and drink limits
o
Diarrhea
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide
For non-commercial use only

Shire
CONFIDENTIAL
Page 21
Protocol SHP633-303
Version 2 / 22 Nov 2016

Gastrointestinal-specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) to the beginning of 
the prospective study period:

Adverse events related to teduglutide

All SAEs

All Adverse Events of Special Interest (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study (TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compiled for classification of 
qualitative safety data.
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by enrollment in TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 22
Protocol SHP633-303
Version 2 / 22 Nov 2016
STUDY SCHEDULES
Table 1-1: Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment
Note
Informed consent/assent
Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study-
related procedures, including retrospective data collection.
Study eligibility
Weighta
The last representative value for weight during each 12-week interval 
throughout the retrospective data collection period will be captured.
Height and head circumferencea
The last representative value for height during each 12-week interval 
throughout the retrospective data collection period will be captured. Head 
circumference should be provided for subjects 36 months of age and younger 
at the time the data were collected, if available.
Prior teduglutide treatment
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, 
compassionate use, and named-patient access programs.
Parenteral support (PS) 
prescribeda
The last representative PS prescription during each 12-week interval 
throughout the retrospective period and at the beginning and end of any 
teduglutide treatment will be collected. Data collected should include weekly 
prescribed volume, calories, average hours per day, and days per week of 
prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED-C13-003
Teduglutide-related AEs
Teduglutide-related AEs must be deemed by the investigator to be related to 
teduglutide treatment.
AEs of special interest
Serious adverse events (SAEs)
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED-C13-003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data 
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a The first 12-week interval begins at TED-C13-003 EOS visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 23
Protocol SHP633-303
Version 2 / 22 Nov 2016
Table 1-2: Schedule of Events for Screening and End of Study or Early Termination
Screening
End of Study or Early 
Termination
Visit Type
Site
Site
Informed consent/assent
X
Study eligibility
X
Demographics, medical history, SBS historya
X
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriab
X
Adverse events
X
X
Concomitant medications and GI proceduresc
X
X
Physical examination and vital signs, including weight
X
X
Height and head circumferenced
X
X
Review intake and output diariese
X
Record PS prescription and adjust as neededf
X
X
Safety laboratory testsg
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-Scales
X
Antibodies to teduglutideh
X
Fecal occult blood testingi
(X)
Colonoscopy or sigmoidoscopyj
(X)
Pregnancy testingk
(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
a If the subject has any changes to the medical history and SBS history that had been collected at the baseline of the TED-C13-
003 study, then the updated medical history and SBS history will be collected.
b Subjects who meet ≥1 teduglutide treatment inclusion criteria may proceed to the pre-treatment visit if the investigator, subject, 
and parent or legal guardian agrees to proceed with teduglutide therapy (Table 1-4).
c Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
d Head circumference will be measured in subjects 36 months of age and younger.
e The intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48-hour period of nutritional stability before the EOS/ET visit.
f Parenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after 
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix 2.
g Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
h Required for all teduglutide-exposed subjects.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 48-
60 weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no-teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section 7.2.2.10 for details.
k Pregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 24
Protocol SHP633-303
Version 2 / 22 Nov 2016
Table 1-3: Schedule of Events for No Teduglutide Treatment Period
Visit Number
NTx
Visit Type
Site
Visit Frequencya
Every 12 weeks
Window (days)b
±7
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriac
X
Adverse events
X
Concomitant medications and GI proceduresd
X
Physical examination and vital signs, including weight
X
Height and head circumferencee
X
Review intake and output diariesf
X
Record PS prescription and adjust as neededg
X
Safety laboratory testsh
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-Scales
X
Antibodies to teduglutidei
(X)
Fecal occult blood testingj
Annually
Colonoscopy or sigmoidoscopyk
(X)
Serum samplel
Every 24 weeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
a The first NTx visit after the screening visit must occur within 2 to 12 weeks of screening.
b Window is relative to the first NTx visit in the current no-teduglutide treatment period.
c Subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed to the pre-treatment visit if the investigator, subject, 
and parent or legal guardian agree to proceed with teduglutide therapy (Table 1-4).
d Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
e Head circumference will be measured in subjects 36 months of age and younger.
f Intake diaries will collect actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section 7.2.2.10 for more detail.
g Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix 2.
h Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
iSubjects who have been treated previously and test positive for teduglutide antibodies should have follow-up samples collected 
every 12 weeks during the study until a negative result is obtained.
jFecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
k The need for colonoscopy/sigmoidoscopy in response to a positive fecal occult blood test during a no-teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy/sigmoidoscopy at 5-year intervals or more often as needed. See Section 7.2.2.10 for 
details.
l Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 25
Protocol SHP633-303
Version 2 / 22 Nov 2016
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Px
Cx
D1
Cx
W1
Cx
W2
Phone contact is required approximately 1 week after PS adjustment
Cx
W4
Phone contact is required approximately 1 week after PS adjustment
Cx 
W6
Phone contact is required approximately 1 week after PS adjustment
Cx 
W9
Phone contact is required approximately 1 week after PS adjustment
Cx 
W12
Phone contact is required approximately 1 week after PS adjustment
Cx 
W16
Phone contact is required approximately 1 week after PS adjustment
Cx 
W20
Phone contact is required approximately 1 week after PS adjustment
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28b
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phonea
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window (days)c
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteria
X
Xd
Dispense intake 
and output diaries
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant 
medications and 
GI
procedurese
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examination and 
vital signs, 
including weight
X
X
X
X
X
X
X
X
X
X
X
X
Height and head 
circumferencef
X
X
X
X
Review intake 
and output 
diariesg
X
X
X
X
X
X
X
X
X
X
X
X
X
Record PS Rx 
and adjust as 
neededh
X
X
X
X
X
X
X
X
X
X
X
X
X
Safety laboratory 
testsi
Xi
X
X
X
X
X
X
X
X
X
X
(X)
X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms 
Module Sub-
X
X
X
For non-commercial use only

Shire
CONFIDENTIAL
Page 26
Protocol SHP633-303
Version 2 / 22 Nov 2016
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Scales
Antibodies to 
teduglutidej
X
X
X
X
Fecal occult 
blood testing
X
X
X
Colonoscopy/
Sigmoidoscopyk
(X)
(X)
(X)
Pregnancy 
testingl
X
X
X
X
X
X
X
X
X
Serum samplem
X
X
Evaluate escape 
criterian
X
X
Dispense study 
drugo
X
X
X
X
X
X
X
X
X
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing 
potential; FU=follow-up; GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio;
SBS=short bowel syndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
a Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria).
b The investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within 7 days of the CxW28 visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-2) will take place in lieu of the CxW28 visit.
c Visit windows are relative to the CxD1 visit.
d Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
e Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and associated pathology results.
f Head circumference will be measured in subjects 36 months of age and younger.
g Intake diaries will collect actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except 
at pretreatment visit), for 1 week following PS adjustment, and daily during the 4-week follow-up period. Urine and stool output should be recorded in the output diary over a 48-
hour period of nutritional stability before every clinic visit, and within 1 week of implementing a change in the PS prescription. See Section 7.2.2.12 for more detail.
h Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment 
provided in Appendix 2.
i Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed by a central laboratory. Clinical chemistry and 
urinalysis must also be performed within approximately 5-7 days of any adjustment to the PS prescription. Safety labs performed between clinic visits may be performed locally. 
Unscheduled lab results will not be captured in the eCRFs. If abnormal results are considered an adverse event, an AE form will be completed. Collect PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug-induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviation.
jSamples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
For non-commercial use only

Shire
CONFIDENTIAL
Page 27
Protocol SHP633-303
Version 2 / 22 Nov 2016
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
k The teduglutide-naïve subjects age 12 and older will undergo colonoscopy/sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy/sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy/sigmoidoscopy will be performed. The need for colonoscopy/sigmoidoscopy in response to positive FOBT results at 
CxW12 is at the discretion of the investigator. Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will 
undergo colonoscopy/sigmoidoscopy. See Section 7.2.2.10 for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all other visits according to the study 
schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.
n If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See 
Section 6.2.3 for dose adjustment.
For non-commercial use only

Shire
CONFIDENTIAL
Page 28
Protocol SHP633-303
Version 2/ 22 Nov 2016
1
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options
Short bowel syndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. It is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with SBS (Khan et al. 
2015; Wales et al. 2004). Unlike the adult population, the majority of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy. 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 years of the initial diagnosis (Khan et al. 2015). 
Nevertheless, despite optimal medical management, many pediatric subjects remain dependent 
on PS. Complications of long-term PS include liver disease, catheter-related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality of life is poor (Squires et al. 
2012). Accelerating the adaptive process and achieving enteral autonomy is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al. 2015; Squires et al. 2012).
Intestinal adaptation is driven by hormonal cues in response to nutrient malabsorption (Drucker 
and Yusta 2014). Chief among these is hormones glucagon-like peptide 2 (GLP-2), which is 
secreted from L-type enteroendocrine cells that reside in the intestinal epithelium in the ileum 
and colon. Resection of these regions may impair the adaptive response by limiting endogenous 
production of GLP-2.
1.2
Product Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP-2 that regulates 
the functional and structural integrity of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33-amino acid peptide that differs from native GLP-2 in the substitution of 
glycine for alanine at the second position at the N-terminus. As a result, teduglutide demonstrates 
resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and therefore maintains a longer 
elimination half-life (t1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t1/2 of approximately 7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and crypt depth in the intestinal 
epithelium, thereby increasing the absorptive surface area of the intestines (Tappenden et al. 
2013; Thymann et al. 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (REVESTIVE™) on 30 
August 2012 and a New Drug Application (NDA) for teduglutide (GATTEX®) was approved by 
the United States (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 29
Protocol SHP633-303
Version 2/ 22 Nov 2016
European Commission granted an extension of the Market Authorization for teduglutide 
(REVESTIVE™) for the treatment of patients aged 1 year and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric subjects
One Phase 3 study, TED-C13-003, was completed in pediatric SBS subjects in the US and 
United Kingdom (UK). In this study, teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1-17. Thirty-seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for 12 weeks. Five additional pediatric subjects were enrolled in an 
observational standard of care (SOC) cohort. There were clear dose-dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day doses compared to SOC and the 0.0125 
mg/kg/day dose. In the 0.025 mg/kg/day cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in 1 subject, and a reduction of 
3.94 hours per day infusion time. In the 0.05 mg/kg/day cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day infusion time. Teduglutide was generally safe and well 
tolerated by pediatric subjects in all dosing cohorts. There were no deaths during the study and 
no treatment-emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study were due to adverse events (AEs).
TED-C14-006 is an ongoing study which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a 2-week minimum 
screening period, a 24-week treatment period, and a 4-week follow-up period. During the 
screening period, subjects will choose into which arm to enroll. During the 24-week treatment 
period, subjects in the SOC treatment arm will receive standard medical therapy for SBS; while 
those in the teduglutide treatment arm will receive daily subcutaneous (SC) injections of 
teduglutide (study drug) in addition to standard medical therapy. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double-blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day of teduglutide administered subcutaneously for 
24 weeks.
Always refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy and safety of teduglutide (SHP633).
For non-commercial use only

Shire
CONFIDENTIAL
Page 30
Protocol SHP633-303
Version 2/ 22 Nov 2016
2
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to 
evaluate the safety and efficacy of teduglutide in pediatric subjects with SBS who completed the 
TED-C13-003 study. In addition to evaluating the long-term safety and durability of efficacy 
after 12 weeks of treatment in TED-C13-003, this extension study will evaluate the need for 
additional teduglutide treatment in these subjects, and will allow for the first-time treatment of 
teduglutide-naïve subjects who participated in the SOC treatment arm in TED-C13-003.
2.2
Study Objectives
2.2.1
Primary Objectives
The primary objective of the study is to evaluate the long-term safety and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED-C13-003.
2.2.2
Secondary Objectives
The secondary objective of this study is to evaluate the long-term efficacy of teduglutide 
treatment in pediatric subjects with SBS who completed TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 31
Protocol SHP633-303
Version 2/ 22 Nov 2016
3
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects who completed the TED-C13-003 study (the core 
study). At the time of entry into the TED-C13-003 study, subjects were less than 18 years of age, 
were dependent on parenteral nutrition to provide at least 30% of their caloric or fluid needs, and 
had not been able to significantly reduce PS for at least 3 months prior to enrollment. During the 
core study, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day, 0.025 mg/kg/day, or 0.05 mg/kg/day dose cohort based on the timing of their 
enrollment in the study. The cohorts were filled in a sequential manner.
Approximately 40 subjects who completed the core study are expected to enroll in this extension 
study. Subjects who previously received teduglutide during the core study, as well as subjects 
who were in the SOC treatment group, may be eligible to receive teduglutide treatment in this 
extension study. To be eligible for treatment with teduglutide in this extension study, subjects 
must meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately every 12 weeks for safety, parenteral support (PS) requirements, and 
quality of life. At any point during an NTT period, subjects who meet ≥1 teduglutide treatment 
inclusion criteria may proceed directly to the pretreatment visit if the investigator, subject, and 
parent or legal guardian agrees to proceed with teduglutide therapy.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long-term follow-up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analysis suggested that pediatric patients, ages 1-17 years-old, are likely to require the same 
dose as used in adults, namely 0.05 mg/kg/day (Mouksassi et al. 2009). In this extension study to 
TED-C13-003, repeat doses of teduglutide 0.05 mg/kg/day will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed 12-week pediatric study (TED-C13-
003) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
For non-commercial use only

Shire
CONFIDENTIAL
Page 32
Protocol SHP633-303
Version 2/ 22 Nov 2016
studies as well as the pediatric (core) study (TED-C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults (O'Keefe et al. 2006).
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED-C14-006 study, 
consisting of 24 weeks of teduglutide treatment, followed by a 4-week follow-up period. The 
follow-up period is a mechanism to evaluate whether continued teduglutide is needed. If a 
subject deteriorates during the follow-up period, the subject may be evaluated immediately for 
additional teduglutide treatment. Subjects who clinically deteriorate or stop improving at any 
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED-C13-003 and TED-C14-006, to ensure sufficient safety monitoring and 
weaning of PS. During the NTT period, visits occur every 12 weeks, a frequency that is 
consistent with standard medical practices.
Measures and Parameters
To evaluate efficacy and safety from the time subjects completed the core study to the time they 
enter this extension study, retrospective data collection is planned for this study. The 
retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. In addition to this retrospective data 
collection, prospective study assessments of safety and efficacy will be completed as a part of 
this study.
3.1.1
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be 
completed before any other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study; however subjects may 
consent to retrospective data collection only. Subjects may not consent to the prospective data 
collection only. After informed consent/assent is obtained, study eligibility will be assessed for 
all subjects.
3.1.2
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and 
Section 7.1.1. For subjects that only consent to retrospective data collection, these procedures are 
all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study. Retrospective data collection may begin any time after informed consent/assent is 
obtained for this study. The following data will be collected:
For non-commercial use only

Shire
CONFIDENTIAL
Page 33
Protocol SHP633-303
Version 2/ 22 Nov 2016

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
3.1.3
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history and short bowel syndrome history. Prescription parenteral support 
requirements will be collected at screening. Additionally, intake diaries will be dispensed at the 
screening visit for collection of actual PS volume and hours per day (Section 7.2.2.12). Diary 
data for PS volume will be collected for at least 2 weeks after the ICF (and if applicable, the 
informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately 
every 12 weeks for safety, PS requirements, and quality of life. Diary data for PS volume will be 
collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including 
during an NTT period, subjects who meet ≥1 teduglutide treatment inclusion criteria, may 
proceed immediately to the pretreatment visit if the investigator, subject, and parent or legal 
guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28-week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily, followed by a 
4-week follow-up (no treatment) period (Figure 3-1). During the 28-week cycle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality of life assessments will be made approximately every 
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation (Appendix 2).
Rationale: Measures of long-term safety will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
For non-commercial use only

Shire
CONFIDENTIAL
Page 34
Protocol SHP633-303
Version 2/ 22 Nov 2016
by reduction in PS and improvement in pediatric quality of life measures (Pediatric Quality of 
Life Inventory [PedsQL], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pivotal Phase 3 adult 
clinical trials and the completed Phase 3 pediatric study (TED-C13-003), and will be used as an 
endpoint in this extension study. In previous clinical studies, a reduction of this magnitude was 
associated with a reduction in the number of days per week of PS, and increases in enteral 
intake. Reduction in volume and time of PS due to improved enteral absorption may provide a 
pediatric subject with opportunities for more age-appropriate activities including oral 
rehabilitation. Quality of life assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI-specific screening tests,
including fecal occult blood testing and colonoscopy/sigmoidoscopy, which are commonly part 
of the routine care of these subjects, will be performed to ensure safety. This study captures long-
term safety data on polyps and other colonic mucosal changes in teduglutide-exposed subjects 
using the surveillance strategy proposed in Section 7.2.2.10.
Figure 3-1:
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide 
at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey 
lines). If an escape criterion is met during the follow-up period, subjects may proceed directly to another pretreatment visit.
3.2
Duration and Study Completion Definition
A subject will be considered enrolled in the study once the subject has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility 
Criteria. The study will continue for at least 1 year, and until each subject has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
3 years. The study will be completed in approximately 40 months. A subject will be considered 
as having completed the study if the subject has not withdrawn early from the study for any 
reason prior to completing the EOS visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 35
Protocol SHP633-303
Version 2/ 22 Nov 2016
The study completion date is defined as the date the final subject, across all sites, completes their 
final protocol-defined assessment. Please note that this includes the follow-up visit or contact 
(last safety contact), whichever is later. The study completion date will be used to ascertain 
timing for study results posting and reporting.
For non-commercial use only

Shire
CONFIDENTIAL
Page 36
Protocol SHP633-303
Version 2/ 22 Nov 2016
4
STUDY POPULATION
Each subject and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any study-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility does not impact study eligibility.
4.1
Study Inclusion Eligibility Criteria
The subject will not be considered eligible for the study without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing any 
study-related procedures. 
2. Subject completed the TED-C13-003 study (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully adhere to study requirements as 
defined in this protocol.
4.2
Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study.
4.3
Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria
and none of the teduglutide treatment exclusion criteria are met. In addition, the investigator and 
the subject (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.4
Teduglutide Treatment Inclusion Criteria
1. Subject is teduglutide-naïve, receiving PS, and unable to significantly reduce PS or 
advance enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 
3 months prior to and during the teduglutide pretreatment visit, as assessed by the 
investigator. Transient instability for events such as interruption of central access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2. Subject was previously treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b. Decreased PS requirement during prior teduglutide treatment, followed by 
cessation of improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite 
maximal tolerated enteral nutrition following teduglutide discontinuation
d. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid 
and electrolyte intake following teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 37
Protocol SHP633-303
Version 2/ 22 Nov 2016
e.
Severe diarrhea related to teduglutide discontinuation
4.5
Teduglutide Treatment Exclusion Criteria
1. Body weight <10 kg at the pretreatment visit
2. Unresected GI polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3. History of cancer in the previous 5 years except surgically curative skin cancers
4. Serial transverse enteroplasty or other major intestinal surgery within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5. Intestinal or other major surgery planned or scheduled to occur during the 28-week 
cycle
6. Clinically significant intestinal stricture or obstruction
7. Clinically significant, active or recurrent pancreatic or biliary disease
8. Active, severe, or unstable, clinically significant hepatic impairment or injury, 
including the following laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9. Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) 
below 50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the 
exception of subjects who had undergone ventricular or atrial septal defect repair, or 
patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine,
Omegaven, or Smoflipid) within 3 months or 5.5 half-lives of the experimental drug, 
whichever is longer, prior to the pretreatment visit and for the duration of the 28-week 
cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 
(GLP-2) (not including teduglutide), insulin-like growth factor-1 (IGF-1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months 
prior to the pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, 
closely-related compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
For non-commercial use only

Shire
CONFIDENTIAL
Page 38
Protocol SHP633-303
Version 2/ 22 Nov 2016
17. Sexually active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 days after the treatment period 
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts 
the subject at any undue risk, prevents completion of the study, or interferes with 
analysis of the study results
4.6
Follow-up Period Escape Criteria
At the discretion of the investigator, the follow-up period may be interrupted and the subject may 
proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1. Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal 
tolerated enteral nutrition following teduglutide discontinuation
3. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and 
electrolyte intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
4.7
Reproductive Potential
4.7.1
Female Contraception
To be eligible for treatment with teduglutide, sexually active females of child-bearing potential 
must use an acceptable form of contraception throughout the study period and for 30 days 
following the last dose of investigational product. If hormonal contraceptives are used, they 
should be administered according to the package insert. Females of child-bearing potential who 
are not currently sexually active must agree to use acceptable contraception, as defined below, if 
they become sexually active during the period of the study and 30 days following the last dose of 
investigational product. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:

Premenarchal and either Tanner Stage 1 or less than age 9 years, or

Females of child-bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin (-HCG) pregnancy test at the teduglutide pretreatment visit. Females of 
child-bearing potential must agree to abstain from sexual activity that could result in 
pregnancy or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:

Abstinence

Intrauterine devices plus condoms

Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
For non-commercial use only

Shire
CONFIDENTIAL
Page 39
Protocol SHP633-303
Version 2/ 22 Nov 2016

Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 days prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually active during the study, they should use 1 of the other acceptable methods noted 
above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
4.8
Discontinuation of Subjects 
4.8.1
Teduglutide Discontinuation
If the investigational product is discontinued prematurely during a teduglutide treatment cycle
and the subject wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow-up period will ensue, consisting of weekly telephone visits 
(CxW25-27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility according to the study 
schedules. 
Comments (spontaneous or elicited) or complaints made by the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.3. The investigator is encouraged to discuss withdrawal of a subject 
from investigational product with the medical monitor, when possible.
4.8.2
Study Withdrawal
At any time during the study, the investigator or sponsor may withdraw a subject, or a subject 
may withdraw from the study, for any reason, without prejudice to their future medical care by 
the physician or at the institution.
If a subject withdraws from the study during a teduglutide cycle, the evaluations listed for the 
EOT visit are to be performed as completely as possible. Whenever possible, the subject will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contacted 
weekly by phone during the interim period between EOT and ET for safety follow-up.
If a subject withdraws from the study during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completely as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3
Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study must 
be determined by the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than 1 reason, each reason should be documented in the source 
document, and the most clinically relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:

Adverse event
For non-commercial use only

Shire
CONFIDENTIAL
Page 40
Protocol SHP633-303
Version 2/ 22 Nov 2016

Protocol deviation

Lack of efficacy

Physician decision

Withdrawal by subject

Withdrawal by parent/guardian

Lost to follow-up

Pregnancy (Discontinuation of treatment only)

Death

Other
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations, and return any unused investigational product.
For non-commercial use only

Shire
CONFIDENTIAL
Page 41
Protocol SHP633-303
Version 2/ 22 Nov 2016
5
CONCOMITANT TREATMENT
5.1
Concomitant Medications and GI Procedures
Concomitant treatment will be collected for the prospective period only and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this
study. Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medication changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may increase absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, and digoxin). Accordingly, due consideration should be given to 
modifying concomitant medication regimens. Down-titration of concomitant medications should 
be considered when drugs, especially those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.1
Permitted Treatment
Standard medical therapy for SBS should be continued.
5.1.2
Prohibited Treatment
The mechanism of action of teduglutide may increase enteral absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, digoxin), so consideration should be given to modifying 
concomitant enteral medication regimens. Down-titration of concomitant enteral medications 
should be considered when drugs, especially those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy
Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon-like peptide-2 (not-including teduglutide)
Any
Glucagon-like peptide-1 analog or human growth hormone
3 months
Octreotide or dipeptidyl peptidase 4 inhibitors
3 months
Biological therapy (eg, antitumor necrosis factor)
6 months
For non-commercial use only

Shire
CONFIDENTIAL
Page 42
Protocol SHP633-303
Version 2/ 22 Nov 2016
6
INVESTIGATIONAL PRODUCT
6.1
Identity of Investigational Product
The test product is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L-histidine, mannitol, monobasic sodium 
phosphate monohydrate, and dibasic sodium phosphate as excipients. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.1
Blinding the Treatment Assignment
Not applicable for this open-label study.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology for Investigational Product Management
An interactive web-based response system (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory management and supply ordering, investigational product expiration tracking and 
management, and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The IWRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.2
Allocation of Subjects to Treatment
This is an open-label study. Subjects will retain their assigned subject number from the 
TED-C13-003 study. Assessment of need for teduglutide treatment should be guided by the 
teduglutide treatment inclusion criteria. If the investigator, subject, and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit (Table 1-4).
6.2.3
Dosing
If teduglutide treatment eligibility is established at the pretreatment visit and again, confirmed at 
the CxD1 visit, the subject will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered by SC injection once daily (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than 3 hours 
later.
For non-commercial use only

Shire
CONFIDENTIAL
Page 43
Protocol SHP633-303
Version 2/ 22 Nov 2016
The subject should be dosed at approximately the same time each day. Consecutive doses should 
be separated by at least 12 hours. Each day, the injection site should be rotated.
The first SC injection in teduglutide-naïve subjects should be administered under the supervision 
of the investigator or designee and the subject observed for hypersensitivity reactions for at least 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the Instructions for Use. 
Following each 24-week teduglutide treatment period, subjects will enter a 4-week follow-up 
period. During the follow-up, the investigator will assess the subject via weekly telephone visits. 
At any time during the follow-up period, if escape criteria are met, the subject may proceed 
directly to another Pretreatment visit to assess treatment eligibility for another cycle 
(Section 4.6). Following the completion of the 4-week follow-up, the subject will continue in the 
study off teduglutide. Additional 28-week cycles may be repeated if treatment eligibility is 
established each time. 
6.2.4
Unblinding the Treatment Assignment
Not applicable for this open-label study.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification will be applied to the investigational 
product(s) container.
The study drug will be packaged, labeled, and shipped to the study site by the sponsor or 
designee. Kits containing 7 vials of study drug will be supplied and these will be labeled in 
accordance with applicable regulatory requirements. Sterile water for injection syringes will also 
be provided separately and will be labeled in accordance with the applicable regulatory 
requirements.
All study drug used in this study will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2
Packaging
Teduglutide will be provided in a 3 mL sterile, single-use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL) will be provided in a prefilled syringe.
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the sponsor.
For non-commercial use only

Shire
CONFIDENTIAL
Page 44
Protocol SHP633-303
Version 2/ 22 Nov 2016
6.3.3
Storage and Handling
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Limited responsibility may be delegated to the pharmacy or 
member of the study team, but this delegation must be documented.
Study drug must be kept in a locked area with access restricted to specific study personnel. Study 
drug will be stored refrigerated at a temperature between 2-8°C (35.6-46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2-25°C, or 35.6-77°F). Parent/legal guardian 
will be instructed to keep the subject’s study drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study drug may be refrigerated. The study drug is for single use only, and should be used within 
3 hours following reconstitution.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed by the pharmacy or nominated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed number of subjects. The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. The 
investigator is to keep a current record of the inventory and dispensation of all clinical supplies. 
This record will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any discrepancy or deficiency will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any unauthorized situation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 45
Protocol SHP633-303
Version 2/ 22 Nov 2016
The investigator has overall responsibility for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study protocol. All dispensed 
study medication will be documented in the interactive response technology system and/or other 
investigational product record (eg, investigation product accountability form). The investigator is 
responsible for assuring the retrieval of all study supplies from subjects.
All used and unused study drug vials must be returned by the subjects and/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unused study drug vials to the same subject. All original containers, whether empty 
or containing study drug will be returned to the pharmacy. Returned study drugs will NOT be 
relabeled or reassigned for use by other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may be destroyed on site without approval by the sponsor.
Please see the Pharmacy Manual for additional information.
6.5
Subject Compliance
Subjects will be instructed to bring their unused investigational product and empty/used 
investigational product packaging to every visit. Drug accountability will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper-evident sealed container (eg, bottles, trays, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 46
Protocol SHP633-303
Version 2/ 22 Nov 2016
7
STUDY PROCEDURES
7.1
Study Schedule
Detailed study procedures and assessments to be performed for subjects throughout the study are 
outlined in the Schedule of Assessments (Table 1-1, Table 1-2, Table 1-3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing any study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject (Table 1-1).
7.1.1
Retrospective Data Collection
Retrospective data are defined as specific safety and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. Retrospective PS and growth data will be 
captured in 12-week intervals, with the first 12-week interval beginning at the TED-C13-003
EOS visit. All available retrospective data should be captured in the corresponding eCRFs. 
Failure to collect retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent only to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study:

Informed consent, and informed assent (if applicable)

Study eligibility is determined
o
A screen failure is a subject who has given informed consent and failed to meet 
the study inclusion eligibility criteria. Subjects cannot be rescreened once they 
have been designated as a screen failure.

Prior teduglutide use (as prescribed)
o
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, compassionate 
use, and named-patient access programs.
o
Collect start and end dates when a subject’s teduglutide use was interrupted. 

Parenteral support (as prescribed)
o
The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide treatment 
will be collected. Usually, the prescription at the end of the interval will represent
the status of intestinal adaptation. However, transient alterations in PS related to 
loss of central venous access or acute illness are not representative of intestinal 
adaptation. When such events occur at the end of a 12-week interval, earlier, more 
representative PS prescription data should be recorded.
For non-commercial use only

Shire
CONFIDENTIAL
Page 47
Protocol SHP633-303
Version 2/ 22 Nov 2016
Data collected should include weekly prescribed volume, calories, average hours 
per day, and days per week of prescribed PS. Hours per day should be averaged 
over the days where PS is prescribed.

Growth (height, head circumference, and weight)
o
The last representative value for height, during each 12-week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and younger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.

Adverse events
o
All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study. The details of data collection and safety reporting for these events 
can be found in Section 8.
o
End dates for AEs ongoing at the end of TED-C13-003 will be collected.
7.1.2
Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:

Informed consent, and informed assent (if applicable)

Study eligibility is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study inclusion eligibility criteria. Subjects cannot be 
rescreened once they have been designated as a screen failure.

Demographics, updates to medical history and SBS history

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Record PS prescription and adjust as needed
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 48
Protocol SHP633-303
Version 2/ 22 Nov 2016
7.1.3
Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide-treatment cycle, subjects will be followed 
approximately every 12 weeks for safety and efficacy assessments. No-teduglutide treatment 
visits are numbered sequentially (NT1, NT2, etc.), even if interrupted by the treatment cycles. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period.
Assessments will be performed as outlined in Table 1-3 and described below.

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS  prescription and adjust as needed

Safety laboratory tests (ie, clinical chemistry, hematology, and urinalysis)

PedsQL Generic Core Scale/PedsQL Family Impact Module/ PedsQL 
Gastrointestinal Symptoms Module Sub-Scales

Antibodies to teduglutide, if and when required

Fecal occult blood testing, as indicated (see Section 7.2.2.10)

Colonoscopy/sigmoidoscopy, as indicated (see Section 7.2.2.10)

Serum sample, as indicated
Teduglutide treatment may be considered at any time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may proceed to the pretreatment visit immediately to determine 
eligibility. 
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
7.1.4.1
Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may proceed to the pretreatment visit immediately. Similarly, 
subjects who meet escape criteria during the teduglutide follow-up period may proceed to the 
pretreatment visit immediately.
In general, pretreatment assessments may occur over a period of up to 21 days. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:

Evaluate teduglutide eligibility (treatment inclusion/exclusion criteria)

Dispense intake and output diaries
For non-commercial use only

Shire
CONFIDENTIAL
Page 49
Protocol SHP633-303
Version 2/ 22 Nov 2016

Adverse events, concomitant medications, and concomitant GI procedures

Fecal occult blood testing

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy as 
indicated

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries 

Record PS prescription and adjust as needed.

Safety laboratory tests
(In addition to clinical chemistry, hematology, and urinalysis, labs at this visit
include prothrombin time [PT] international normalized ratio [INR]. 
Subsequent prothrombin time/international normalized ratio (PT/INR) 
measurement is only required to evaluate for suspected drug-induced liver 
injury [DILI]).

Pregnancy testing (serum)

Serum sample
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24)
The open-label teduglutide treatment period will comprise 24 weeks, during which all 
assessments and procedures listed for Visits CxD1-CxW24 in Table 1-4 shall be completed. 
Cycles are numbered sequentially, such that the first visit of the first cycle is C1D1, and the first 
visit of the second cycle is C2D1, etc. Visit windows are calculated relative to the date of first 
investigational product administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1-4 and as described 
below:
Two weeks of intake diary data are required before drug is administered at CxD1.

Confirm teduglutide treatment eligibility

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests
For non-commercial use only

Shire
CONFIDENTIAL
Page 50
Protocol SHP633-303
Version 2/ 22 Nov 2016

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing (urine)

Dispense study drug
SITE VISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects will return for clinic visits on cycle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:

Dispense and review intake and output diaries (every effort should be made to 
complete 2 weeks of intake diary entries prior to each clinic visit and to 
complete 48 hours of output diary entries during a period of nutritional stability
prior to each clinic visit)

Physical examination and vital signs, including weight

Record PS prescription and adjust as needed

Safety laboratory tests

Urine pregnancy testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, 
CxW24)

Study drug dispensation (except for CxW24)

Adverse events, concomitant medications and concomitant GI procedures
In addition, at CxW12 and CxW24 Visits ONLY, the following procedures will be performed:

Height and head circumference

Antibodies to teduglutide

Fecal occult blood testing (FOBT)

GI-specific testing, including colonoscopy or sigmoidoscopy as indicated

Quality of life measurements
At CxW24 ONLY, a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
PHONE VISITS
Phone visits are required approximately 1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-4 and described 
below:

Review intake and output diaries
For non-commercial use only

Shire
CONFIDENTIAL
Page 51
Protocol SHP633-303
Version 2/ 22 Nov 2016

Safety laboratory tests (clinical chemistry and urinalysis)

Record PS prescription and adjust as needed

Obtain AEs, concomitant medications, and concomitant GI procedures

Evaluate escape criteria
7.1.5
Teduglutide Follow-up Period
The safety follow-up period for this protocol is 4 weeks (Weeks 25-28 of the cycle). Phone visits 
will occur on cycle Weeks 25, 26, and 27 for all subjects. Phone visit assessments and 
procedures at Weeks 25-27 will be the same as for telephone visits performed during the 
teduglutide treatment period. In addition, subjects will be evaluated for follow-up period escape 
criteria. If escape criteria are met at any time during the follow-up period, the subject may 
proceed directly to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pretreatment assessments occur within 7 days of the CxW28 
visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Section 7.1.6) 
will take place in lieu of the CxW28 visit. Otherwise, following completion of the 28-week 
treatment cycle, the subject will proceed to an NTT visit within approximately 12 weeks.
At Cycle Week 28 (CxW28), subjects will return to the study site. In addition to the assessments 
performed at Weeks 25-27, the following procedures will be performed at CxW28 only:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Antibodies to teduglutide

Pregnancy testing (urine)

Evaluate escape criteria
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study site for the end of study/early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-2 and as 
described here. If a subject discontinues the study prematurely, the assessments for the EOS/ET 
visit are to be performed as completely as possible (see Section 4.8.2).

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference
For non-commercial use only

Shire
CONFIDENTIAL
Page 52
Protocol SHP633-303
Version 2/ 22 Nov 2016

Review intake and output diaries (the intake diary should be completed daily 
for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should 
be completed daily over a 48-hour period of nutritional stability before the 
EOS/ET visit)

Record PS prescription and adjust as needed

Safety laboratory tests

Fecal occult blood testing, as indicated

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy, as 
indicated

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing, as needed
7.2
Study Evaluations and Procedures
7.2.1
Retrospective Data Collection
Retrospective data are being collected to evaluate the safety, tolerability, and efficacy of 
teduglutide during the interval between a subject's completion of the TED-C13-003 study and the 
date the ICF (and if applicable, assent) is signed for the SHP633-303 study.
7.2.1.1
Growth (Height, Weight, and Head Circumference)
Retrospective body height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z-score, weight z-score, body mass index (BMI), and BMI z-score will be calculated by 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analysis plan (SAP).
7.2.1.2
Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency will be 
recorded on the appropriate eCRF page.
7.2.1.3
Parenteral Support Prescribed
Retrospective parenteral support entries consist of 1 prescription per 12-week interval during the 
retrospective period. If the subject has multiple PS prescriptions in a 12-week interval, the last 
representative prescription from the interval should be used (see Section 7.1.1). In addition, PS 
prescriptions at the beginning and end of any retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekly volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
For non-commercial use only

Shire
CONFIDENTIAL
Page 53
Protocol SHP633-303
Version 2/ 22 Nov 2016
7.2.1.4
Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESIs) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide, 
that occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safety reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED-C13-003 will be collected.
7.2.2
Prospective Data Collection
7.2.2.1
Demographics, Medical History, and SBS History
Demographics, updates to medical history, and updates to SBS history will be obtained at 
screening. Medical history for purposes of this extension study will consist of updates to the 
medical history collected at the start of the TED-C13-003 core study. If the subject has any 
changes to the SBS history since the baseline visit of the TED-C13-003 study, that information 
(updated SBS history) will also be collected.
7.2.2.2
Physical Examination
Physical examinations will be performed according to the study schedules. Any new clinically 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF.
7.2.2.3
Adverse Event Collection
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body temperature 
(°C/°F). Blood pressure should be determined by cuff (using the same method, the same arm, 
and in the same position throughout the study).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each study visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z-score, weight z-score, BMI, and BMI z-score will be 
calculated by the sponsor using the site-provided height and weight data collected at each site 
visit.
New clinically significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
For non-commercial use only

Shire
CONFIDENTIAL
Page 54
Protocol SHP633-303
Version 2/ 22 Nov 2016
7.2.2.5
Clinical Laboratory Tests
Safety laboratory tests to be performed at site visits consist of clinical chemistry, hematology, 
and urinalysis and will be performed as outlined in the study plan (Table 1-2, Table 1-3, and 
Table 1-4). Scheduled laboratory testing will be processed by a central lab. All laboratory assays 
will be performed according to the central laboratory’s normal procedures. Reference ranges are 
to be supplied by the laboratory. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Abnormal clinical laboratory values, which are unexpected or not 
explained by the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safety labs within approximately 
5-7 days after a PS adjustment. Safety labs performed after PS adjustment and between site visits 
will consist of clinical chemistry and urinalysis and may be processed by the central laboratory 
or a local laboratory. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate any new clinically significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safety labs, but lack of urinalysis will not constitute a protocol deviation.
New clinically significant labs should be reported as AEs.
The following clinical laboratory assessments will be performed according to the study 
schedules:
For non-commercial use only

Shire
CONFIDENTIAL
Page 55
Protocol SHP633-303
Version 2/ 22 Nov 2016
Table 7-1: List of Laboratory Tests 
Hematology:

Hematocrit

Hemoglobin

Platelet count

Red blood cell count

Red blood cell morphology, if needed

White blood cell count with differential
Coagulation:
Prothrombin time/International normalized ratio
Urinalysis:

Blood

Glucose

Leukocytes

Microscopic analysis

pH

Protein

Specific gravity
Pregnancy tests (females of childbearing potential):

Serum β-HCG (screening)

Urine β-HCG (all other visits)
Biochemistry:

Albumin

Alkaline phosphatase

Alanine aminotransferase

Amylase

Aspartate aminotransferase

Bicarbonate

Bilirubin (total and indirect)

Blood urea nitrogen

Calcium (total)

Chloride

Cholesterol

C-reactive protein

Creatinine

Estimated Glomerular Filtration Rate
(Schwartz formula)

Gamma-glutamyl transferase

Glucose

Lipase

Magnesium

Phosphorus

Potassium

Sodium

Triglycerides

Uric acid
For non-commercial use only

Shire
CONFIDENTIAL
Page 56
Protocol SHP633-303
Version 2/ 22 Nov 2016
7.2.2.6
Serum Sampling
Serum samples will be collected and stored for future analysis at the following times:

At the pretreatment visit. If the subject met a follow-up period escape criterion, 
the serum sample will not be collected at the pretreatment visit

At the CxW24 (EOT) visit

During NTT: Approximately every 24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and any specialty laboratories will be 
blinded to the subject’s identity. The sample and/or extracted material will otherwise be stored 
for up to 15 years from the end of the study after which time it will be destroyed. Upon written 
request, subjects will be permitted to withdraw their sample from the analysis and have their 
sample and/or extracted material destroyed. Any results already generated from the samples will 
not be removed from any analyses that have already been performed.
7.2.2.7
Pregnancy Testing
A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy tests will be administered at all other visits according to the study schedules, or if 
pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the 
study.
7.2.2.8
Antibody Testing
Blood samples will be drawn for the analysis of antibodies to teduglutide according to the 
Schedule of Assessments (Table 1-2, Table 1-3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least 14 hours after dosing. Subjects who test 
positive for antibodies to teduglutide will also be tested for neutralizing antibody. Subjects who 
have been previously treated with teduglutide, and who test positive for antibodies to 
teduglutide, will have follow-up blood draws for antibodies to teduglutide every 12 weeks while 
on study until a negative result is obtained.
7.2.2.9
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study. The volumes of blood to be drawn from each subject will vary depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annually are shown 
in Table 7-2.
For non-commercial use only

Shire
CONFIDENTIAL
Page 57
Protocol SHP633-303
Version 2/ 22 Nov 2016
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
Assessment
Sample 
Volume (mL)
No. Samples per two 28-week 
Teduglutide Cycles
Total 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety
Biochemistry and -hCGa
2.5
24
60
Hematology
2
24
48
Coagulation Parameters
1
2
2
Antibodies
2
8
16
Serum storage samples
3
4
12
Total mL per 2, 28-week Treatment Cycles (Approximate Annual Volume):
138
Subjects Not Receiving Teduglutide Treatmentb
Assessment
Sample 
Volume (mL)
No. Samples per 4 NTT Visits
Total 
Volume (mL)
Safety
Biochemistry
2.5
4
10
Hematology
2
4
8
Serum storage samples
3
2
6
Total mL per 4 “No Teduglutide Treatment” Visits 48-week period:
24
β-hCG=beta-human chorionic gonadotropin; NTT=no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
b Subjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti-teduglutide 
antibodies will require blood samples for antibody testing every 12 weeks until they test negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by the manufacturer or laboratory 
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they require the same type of tube, the assessments should be combined. Blood 
volume estimates do not include safety labs performed after PS adjustment, and anti-teduglutide 
antibody testing during no-teduglutide treatment.
7.2.2.10
Gastrointestinal-specific Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week 24 of the teduglutide cycle. During NTT periods, FOBT must be performed on 
teduglutide-exposed subjects (subjects who have received teduglutide any time in the past and 
are therefore not teduglutide-naïve) on a roughly annual basis (approximately every 48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY OR SIGMOIDOSCOPY
Teduglutide-naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pretreatment visit if one has not been performed within 1 year.
Subjects of any age with newly positive FOBT results at the pretreatment visit for which a 
readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy or 
sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a 
readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
For non-commercial use only

Shire
CONFIDENTIAL
Page 58
Protocol SHP633-303
Version 2/ 22 Nov 2016
colonoscopy or sigmoidoscopy in response to positive FOBTs at any other point during the 
study, or to reevaluate persistently positive FOBTs is at the discretion of the investigator.
Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks 
of study drug exposure) will undergo colonoscopy or sigmoidoscopy. While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 year intervals or 
more often as needed.
Upper endoscopy may be performed along with any colonoscopy or sigmoidoscopy at the 
investigator’s discretion. If a polyp is found, adherence to current polyp follow-up guidelines is 
recommended. Subjects with unresected GI polyps, polyposis conditions, premalignant change 
or malignancy in the GI tract will be excluded from teduglutide treatment.
7.2.2.11
Nutritional Support
Nutritional support includes PS, enteral nutrition, and other food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety laboratory results. Intake and output diaries will include data to be 
considered in the adjustment of each subject’s nutritional support. Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2.
7.2.2.12
Diaries
STUDY DRUG ADMINISTRATION DIARY
A study drug administration diary will record administration of teduglutide. This diary should be 
completed by the subject (or parent/legally authorized representative, as applicable) daily during 
the teduglutide treatment period (between visits CxD1 and CxW24).
INTAKE DIARY
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary 
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week teduglutide treatment period, the intake diary will also be completed for 1 week 
following PS adjustments. The intake diary will also be completed daily during the 4-week 
follow-up period. The following data will be captured in the intake diaries:

Parenteral support volume and infusion duration

Site personnel will determine the actual PS daily calories based on diary entries
OUTPUT DIARY
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional 
stability before every clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cycle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:

Toilet-trained subjects (who do not wear diapers)
Measure and record all urine output in mL or cc
For non-commercial use only

Shire
CONFIDENTIAL
Page 59
Protocol SHP633-303
Version 2/ 22 Nov 2016

Nontoilet-trained subjects (who wear diapers)
Measure and record the weight of all urine-only diapers. Urine volume will be 
calculated using the following formula: 1 g (scale weight) = 1 mL or 1 cc

At the discretion of the investigator, the parent or legal guardian may be asked 
to collect the first void after the daily PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):

Toilet-trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool 
consistency using the Bristol Stool Form Scale (see Output diary)

Nontoilet-trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed 
urine and stool) as stool output and score the stool consistency using the Bristol 
Stool Form Scale (see Output diary). Stool volume will be calculated using the 
formula: 1 g (scale weight)=1 mL or 1 cc
All ostomy output volume should be recorded. Ostomy output will not be scored using the 
Bristol scale.
All available diary data will be reviewed by the investigator or their designee at each clinic and 
telephone visit to assess clinical status and opportunity for PS reduction and advance in feeds.
7.2.2.13
Health-related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes less than 4 minutes to 
complete. The scales include self-reports for pediatric subjects and adolescents aged 5 to 
18 years and proxy-reports from parents of pediatric subjects aged 2 to 18 years.
Field trials have shown that the internal consistency reliability of the PedsQL was excellent, with 
alphas for the generic core scales in both self- and proxy-report greater than the 0.70 standard, 
and alphas for the full 23-item scale approaching 0.90 for self- and proxy-report. Missing data 
were minimal. Item response distributions were across the full scale range, with no floor effects, 
and minimal ceiling effects.
The validity of the PedsQL Generic Core Scales was demonstrated through known group 
comparisons, and correlations with other measures of disease burden. The PedsQL self- and 
proxy-report distinguished between pediatric subjects with and without a chronic health 
condition, and within the group of pediatric subjects with a chronic condition, between those 
who did or did not have an overnight hospital visit in the last 12 months. Further, both child 
self-report and parent proxy-report correlated significantly with the number of days the child was 
too ill to pursue normal activities, needed someone to care for him or her, missed school in the 
last month, the number of days the parent missed from work in the last month, and parent-report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
For non-commercial use only

Shire
CONFIDENTIAL
Page 60
Protocol SHP633-303
Version 2/ 22 Nov 2016
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (PEDSQL™), ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health-related quality of life (HRQoL) 
in pediatric subjects and adolescents (2-18 years of age). The developmentally appropriate 
PedsQL Generic Core Scale will be completed by either the parent or legal guardian and subject 
as indicated in Table 7-3 at the time points as outlined in Table 1-2, Table 1-3, and Table 1-4.
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report
Completed by
Parent Report for Toddlers (ages 2-4)
Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Young Pediatric subjects 
(ages 5-7)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Pediatric subjects 
(ages 8-12)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Teens (ages 13-18)
Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2-4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8-12), and Teens (ages 13-18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Family Impact Module is a parent-report multidimensional instrument that will be 
completed by the parent or legal guardian, as outlined in Table 1-2, Table 1-3, and Table 1-4.
The PedsQL Family Impact Module is a specific module of the PedsQL that is used to measure 
the impact of pediatric chronic health conditions on parents and the family (Varni et al. 2004). 
The 36-item PedsQL Family Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry (5 items). Two additional scales measure parent-
reported family functioning as follows: 1) Daily Activities (3 items), and 2) Family Relationships 
(5 items). The PedsQL Family Impact Module should take the parent or legal guardian 
approximately 5-10 minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Gastrointestinal Symptom Module is a disease-specific 58-item module, comprised 
of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Symptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink Limits (6 items) and Diarrhea (7 items) were identified as 
For non-commercial use only

Shire
CONFIDENTIAL
Page 61
Protocol SHP633-303
Version 2/ 22 Nov 2016
clinically relevant and appropriate for the symptoms experienced in this pediatric study 
population, and therefore, are the only scales used in this study. The scales will be completed by 
either the parent or legal guardian and subject as indicated in Table 7-3 at the time points 
outlined in Table 1-2, Table 1-3, and Table 1-4.
For non-commercial use only

Shire
CONFIDENTIAL
Page 62
Protocol SHP633-303
Version 2/ 22 Nov 2016
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD OF OBSERVATION
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any nonserious AEs related to teduglutide that occurred during this 
time and any AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment-related event:

The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.

The event cannot be explained by the subject’s medical condition, other therapies, or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this study
in the eCRF.
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow-up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the study, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of symptoms should be 
recorded. If a diagnosis has not been made, then each symptom should be listed individually. All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. Closure indicates that an outcome is reached, stabilization achieved 
(the investigator does not expect any further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
For non-commercial use only

Shire
CONFIDENTIAL
Page 63
Protocol SHP633-303
Version 2/ 22 Nov 2016
8.1.1
Severity Categorization
The severity of all AEs must be recorded during the course of the event including the start and 
stop dates for each change in severity. An event that changes in severity should be captured as a 
new event. Worsening of pre-treatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
Note that the severity of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) grading criteria (Table 8-1).
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause-and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
The following additional guidance may be helpful:
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
For non-commercial use only

Shire
CONFIDENTIAL
Page 64
Protocol SHP633-303
Version 2/ 22 Nov 2016
Term
Relationship Definition
accident.
Not Related
The event can be readily explained by other factors such as the 
subject’s underlying medical condition, concomitant therapy, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled physical examinations must 
be reported as AEs if the investigator considers the finding to be a clinically significant change 
from the baseline.
8.1.3
Outcome Categorization
The outcome of all AEs must be recorded during the course of the study in the eCRF. Outcomes 
are as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae

Recovering/Resolving

Unknown
8.1.4
Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the disease and are part of the efficacy 
data to be collected in the study; however, significant worsening of the symptoms should be 
recorded as an AE.
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory or vital sign can represent an AE if the change is
clinically relevant or if, during the study, a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an already abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
For non-commercial use only

Shire
CONFIDENTIAL
Page 65
Protocol SHP633-303
Version 2/ 22 Nov 2016
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study, further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign is clinically significant and 
therefore represents an AE.
8.1.6
Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core study until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633-303 study until the defined follow-up 
period stated in Section 7.1.5.
Any report of pregnancy for any female study participant must be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy Report Form. A copy of the Shire 
Investigational and Marketed Products Pregnancy Report Form (and any applicable follow-up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency contact information section of the protocol. In the event a subject becomes pregnant 
after signing the ICF (and, if applicable, assent), teduglutide administration must be discontinued 
immediately.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. For pregnancy reports during the prospective period of observation, it is 
the responsibility of the investigator to obtain this information within 30 calendar days after the 
initial notification and approximately 30 calendar days post partum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633-303), the initial notification date will be the date the pregnancy is recorded for this 
study and outcome and infant condition information may be collected anytime post partum.
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire Clinical Study Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required by the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Nonserious AEs as required by the Protocol as well as the Shire Investigational and Marketed 
Products Pregnancy Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy onset date.
For non-commercial use only

Shire
CONFIDENTIAL
Page 66
Protocol SHP633-303
Version 2/ 22 Nov 2016
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse – Persistent or sporadic intentional intake of investigational product 
when used for a nonmedical purpose (eg, to alter one’s state of consciousness or 
get high) in a manner that may be detrimental to the individual and/or society

Misuse – Intentional use of investigational product other than as directed or 
indicated at any dose (Note: this includes a situation where the investigational 
product is not used as directed at the dose prescribed by the protocol)

Overdose – Administration of a dose greater than the allocated dose of the study 
medication or at a frequency greater than the dosing interval specified by the 
protocol

Medication Error – An error made in prescribing, dispensing, administration, 
and/or use of an investigational product. For studies, medication errors are 
reportable to the sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors

Medication errors should be collected/reported for all products under 
investigation

The administration and/or use of an expired investigational product should 
be considered as a reportable medication error
All investigational product provided to pediatric subjects should be supervised by the 
parent/legally-authorized representative/caregiver.
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference for safety information for this study is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
For non-commercial use only

Shire
CONFIDENTIAL
Page 67
Protocol SHP633-303
Version 2/ 22 Nov 2016
8.2.2
Reporting Procedures
All SAEs experienced during the retrospective period of observation for the protocol must be 
reported by the investigator to the Shire Global Pharmacovigilance and Risk Management 
Department and the Shire Medical Monitor within 24 hours of first awareness of the event.
All initial and follow-up SAE reports for SAEs experienced during the prospective period of 
observation must be reported by the investigator to the Shire Global Pharmacovigilance and Risk 
Management Department and the Shire Medical Monitor within 24 hours of the first awareness 
of the event. Note: The 24-hour reporting requirement for SAEs does not apply to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by the investigator to the Shire Global 
Pharmacovigilance and Risk Management Department and the Shire Medical Monitor within 24 
hours of the first awareness of the event even if the event does not fulfill seriousness criterion.
The investigator must complete, sign, and date the Shire Clinical Study Adverse Event Form for 
SAEs and Nonserious AEs as Required by Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e-mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy of the completed Shire Clinical 
Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as Required 
by Protocol (and any applicable follow-up reports) must also be sent to the Shire Medical 
Monitor or designee using the details specified in the emergency contact information section of 
the protocol.
8.2.3
Serious Adverse Event Definition
A SAE is any untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 

Results in death

Is life-threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it was more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospitalization for an elective or previously scheduled surgery that meet(s) serious 
criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity

Is a congenital abnormality/birth defect
For non-commercial use only

Shire
CONFIDENTIAL
Page 68
Protocol SHP633-303
Version 2/ 22 Nov 2016

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency or 
drug abuse.
8.2.4
Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Pharmacovigilance and Risk Management Department and the Shire Medical 
Monitor within 24 hours of first awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow-up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Pharmacovigilance and Risk Management Department and the Shire Medical Monitor 
within 24 hours of the first awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within 24 hours of the first awareness of 
the event.
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For non-commercial use only

Shire
CONFIDENTIAL
Page 69
Protocol SHP633-303
Version 2/ 22 Nov 2016
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notifying the 
relevant regulatory authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notifying active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
8.3
Adverse Events of Special Interest
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
the investigator to the sponsor is required.
The AEs of special interest that require expedited regulatory reporting include the following:

Growth of pre-existing polyps of the colon

Benign neoplasia of the GI tract including the hepatobiliary system

Tumor-promoting ability (eg, benign and/or malignant neoplasia of any kind, 
not limited to those of the GI or hepatobiliary system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within 24 hours of first awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5 apply only to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contacting the sponsor/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may include but are 
not limited to hospitalization, AEs, a lapse in investigational product delivery, etc.
Study drug must be discontinued if any of the following events occur:
For non-commercial use only

Shire
CONFIDENTIAL
Page 70
Protocol SHP633-303
Version 2/ 22 Nov 2016

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to 
be related to study drug. This does not include the presence of anti-teduglutide 
antibodies, mild injection site reactions or mild symptoms that according to the 
investigator do not pose a significant risk to the subject.

An AE listed in (Table 8-1) that is of NCI CTCAE severity Grade 3 or 4 and 
considered to be related to study drug administration

Confirmed drug-induced liver injury (DILI) related to teduglutide (see Section 
8.4.2)
8.4.1
Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only)
The investigational product may be discontinued if the subject has an AE listed in Table 8-1 that 
is of severity ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor or designee as soon as possible. Teduglutide administration must be 
discontinued if the AE is considered related to the investigational product. The length of the dose 
interruption, and whether teduglutide administration resumes or is permanently discontinued, 
depends on the clinical situation.
Investigators and the data monitoring committee (DMC) should be guided by the descriptions of 
Grade 3 and 4 events, as they relate to known and possible risks associated with the 
administration of teduglutide.
For non-commercial use only

Shire
CONFIDENTIAL
Page 71
Protocol SHP633-303
Version 2/ 22 Nov 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events
Grade 3 Description
Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps
Severe or medically significant but not 
immediately life threatening; 
hospitalization or prolongation of 
existing hospitalization indicated; 
disabling; limiting self-care activities of 
daily living
Life-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction
Hospitalization indicated; elective 
operative intervention indicated; limiting
self-care activities of daily living; 
disabling
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis
Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation
Not Applicable
Life-threatening consequences; urgent 
intervention indicated
Gallbladder obstruction
Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospitalization indicated; nonemergent 
operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection
Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicated
Life-threatening consequences; urgent 
intervention indicated
Adverse Events
Grade 3 Description
Grade 4 Description
Alkaline Phosphatase 
increased
>5.0 to 20.0x ULN
>20.0x ULN
Blood bilirubin increased
>3.0 to 10.0x ULN
>10.0x ULN
Bile duct stenosis
Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis
Severe pain; vomiting; medical 
intervention indicated (eg, analgesia, 
nutritional support)
Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis
Severely altered gastrointestinal function; 
tube feeding or hospitalization indicated; 
elective operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Pancreas infection
Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicated
Life-threatening consequences; urgent 
intervention indicated
For non-commercial use only

Shire
CONFIDENTIAL
Page 72
Protocol SHP633-303
Version 2/ 22 Nov 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events
Grade 3 Description
Grade 4 Description
Serum amylase increaseda
>2.0 to 5.0x ULN
>5.0x ULN
Lipase increaseda
>2.0 to 5.0x ULN
>5.0x ULN
Cardiovascular Disease
Heart failure
Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicated
Life-threatening consequences; urgent 
intervention indicated (eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, 14 June 2010
ULN=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may need to be interrupted if the subject has 
clinical and laboratory evidence of potential DILI, in the absence of an alternative explanation, 
as identified by the following criteria:

ALT or AST >8x ULN

ALT or AST >5x ULN and >2x baseline value for more than 2 weeks

(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN 
or INR>1.5)

ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
All laboratory values suggestive of potentially new DILI should be repeated and verified within 
3 days. International normalized ratio should be measured with this set of verification laboratory 
assessments and an inquiry should be made as to the presence of clinical symptoms consistent 
with new liver injury. The subject should be followed closely to determine the trajectory of the 
laboratory abnormalities and to evaluate the cause of liver injury. This evaluation may include, 
as clinically indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cytomegalovirus IgM, 
Epstein-Barr virus antibody panel), hepatobiliary obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti-actin, or anti-liver kidney microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
For non-commercial use only

Shire
CONFIDENTIAL
Page 73
Protocol SHP633-303
Version 2/ 22 Nov 2016
Teduglutide administration must be permanently discontinued if DILI is confirmed and deemed 
related to study drug.
8.5
Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may recommend stopping the study if:

≥2 subjects develop the same event listed in Table 8-1 of severity CTCAE 
Grade 3
or

1 subject develops an event listed in Table 8-1 of severity CTCAE Grade 4 
which is attributable to investigational product or is not reasonably related to
the underlying disease process
For non-commercial use only

Shire
CONFIDENTIAL
Page 74
Protocol SHP633-303
Version 2/ 22 Nov 2016
9
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
in the eCRF. A study monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safety follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality control and data validation procedures are applied to ensure the validity and 
accuracy of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed 
using SAS® (SAS Institute, Cary, NC, USA) version 9.3 or higher.
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4
Planned Interim Analysis, and Data Monitoring Committee
An interim analysis of all retrospective data will be conducted. Other interim analyses may also 
be conducted if needed.
A DMC will be involved in the management of this study. The DMC members will review the 
data approximately every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety data (ie, AEs, laboratory assessments, physical examinations, etc.) 
from study assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only

Shire
CONFIDENTIAL
Page 75
Protocol SHP633-303
Version 2/ 22 Nov 2016
The DMC will be an external, independent board comprised of physicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory in nature. The DMC will be governed by a 
Charter agreed to by members of the Board and the sponsor. Members of the Board may not be 
study investigators or be employed at the same institution as a study investigator, individuals 
employed by the sponsor, independent contractors hired by the sponsor, or members of 
regulatory agencies. The DMC may make recommendations to the sponsor regarding study 
aspects including stopping, modifying or continuing the study; however, the sponsor will have 
the final responsibility to determine whether the study should be modified or temporarily or 
permanently stopped.
9.5
Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects was determined by enrollment in 
TED-C13-003.
9.6
Study Population
The safety population includes all enrolled subjects in the study. The safety population will be 
used for both safety and efficacy analyses.
9.7
Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or 
first exposure to teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
9.8
Safety Analyses
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safety data as well as for the difference from baseline, if applicable. Frequency 
counts will be compiled for classification of qualitative safety data.
For non-commercial use only

Shire
CONFIDENTIAL
Page 76
Protocol SHP633-303
Version 2/ 22 Nov 2016
9.8.1
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study 
period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing including fetal occult blood testing and 
colonoscopy or sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) 
to the beginning of the prospective study period:

Adverse events related to teduglutide

All SAEs

All AESIs (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study 
(TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), 
and body mass index
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by System Organ Class and by preferred term. Serious adverse events will be further 
summarized by severity and relationship to investigational product. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization-Drug 
Dictionary (WHO-DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history (including 
surgical/procedural history) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by system organ class and preferred term. 
For clinical laboratory tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
For non-commercial use only

Shire
CONFIDENTIAL
Page 77
Protocol SHP633-303
Version 2/ 22 Nov 2016
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional safety parameters and measures will include change in body weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z-score, BMI, and BMI z-score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9
Other Analyses
9.9.1
Health-related Quality of Life Analyses
Health economics and outcomes research endpoints will be analyzed at approximately 12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study period. The beginning of 
each treatment cycle (CxD1) will be an additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:

Food and drink limits

Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 78
Protocol SHP633-303
Version 2/ 22 Nov 2016
10
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH Good Clinical Practice (GCP) Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO as necessary. 
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
For non-commercial use only

Shire
CONFIDENTIAL
Page 79
Protocol SHP633-303
Version 2/ 22 Nov 2016
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an EOS declaration to the relevant competent authority as required by
Article 10 (c) of Directive 2001/20/EC.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by the signed and dated signature of the 
principal investigator (single-site study) or coordinating principal investigator (multicenter 
study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH 
Guidance E3 (1995). 
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 80
Protocol SHP633-303
Version 2/ 22 Nov 2016
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by international regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly into the 
eCRF.
Electronic case report forms should be approved by the investigator per study specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory reports, and histology and 
pathology reports.
All key data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the eCRF 
entries against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory authorities, or the IRB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X-rays etc.). Nonstudy site personnel will not 
disclose any personal information or personal medical information.
For non-commercial use only

Shire
CONFIDENTIAL
Page 81
Protocol SHP633-303
Version 2/ 22 Nov 2016
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA, 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Agency) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory authorities), the 
European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory 
Agency, other regulatory authorities, the sponsor or its representatives, and the IRB/EC for each 
site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, where 
applicable, from all study subjects prior to any study-related procedures including screening 
assessments. All consent and assent documentation must be in accordance with applicable 
regulations and GCP. Each subject or the subject’s legally-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully executed signature pages) must be given to the subject or the 
subject’s legally-authorized representative, as applicable. This document may require translation 
into the local language. Signed consent forms must remain in each subject’s study file and must 
be available for verification at any time.
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legally-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study subject.
For non-commercial use only

Shire
CONFIDENTIAL
Page 82
Protocol SHP633-303
Version 2/ 22 Nov 2016
The principal investigator provides the sponsor with a copy of the consent form, and assent form 
where applicable, which was reviewed by the IRB/EC and which received their favorable 
opinion/approval. A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study unless it is agreed to 
and documented (abiding by regulatory guidelines and national provisions) prior to study start 
that another party (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally, if the IRB/EC requires modification of the sample subject information and 
consent document provided by the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity as defined by HIPAA must provide documentation of 
this fact to the sponsor (or designee).
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representatives 
review their medical records and data collected during the study. These records and data may, in 
For non-commercial use only

Shire
CONFIDENTIAL
Page 83
Protocol SHP633-303
Version 2/ 22 Nov 2016
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP633; national or local regulatory authorities; and the IRBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subject).
The results of studies – containing subjects’ unique identifying number, relevant medical 
records, and possibly initials and dates of birth – will be recorded. They may be transferred to, 
and used in, other countries which may not afford the same level of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities.
10.5
Study Results / Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the 
publication steering committee is to act as a noncommercial body that advises or decides on 
dissemination of scientific study data in accordance with the scope of this policy.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the
publisher and copyright law, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
For non-commercial use only

Shire
CONFIDENTIAL
Page 84
Protocol SHP633-303
Version 2/ 22 Nov 2016
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any rights to authorship of 
publications.
For non-commercial use only

Shire
CONFIDENTIAL
Page 85
Protocol SHP633-303
Version 2/ 22 Nov 2016
11
REFERENCES
Drucker, D. J. & Yusta, B. 2014. Physiology and pharmacology of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonomy in Children with Intestinal Failure: A Multicenter Cohort Study. J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 
analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy, K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs-Lasky, M. & Belle, S. H. 2012. Natural 
history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon-like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL 
Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg, 39, 690-
5.
For non-commercial use only

Shire
CONFIDENTIAL
Page 86
Protocol SHP633-303
Version 2/ 22 Nov 2016
12
APPENDICES
For non-commercial use only

Shire
CONFIDENTIAL
Page 87
Protocol SHP633-303
Version 2/ 22 Nov 2016
APPENDIX 1
PROTOCOL HISTORY
Document
Date
Global/Country/Site Specific
Original Protocol
11 May 2016
Global
Amendment 1
22 Nov 2016
Global
For non-commercial use only

Shire
CONFIDENTIAL
Page 88
Protocol SHP633-303
Version 2/ 22 Nov 2016
APPENDIX 2
GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 

Growth trajectory, including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)

Other clinical evaluations

Serum electrolytes

Blood urea nitrogen /creatinine levels

Changes in stool frequency or volume, including mixed output

Stool consistency (ie, Bristol Stool Scale)

Urine specific gravity

General consideration to possible clinical deterioration in SBS

Inability to maintain weight and growth velocity

Diarrhea (≥10 bowel movements per day, ≥80 mL/kg/day from an ostomy, or 
≥75 mL/kg/day mixed output)

Colic/vomiting frequency increased

Electrolyte changes or imbalance

Skin breakdown 

Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the study.

Nutritional support constituents may be adjusted at the discretion of the investigator.

During the 48-hour output measurement period prior to the subject’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.

If there is a change in enteral nutrition (EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only

Shire
CONFIDENTIAL
Page 89
Protocol SHP633-303
Version 2/ 22 Nov 2016
Figure A-1
Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 90
Protocol SHP633-303
Version 2/ 22 Nov 2016
Figure A-2
Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 91
Protocol SHP633-303
Version 2/ 22 Nov 2016
Figure A-3
Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only

PROTOCOL: SHP633-303
TITLE:
A Retrospective and Prospective, Open-label, Long-term Safety and 
Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED-C13-003
DRUG:
Teduglutide
IND:
IND# 058213
EUDRACT NO.:
2016-000863-17
SPONSOR:
Shire Human Genetic Therapies, Inc.
300 Shire Way, Lexington, MA 02421 USA
PROTOCOL 
HISTORY:
Amendment 1.1: 09 Jan 2017 (United Kingdom-Specific)
Amendment 1: 22 Nov 2016
Original Protocol: 11 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only

Sponsor's (Shire) Approval 
Signature: 
, MD PhD 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-003 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
Shire
CONFIDENTIAL
Page 2
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
For non-commercial use only

Shire
CONFIDENTIAL
Page 3
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
SUMMARY OF CHANGES FROM PREVIOUS VERSION
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1.1
Amendment Date
09 Jan 2017
United-Kingdom-Specific
Description of Change and Rationale
Section(s) Affected by Change
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.
Section 4.7.1
See Appendix 1 for protocol history, including all amendments.
For non-commercial use only

Shire
CONFIDENTIAL
Page 4
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required by Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e-mail address can be found on the form 
(sent under separate cover). A copy of this form must also be sent to the Shire Medical Monitor 
by fax or e-mail using the details below.
, MD PhD
Email: 
Fax: 
For protocol- or safety-related issues during normal business hours (9 am to 5 pm Eastern 
Standard Time), the investigator must contact the Shire Medical Monitor:
, MD PhD, 
Phone: 
Mobile: 
Email: 
Fax: 
For protocol- or safety-related issues outside of normal business hours, the investigator 
must contact Quintiles Medical Support:
, MD, 
Phone: 
 (medical emergencies – United States)
Phone: 
 (medical emergencies – Global)
Email: 
r 
n-commercial use only

Shire
CONFIDENTIAL
Page 5
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints to Shire within 
24 hours. This includes any instances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint
E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire (USA) 
For non-commercial use only

Shire
CONFIDENTIAL
Page 6
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSION........................................................3
EMERGENCY CONTACT INFORMATION................................................................................4
PRODUCT QUALITY COMPLAINTS..........................................................................................5
TABLE OF CONTENTS.................................................................................................................6
LIST OF TABLES.........................................................................................................................11
LIST OF FIGURES .......................................................................................................................11
LIST OF APPENDICES................................................................................................................11
ABBREVIATIONS .......................................................................................................................12
STUDY SYNOPSIS ......................................................................................................................14
STUDY SCHEDULES..................................................................................................................20
1
BACKGROUND INFORMATION.......................................................................................26
1.1
Indication and Current Treatment Options...............................................................26
1.2
Product Background.................................................................................................26
1.3
Clinical Studies with Teduglutide in Pediatric Subjects ..........................................27
2
STUDY OBJECTIVES AND PURPOSE ..............................................................................28
2.1
Rationale for the Study.............................................................................................28
2.2
Study Objectives ......................................................................................................28
2.2.1
Primary Objectives .........................................................................................28
2.2.2
Secondary Objectives .....................................................................................28
3
STUDY DESIGN ...................................................................................................................29
3.1
Study Design and Flow Chart ..................................................................................29
3.1.1
Informed Consent/Assent and Eligibility .......................................................30
3.1.2
Retrospective Data Collection........................................................................30
3.1.3
Prospective Data Collection and Treatment ...................................................31
3.2
Duration and Study Completion Definition .............................................................32
4
STUDY POPULATION.........................................................................................................34
4.1
Study Inclusion Eligibility Criteria ..........................................................................34
4.2
Study Exclusion Eligibility Criteria .........................................................................34
4.3
Teduglutide Eligibility Criteria ................................................................................34
4.4
Teduglutide Treatment Inclusion Criteria................................................................34
4.5
Teduglutide Treatment Exclusion Criteria...............................................................35
4.6
Follow-up Period Escape Criteria ............................................................................36
4.7
Reproductive Potential .............................................................................................36
4.7.1
Female Contraception.....................................................................................36
4.8
Discontinuation of Subjects .....................................................................................37
For non-commercial use only

Shire
CONFIDENTIAL
Page 7
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
4.8.1
Teduglutide Discontinuation ..........................................................................37
4.8.2
Study Withdrawal ...........................................................................................37
4.8.3
Reasons for Discontinuation...........................................................................37
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit ..................38
5
CONCOMITANT TREATMENT..........................................................................................39
5.1
Concomitant Medications and GI Procedures..........................................................39
5.1.1
Permitted Treatment .......................................................................................39
5.1.2
Prohibited Treatment ......................................................................................39
6
INVESTIGATIONAL PRODUCT ........................................................................................40
6.1
Identity of Investigational Product...........................................................................40
6.1.1
Blinding the Treatment Assignment...............................................................40
6.2
Administration of Investigational Product(s)...........................................................40
6.2.1
Interactive Response Technology for Investigational Product 
Management ...................................................................................................40
6.2.2
Allocation of Subjects to Treatment...............................................................40
6.2.3
Dosing.............................................................................................................40
6.2.4
Unblinding the Treatment Assignment...........................................................41
6.3
Labeling, Packaging, Storage, and Handling ...........................................................41
6.3.1
Labeling..........................................................................................................41
6.3.2
Packaging........................................................................................................41
6.3.3
Storage and Handling .....................................................................................42
6.4
Drug Accountability.................................................................................................42
6.5
Subject Compliance..................................................................................................43
7
STUDY PROCEDURES........................................................................................................44
7.1
Study Schedule.........................................................................................................44
7.1.1
Retrospective Data Collection........................................................................44
7.1.2
Screening ........................................................................................................45
7.1.3
Visits for Subjects Not Receiving Teduglutide ..............................................46
7.1.4
Visits for Subjects Receiving Teduglutide Treatment....................................46
7.1.4.1
Pretreatment Visit...................................................................................46
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24).....................................47
7.1.5
Teduglutide Follow-up Period........................................................................49
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)..........................49
7.2
Study Evaluations and Procedures ...........................................................................50
7.2.1
Retrospective Data Collection........................................................................50
7.2.1.1
Growth (Height, Weight, and Head Circumference) .............................50
7.2.1.2
Prior Teduglutide Treatment Prescribed ................................................50
7.2.1.3
Parenteral Support Prescribed ................................................................51
For non-commercial use only

Shire
CONFIDENTIAL
Page 8
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
7.2.1.4
Adverse Events.......................................................................................51
7.2.2
Prospective Data Collection ...........................................................................51
7.2.2.1
Demographics, Medical History, and SBS History................................51
7.2.2.2
Physical Examination.............................................................................51
7.2.2.3
Adverse Event Collection.......................................................................51
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body 
Mass Index (BMI) ..................................................................................51
7.2.2.5
Clinical Laboratory Tests.......................................................................52
7.2.2.6
Serum Sampling.....................................................................................54
7.2.2.7
Pregnancy Testing..................................................................................54
7.2.2.8
Antibody Testing....................................................................................54
7.2.2.9
Volume of Blood....................................................................................54
7.2.2.10
Gastrointestinal-specific Testing............................................................55
7.2.2.11
Nutritional Support.................................................................................56
7.2.2.12
Diaries ....................................................................................................56
7.2.2.13
Health-related Quality of Life Assessments...........................................57
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................60
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................60
8.1.1
Severity Categorization ..................................................................................61
8.1.2
Relationship Categorization............................................................................61
8.1.3
Outcome Categorization.................................................................................62
8.1.4
Symptoms of the Disease under Study...........................................................62
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period 
of Observation Only) ......................................................................................62
8.1.6
Pregnancy .......................................................................................................63
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only) ..........................................................................................64
8.2
Serious Adverse Event Procedures ..........................................................................64
8.2.1
Reference Safety Information.........................................................................64
8.2.2
Reporting Procedures......................................................................................65
8.2.3
Serious Adverse Event Definition ..................................................................65
8.2.4
Serious Adverse Event Collection Time Frame .............................................66
8.2.5
Serious Adverse Event Onset and Resolution Dates......................................66
8.2.6
Fatal Outcome.................................................................................................66
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and 
Site Reporting.................................................................................................67
8.3
Adverse Events of Special Interest...........................................................................67
For non-commercial use only

Shire
CONFIDENTIAL
Page 9
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only).........................................................................................................................67
8.4.1
Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only) .................................68
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)......................................................70
8.5
Early Termination of the Clinical Study (Prospective Period of Observation 
Only).........................................................................................................................70
9
DATA MANAGEMENT AND STATISTICAL METHODS...............................................71
9.1
Data Collection.........................................................................................................71
9.2
Clinical Data Management.......................................................................................71
9.3
Statistical Analysis Process......................................................................................71
9.4
Planned Interim Analysis, and Data Monitoring Committee...................................71
9.5
Sample Size Calculation and Power Considerations................................................72
9.6
Study Population ......................................................................................................72
9.7
Efficacy Analyses.....................................................................................................72
9.7.1
Efficacy Endpoints..........................................................................................72
9.8
Safety Analyses........................................................................................................72
9.8.1
Safety Endpoints.............................................................................................73
9.9
Other Analyses .........................................................................................................74
9.9.1
Health-related Quality of Life Analyses.........................................................74
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES...........................................75
10.1
Sponsor’s Responsibilities .......................................................................................75
10.1.1
Good Clinical Practice Compliance................................................................75
10.1.2
Indemnity/Liability and Insurance..................................................................75
10.1.3
Public Posting of Study Information ..............................................................75
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ................75
10.1.5
Study Suspension, Termination, and Completion ..........................................76
10.2
Investigator’s Responsibilities .................................................................................76
10.2.1
Good Clinical Practice Compliance................................................................76
10.2.2
Protocol Adherence and Investigator Agreement...........................................76
10.2.3
Documentation and Retention of Records......................................................77
10.2.3.1
Case Report Forms.................................................................................77
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents..............................................................................................77
10.2.3.3
Audit/Inspection.....................................................................................78
10.2.3.4
Financial Disclosure...............................................................................78
10.3
Ethical Considerations..............................................................................................78
For non-commercial use only

Shire
CONFIDENTIAL
Page 10
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
10.3.1
Informed Consent ...........................................................................................78
10.3.2
Institutional Review Board or Ethics Committee...........................................79
10.4
Privacy and Confidentiality......................................................................................79
10.5
Study Results / Publication Policy ...........................................................................80
11 REFERENCES .......................................................................................................................82
12 APPENDICES ........................................................................................................................83
For non-commercial use only

Shire
CONFIDENTIAL
Page 11
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
LIST OF TABLES
Table 1-1:
Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................20
Table 1-2:
Schedule of Events for Screening and End of Study or Early 
Termination ...................................................................................................21
Table 1-3:
Schedule of Events for No Teduglutide Treatment Period ...........................22
Table 1-4:
Schedule of Events for Teduglutide Treatment Period .................................23
Table 5-1: 
Prohibited Treatment.....................................................................................39
Table 7-1:
List of Laboratory Tests ................................................................................53
Table 7-2:
Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................55
Table 7-3:
Developmentally Appropriate PedsQL™Generic Core Scales .....................58
Table 8-1:
CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only) ................................68
LIST OF FIGURES
Figure 3-1:
Study Design Flow Chart ..............................................................................32
LIST OF APPENDICES
Appendix 1
Protocol History.............................................................................................84
Appendix 2
Guidelines for Nutritional Support Management During the Study .............87
For non-commercial use only

Shire
CONFIDENTIAL
Page 12
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
-HCG
beta-human chorionic gonadotropin
BMI
body mass index
CRA
clinical research associate
CRO
contract research organization
CSR
clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
drug-induced livery injury
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase 4
EC
ethics committee
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EN
enteral nutrition
EOS
end of study
EOT
end of treatment
ET
early termination
EU
European Union
FDA
Food and Drug Administration
FOBT
fecal occult blood test
FOCBP
female of child-bearing potential
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide 1
GLP-2
glucagon-like peptide 2
HIPAA
Health Insurance Portability and Accountability Act
ICF
informed consent form
ICH
International Conference on Harmonization
IGF-1
insulin-like growth factor 1
IRB
institutional review board
IV
intravenous
IWRS
interactive web-based response system
MedDRA
Medical Dictionary for Regulatory Activities
NCI
National Cancer Institute
NDA
new drug application
NTT
no-teduglutide treatment
For non-commercial use only

Shire
CONFIDENTIAL
Page 13
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
PDA
patent ductus arteriosus
PedsQL
Pediatric Quality of Life Inventory
PS
parenteral support
PT/INR
prothrombin time/international normalized ratio
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SBS
short bowel syndrome
SC
subcutaneous
SOC
standard of care
t1/2
elimination half-life
TESAE
treatment-emergent serious adverse event
UK
United Kingdom
ULN
upper limit of normal
US
United States
WHO-DD
World Health Organization-Drug Dictionary
For non-commercial use only

Shire
CONFIDENTIAL
Page 14
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
STUDY SYNOPSIS
Protocol number: SHP633-303
Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003
Number of subjects (total and for each treatment arm):
Approximately 40 subjects who completed the TED-C13-003 study, including subjects in the standard of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED-C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the United States (US) and the United Kingdom (UK) will participate in 
this extension study.
Study period (planned):
October 2016-September 2019
Clinical phase:
3 Extension
Objectives:
Primary: To evaluate the long-term safety and tolerability of teduglutide treatment in pediatric subjects with short 
bowel syndrome (SBS) who completed TED-C13-003.
Secondary: To evaluate long-term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED-C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED-C13-003 study. In addition to 
evaluating the long-term safety and durability of efficacy after 12 weeks of treatment in TED-C13-003, this 
extension study will evaluate the need for additional teduglutide treatment in these subjects, and will allow for the 
first-time treatment of teduglutide-naïve subjects who participated in the standard of care (SOC) treatment arm in 
TED-C13-003.
Investigational product, dose, and mode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED-C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
between the date of the TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only

Shire
CONFIDENTIAL
Page 15
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and Section 7.1.1. For subjects 
that only consent to retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were completed in the course 
of the subject’s standard medical care between the date of the TED-C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide treatment

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1-2. These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. Prescription parenteral support requirements will be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section 7.2.2.12). Diary data for PS volume will be collected for at least 2 weeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no-teduglutide treatment [NTT] period), will be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed immediately to the pretreatment visit if 
the investigator, subject, and parent or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4-week follow-up (no treatment) period (Figure 3-1). During 
the 28-week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 weeks. To maintain 
consistency across centers, all attempts should be made to follow the nutritional support adjustment guidelines 
(developed with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only

Shire
CONFIDENTIAL
Page 16
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 
1 week after adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects 
discontinue teduglutide at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be 
performed weekly (solid grey lines). If an escape criterion is met during the follow-up period, subjects may proceed directly 
to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet all of the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.
Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study-related procedures.
2.
Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
3.
Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria, and none of the 
teduglutide treatment exclusion criteria, are met. In addition, the investigator and the subject (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria:
1.
Subject is teduglutide-naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by the investigator. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.
Subject was previously treated with teduglutide and at least 1 of the following criteria is satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b.
Decreased PS requirement during prior teduglutide treatment, followed by cessation of 
For non-commercial use only

Shire
CONFIDENTIAL
Page 17
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition following teduglutide discontinuation
d.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.
Body weight <10 kg at the pretreatment visit
2.
Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.
History of cancer in the previous 5 years except surgically curative skin cancers
4.
Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10 cm, and endoscopic procedures are allowed.
5.
Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6.
Clinically significant intestinal stricture or obstruction
7.
Clinically significant, active or recurrent pancreatic or biliary disease
8.
Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b.
Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9.
Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects 
who had undergone ventricular or atrial septal defect repair, or patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, or 
Smoflipid) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the 
pretreatment visit and for the duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) (not 
including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, within 3 months 
preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior to the 
pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related 
compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16. Pregnant or lactating female subjects
17. Sexually active female subjects of child-bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the subject at any 
undue risk, prevents completion of the study, or interferes with analysis of the study results
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow-up period may be interrupted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
For non-commercial use only

Shire
CONFIDENTIAL
Page 18
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
1.
Increasing PS requirements following teduglutide discontinuation
2.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated enteral 
nutrition following teduglutide discontinuation
3.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake 
following teduglutide discontinuation
4.
Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvement in the study:
A subject will be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple 28-week treatment cycles. The study will continue for at least 1 year, and until each 
subject has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately 3 years. A subject will be considered as having completed the study if the subject has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.

Planned duration of no-teduglutide treatment periods: variable, depending on disease course

Planned duration of the teduglutide pretreatment visit: 1-21 days

Planned teduglutide treatment cycle duration: 28 weeks. Each cycle consists of 24 weeks of 
teduglutide treatment followed by a 4-week follow-up period (no treatment)
Endpoints and statistical analysis:

The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
Health Economics and Outcomes Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an 
additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:
o
Food and drink limits
o
Diarrhea
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output
For non-commercial use only

Shire
CONFIDENTIAL
Page 19
Protocol Amendment 1.1
SHP633-303
09 Jan 2017

Antibodies to teduglutide

Gastrointestinal-specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) to the beginning of 
the prospective study period:

Adverse events related to teduglutide

All SAEs

All Adverse Events of Special Interest (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study (TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compiled for classification of 
qualitative safety data.
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by enrollment in TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 20
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
STUDY SCHEDULES
Table 1-1: Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment
Note
Informed consent/assent
Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study-related 
procedures, including retrospective data collection.
Study eligibility
Weighta
The last representative value for weight during each 12-week interval 
throughout the retrospective data collection period will be captured.
Height and head circumferencea
The last representative value for height during each 12-week interval 
throughout the retrospective data collection period will be captured. Head 
circumference should be provided for subjects 36 months of age and younger at 
the time the data were collected, if available.
Prior teduglutide treatment
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, 
compassionate use, and named-patient access programs.
Parenteral support (PS) 
prescribeda
The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per week of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED-C13-003
Teduglutide-related AEs
Teduglutide-related AEs must be deemed by the investigator to be related to 
teduglutide treatment.
AEs of special interest
Serious adverse events (SAEs)
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED-C13-003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a  The first 12-week interval begins at TED-C13-003 EOS visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 21
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 1-2: Schedule of Events for Screening and End of Study or Early Termination
Screening
End of Study or Early 
Termination
Visit Type
Site
Site
Informed consent/assent
X
Study eligibility
X
Demographics, medical history, SBS historya
X
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriab
X
Adverse events
X
X
Concomitant medications and GI proceduresc
X
X
Physical examination and vital signs, including weight
X
X
Height and head circumferenced
X
X
Review intake and output diariese
X
Record PS prescription and adjust as neededf
X
X
Safety laboratory testsg
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-Scales
X
Antibodies to teduglutideh
X
Fecal occult blood testingi
(X)
Colonoscopy or sigmoidoscopyj
(X)
Pregnancy testingk
(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
a If the subject has any changes to the medical history and SBS history that had been collected at the baseline of the TED-C13-
003 study, then the updated medical history and SBS history will be collected.
b Subjects who meet ≥1 teduglutide treatment inclusion criteria may proceed to the pre-treatment visit if the investigator, subject, 
and parent or legal guardian agrees to proceed with teduglutide therapy (Table 1-4).
c Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
d Head circumference will be measured in subjects 36 months of age and younger.
e The intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48-hour period of nutritional stability before the EOS/ET visit.
f Parenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix 2.
g Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
h Required for all teduglutide-exposed subjects.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 48-
60 weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no-teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section 7.2.2.10 for details.
k Pregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 22
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 1-3: Schedule of Events for No Teduglutide Treatment Period
Visit Number
NTx
Visit Type
Site
Visit Frequencya
Every 12 weeks
Window (days)b
±7
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriac
X
Adverse events
X
Concomitant medications and GI proceduresd
X
Physical examination and vital signs, including weight
X
Height and head circumferencee
X
Review intake and output diariesf 
X
Record PS prescription and adjust as neededg
X
Safety laboratory testsh
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-Scales
X
Antibodies to teduglutidei
(X)
Fecal occult blood testingj
Annually
Colonoscopy or sigmoidoscopyk
(X)
Serum samplel
Every 24 weeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
a The first NTx visit after the screening visit must occur within 2 to 12 weeks of screening.
b Window is relative to the first NTx visit in the current no-teduglutide treatment period.
c Subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed to the pre-treatment visit if the investigator, subject, 
and parent or legal guardian agree to proceed with teduglutide therapy (Table 1-4).
d Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
e Head circumference will be measured in subjects 36 months of age and younger.
f Intake diaries will collect actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section 7.2.2.10 for more detail.
g Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix 2.
h Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
i Subjects who have been treated previously and test positive for teduglutide antibodies should have follow-up samples collected 
every 12 weeks during the study until a negative result is obtained.
j Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
k The need for colonoscopy/sigmoidoscopy in response to a positive fecal occult blood test during a no-teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy/sigmoidoscopy at 5-year intervals or more often as needed. See Section 7.2.2.10 for 
details.
l Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 23
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Px
Cx
D1
Cx
W1
Cx
W2
Phone contact is required approximately 1 week after PS adjustment
Cx
W4
Phone contact is required approximately 1 week after PS adjustment
Cx 
W6
Phone contact is required approximately 1 week after PS adjustment
Cx 
W9
Phone contact is required approximately 1 week after PS adjustment
Cx 
W12
Phone contact is required approximately 1 week after PS adjustment
Cx 
W16
Phone contact is required approximately 1 week after PS adjustment
Cx 
W20
Phone contact is required approximately 1 week after PS adjustment
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28b
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phonea
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window (days)c
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteria
X
Xd
Dispense intake 
and output diaries
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant 
medications and 
GI
procedurese
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examination and 
vital signs, 
including weight
X
X
X
X
X
X
X
X
X
X
X
X
Height and head 
circumferencef
X
X
X
X
Review intake 
and output 
diariesg
X
X
X
X
X
X
X
X
X
X
X
X
X
Record PS Rx 
and adjust as 
neededh
X
X
X
X
X
X
X
X
X
X
X
X
X
Safety laboratory 
testsi
Xi
X
X
X
X
X
X
X
X
X
X
(X)
X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms 
X
X
X
For non-commercial use only

Shire
CONFIDENTIAL
Page 24
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Module Sub-
Scales
Antibodies to 
teduglutidej
X
X
X
X
Fecal occult 
blood testing
X
X
X
Colonoscopy/
Sigmoidoscopyk
(X)
(X)
(X)
Pregnancy 
testingl
X
X
X
X
X
X
X
X
X
Serum samplem
X
X
Evaluate escape 
criterian
X
X
Dispense study 
drugo
X
X
X
X
X
X
X
X
X
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing 
potential; FU=follow-up; GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio; 
SBS=short bowel syndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
a Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria).
b The investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within 7 days of the CxW28 visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-2) will take place in lieu of the CxW28 visit.
c Visit windows are relative to the CxD1 visit.
d Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
e Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and associated pathology results.
f Head circumference will be measured in subjects 36 months of age and younger.
g Intake diaries will collect actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except 
at pretreatment visit), for 1 week following PS adjustment, and daily during the 4-week follow-up period. Urine and stool output should be recorded in the output diary over a 48-
hour period of nutritional stability before every clinic visit, and within 1 week of implementing a change in the PS prescription. See Section 7.2.2.12 for more detail.
h Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment 
provided in Appendix 2.
i Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed by a central laboratory. Clinical chemistry and 
urinalysis must also be performed within approximately 5-7 days of any adjustment to the PS prescription. Safety labs performed between clinic visits may be performed locally. 
Unscheduled lab results will not be captured in the eCRFs. If abnormal results are considered an adverse event, an AE form will be completed. Collect PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug-induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 25
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
j Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
k The teduglutide-naïve subjects age 12 and older will undergo colonoscopy/sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy/sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy/sigmoidoscopy will be performed. The need for colonoscopy/sigmoidoscopy in response to positive FOBT results at 
CxW12 is at the discretion of the investigator. Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will 
undergo colonoscopy/sigmoidoscopy. See Section 7.2.2.10 for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all other visits according to the study 
schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.
n If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See 
Section 6.2.3 for dose adjustment.
For non-commercial use only

Shire
CONFIDENTIAL
Page 26
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
1
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options
Short bowel syndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. It is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with SBS (Khan et al. 
2015; Wales et al. 2004). Unlike the adult population, the majority of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy. 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 years of the initial diagnosis (Khan et al. 2015). 
Nevertheless, despite optimal medical management, many pediatric subjects remain dependent 
on PS. Complications of long-term PS include liver disease, catheter-related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality of life is poor (Squires et al. 
2012). Accelerating the adaptive process and achieving enteral autonomy is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al. 2015; Squires et al. 2012).
Intestinal adaptation is driven by hormonal cues in response to nutrient malabsorption (Drucker 
and Yusta 2014). Chief among these is hormones glucagon-like peptide 2 (GLP-2), which is 
secreted from L-type enteroendocrine cells that reside in the intestinal epithelium in the ileum 
and colon. Resection of these regions may impair the adaptive response by limiting endogenous 
production of GLP-2.
1.2
Product Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP-2 that regulates 
the functional and structural integrity of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33-amino acid peptide that differs from native GLP-2 in the substitution of 
glycine for alanine at the second position at the N-terminus. As a result, teduglutide demonstrates 
resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and therefore maintains a longer 
elimination half-life (t1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t1/2 of approximately 7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and crypt depth in the intestinal 
epithelium, thereby increasing the absorptive surface area of the intestines (Tappenden et al. 
2013; Thymann et al. 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (REVESTIVE™) on 30 
August 2012 and a New Drug Application (NDA) for teduglutide (GATTEX®) was approved by 
the United States (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 27
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
European Commission granted an extension of the Market Authorization for teduglutide 
(REVESTIVE™) for the treatment of patients aged 1 year and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3
Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 study, TED-C13-003, was completed in pediatric SBS subjects in the US and 
United Kingdom (UK). In this study, teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1-17. Thirty-seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for 12 weeks. Five additional pediatric subjects were enrolled in an 
observational standard of care (SOC) cohort. There were clear dose-dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day doses compared to SOC and the 0.0125 
mg/kg/day dose. In the 0.025 mg/kg/day cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in 1 subject, and a reduction of 
3.94 hours per day infusion time. In the 0.05 mg/kg/day cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day infusion time. Teduglutide was generally safe and well 
tolerated by pediatric subjects in all dosing cohorts. There were no deaths during the study and 
no treatment-emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study were due to adverse events (AEs).
TED-C14-006 is an ongoing study which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a 2-week minimum 
screening period, a 24-week treatment period, and a 4-week follow-up period. During the 
screening period, subjects will choose into which arm to enroll. During the 24-week treatment 
period, subjects in the SOC treatment arm will receive standard medical therapy for SBS; while 
those in the teduglutide treatment arm will receive daily subcutaneous (SC) injections of 
teduglutide (study drug) in addition to standard medical therapy. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double-blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day of teduglutide administered subcutaneously for 
24 weeks.
Always refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy and safety of teduglutide (SHP633).
For non-commercial use only

Shire
CONFIDENTIAL
Page 28
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
2
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to 
evaluate the safety and efficacy of teduglutide in pediatric subjects with SBS who completed the 
TED-C13-003 study. In addition to evaluating the long-term safety and durability of efficacy 
after 12 weeks of treatment in TED-C13-003, this extension study will evaluate the need for 
additional teduglutide treatment in these subjects, and will allow for the first-time treatment of 
teduglutide-naïve subjects who participated in the SOC treatment arm in TED-C13-003.
2.2
Study Objectives
2.2.1
Primary Objectives
The primary objective of the study is to evaluate the long-term safety and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED-C13-003.
2.2.2
Secondary Objectives
The secondary objective of this study is to evaluate the long-term efficacy of teduglutide 
treatment in pediatric subjects with SBS who completed TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 29
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
3
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects who completed the TED-C13-003 study (the core 
study). At the time of entry into the TED-C13-003 study, subjects were less than 18 years of age, 
were dependent on parenteral nutrition to provide at least 30% of their caloric or fluid needs, and 
had not been able to significantly reduce PS for at least 3 months prior to enrollment. During the 
core study, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day, 0.025 mg/kg/day, or 0.05 mg/kg/day dose cohort based on the timing of their 
enrollment in the study. The cohorts were filled in a sequential manner.
Approximately 40 subjects who completed the core study are expected to enroll in this extension 
study. Subjects who previously received teduglutide during the core study, as well as subjects 
who were in the SOC treatment group, may be eligible to receive teduglutide treatment in this 
extension study. To be eligible for treatment with teduglutide in this extension study, subjects 
must meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately every 12 weeks for safety, parenteral support (PS) requirements, and 
quality of life. At any point during an NTT period, subjects who meet ≥1 teduglutide treatment 
inclusion criteria may proceed directly to the pretreatment visit if the investigator, subject, and 
parent or legal guardian agrees to proceed with teduglutide therapy.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long-term follow-up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analysis suggested that pediatric patients, ages 1-17 years-old, are likely to require the same 
dose as used in adults, namely 0.05 mg/kg/day (Mouksassi et al. 2009). In this extension study to 
TED-C13-003, repeat doses of teduglutide 0.05 mg/kg/day will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed 12-week pediatric study (TED-C13-
003) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
For non-commercial use only

Shire
CONFIDENTIAL
Page 30
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
studies as well as the pediatric (core) study (TED-C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults (O'Keefe et al. 2006).
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED-C14-006 study, 
consisting of 24 weeks of teduglutide treatment, followed by a 4-week follow-up period. The 
follow-up period is a mechanism to evaluate whether continued teduglutide is needed. If a 
subject deteriorates during the follow-up period, the subject may be evaluated immediately for 
additional teduglutide treatment. Subjects who clinically deteriorate or stop improving at any 
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED-C13-003 and TED-C14-006, to ensure sufficient safety monitoring and 
weaning of PS. During the NTT period, visits occur every 12 weeks, a frequency that is 
consistent with standard medical practices.
Measures and Parameters
To evaluate efficacy and safety from the time subjects completed the core study to the time they 
enter this extension study, retrospective data collection is planned for this study. The 
retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. In addition to this retrospective data 
collection, prospective study assessments of safety and efficacy will be completed as a part of 
this study.
3.1.1
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be 
completed before any other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study; however subjects may 
consent to retrospective data collection only. Subjects may not consent to the prospective data 
collection only. After informed consent/assent is obtained, study eligibility will be assessed for 
all subjects.
3.1.2
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and 
Section 7.1.1. For subjects that only consent to retrospective data collection, these procedures are 
all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
For non-commercial use only

Shire
CONFIDENTIAL
Page 31
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
this study. Retrospective data collection may begin any time after informed consent/assent is 
obtained for this study. The following data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
3.1.3
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history and short bowel syndrome history. Prescription parenteral support 
requirements will be collected at screening. Additionally, intake diaries will be dispensed at the 
screening visit for collection of actual PS volume and hours per day (Section 7.2.2.12). Diary 
data for PS volume will be collected for at least 2 weeks after the ICF (and if applicable, the 
informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately 
every 12 weeks for safety, PS requirements, and quality of life. Diary data for PS volume will be 
collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including 
during an NTT period, subjects who meet ≥1 teduglutide treatment inclusion criteria, may 
proceed immediately to the pretreatment visit if the investigator, subject, and parent or legal 
guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28-week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily, followed by a 
4-week follow-up (no treatment) period (Figure 3-1). During the 28-week cycle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality of life assessments will be made approximately every 
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
For non-commercial use only

Shire
CONFIDENTIAL
Page 32
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation (Appendix 2).
Rationale: Measures of long-term safety will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
by reduction in PS and improvement in pediatric quality of life measures (Pediatric Quality of 
Life Inventory [PedsQL], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pivotal Phase 3 adult clinical 
trials and the completed Phase 3 pediatric study (TED-C13-003), and will be used as an endpoint 
in this extension study. In previous clinical studies, a reduction of this magnitude was associated 
with a reduction in the number of days per week of PS, and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may provide a pediatric subject 
with opportunities for more age-appropriate activities including oral rehabilitation. Quality of life 
assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI-specific screening tests, 
including fecal occult blood testing and colonoscopy/sigmoidoscopy, which are commonly part 
of the routine care of these subjects, will be performed to ensure safety. This study captures long-
term safety data on polyps and other colonic mucosal changes in teduglutide-exposed subjects 
using the surveillance strategy proposed in Section 7.2.2.10.
Figure 3-1:
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide 
at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey 
lines). If an escape criterion is met during the follow-up period, subjects may proceed directly to another pretreatment visit.
3.2
Duration and Study Completion Definition
A subject will be considered enrolled in the study once the subject has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility 
For non-commercial use only

Shire
CONFIDENTIAL
Page 33
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Criteria. The study will continue for at least 1 year, and until each subject has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
3 years. The study will be completed in approximately 40 months. A subject will be considered 
as having completed the study if the subject has not withdrawn early from the study for any 
reason prior to completing the EOS visit.
The study completion date is defined as the date the final subject, across all sites, completes their 
final protocol-defined assessment. Please note that this includes the follow-up visit or contact 
(last safety contact), whichever is later. The study completion date will be used to ascertain 
timing for study results posting and reporting.
For non-commercial use only

Shire
CONFIDENTIAL
Page 34
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
4
STUDY POPULATION
Each subject and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any study-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility does not impact study eligibility.
4.1
Study Inclusion Eligibility Criteria
The subject will not be considered eligible for the study without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing any study-
related procedures. 
2. Subject completed the TED-C13-003 study (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully adhere to study requirements as defined 
in this protocol.
4.2
Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study.
4.3
Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria 
and none of the teduglutide treatment exclusion criteria are met. In addition, the investigator and 
the subject (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.4
Teduglutide Treatment Inclusion Criteria
1. Subject is teduglutide-naïve, receiving PS, and unable to significantly reduce PS or advance 
enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to 
and during the teduglutide pretreatment visit, as assessed by the investigator. Transient 
instability for events such as interruption of central access or treatment for sepsis is allowed 
if the PS returns to within 10% of baseline prior to the event.
2. Subject was previously treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b. Decreased PS requirement during prior teduglutide treatment, followed by 
cessation of improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite 
maximal tolerated enteral nutrition following teduglutide discontinuation
d. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid 
and electrolyte intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 35
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
4.5
Teduglutide Treatment Exclusion Criteria
1. Body weight <10 kg at the pretreatment visit
2. Unresected GI polyp, known polyposis condition, premalignant change, or malignancy, in 
the GI tract
3. History of cancer in the previous 5 years except surgically curative skin cancers
4. Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the 
teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor 
intestinal resections ≤10 cm, and endoscopic procedures are allowed.
5. Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6. Clinically significant intestinal stricture or obstruction
7. Clinically significant, active or recurrent pancreatic or biliary disease
8. Active, severe, or unstable, clinically significant hepatic impairment or injury, including the 
following laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9. Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of 
subjects who had undergone ventricular or atrial septal defect repair, or patent ductus 
arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, 
Omegaven, or Smoflipid) within 3 months or 5.5 half-lives of the experimental drug, 
whichever is longer, prior to the pretreatment visit and for the duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-
2) (not including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, 
within 3 months preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior 
to the pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-
related compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment 
visit
16. Pregnant or lactating female subjects 
17. Sexually active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 days after the treatment period 
For non-commercial use only

Shire
CONFIDENTIAL
Page 36
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the 
subject at any undue risk, prevents completion of the study, or interferes with analysis of the 
study results
4.6
Follow-up Period Escape Criteria
At the discretion of the investigator, the follow-up period may be interrupted and the subject may 
proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1. Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition following teduglutide discontinuation
3. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
4.7
Reproductive Potential
4.7.1
Female Contraception
To be eligible for treatment with teduglutide, sexually active females of child-bearing potential 
must use an acceptable form of contraception throughout the study period and for 30 days 
following the last dose of investigational product. If hormonal contraceptives are used, they 
should be administered according to the package insert. Females of child-bearing potential who 
are not currently sexually active must agree to use acceptable contraception, as defined below, if 
they become sexually active during the period of the study and 30 days following the last dose of 
investigational product. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:

Premenarchal and either Tanner Stage 1 or less than age 9 years, or

Females of child-bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin (-HCG) pregnancy test at the teduglutide pretreatment visit. Females of 
child-bearing potential must agree to abstain from sexual activity that could result in 
pregnancy or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:

True abstinence: Abstention of sexual activity that is in line with the preferred and usual 
lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception).

Intrauterine devices plus condoms

Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
For non-commercial use only

Shire
CONFIDENTIAL
Page 37
Protocol Amendment 1.1
SHP633-303
09 Jan 2017

Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 days prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually active during the study, they should use 1 of the other acceptable methods noted 
above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
4.8
Discontinuation of Subjects 
4.8.1
Teduglutide Discontinuation
If the investigational product is discontinued prematurely during a teduglutide treatment cycle 
and the subject wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow-up period will ensue, consisting of weekly telephone visits 
(CxW25-27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility according to the study 
schedules. 
Comments (spontaneous or elicited) or complaints made by the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.3. The investigator is encouraged to discuss withdrawal of a subject 
from investigational product with the medical monitor, when possible.
4.8.2
Study Withdrawal
At any time during the study, the investigator or sponsor may withdraw a subject, or a subject 
may withdraw from the study, for any reason, without prejudice to their future medical care by 
the physician or at the institution.
If a subject withdraws from the study during a teduglutide cycle, the evaluations listed for the 
EOT visit are to be performed as completely as possible. Whenever possible, the subject will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contacted 
weekly by phone during the interim period between EOT and ET for safety follow-up.
If a subject withdraws from the study during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completely as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3
Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study must 
be determined by the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than 1 reason, each reason should be documented in the source 
document, and the most clinically relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
For non-commercial use only

Shire
CONFIDENTIAL
Page 38
Protocol Amendment 1.1
SHP633-303
09 Jan 2017

Adverse event

Protocol deviation

Lack of efficacy

Physician decision

Withdrawal by subject

Withdrawal by parent/guardian

Lost to follow-up

Pregnancy (Discontinuation of treatment only)

Death

Other
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations, and return any unused investigational product.
For non-commercial use only

Shire
CONFIDENTIAL
Page 39
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
5
CONCOMITANT TREATMENT
5.1
Concomitant Medications and GI Procedures
Concomitant treatment will be collected for the prospective period only and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study. Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medication changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may increase absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, and digoxin). Accordingly, due consideration should be given to 
modifying concomitant medication regimens. Down-titration of concomitant medications should 
be considered when drugs, especially those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.1
Permitted Treatment
Standard medical therapy for SBS should be continued.
5.1.2
Prohibited Treatment
The mechanism of action of teduglutide may increase enteral absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, digoxin), so consideration should be given to modifying 
concomitant enteral medication regimens. Down-titration of concomitant enteral medications 
should be considered when drugs, especially those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy
Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon-like peptide-2 (not-including teduglutide)
Any
Glucagon-like peptide-1 analog or human growth hormone
3 months
Octreotide or dipeptidyl peptidase 4 inhibitors
3 months
Biological therapy (eg, antitumor necrosis factor)
6 months
For non-commercial use only

Shire
CONFIDENTIAL
Page 40
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
6
INVESTIGATIONAL PRODUCT
6.1
Identity of Investigational Product
The test product is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L-histidine, mannitol, monobasic sodium 
phosphate monohydrate, and dibasic sodium phosphate as excipients. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.1
Blinding the Treatment Assignment
Not applicable for this open-label study.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology for Investigational Product Management
An interactive web-based response system (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory management and supply ordering, investigational product expiration tracking and 
management, and return of investigational product. Please refer to the Study Manual for
additional details regarding the IWRS.
The IWRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.2
Allocation of Subjects to Treatment
This is an open-label study. Subjects will retain their assigned subject number from the 
TED-C13-003 study. Assessment of need for teduglutide treatment should be guided by the 
teduglutide treatment inclusion criteria. If the investigator, subject, and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit (Table 1-4).
6.2.3
Dosing
If teduglutide treatment eligibility is established at the pretreatment visit and again, confirmed at 
the CxD1 visit, the subject will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered by SC injection once daily (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 41
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Teduglutide should be used as soon as possible after reconstitution, but no more than 3 hours 
later.
The subject should be dosed at approximately the same time each day. Consecutive doses should 
be separated by at least 12 hours. Each day, the injection site should be rotated.
The first SC injection in teduglutide-naïve subjects should be administered under the supervision 
of the investigator or designee and the subject observed for hypersensitivity reactions for at least 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the Instructions for Use. 
Following each 24-week teduglutide treatment period, subjects will enter a 4-week follow-up 
period. During the follow-up, the investigator will assess the subject via weekly telephone visits. 
At any time during the follow-up period, if escape criteria are met, the subject may proceed 
directly to another Pretreatment visit to assess treatment eligibility for another cycle 
(Section 4.6). Following the completion of the 4-week follow-up, the subject will continue in the 
study off teduglutide. Additional 28-week cycles may be repeated if treatment eligibility is 
established each time. 
6.2.4
Unblinding the Treatment Assignment
Not applicable for this open-label study.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification will be applied to the investigational 
product(s) container.
The study drug will be packaged, labeled, and shipped to the study site by the sponsor or 
designee. Kits containing 7 vials of study drug will be supplied and these will be labeled in 
accordance with applicable regulatory requirements. Sterile water for injection syringes will also 
be provided separately and will be labeled in accordance with the applicable regulatory 
requirements.
All study drug used in this study will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2
Packaging
Teduglutide will be provided in a 3 mL sterile, single-use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL) will be provided in a prefilled syringe.
For non-commercial use only

Shire
CONFIDENTIAL
Page 42
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the sponsor.
6.3.3
Storage and Handling
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Limited responsibility may be delegated to the pharmacy or 
member of the study team, but this delegation must be documented.
Study drug must be kept in a locked area with access restricted to specific study personnel. Study 
drug will be stored refrigerated at a temperature between 2-8°C (35.6-46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2-25°C, or 35.6-77°F). Parent/legal guardian 
will be instructed to keep the subject’s study drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study drug may be refrigerated. The study drug is for single use only, and should be used within 
3 hours following reconstitution.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed by the pharmacy or nominated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed number of subjects. The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. The 
investigator is to keep a current record of the inventory and dispensation of all clinical supplies. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 43
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
This record will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any discrepancy or deficiency will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any unauthorized situation.
The investigator has overall responsibility for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study protocol. All dispensed 
study medication will be documented in the interactive response technology system and/or other 
investigational product record (eg, investigation product accountability form). The investigator is 
responsible for assuring the retrieval of all study supplies from subjects.
All used and unused study drug vials must be returned by the subjects and/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unused study drug vials to the same subject. All original containers, whether empty 
or containing study drug will be returned to the pharmacy. Returned study drugs will NOT be 
relabeled or reassigned for use by other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may be destroyed on site without approval by the sponsor.
Please see the Pharmacy Manual for additional information.
6.5
Subject Compliance
Subjects will be instructed to bring their unused investigational product and empty/used 
investigational product packaging to every visit. Drug accountability will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper-evident sealed container (eg, bottles, trays, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 44
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
7
STUDY PROCEDURES
7.1
Study Schedule
Detailed study procedures and assessments to be performed for subjects throughout the study are 
outlined in the Schedule of Assessments (Table 1-1, Table 1-2, Table 1-3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing any study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject (Table 1-1).
7.1.1
Retrospective Data Collection
Retrospective data are defined as specific safety and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. Retrospective PS and growth data will be 
captured in 12-week intervals, with the first 12-week interval beginning at the TED-C13-003 
EOS visit. All available retrospective data should be captured in the corresponding eCRFs. 
Failure to collect retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent only to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study:

Informed consent, and informed assent (if applicable)

Study eligibility is determined
o
A screen failure is a subject who has given informed consent and failed to meet 
the study inclusion eligibility criteria. Subjects cannot be rescreened once they 
have been designated as a screen failure.

Prior teduglutide use (as prescribed)
o
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, compassionate 
use, and named-patient access programs.
o
Collect start and end dates when a subject’s teduglutide use was interrupted. 

Parenteral support (as prescribed)
o
The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide treatment 
will be collected. Usually, the prescription at the end of the interval will represent 
the status of intestinal adaptation. However, transient alterations in PS related to 
For non-commercial use only

Shire
CONFIDENTIAL
Page 45
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
loss of central venous access or acute illness are not representative of intestinal 
adaptation. When such events occur at the end of a 12-week interval, earlier, more 
representative PS prescription data should be recorded.
Data collected should include weekly prescribed volume, calories, average hours 
per day, and days per week of prescribed PS. Hours per day should be averaged 
over the days where PS is prescribed. 

Growth (height, head circumference, and weight)
o
The last representative value for height, during each 12-week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and younger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.

Adverse events
o
All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study. The details of data collection and safety reporting for these events 
can be found in Section 8.
o
End dates for AEs ongoing at the end of TED-C13-003 will be collected.
7.1.2
Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:

Informed consent, and informed assent (if applicable)

Study eligibility is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study inclusion eligibility criteria. Subjects cannot be 
rescreened once they have been designated as a screen failure.

Demographics, updates to medical history and SBS history

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Record PS prescription and adjust as needed
For non-commercial use only

Shire
CONFIDENTIAL
Page 46
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3
Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide-treatment cycle, subjects will be followed 
approximately every 12 weeks for safety and efficacy assessments. No-teduglutide treatment 
visits are numbered sequentially (NT1, NT2, etc.), even if interrupted by the treatment cycles. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1-3 and described below.

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS  prescription and adjust as needed

Safety laboratory tests (ie, clinical chemistry, hematology, and urinalysis)

PedsQL Generic Core Scale/PedsQL Family Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub-Scales

Antibodies to teduglutide, if and when required

Fecal occult blood testing, as indicated (see Section 7.2.2.10)

Colonoscopy/sigmoidoscopy, as indicated (see Section 7.2.2.10)

Serum sample, as indicated
Teduglutide treatment may be considered at any time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may proceed to the pretreatment visit immediately to determine 
eligibility. 
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
7.1.4.1
Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may proceed to the pretreatment visit immediately. Similarly, 
subjects who meet escape criteria during the teduglutide follow-up period may proceed to the 
pretreatment visit immediately. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 47
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
In general, pretreatment assessments may occur over a period of up to 21 days. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:

Evaluate teduglutide eligibility (treatment inclusion/exclusion criteria)

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Fecal occult blood testing

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy as indicated

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries 

Record PS prescription and adjust as needed.

Safety laboratory tests
(In addition to clinical chemistry, hematology, and urinalysis, labs at this visit include 
prothrombin time [PT] international normalized ratio [INR]. Subsequent prothrombin 
time/international normalized ratio (PT/INR) measurement is only required to evaluate 
for suspected drug-induced liver injury [DILI]).

Pregnancy testing (serum)

Serum sample
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24)
The open-label teduglutide treatment period will comprise 24 weeks, during which all 
assessments and procedures listed for Visits CxD1-CxW24 in Table 1-4 shall be completed. 
Cycles are numbered sequentially, such that the first visit of the first cycle is C1D1, and the first 
visit of the second cycle is C2D1, etc. Visit windows are calculated relative to the date of first 
investigational product administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1-4 and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.

Confirm teduglutide treatment eligibility

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight
For non-commercial use only

Shire
CONFIDENTIAL
Page 48
Protocol Amendment 1.1
SHP633-303
09 Jan 2017

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing (urine)

Dispense study drug
SITE VISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects will return for clinic visits on cycle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:

Dispense and review intake and output diaries (every effort should be made to complete 2 
weeks of intake diary entries prior to each clinic visit and to complete 48 hours of output 
diary entries during a period of nutritional stability prior to each clinic visit)

Physical examination and vital signs, including weight

Record PS prescription and adjust as needed

Safety laboratory tests

Urine pregnancy testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)

Study drug dispensation (except for CxW24)

Adverse events, concomitant medications and concomitant GI procedures
In addition, at CxW12 and CxW24 Visits ONLY, the following procedures will be performed:

Height and head circumference

Antibodies to teduglutide

Fecal occult blood testing (FOBT)

GI-specific testing, including colonoscopy or sigmoidoscopy as indicated

Quality of life measurements
At CxW24 ONLY, a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 49
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
PHONE VISITS
Phone visits are required approximately 1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-4 and described 
below:

Review intake and output diaries

Safety laboratory tests (clinical chemistry and urinalysis)

Record PS prescription and adjust as needed

Obtain AEs, concomitant medications, and concomitant GI procedures

Evaluate escape criteria
7.1.5
Teduglutide Follow-up Period
The safety follow-up period for this protocol is 4 weeks (Weeks 25-28 of the cycle). Phone visits 
will occur on cycle Weeks 25, 26, and 27 for all subjects. Phone visit assessments and 
procedures at Weeks 25-27 will be the same as for telephone visits performed during the 
teduglutide treatment period. In addition, subjects will be evaluated for follow-up period escape 
criteria. If escape criteria are met at any time during the follow-up period, the subject may 
proceed directly to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pretreatment assessments occur within 7 days of the CxW28 
visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Section 7.1.6) 
will take place in lieu of the CxW28 visit. Otherwise, following completion of the 28-week 
treatment cycle, the subject will proceed to an NTT visit within approximately 12 weeks.
At Cycle Week 28 (CxW28), subjects will return to the study site. In addition to the assessments 
performed at Weeks 25-27, the following procedures will be performed at CxW28 only:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Antibodies to teduglutide

Pregnancy testing (urine)

Evaluate escape criteria
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study site for the end of study/early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-2 and as 
For non-commercial use only

Shire
CONFIDENTIAL
Page 50
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
described here. If a subject discontinues the study prematurely, the assessments for the EOS/ET 
visit are to be performed as completely as possible (see Section 4.8.2).

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries (the intake diary should be completed daily for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily over a 48-hour period of nutritional stability before the EOS/ET visit)

Record PS prescription and adjust as needed

Safety laboratory tests

Fecal occult blood testing, as indicated

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy, as indicated

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing, as needed
7.2
Study Evaluations and Procedures
7.2.1
Retrospective Data Collection
Retrospective data are being collected to evaluate the safety, tolerability, and efficacy of 
teduglutide during the interval between a subject's completion of the TED-C13-003 study and the 
date the ICF (and if applicable, assent) is signed for the SHP633-303 study.
7.2.1.1
Growth (Height, Weight, and Head Circumference)
Retrospective body height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z-score, weight z-score, body mass index (BMI), and BMI z-score will be calculated by 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analysis plan (SAP).
7.2.1.2
Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency will be 
recorded on the appropriate eCRF page.
For non-commercial use only

Shire
CONFIDENTIAL
Page 51
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
7.2.1.3
Parenteral Support Prescribed
Retrospective parenteral support entries consist of 1 prescription per 12-week interval during the 
retrospective period. If the subject has multiple PS prescriptions in a 12-week interval, the last 
representative prescription from the interval should be used (see Section 7.1.1). In addition, PS 
prescriptions at the beginning and end of any retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekly volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
7.2.1.4
Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESIs) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide, 
that occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safety reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED-C13-003 will be collected.
7.2.2
Prospective Data Collection
7.2.2.1
Demographics, Medical History, and SBS History
Demographics, updates to medical history, and updates to SBS history will be obtained at 
screening. Medical history for purposes of this extension study will consist of updates to the 
medical history collected at the start of the TED-C13-003 core study. If the subject has any 
changes to the SBS history since the baseline visit of the TED-C13-003 study, that information 
(updated SBS history) will also be collected.
7.2.2.2
Physical Examination
Physical examinations will be performed according to the study schedules. Any new clinically 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF.
7.2.2.3
Adverse Event Collection
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body temperature 
For non-commercial use only

Shire
CONFIDENTIAL
Page 52
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
(°C/°F). Blood pressure should be determined by cuff (using the same method, the same arm, 
and in the same position throughout the study).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each study visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z-score, weight z-score, BMI, and BMI z-score will be 
calculated by the sponsor using the site-provided height and weight data collected at each site 
visit.
New clinically significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.2.5
Clinical Laboratory Tests
Safety laboratory tests to be performed at site visits consist of clinical chemistry, hematology, 
and urinalysis and will be performed as outlined in the study plan (Table 1-2, Table 1-3, and 
Table 1-4). Scheduled laboratory testing will be processed by a central lab. All laboratory assays 
will be performed according to the central laboratory’s normal procedures. Reference ranges are 
to be supplied by the laboratory. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Abnormal clinical laboratory values, which are unexpected or not 
explained by the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safety labs within approximately 
5-7 days after a PS adjustment. Safety labs performed after PS adjustment and between site visits 
will consist of clinical chemistry and urinalysis and may be processed by the central laboratory 
or a local laboratory. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate any new clinically significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safety labs, but lack of urinalysis will not constitute a protocol deviation.
New clinically significant labs should be reported as AEs.
The following clinical laboratory assessments will be performed according to the study 
schedules:
For non-commercial use only

Shire
CONFIDENTIAL
Page 53
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 7-1: List of Laboratory Tests 
Hematology:

Hematocrit

Hemoglobin

Platelet count

Red blood cell count

Red blood cell morphology, if needed

White blood cell count with differential
Coagulation:
Prothrombin time/International normalized ratio
Urinalysis:

Blood

Glucose

Leukocytes

Microscopic analysis

pH

Protein

Specific gravity
Pregnancy tests (females of childbearing potential):

Serum β-HCG (screening)

Urine β-HCG (all other visits)
Biochemistry:

Albumin

Alkaline phosphatase

Alanine aminotransferase

Amylase

Aspartate aminotransferase

Bicarbonate

Bilirubin (total and indirect)

Blood urea nitrogen

Calcium (total)

Chloride

Cholesterol

C-reactive protein

Creatinine

Estimated Glomerular Filtration Rate 
(Schwartz formula)

Gamma-glutamyl transferase

Glucose

Lipase

Magnesium

Phosphorus

Potassium

Sodium

Triglycerides

Uric acid
For non-commercial use only

Shire
CONFIDENTIAL
Page 54
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
7.2.2.6
Serum Sampling
Serum samples will be collected and stored for future analysis at the following times:

At the pretreatment visit. If the subject met a follow-up period escape criterion, the serum 
sample will not be collected at the pretreatment visit

At the CxW24 (EOT) visit

During NTT: Approximately every 24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and any specialty laboratories will be 
blinded to the subject’s identity. The sample and/or extracted material will otherwise be stored 
for up to 15 years from the end of the study after which time it will be destroyed. Upon written 
request, subjects will be permitted to withdraw their sample from the analysis and have their 
sample and/or extracted material destroyed. Any results already generated from the samples will 
not be removed from any analyses that have already been performed.
7.2.2.7
Pregnancy Testing
A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy tests will be administered at all other visits according to the study schedules, or if 
pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the 
study.
7.2.2.8
Antibody Testing
Blood samples will be drawn for the analysis of antibodies to teduglutide according to the 
Schedule of Assessments (Table 1-2, Table 1-3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least 14 hours after dosing. Subjects who test 
positive for antibodies to teduglutide will also be tested for neutralizing antibody. Subjects who 
have been previously treated with teduglutide, and who test positive for antibodies to 
teduglutide, will have follow-up blood draws for antibodies to teduglutide every 12 weeks while 
on study until a negative result is obtained.
7.2.2.9
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study. The volumes of blood to be drawn from each subject will vary depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annually are shown 
in Table 7-2.
For non-commercial use only

Shire
CONFIDENTIAL
Page 55
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
Assessment
Sample 
Volume (mL)
No. Samples per two 28-week 
Teduglutide Cycles
Total 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety
Biochemistry and -hCGa
2.5
24
60
Hematology
2
24
48
Coagulation Parameters
1
2
2
Antibodies
2
8
16
Serum storage samples
3
4
12
Total mL per 2, 28-week Treatment Cycles (Approximate Annual Volume):
138
Subjects Not Receiving Teduglutide Treatmentb
Assessment
Sample 
Volume (mL)
No. Samples per 4 NTT Visits
Total 
Volume (mL)
Safety
Biochemistry
2.5
4
10
Hematology
2
4
8
Serum storage samples
3
2
6
Total mL per 4 “No Teduglutide Treatment” Visits 48-week period:
24
β-hCG=beta-human chorionic gonadotropin; NTT=no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
b Subjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti-teduglutide 
antibodies will require blood samples for antibody testing every 12 weeks until they test negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by the manufacturer or laboratory 
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they require the same type of tube, the assessments should be combined. Blood 
volume estimates do not include safety labs performed after PS adjustment, and anti-teduglutide 
antibody testing during no-teduglutide treatment.
7.2.2.10
Gastrointestinal-specific Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week 24 of the teduglutide cycle. During NTT periods, FOBT must be performed on 
teduglutide-exposed subjects (subjects who have received teduglutide any time in the past and 
are therefore not teduglutide-naïve) on a roughly annual basis (approximately every 48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY OR SIGMOIDOSCOPY
Teduglutide-naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pretreatment visit if one has not been performed within 1 year.
Subjects of any age with newly positive FOBT results at the pretreatment visit for which a 
readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy or 
For non-commercial use only

Shire
CONFIDENTIAL
Page 56
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a 
readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
colonoscopy or sigmoidoscopy in response to positive FOBTs at any other point during the 
study, or to reevaluate persistently positive FOBTs is at the discretion of the investigator.
Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks 
of study drug exposure) will undergo colonoscopy or sigmoidoscopy. While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 year intervals or 
more often as needed.
Upper endoscopy may be performed along with any colonoscopy or sigmoidoscopy at the 
investigator’s discretion. If a polyp is found, adherence to current polyp follow-up guidelines is 
recommended. Subjects with unresected GI polyps, polyposis conditions, premalignant change 
or malignancy in the GI tract will be excluded from teduglutide treatment.
7.2.2.11
Nutritional Support
Nutritional support includes PS, enteral nutrition, and other food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety laboratory results. Intake and output diaries will include data to be 
considered in the adjustment of each subject’s nutritional support. Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2.
7.2.2.12
Diaries
STUDY DRUG ADMINISTRATION DIARY
A study drug administration diary will record administration of teduglutide. This diary should be 
completed by the subject (or parent/legally authorized representative, as applicable) daily during 
the teduglutide treatment period (between visits CxD1 and CxW24).
INTAKE DIARY
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary 
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week teduglutide treatment period, the intake diary will also be completed for 1 week 
following PS adjustments. The intake diary will also be completed daily during the 4-week 
follow-up period. The following data will be captured in the intake diaries:

Parenteral support volume and infusion duration

Site personnel will determine the actual PS daily calories based on diary entries
OUTPUT DIARY
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional 
stability before every clinic visit; in addition, output should be recorded for subjects that are in a 
For non-commercial use only

Shire
CONFIDENTIAL
Page 57
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
teduglutide treatment cycle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:

Toilet-trained subjects (who do not wear diapers)
Measure and record all urine output in mL or cc 

Nontoilet-trained subjects (who wear diapers)
Measure and record the weight of all urine-only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL or 1 cc

At the discretion of the investigator, the parent or legal guardian may be asked to collect 
the first void after the daily PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):

Toilet-trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency using the 
Bristol Stool Form Scale (see Output diary)

Nontoilet-trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency using the Bristol Stool Form Scale 
(see Output diary). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mL or 1 cc
All ostomy output volume should be recorded. Ostomy output will not be scored using the 
Bristol scale.
All available diary data will be reviewed by the investigator or their designee at each clinic and 
telephone visit to assess clinical status and opportunity for PS reduction and advance in feeds.
7.2.2.13
Health-related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes less than 4 minutes to 
complete. The scales include self-reports for pediatric subjects and adolescents aged 5 to 
18 years and proxy-reports from parents of pediatric subjects aged 2 to 18 years.
Field trials have shown that the internal consistency reliability of the PedsQL was excellent, with 
alphas for the generic core scales in both self- and proxy-report greater than the 0.70 standard, 
and alphas for the full 23-item scale approaching 0.90 for self- and proxy-report. Missing data 
were minimal. Item response distributions were across the full scale range, with no floor effects, 
and minimal ceiling effects.
The validity of the PedsQL Generic Core Scales was demonstrated through known group 
comparisons, and correlations with other measures of disease burden. The PedsQL self- and 
proxy-report distinguished between pediatric subjects with and without a chronic health 
For non-commercial use only

Shire
CONFIDENTIAL
Page 58
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
condition, and within the group of pediatric subjects with a chronic condition, between those 
who did or did not have an overnight hospital visit in the last 12 months. Further, both child 
self-report and parent proxy-report correlated significantly with the number of days the child was 
too ill to pursue normal activities, needed someone to care for him or her, missed school in the 
last month, the number of days the parent missed from work in the last month, and parent-report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (PEDSQL™), ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health-related quality of life (HRQoL) 
in pediatric subjects and adolescents (2-18 years of age). The developmentally appropriate 
PedsQL Generic Core Scale will be completed by either the parent or legal guardian and subject 
as indicated in Table 7-3 at the time points as outlined in Table 1-2, Table 1-3, and Table 1-4.
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report
Completed by
Parent Report for Toddlers (ages 2-4)
Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Young Pediatric subjects 
(ages 5-7)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Pediatric subjects 
(ages 8-12)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Teens (ages 13-18)
Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2-4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8-12), and Teens (ages 13-18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Family Impact Module is a parent-report multidimensional instrument that will be 
completed by the parent or legal guardian, as outlined in Table 1-2, Table 1-3, and Table 1-4.
The PedsQL Family Impact Module is a specific module of the PedsQL that is used to measure 
the impact of pediatric chronic health conditions on parents and the family (Varni et al. 2004). 
The 36-item PedsQL Family Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry (5 items). Two additional scales measure parent-
For non-commercial use only

Shire
CONFIDENTIAL
Page 59
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
reported family functioning as follows: 1) Daily Activities (3 items), and 2) Family Relationships 
(5 items). The PedsQL Family Impact Module should take the parent or legal guardian 
approximately 5-10 minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Gastrointestinal Symptom Module is a disease-specific 58-item module, comprised 
of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Symptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink Limits (6 items) and Diarrhea (7 items) were identified as 
clinically relevant and appropriate for the symptoms experienced in this pediatric study 
population, and therefore, are the only scales used in this study. The scales will be completed by 
either the parent or legal guardian and subject as indicated in Table 7-3 at the time points 
outlined in Table 1-2, Table 1-3, and Table 1-4.
For non-commercial use only

Shire
CONFIDENTIAL
Page 60
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD OF OBSERVATION
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any nonserious AEs related to teduglutide that occurred during this 
time and any AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment-related event:

The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.

The event cannot be explained by the subject’s medical condition, other therapies, or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this study 
in the eCRF.
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow-up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the study, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of symptoms should be 
recorded. If a diagnosis has not been made, then each symptom should be listed individually. All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. Closure indicates that an outcome is reached, stabilization achieved 
For non-commercial use only

Shire
CONFIDENTIAL
Page 61
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
(the investigator does not expect any further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
8.1.1
Severity Categorization
The severity of all AEs must be recorded during the course of the event including the start and 
stop dates for each change in severity. An event that changes in severity should be captured as a 
new event. Worsening of pre-treatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
Note that the severity of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) grading criteria (Table 8-1).
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause-and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
The following additional guidance may be helpful:
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
For non-commercial use only

Shire
CONFIDENTIAL
Page 62
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Term
Relationship Definition
suspected response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
Not Related
The event can be readily explained by other factors such as the 
subject’s underlying medical condition, concomitant therapy, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled physical examinations must 
be reported as AEs if the investigator considers the finding to be a clinically significant change 
from the baseline.
8.1.3
Outcome Categorization
The outcome of all AEs must be recorded during the course of the study in the eCRF. Outcomes 
are as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae

Recovering/Resolving

Unknown
8.1.4
Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the disease and are part of the efficacy 
data to be collected in the study; however, significant worsening of the symptoms should be 
recorded as an AE.
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory or vital sign can represent an AE if the change is 
clinically relevant or if, during the study, a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an already abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 63
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study, further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign is clinically significant and 
therefore represents an AE.
8.1.6
Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core study until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633-303 study until the defined follow-up 
period stated in Section 7.1.5.
Any report of pregnancy for any female study participant must be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy Report Form. A copy of the Shire 
Investigational and Marketed Products Pregnancy Report Form (and any applicable follow-up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency contact information section of the protocol. In the event a subject becomes pregnant 
after signing the ICF (and, if applicable, assent), teduglutide administration must be discontinued 
immediately.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. For pregnancy reports during the prospective period of observation, it is 
the responsibility of the investigator to obtain this information within 30 calendar days after the 
initial notification and approximately 30 calendar days post partum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633-303), the initial notification date will be the date the pregnancy is recorded for this 
study and outcome and infant condition information may be collected anytime post partum.
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire Clinical Study Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required by the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Nonserious AEs as required by the Protocol as well as the Shire Investigational and Marketed 
For non-commercial use only

Shire
CONFIDENTIAL
Page 64
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Products Pregnancy Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy onset date.
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may be detrimental to the individual and/or society

Misuse – Intentional use of investigational product other than as directed or indicated 
at any dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed by the protocol)

Overdose – Administration of a dose greater than the allocated dose of the study 
medication or at a frequency greater than the dosing interval specified by the protocol

Medication Error – An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors

Medication errors should be collected/reported for all products under 
investigation

The administration and/or use of an expired investigational product should 
be considered as a reportable medication error
All investigational product provided to pediatric subjects should be supervised by the 
parent/legally-authorized representative/caregiver.
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference for safety information for this study is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
For non-commercial use only

Shire
CONFIDENTIAL
Page 65
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
8.2.2
Reporting Procedures
All SAEs experienced during the retrospective period of observation for the protocol must be 
reported by the investigator to the Shire Global Pharmacovigilance and Risk Management 
Department and the Shire Medical Monitor within 24 hours of first awareness of the event.
All initial and follow-up SAE reports for SAEs experienced during the prospective period of 
observation must be reported by the investigator to the Shire Global Pharmacovigilance and Risk 
Management Department and the Shire Medical Monitor within 24 hours of the first awareness 
of the event. Note: The 24-hour reporting requirement for SAEs does not apply to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by the investigator to the Shire Global 
Pharmacovigilance and Risk Management Department and the Shire Medical Monitor within 24 
hours of the first awareness of the event even if the event does not fulfill seriousness criterion.
The investigator must complete, sign, and date the Shire Clinical Study Adverse Event Form for 
SAEs and Nonserious AEs as Required by Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e-mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy of the completed Shire Clinical 
Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as Required 
by Protocol (and any applicable follow-up reports) must also be sent to the Shire Medical 
Monitor or designee using the details specified in the emergency contact information section of 
the protocol.
8.2.3
Serious Adverse Event Definition
A SAE is any untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 

Results in death

Is life-threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it was more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospitalization for an elective or previously scheduled surgery that meet(s) serious 
criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity

Is a congenital abnormality/birth defect
For non-commercial use only

Shire
CONFIDENTIAL
Page 66
Protocol Amendment 1.1
SHP633-303
09 Jan 2017

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency or 
drug abuse.
8.2.4
Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Pharmacovigilance and Risk Management Department and the Shire Medical 
Monitor within 24 hours of first awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow-up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Pharmacovigilance and Risk Management Department and the Shire Medical Monitor 
within 24 hours of the first awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within 24 hours of the first awareness of 
the event.
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For non-commercial use only

Shire
CONFIDENTIAL
Page 67
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notifying the 
relevant regulatory authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notifying active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
8.3
Adverse Events of Special Interest
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
the investigator to the sponsor is required.
The AEs of special interest that require expedited regulatory reporting include the following:

Growth of pre-existing polyps of the colon

Benign neoplasia of the GI tract including the hepatobiliary system

Tumor-promoting ability (eg, benign and/or malignant neoplasia of any kind, not limited 
to those of the GI or hepatobiliary system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within 24 hours of first awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5 apply only to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contacting the sponsor/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may include but are 
not limited to hospitalization, AEs, a lapse in investigational product delivery, etc.
For non-commercial use only

Shire
CONFIDENTIAL
Page 68
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Study drug must be discontinued if any of the following events occur:

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to be related 
to study drug. This does not include the presence of anti-teduglutide antibodies, mild
injection site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.

An AE listed in (Table 8-1) that is of NCI CTCAE severity Grade 3 or 4 and considered 
to be related to study drug administration

Confirmed drug-induced liver injury (DILI) related to teduglutide (see Section 8.4.2)
8.4.1
Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only)
The investigational product may be discontinued if the subject has an AE listed in Table 8-1 that 
is of severity ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor or designee as soon as possible. Teduglutide administration must be 
discontinued if the AE is considered related to the investigational product. The length of the dose 
interruption, and whether teduglutide administration resumes or is permanently discontinued, 
depends on the clinical situation.
Investigators and the data monitoring committee (DMC) should be guided by the descriptions of 
Grade 3 and 4 events, as they relate to known and possible risks associated with the 
administration of teduglutide.
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events
Grade 3 Description
Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps
Severe or medically significant but not 
immediately life threatening; 
hospitalization or prolongation of 
existing hospitalization indicated; 
disabling; limiting self-care activities of 
daily living
Life-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction
Hospitalization indicated; elective 
operative intervention indicated; limiting 
self-care activities of daily living; 
disabling
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis
Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation
Not Applicable
Life-threatening consequences; urgent 
For non-commercial use only

Shire
CONFIDENTIAL
Page 69
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events
Grade 3 Description
Grade 4 Description
intervention indicated
Gallbladder obstruction
Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospitalization indicated; nonemergent 
operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection
Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicated
Life-threatening consequences; urgent 
intervention indicated
Adverse Events
Grade 3 Description
Grade 4 Description
Alkaline Phosphatase 
increased
>5.0 to 20.0x ULN
>20.0x ULN
Blood bilirubin increased
>3.0 to 10.0x ULN
>10.0x ULN
Bile duct stenosis
Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis
Severe pain; vomiting; medical 
intervention indicated (eg, analgesia, 
nutritional support)
Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis
Severely altered gastrointestinal function; 
tube feeding or hospitalization indicated; 
elective operative intervention indicated
Life-threatening consequences; urgent 
operative intervention indicated
Pancreas infection
Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicated
Life-threatening consequences; urgent 
intervention indicated
Serum amylase increaseda
>2.0 to 5.0x ULN
>5.0x ULN
Lipase increaseda
>2.0 to 5.0x ULN
>5.0x ULN
Cardiovascular Disease
Heart failure
Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicated
Life-threatening consequences; urgent 
intervention indicated (eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, 14 June 2010
ULN=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis
For non-commercial use only

Shire
CONFIDENTIAL
Page 70
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may need to be interrupted if the subject has 
clinical and laboratory evidence of potential DILI, in the absence of an alternative explanation, 
as identified by the following criteria:

ALT or AST >8x ULN

ALT or AST >5x ULN and >2x baseline value for more than 2 weeks

(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)

ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory values suggestive of potentially new DILI should be repeated and verified within 
3 days. International normalized ratio should be measured with this set of verification laboratory 
assessments and an inquiry should be made as to the presence of clinical symptoms consistent 
with new liver injury. The subject should be followed closely to determine the trajectory of the 
laboratory abnormalities and to evaluate the cause of liver injury. This evaluation may include, 
as clinically indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cytomegalovirus IgM, 
Epstein-Barr virus antibody panel), hepatobiliary obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti-actin, or anti-liver kidney microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permanently discontinued if DILI is confirmed and deemed 
related to study drug.
8.5
Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may recommend stopping the study if:

≥2 subjects develop the same event listed in Table 8-1 of severity CTCAE Grade 3
or

1 subject develops an event listed in Table 8-1 of severity CTCAE Grade 4 which is 
attributable to investigational product or is not reasonably related to the underlying 
disease process
For non-commercial use only

Shire
CONFIDENTIAL
Page 71
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
9
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
in the eCRF. A study monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safety follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality control and data validation procedures are applied to ensure the validity and 
accuracy of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed 
using SAS® (SAS Institute, Cary, NC, USA) version 9.3 or higher.
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4
Planned Interim Analysis, and Data Monitoring Committee
An interim analysis of all retrospective data will be conducted. Other interim analyses may also 
be conducted if needed.
A DMC will be involved in the management of this study. The DMC members will review the 
data approximately every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety data (ie, AEs, laboratory assessments, physical examinations, etc.) 
from study assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only

Shire
CONFIDENTIAL
Page 72
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
The DMC will be an external, independent board comprised of physicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory in nature. The DMC will be governed by a 
Charter agreed to by members of the Board and the sponsor. Members of the Board may not be 
study investigators or be employed at the same institution as a study investigator, individuals 
employed by the sponsor, independent contractors hired by the sponsor, or members of 
regulatory agencies. The DMC may make recommendations to the sponsor regarding study 
aspects including stopping, modifying or continuing the study; however, the sponsor will have 
the final responsibility to determine whether the study should be modified or temporarily or 
permanently stopped.
9.5
Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects was determined by enrollment in 
TED-C13-003.
9.6
Study Population
The safety population includes all enrolled subjects in the study. The safety population will be 
used for both safety and efficacy analyses.
9.7
Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or 
first exposure to teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
9.8
Safety Analyses
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
For non-commercial use only

Shire
CONFIDENTIAL
Page 73
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
for quantitative safety data as well as for the difference from baseline, if applicable. Frequency 
counts will be compiled for classification of qualitative safety data.
9.8.1
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study 
period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing including fetal occult blood testing and colonoscopy or 
sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) 
to the beginning of the prospective study period:

Adverse events related to teduglutide

All SAEs

All AESIs (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study 
(TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
body mass index
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by System Organ Class and by preferred term. Serious adverse events will be further 
summarized by severity and relationship to investigational product. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization-Drug 
Dictionary (WHO-DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history (including 
surgical/procedural history) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by system organ class and preferred term. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 74
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
For clinical laboratory tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional safety parameters and measures will include change in body weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z-score, BMI, and BMI z-score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9
Other Analyses
9.9.1
Health-related Quality of Life Analyses
Health economics and outcomes research endpoints will be analyzed at approximately 12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study period. The beginning of 
each treatment cycle (CxD1) will be an additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:

Food and drink limits

Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 75
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
10
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH Good Clinical Practice (GCP) Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO as necessary. 
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 76
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an EOS declaration to the relevant competent authority as required by 
Article 10 (c) of Directive 2001/20/EC.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by the signed and dated signature of the 
principal investigator (single-site study) or coordinating principal investigator (multicenter 
study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH 
Guidance E3 (1995). 
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 77
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by international regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly into the 
eCRF.
Electronic case report forms should be approved by the investigator per study specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory reports, and histology and 
pathology reports.
All key data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the eCRF 
entries against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory authorities, or the IRB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X-rays etc.). Nonstudy site personnel will not 
disclose any personal information or personal medical information.
For non-commercial use only

Shire
CONFIDENTIAL
Page 78
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA, 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Agency) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory authorities), the 
European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory 
Agency, other regulatory authorities, the sponsor or its representatives, and the IRB/EC for each 
site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for
ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, where 
applicable, from all study subjects prior to any study-related procedures including screening 
assessments. All consent and assent documentation must be in accordance with applicable 
regulations and GCP. Each subject or the subject’s legally-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully executed signature pages) must be given to the subject or the 
subject’s legally-authorized representative, as applicable. This document may require translation 
into the local language. Signed consent forms must remain in each subject’s study file and must 
be available for verification at any time.
For non-commercial use only

Shire
CONFIDENTIAL
Page 79
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legally-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study subject.
The principal investigator provides the sponsor with a copy of the consent form, and assent form 
where applicable, which was reviewed by the IRB/EC and which received their favorable 
opinion/approval. A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study unless it is agreed to 
and documented (abiding by regulatory guidelines and national provisions) prior to study start 
that another party (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally, if the IRB/EC requires modification of the sample subject information and 
consent document provided by the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity as defined by HIPAA must provide documentation of 
this fact to the sponsor (or designee).
For non-commercial use only

Shire
CONFIDENTIAL
Page 80
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representatives 
review their medical records and data collected during the study. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP633; national or local regulatory authorities; and the IRBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subject).
The results of studies – containing subjects’ unique identifying number, relevant medical 
records, and possibly initials and dates of birth – will be recorded. They may be transferred to, 
and used in, other countries which may not afford the same level of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities.
10.5
Study Results / Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the 
publication steering committee is to act as a noncommercial body that advises or decides on 
dissemination of scientific study data in accordance with the scope of this policy.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
For non-commercial use only

Shire
CONFIDENTIAL
Page 81
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any rights to authorship of 
publications.
For non-commercial use only

Shire
CONFIDENTIAL
Page 82
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
11
REFERENCES
Drucker, D. J. & Yusta, B. 2014. Physiology and pharmacology of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonomy in Children with Intestinal Failure: A Multicenter Cohort Study. J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 
analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy, K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs-Lasky, M. & Belle, S. H. 2012. Natural 
history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon-like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL 
Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg, 39, 690-
5.
For non-commercial use only

Shire
CONFIDENTIAL
Page 83
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
12
APPENDICES
For non-commercial use only

Shire
CONFIDENTIAL
Page 84
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
APPENDIX 1
PROTOCOL HISTORY
Document
Date
Global/Country/Site Specific
Original Protocol
11 May 2016
Global
Amendment 1
22 Nov 2016
Global
Amendment 1.1
09 Jan 2017
UK Specific
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Title of the Shire medical monitor has been changed to Medical 
Director for clarity.
Protocol Signature Page
Emergency Contact Information
Clarification has been made that during the no-teduglutide treatment 
period, visits will take place approximately every 12 weeks.
Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3-1
The study design flow chart has been edited for clarity.
Synopsis
Figure 3-1
The collection of all actual and prescribed enteral nutrition data has 
been removed to reduce the burden on the subjects and investigators. 
Enteral nutrition data are not required as the efficacy endpoints are 
limited to parenteral support parameters.
Synopsis
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.2, 7.1.3, 7.1.4.1, 
7.1.4.2, 7.1.6, 7.2.2.11, 7.2.2.12
Exclusion criterion 11 has been revised to add Smoflipid as other 
experimental drugs that are allowed prior and during the study. Like 
glutamine and Omegaven, Smoflipid is not expected to interfere with 
the assessments of safety and efficacy of teduglutide and many subjects 
may already be receiving the treatments off-label as part of standard 
medical therapy.  
Synopsis
Section 4.5
Exclusion criterion 12 and prohibited treatment have been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to 3 months for consistency with other teduglutide studies. 
Synopsis
Section 4.5
Table 5-1
Retrospective data collection has been removed from the duration of the 
study for clarity.
Synopsis
Language in efficacy and safety endpoints has been clarified.
Synopsis
Sections 9.7.1, 9.8.1
Instructions on recording retrospective data for teduglutide and PS 
usage, and growth parameters have been refined.
Table 1-1
Sections 7.1.1, 7.2.1.2, 7.2.1.3
Completion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.
Table 1-2, Table 1-3, Table 1-4
Sections 7.1.2, 7.1.4.1, 7.1.4.2, 7.1.6, 
7.2.2.12
For non-commercial use only

Shire
CONFIDENTIAL
Page 85
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
The requirement for urine specimen collection has been revised so that 
a lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects wearing diapers).
Table 1-2, Table 1-3, Table 1-4
Section 7.2.2.5
Clarification has been made that the first no-teduglutide treatment visit 
after the screening visit will occur within 2 to 12 weeks of the screening 
(formerly within 12 weeks of screening). 
Synopsis
Table 1-3
Sections  3.1.3, 7.1.2
Windows have been clarified for visits during the no-teduglutide and 
teduglutide treatment periods.
Table 1-3, Table 1-4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. By definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. 
Table 1-3 
Sections 7.2.2.8, 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. 
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.3, 7.2.2.10
Removal of former footnote j on fecal occult blood test for clarity.
Table 1-4
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit.  
Table 1-4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects 
with SBS has been clarified, and text on intestinal adaptation has been 
refined.
Section 1.1
Status of current teduglutide approvals for use has been updated.
Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced with ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency with other 
studies.
Synopsis
Sections 3.1, 3.1.3
Evaluations to be performed when a subject discontinues teduglutide or 
when withdraws from the study have been clarified.
Sections 4.8.1, 4.8.2
Withdrawal by parent/guardian has been added as reason for 
discontinuation.
Section 4.8.3
COUMADIN has been changed to warfarin for clarity.
Sections 5.1,  5.1.2
Clarification has been made on handling of study drug, which is for 
single use only and should be used within 3 hours following 
reconstitution.  
Section 6.3.3
The investigator or designee may now dispense the unused study drug 
vials to the same subject if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
drug has been clarified.
Section 6.4
Paragraph on the purpose of prospective data collection has been 
deleted for clarity.
Section 7.2.2
Clarification has been made on the collection of medical history and 
SBS history.
Synopsis
Sections 3.1.3, 7.1.2, 7.2.2.1
For non-commercial use only

Shire
CONFIDENTIAL
Page 86
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. 
Section 7.2.2.3
Clarification has been made that local laboratory results are not 
required to be entered in the eCRFs. (formerly Section 7.2.2.4)
Section 7.2.2.5
Collection of urine sodium and urine osmolality has been removed.
Section 7.2.2.5
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow-up period escape 
criterion. (formerly Section 7.2.2.5)
Section 7.2.2.6
Nutritional support and diaries (formerly in Section 7.2.2.9) have been 
moved under separate sections (Sections 7.2.2.11 and 7.2.2.12, 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be reviewed at each clinic and telephone 
visit.
Sections 7.2.2.11, 7.2.2.12 
Performance of dipstick specific gravity tests by the subject at home on 
the first urine produced after the daily infusions of PS has been 
removed. It is now at the discretion of the investigator for all subjects, 
not just those in diapers. This change is to align with standard medical 
practice.
Section 7.2.2.12
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related) to teduglutide need 
to be reported. No changes to the protocol were made for the reporting 
of all AEs of special interest or any serious adverse events, regardless 
of relationship to teduglutide, that occurred during the retrospective 
period.
Section 8.1
The timeframe for collecting and reporting AESIs and SAEs occurring 
during the retrospective period of the study has been clarified.
Sections 8.2.2, 8.2.4, 8.3
Minor clarifications have been made to the language on dose 
interruption.
Sections 8.4, 8.4.1
Unscheduled safety follow up assessments (including visits conducted 
after EOS) are not to be recorded. However, clarification has been made 
that they are to be collected where requested.
Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.
Section 9.4
The protocol now refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.
Section 9.4
Minor corrections have been made to the guidelines for nutritional 
support management during the study.
Appendix 2
For non-commercial use only

Shire
CONFIDENTIAL
Page 87
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
APPENDIX 2
GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 

Growth trajectory, including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)

Other clinical evaluations

Serum electrolytes

Blood urea nitrogen /creatinine levels

Changes in stool frequency or volume, including mixed output

Stool consistency (ie, Bristol Stool Scale)

Urine specific gravity

General consideration to possible clinical deterioration in SBS

Inability to maintain weight and growth velocity

Diarrhea (≥10 bowel movements per day, ≥80 mL/kg/day from an ostomy, or 
≥75 mL/kg/day mixed output)

Colic/vomiting frequency increased

Electrolyte changes or imbalance

Skin breakdown 

Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the study.

Nutritional support constituents may be adjusted at the discretion of the investigator.

During the 48-hour output measurement period prior to the subject’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.

If there is a change in enteral nutrition (EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only

Shire
CONFIDENTIAL
Page 88
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Figure A-1
Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 89
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Figure A-2
Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 90
Protocol Amendment 1.1
SHP633-303
09 Jan 2017
Figure A-3
Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only

PROTOCOL: SHP633-303
TITLE:
A Retrospective and Prospective, Open-label, Long-term Safety and 
Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED-C13-003
DRUG:
Teduglutide
IND:
IND# 058213
EUDRACT NO.:
2016-000863-17
SPONSOR:
Shire Human Genetic Therapies, Inc.
300 Shire Way, Lexington, MA 02421 USA
PROTOCOL 
HISTORY:
Amendment 2: 17 Mar 2017
Amendment 1.1: 09 Jan 2017 (United Kingdom-Specific)
Amendment 1: 22 Nov 2016
Original Protocol: 11 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only

PAGE 
Sponsor's (Shire) Approval 
-
_ 
_J 
Andrew Grim
1 
I 
r 
1 
II 
L
evelopment 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-003 
I have fully discussed the objective(s) of this study and the contents ofthis protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
Shire
CONFIDENTIAL
Page 2
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
PROTOCOL SIGNATURE PAGE
For non-commercial use only

Shire
CONFIDENTIAL
Page 3
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
SUMMARY OF CHANGES FROM PREVIOUS VERSION
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2
Amendment Date
17 Mar 2017
Global
Description of Change and Rationale
Section(s) Affected by Change
Updated emergency contact information.
Emergency Contact Information; 
Section 8.1.6; Section 8.2.2; Section 
8.2.4
Revised teduglutide treatment inclusion criterion #1 to ensure that
subjects whose prior exposure to teduglutide in Study TED-C13-003 
may not have been enough to assess efficacy are eligible to receive
treatment in Study SHP633-303.
Study Synopsis; Section 4.4
Revised teduglutide treatment exclusion criterion #11 to add 
teduglutide to the list of experimental drugs exempt of a washout period 
before initiating teduglutide treatment in Study SHP633-303. 
Study Synopsis; Section 4.5; Section 
5.1.2
A footnote was added at the pretreatment visit in the Schedule of 
Events for Subjects While Receiving Teduglutide to underscore that,
when the first pretreatment visit (P1) follows the screening visit, it must 
occur within 12 weeks of screening.
Table 1-4
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.
Section 4.7.1
Clarification that ancillary components, in addition to sterile water for 
injection syringes, will also be provided and labeled in accordance with 
the applicable regulatory requirements.
Section 6.3.1
A footnote was added in Table 7-3 to clarify that subjects older than 
18 years of age will continue to use the Child Self Report and Parent 
Proxy-Report for Teens (ages 13-18) when completing the Pediatric 
Quality of Life Generic Core Scale (PEDSQL™).
Section 7.2.2.13 (Table 7-3)
Revised the text on severity categorization to specify that a severe 
treatment-emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study 
(Section 8.5) will also be graded according to the National Cancer 
Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) severity grading criteria, in addition to the standard severity 
categorization. These events are no longer limited to only the events 
described in Table 8-1, entitled “CTCAE Criteria for Adverse Events 
that May Lead to Dose Interruption (Prospective Period of Observation 
Only). Therefore, Table 8-1 has been deleted.
Section 8.1.1; Section 8.4; Section 
8.4.1; Table 8-1 (deleted)
Revised the criteria for early termination of the study as requested by 
the US FDA in their letter dated 06 Jan 2017: stopping criteria were 
extended to all NCI CTCAE Grade 3 and 4 severity events reported as
related to the investigational product, and no longer limited to the 
events described in Table 8-1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of 
Section 8.5
For non-commercial use only

Shire
CONFIDENTIAL
Page 4
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2
Amendment Date
17 Mar 2017
Global
Description of Change and Rationale
Section(s) Affected by Change
Observation Only).
See Appendix 1 for protocol history, including all amendments.
For non-commercial use only

Shire
CONFIDENTIAL
Page 5
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required by Protocol within 24 hours to the Shire Global Drug Safety Department. Applicable 
fax numbers and e-mail address can be found on the form (sent under separate cover). A copy of 
this form must also be sent to the Shire Medical Monitor by fax or e-mail using the details 
below.
, MD PhD
Email: 
Fax: 
For protocol- or safety-related issues, the investigator must contact Quintiles Medical 
Support:
Primary contact for United States and backup contact for United Kingdom
, MD, 
Mobile: 
US Toll Free number: 
Phone: 
 (medical emergencies – US)
Email: 
Primary contact for United Kingdom and backup contact for United States
, MD, 
Mobile: 
Phone: 
Phone: 
 (medical emergencies – UK)
Email: 
In addition, the investigator may also contact the Shire Medical Monitor:
, MD PhD, 
Phone: 
Mobile: 
Email: 
-
mer al use only

Shire
CONFIDENTIAL
Page 6
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints to Shire within 
24 hours. This includes any instances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint
E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire (USA) 
For non-commercial u
 only

Shire
CONFIDENTIAL
Page 7
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSION........................................................3
EMERGENCY CONTACT INFORMATION................................................................................5
PRODUCT QUALITY COMPLAINTS..........................................................................................6
TABLE OF CONTENTS.................................................................................................................7
LIST OF TABLES.........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
LIST OF APPENDICES................................................................................................................12
ABBREVIATIONS .......................................................................................................................13
STUDY SYNOPSIS ......................................................................................................................15
STUDY SCHEDULES..................................................................................................................21
1
BACKGROUND INFORMATION.......................................................................................27
1.1
Indication and Current Treatment Options...............................................................27
1.2
Product Background.................................................................................................27
1.3
Clinical Studies with Teduglutide in Pediatric Subjects ..........................................28
2
STUDY OBJECTIVES AND PURPOSE ..............................................................................29
2.1
Rationale for the Study.............................................................................................29
2.2
Study Objectives ......................................................................................................29
2.2.1
Primary Objectives .........................................................................................29
2.2.2
Secondary Objectives .....................................................................................29
3
STUDY DESIGN ...................................................................................................................30
3.1
Study Design and Flow Chart ..................................................................................30
3.1.1
Informed Consent/Assent and Eligibility .......................................................31
3.1.2
Retrospective Data Collection........................................................................31
3.1.3
Prospective Data Collection and Treatment ...................................................32
3.2
Duration and Study Completion Definition .............................................................34
4
STUDY POPULATION.........................................................................................................35
4.1
Study Inclusion Eligibility Criteria ..........................................................................35
4.2
Study Exclusion Eligibility Criteria .........................................................................35
4.3
Teduglutide Eligibility Criteria ................................................................................35
4.4
Teduglutide Treatment Inclusion Criteria................................................................35
4.5
Teduglutide Treatment Exclusion Criteria...............................................................36
4.6
Follow-up Period Escape Criteria ............................................................................37
4.7
Reproductive Potential .............................................................................................37
4.7.1
Female Contraception.....................................................................................37
For non-commercial use only

Shire
CONFIDENTIAL
Page 8
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
4.8
Discontinuation of Subjects .....................................................................................38
4.8.1
Teduglutide Discontinuation ..........................................................................38
4.8.2
Study Withdrawal ...........................................................................................38
4.8.3
Reasons for Discontinuation...........................................................................39
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit ..................39
5
CONCOMITANT TREATMENT..........................................................................................40
5.1
Concomitant Medications and GI Procedures..........................................................40
5.1.1
Permitted Treatment .......................................................................................40
5.1.2
Prohibited Treatment ......................................................................................40
6
INVESTIGATIONAL PRODUCT ........................................................................................42
6.1
Identity of Investigational Product...........................................................................42
6.1.1
Blinding the Treatment Assignment...............................................................42
6.2
Administration of Investigational Product(s)...........................................................42
6.2.1
Interactive Response Technology for Investigational Product 
Management ...................................................................................................42
6.2.2
Allocation of Subjects to Treatment...............................................................42
6.2.3
Dosing.............................................................................................................42
6.2.4
Unblinding the Treatment Assignment...........................................................43
6.3
Labeling, Packaging, Storage, and Handling ...........................................................43
6.3.1
Labeling..........................................................................................................43
6.3.2
Packaging........................................................................................................43
6.3.3
Storage and Handling .....................................................................................44
6.4
Drug Accountability.................................................................................................44
6.5
Subject Compliance..................................................................................................45
7
STUDY PROCEDURES........................................................................................................46
7.1
Study Schedule.........................................................................................................46
7.1.1
Retrospective Data Collection........................................................................46
7.1.2
Screening ........................................................................................................47
7.1.3
Visits for Subjects Not Receiving Teduglutide ..............................................48
7.1.4
Visits for Subjects Receiving Teduglutide Treatment....................................48
7.1.4.1
Pretreatment Visit...................................................................................48
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24).....................................49
7.1.5
Teduglutide Follow-up Period........................................................................51
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)..........................51
7.2
Study Evaluations and Procedures ...........................................................................52
7.2.1
Retrospective Data Collection........................................................................52
7.2.1.1
Growth (Height, Weight, and Head Circumference) .............................52
For non-commercial use only

Shire
CONFIDENTIAL
Page 9
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
7.2.1.2
Prior Teduglutide Treatment Prescribed ................................................52
7.2.1.3
Parenteral Support Prescribed ................................................................53
7.2.1.4
Adverse Events.......................................................................................53
7.2.2
Prospective Data Collection ...........................................................................53
7.2.2.1
Demographics, Medical History, and SBS History................................53
7.2.2.2
Physical Examination.............................................................................53
7.2.2.3
Adverse Event Collection.......................................................................53
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body 
Mass Index (BMI) ..................................................................................53
7.2.2.5
Clinical Laboratory Tests.......................................................................54
7.2.2.6
Serum Sampling.....................................................................................56
7.2.2.7
Pregnancy Testing..................................................................................56
7.2.2.8
Antibody Testing....................................................................................56
7.2.2.9
Volume of Blood....................................................................................56
7.2.2.10
Gastrointestinal-specific Testing............................................................57
7.2.2.11
Nutritional Support.................................................................................58
7.2.2.12
Diaries ....................................................................................................58
7.2.2.13
Health-related Quality of Life Assessments...........................................59
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................62
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................62
8.1.1
Severity Categorization ..................................................................................63
8.1.2
Relationship Categorization............................................................................63
8.1.3
Outcome Categorization.................................................................................64
8.1.4
Symptoms of the Disease under Study...........................................................64
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period 
of Observation Only) ......................................................................................64
8.1.6
Pregnancy .......................................................................................................65
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only) ..........................................................................................66
8.2
Serious Adverse Event Procedures ..........................................................................67
8.2.1
Reference Safety Information.........................................................................67
8.2.2
Reporting Procedures......................................................................................67
8.2.3
Serious Adverse Event Definition ..................................................................67
8.2.4
Serious Adverse Event Collection Time Frame .............................................68
8.2.5
Serious Adverse Event Onset and Resolution Dates......................................68
8.2.6
Fatal Outcome.................................................................................................69
For non-commercial use only

Shire
CONFIDENTIAL
Page 10
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and 
Site Reporting.................................................................................................69
8.3
Adverse Events of Special Interest...........................................................................69
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only).........................................................................................................................70
8.4.1
Dose Interruption Criteria Based on Adverse Event Severity and 
Relationship to Investigational Product (Prospective Period of 
Observation Only) ..........................................................................................70
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)......................................................70
8.5
Early Termination of the Clinical Study (Prospective Period of Observation 
Only).........................................................................................................................71
9
DATA MANAGEMENT AND STATISTICAL METHODS...............................................72
9.1
Data Collection.........................................................................................................72
9.2
Clinical Data Management.......................................................................................72
9.3
Statistical Analysis Process......................................................................................72
9.4
Planned Interim Analysis, and Data Monitoring Committee...................................72
9.5
Sample Size Calculation and Power Considerations................................................73
9.6
Study Population ......................................................................................................73
9.7
Efficacy Analyses.....................................................................................................73
9.7.1
Efficacy Endpoints..........................................................................................73
9.8
Safety Analyses........................................................................................................73
9.8.1
Safety Endpoints.............................................................................................74
9.9
Other Analyses .........................................................................................................75
9.9.1
Health-related Quality of Life Analyses.........................................................75
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES...........................................76
10.1
Sponsor’s Responsibilities .......................................................................................76
10.1.1
Good Clinical Practice Compliance................................................................76
10.1.2
Indemnity/Liability and Insurance..................................................................76
10.1.3
Public Posting of Study Information ..............................................................76
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ................77
10.1.5
Study Suspension, Termination, and Completion ..........................................77
10.2
Investigator’s Responsibilities .................................................................................77
10.2.1
Good Clinical Practice Compliance................................................................77
10.2.2
Protocol Adherence and Investigator Agreement...........................................78
10.2.3
Documentation and Retention of Records......................................................78
10.2.3.1
Case Report Forms.................................................................................78
For non-commercial use only

Shire
CONFIDENTIAL
Page 11
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents..............................................................................................78
10.2.3.3
Audit/Inspection.....................................................................................79
10.2.3.4
Financial Disclosure...............................................................................79
10.3
Ethical Considerations..............................................................................................79
10.3.1
Informed Consent ...........................................................................................79
10.3.2
Institutional Review Board or Ethics Committee...........................................80
10.4
Privacy and Confidentiality......................................................................................81
10.5
Study Results / Publication Policy ...........................................................................81
11 REFERENCES .......................................................................................................................83
12 APPENDICES ........................................................................................................................84
For non-commercial use only

Shire
CONFIDENTIAL
Page 12
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
LIST OF TABLES
Table 1-1
Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................21
Table 1-2
Schedule of Events for Screening and End of Study or Early 
Termination ...................................................................................................22
Table 1-3
Schedule of Events for No Teduglutide Treatment Period ...........................23
Table 1-4
Schedule of Events for Teduglutide Treatment Period .................................24
Table 5-1 
Prohibited Treatment.....................................................................................41
Table 7-1
List of Laboratory Tests ................................................................................55
Table 7-2
Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................57
Table 7-3
Developmentally Appropriate PedsQL™Generic Core Scales .....................60
LIST OF FIGURES
Figure 3-1
Study Design Flow Chart ..............................................................................33
LIST OF APPENDICES
Appendix 1
Protocol History.............................................................................................85
Appendix 2
Guidelines for Nutritional Support Management During the Study .............89
For non-commercial use only

Shire
CONFIDENTIAL
Page 13
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
-HCG
beta-human chorionic gonadotropin
BMI
body mass index
CRA
clinical research associate
CRO
contract research organization
CSR
clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
drug-induced livery injury
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase 4
EC
ethics committee
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EN
enteral nutrition
EOS
end of study
EOT
end of treatment
ET
early termination
EU
European Union
FDA
Food and Drug Administration
FOBT
fecal occult blood test
FOCBP
female of child-bearing potential
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide 1
GLP-2
glucagon-like peptide 2
HIPAA
Health Insurance Portability and Accountability Act
ICF
informed consent form
ICH
International Conference on Harmonization
IGF-1
insulin-like growth factor 1
IRB
institutional review board
IV
intravenous
IWRS
interactive web-based response system
MedDRA
Medical Dictionary for Regulatory Activities
NCI
National Cancer Institute
NDA
new drug application
For non-commercial use only

Shire
CONFIDENTIAL
Page 14
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
NTT
no-teduglutide treatment
PDA
patent ductus arteriosus
PedsQL
Pediatric Quality of Life Inventory
PS
parenteral support
PT/INR
prothrombin time/international normalized ratio
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SBS
short bowel syndrome
SC
subcutaneous
SOC
standard of care
t1/2
elimination half-life
TEAE
treatment-emergent adverse event
TESAE
treatment-emergent serious adverse event
UK
United Kingdom
ULN
upper limit of normal
US
United States
WHO-DD
World Health Organization-Drug Dictionary
For non-commercial use only

Shire
CONFIDENTIAL
Page 15
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
STUDY SYNOPSIS
Protocol number: SHP633-303
Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003
Number of subjects (total and for each treatment arm):
Approximately 40 subjects who completed the TED-C13-003 study, including subjects in the standard of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED-C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the United States (US) and the United Kingdom (UK) will participate in 
this extension study.
Study period (planned):
October 2016-September 2019
Clinical phase:
3 Extension
Objectives:
Primary: To evaluate the long-term safety and tolerability of teduglutide treatment in pediatric subjects with short 
bowel syndrome (SBS) who completed TED-C13-003.
Secondary: To evaluate long-term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED-C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED-C13-003 study. In addition to 
evaluating the long-term safety and durability of efficacy after 12 weeks of treatment in TED-C13-003, this 
extension study will evaluate the need for additional teduglutide treatment in these subjects, and will allow for the 
first-time treatment of teduglutide-naïve subjects who participated in the standard of care (SOC) treatment arm in 
TED-C13-003.
Investigational product, dose, and mode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED-C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of 
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
between the date of the TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
For non-commercial use only

Shire
CONFIDENTIAL
Page 16
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
for all subjects.
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and Section 7.1.1. For subjects 
that only consent to retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were completed in the course 
of the subject’s standard medical care between the date of the TED-C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide treatment

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1-2. These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. The parenteral support prescription will also be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section 7.2.2.12). Diary data for PS volume will be collected for at least 2 weeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no-teduglutide treatment [NTT] period), will be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed immediately to the pretreatment visit if 
the investigator, subject, and parent or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4-week follow-up (no treatment) period (Figure 3-1). During 
the 28-week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 weeks. To maintain 
consistency across centers, all attempts should be made to follow the nutritional support adjustment guidelines 
(developed with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only

Shire
CONFIDENTIAL
Page 17
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 
1 week after adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects 
discontinue teduglutide at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be 
performed weekly (solid grey lines). If an escape criterion is met during the follow-up period, subjects may proceed directly 
to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet all of the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.
Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study-related procedures.
2.
Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
3.
Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria, and none of the 
teduglutide treatment exclusion criteria, are met. In addition, the investigator and the subject (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria:
1.
Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds (eg, 10% or less 
change in PS or advance in feeds) for at least 3 months prior to and during the teduglutide pretreatment 
visit, as assessed by the investigator. Transient instability for events such as interruption of central access 
or treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the event.
2.
Subject was previously treated with teduglutide and at least 1 of the following criteria is satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b.
Decreased PS requirement during prior teduglutide treatment, followed by cessation of 
For non-commercial use only

Shire
CONFIDENTIAL
Page 18
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition following teduglutide discontinuation
d.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.
Body weight <10 kg at the pretreatment visit
2.
Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.
History of cancer in the previous 5 years except surgically curative skin cancers
4.
Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10 cm, and endoscopic procedures are allowed.
5.
Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6.
Clinically significant intestinal stricture or obstruction
7.
Clinically significant, active or recurrent pancreatic or biliary disease
8.
Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b.
Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9.
Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects 
who had undergone ventricular or atrial septal defect repair, or patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, Smoflipid, 
or teduglutide) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to 
the pretreatment visit and for the duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) (not
including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, within 3 months 
preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior to the 
pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related 
compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16. Pregnant or lactating female subjects
17. Sexually active female subjects of child-bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the subject at any 
undue risk, prevents completion of the study, or interferes with analysis of the study results
For non-commercial use only

Shire
CONFIDENTIAL
Page 19
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow-up period may be interrupted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.
Increasing PS requirements following teduglutide discontinuation
2.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated enteral 
nutrition following teduglutide discontinuation
3.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake 
following teduglutide discontinuation
4.
Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvement in the study:
A subject will be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple 28-week treatment cycles. The study will continue for at least 1 year, and until each 
subject has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately 3 years. A subject will be considered as having completed the study if the subject has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.

Planned duration of no-teduglutide treatment periods: variable, depending on disease course

Planned duration of the teduglutide pretreatment visit: 1-21 days

Planned teduglutide treatment cycle duration: 28 weeks. Each cycle consists of 24 weeks of 
teduglutide treatment followed by a 4-week follow-up period (no treatment)
Endpoints and statistical analysis:

The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
Health Economics and Outcomes Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an 
additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:
o
Food and drink limits
o
Diarrhea
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure
For non-commercial use only

Shire
CONFIDENTIAL
Page 20
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) to the beginning of 
the prospective study period:

Adverse events related to teduglutide

All SAEs

All Adverse Events of Special Interest (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study (TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compiled for classification of 
qualitative safety data.
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by enrollment in TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 21
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
STUDY SCHEDULES
Table 1-1 Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment
Note
Informed consent/assent
Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study-related 
procedures, including retrospective data collection.
Study eligibility
Weighta
The last representative value for weight during each 12-week interval 
throughout the retrospective data collection period will be captured.
Height and head circumferencea
The last representative value for height during each 12-week interval 
throughout the retrospective data collection period will be captured. Head 
circumference should be provided for subjects 36 months of age and younger at 
the time the data were collected, if available.
Prior teduglutide treatment
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, 
compassionate use, and named-patient access programs.
Parenteral support (PS) 
prescribeda
The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per week of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED-C13-003
Teduglutide-related AEs
Teduglutide-related AEs must be deemed by the investigator to be related to 
teduglutide treatment.
AEs of special interest
Serious adverse events (SAEs)
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED-C13-003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a  The first 12-week interval begins at TED-C13-003 EOS visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 22
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Table 1-2 Schedule of Events for Screening and End of Study or Early Termination
Screening
End of Study or Early 
Termination
Visit Type
Site
Site
Informed consent/assent
X
Study eligibility
X
Demographics, medical history, SBS historya
X
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriab
X
Adverse events
X
X
Concomitant medications and GI proceduresc
X
X
Physical examination and vital signs, including weight
X
X
Height and head circumferenced
X
X
Review intake and output diariese
X
Record PS prescription and adjust as neededf
X
X
Safety laboratory testsg
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-Scales
X
Antibodies to teduglutideh
X
Fecal occult blood testingi
(X)
Colonoscopy or sigmoidoscopyj
(X)
Pregnancy testingk
(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
a If the subject has any changes to the medical history and SBS history that had been collected at the baseline of the TED-C13-
003 study, then the updated medical history and SBS history will be collected.
b Subjects who meet ≥1 teduglutide treatment inclusion criteria may proceed to the pretreatment visit if the investigator, subject, 
and parent or legal guardian agrees to proceed with teduglutide therapy (Table 1-4).
c Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
d Head circumference will be measured in subjects 36 months of age and younger.
e The intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48-hour period of nutritional stability before the EOS/ET visit.
f Parenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix 2.
g Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
h Required for all teduglutide-exposed subjects.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 48-
60 weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no-teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section 7.2.2.10 for details.
k Pregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 23
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Table 1-3 Schedule of Events for No Teduglutide Treatment Period
Visit Number
NTx
Visit Type
Site
Visit Frequencya
Every 12 weeks
Window (days)b
±7
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriac
X
Adverse events
X
Concomitant medications and GI proceduresd
X
Physical examination and vital signs, including weight
X
Height and head circumferencee
X
Review intake and output diariesf 
X
Record PS prescription and adjust as neededg
X
Safety laboratory testsh
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-Scales
X
Antibodies to teduglutidei
(X)
Fecal occult blood testingj
Annually
Colonoscopy or sigmoidoscopyk
(X)
Serum samplel
Every 24 weeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
a The first NTx visit after the screening visit must occur within 2 to 12 weeks of screening.
b Window is relative to the first NTx visit in the current no-teduglutide treatment period.
c Subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed to the pretreatment visit if the investigator, subject, 
and parent or legal guardian agree to proceed with teduglutide therapy (Table 1-4).
d Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
e Head circumference will be measured in subjects 36 months of age and younger.
f Intake diaries will collect actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section 7.2.2.10 for more detail.
g Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix 2.
h Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
i Subjects who have been treated previously and test positive for teduglutide antibodies should have follow-up samples collected 
every 12 weeks during the study until a negative result is obtained.
j Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
k The need for colonoscopy/sigmoidoscopy in response to a positive fecal occult blood test during a no-teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy/sigmoidoscopy at 5-year intervals or more often as needed. See Section 7.2.2.10 for 
details.
l Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 24
SHP633-303Protocol Amendment 2
Teduglutide
17 Mar 2017
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Phone contact is required approximately 1 week after PS adjustment
Cx
W4
Phone contact is required approximately 1 week after PS adjustment
Cx 
W6
Phone contact is required approximately 1 week after PS adjustment
Cx 
W9
Phone contact is required approximately 1 week after PS adjustment
Cx 
W12
Phone contact is required approximately 1 week after PS adjustment
Cx 
W16
Phone contact is required approximately 1 week after PS adjustment
Cx 
W20
Phone contact is required approximately 1 week after PS adjustment
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window (days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteria
X
Xe
Dispense intake 
and output diaries
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant 
medications and 
GI
proceduresf
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examination and 
vital signs, 
including weight
X
X
X
X
X
X
X
X
X
X
X
X
Height and head 
circumferenceg
X
X
X
X
Review intake 
and output 
diariesh
X
X
X
X
X
X
X
X
X
X
X
X
X
Record PS Rx 
and adjust as 
neededi
X
X
X
X
X
X
X
X
X
X
X
X
X
Safety laboratory 
testsj
Xj
X
X
X
X
X
X
X
X
X
X
(X)
X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms 
X
X
X
For non-commercial use only

Shire
CONFIDENTIAL
Page 25
SHP633-303Protocol Amendment 2
Teduglutide
17 Mar 2017
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Module Sub-
Scales
Antibodies to 
teduglutidek
X
X
X
X
Fecal occult 
blood testing
X
X
X
Colonoscopy/
Sigmoidoscopyl
(X)
(X)
(X)
Pregnancy 
testingm
X
X
X
X
X
X
X
X
X
Serum samplen
X
X
Evaluate escape 
criteriao
X
X
Dispense study 
drugp
X
X
X
X
X
X
X
X
X
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing 
potential; FU=follow-up; GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio; 
SBS=short bowel syndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
a If the first pretreatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening.
b Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria).
c The investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within 7 days of the CxW28 visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-2) will take place in lieu of the CxW28 visit.
d Visit windows are relative to the CxD1 visit.
e Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
f Concomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and associated pathology results.
g Head circumference will be measured in subjects 36 months of age and younger.
h Intake diaries will collect actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except 
at pretreatment visit), for 1 week following PS adjustment, and daily during the 4-week follow-up period. Urine and stool output should be recorded in the output diary over a 48-
hour period of nutritional stability before every clinic visit, and within 1 week of implementing a change in the PS prescription. See Section 7.2.2.12 for more detail.
i Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment 
provided in Appendix 2.
j Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed by a central laboratory. Clinical chemistry and
urinalysis must also be performed within approximately 5-7 days of any adjustment to the PS prescription. Safety labs performed between clinic visits may be performed locally. 
Unscheduled lab results will not be captured in the eCRFs. If abnormal results are considered an adverse event, an AE form will be completed. Collect PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug-induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
For non-commercial use only

Shire
CONFIDENTIAL
Page 26
SHP633-303Protocol Amendment 2
Teduglutide
17 Mar 2017
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
of urinalysis will not constitute a protocol deviation.
k Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
l The teduglutide-naïve subjects age 12 and older will undergo colonoscopy/sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy/sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy/sigmoidoscopy will be performed. The need for colonoscopy/sigmoidoscopy in response to positive FOBT results at 
CxW12 is at the discretion of the investigator. Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will 
undergo colonoscopy/sigmoidoscopy. See Section 7.2.2.10 for details.
m A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all other visits according to the study 
schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
n Lack of collection of serum samples will not constitute a protocol deviation.
o If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
p The first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See 
Section 6.2.3 for dose adjustment.
For non-commercial use only

Shire
CONFIDENTIAL
Page 27
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
1
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options
Short bowel syndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. It is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with SBS (Khan et al., 
2015; Wales et al., 2004). Unlike the adult population, the majority of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy. 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 years of the initial diagnosis (Khan et al., 2015).
Nevertheless, despite optimal medical management, many pediatric subjects remain dependent 
on PS. Complications of long-term PS include liver disease, catheter-related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality of life is poor (Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al., 2015; Squires et al., 2012).
Intestinal adaptation is driven by hormonal cues in response to nutrient malabsorption (Drucker 
and Yusta, 2014). Chief among these is hormones glucagon-like peptide 2 (GLP-2), which is 
secreted from L-type enteroendocrine cells that reside in the intestinal epithelium in the ileum 
and colon. Resection of these regions may impair the adaptive response by limiting endogenous 
production of GLP-2.
1.2
Product Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP-2 that regulates 
the functional and structural integrity of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33-amino acid peptide that differs from native GLP-2 in the substitution of 
glycine for alanine at the second position at the N-terminus. As a result, teduglutide demonstrates 
resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and therefore maintains a longer 
elimination half-life (t1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t1/2 of approximately 7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and crypt depth in the intestinal 
epithelium, thereby increasing the absorptive surface area of the intestines (Tappenden et al., 
2013; Thymann et al., 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (REVESTIVE™) on 30 
August 2012 and a New Drug Application (NDA) for teduglutide (GATTEX®) was approved by 
the United States (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
For non-commercial use only

Shire
CONFIDENTIAL
Page 28
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
European Commission granted an extension of the Market Authorization for teduglutide 
(REVESTIVE™) for the treatment of patients aged 1 year and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3
Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 study, TED-C13-003, was completed in pediatric SBS subjects in the US and 
United Kingdom (UK). In this study, teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1-17. Thirty-seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for 12 weeks. Five additional pediatric subjects were enrolled in an 
observational standard of care (SOC) cohort. There were clear dose-dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day doses compared to SOC and the 0.0125 
mg/kg/day dose. In the 0.025 mg/kg/day cohort there was a reduction in PS volume at Week 12
of 37%, including complete independence from PS support in 1 subject, and a reduction of 
3.94 hours per day infusion time. In the 0.05 mg/kg/day cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day infusion time. Teduglutide was generally safe and well 
tolerated by pediatric subjects in all dosing cohorts. There were no deaths during the study and 
no treatment-emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study were due to adverse events (AEs).
TED-C14-006 is an ongoing study which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a 2-week minimum 
screening period, a 24-week treatment period, and a 4-week follow-up period. During the 
screening period, subjects will choose into which arm to enroll. During the 24-week treatment 
period, subjects in the SOC treatment arm will receive standard medical therapy for SBS; while 
those in the teduglutide treatment arm will receive daily subcutaneous (SC) injections of 
teduglutide (study drug) in addition to standard medical therapy. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double-blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day of teduglutide administered subcutaneously for 
24 weeks.
Always refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy and safety of teduglutide (SHP633).
For non-commercial use only

Shire
CONFIDENTIAL
Page 29
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
2
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to 
evaluate the safety and efficacy of teduglutide in pediatric subjects with SBS who completed the 
TED-C13-003 study. In addition to evaluating the long-term safety and durability of efficacy 
after 12 weeks of treatment in TED-C13-003, this extension study will evaluate the need for 
additional teduglutide treatment in these subjects, and will allow for the first-time treatment of 
teduglutide-naïve subjects who participated in the SOC treatment arm in TED-C13-003.
2.2
Study Objectives
2.2.1
Primary Objectives
The primary objective of the study is to evaluate the long-term safety and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED-C13-003.
2.2.2
Secondary Objectives
The secondary objective of this study is to evaluate the long-term efficacy of teduglutide 
treatment in pediatric subjects with SBS who completed TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 30
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
3
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects who completed the TED-C13-003 study (the core 
study). At the time of entry into the TED-C13-003 study, subjects were less than 18 years of age, 
were dependent on parenteral nutrition to provide at least 30% of their caloric or fluid needs, and 
had not been able to significantly reduce PS for at least 3 months prior to enrollment. During the 
core study, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day, 0.025 mg/kg/day, or 0.05 mg/kg/day dose cohort based on the timing of their 
enrollment in the study. The cohorts were filled in a sequential manner.
Approximately 40 subjects who completed the core study are expected to enroll in this extension 
study. Subjects who previously received teduglutide during the core study, as well as subjects 
who were in the SOC treatment group, may be eligible to receive teduglutide treatment in this 
extension study. To be eligible for treatment with teduglutide in this extension study, subjects 
must meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately every 12 weeks for safety, parenteral support (PS) requirements, and 
quality of life. At any point during an NTT period, subjects who meet ≥1 teduglutide treatment 
inclusion criteria may proceed directly to the pretreatment visit if the investigator, subject, and 
parent or legal guardian agrees to proceed with teduglutide therapy.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long-term follow-up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analysis suggested that pediatric patients, ages 1-17 years-old, are likely to require the same 
dose as used in adults, namely 0.05 mg/kg/day (Mouksassi et al., 2009). In this extension study 
to TED-C13-003, repeat doses of teduglutide 0.05 mg/kg/day will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed 12-week pediatric study (TED-C13-
003) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
For non-commercial use only

Shire
CONFIDENTIAL
Page 31
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
studies as well as the pediatric (core) study (TED-C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults (O'Keefe et al., 2006).
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED-C14-006 study, 
consisting of 24 weeks of teduglutide treatment, followed by a 4-week follow-up period. The 
follow-up period is a mechanism to evaluate whether continued teduglutide is needed. If a 
subject deteriorates during the follow-up period, the subject may be evaluated immediately for 
additional teduglutide treatment. Subjects who clinically deteriorate or stop improving at any 
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED-C13-003 and TED-C14-006, to ensure sufficient safety monitoring and 
weaning of PS. During the NTT period, visits occur every 12 weeks, a frequency that is 
consistent with standard medical practices.
Measures and Parameters
To evaluate efficacy and safety from the time subjects completed the core study to the time they 
enter this extension study, retrospective data collection is planned for this study. The 
retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. In addition to this retrospective data 
collection, prospective study assessments of safety and efficacy will be completed as a part of 
this study.
3.1.1
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be 
completed before any other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study; however subjects may 
consent to retrospective data collection only. Subjects may not consent to the prospective data 
collection only. After informed consent/assent is obtained, study eligibility will be assessed for 
all subjects.
3.1.2
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and 
Section 7.1.1. For subjects that only consent to retrospective data collection, these procedures are 
all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 32
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
TED-C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study. Retrospective data collection may begin any time after informed consent/assent is 
obtained for this study. The following data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
3.1.3
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history and short bowel syndrome history. The parenteral support prescription will 
also be collected at screening. Additionally, intake diaries will be dispensed at the screening visit 
for collection of actual PS volume and hours per day (Section 7.2.2.12). Diary data for PS 
volume will be collected for at least 2 weeks after the ICF (and if applicable, the informed 
assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately 
every 12 weeks for safety, PS requirements, and quality of life. Diary data for PS volume will be 
collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including 
during an NTT period, subjects who meet ≥1 teduglutide treatment inclusion criteria, may 
proceed immediately to the pretreatment visit if the investigator, subject, and parent or legal 
guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28-week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily, followed by a 
4-week follow-up (no treatment) period (Figure 3-1). During the 28-week cycle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality of life assessments will be made approximately every 
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 33
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation (Appendix 2).
Rationale: Measures of long-term safety will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
by reduction in PS and improvement in pediatric quality of life measures (Pediatric Quality of 
Life Inventory [PedsQL], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pivotal Phase 3 adult clinical 
trials and the completed Phase 3 pediatric study (TED-C13-003), and will be used as an endpoint 
in this extension study. In previous clinical studies, a reduction of this magnitude was associated 
with a reduction in the number of days per week of PS, and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may provide a pediatric subject 
with opportunities for more age-appropriate activities including oral rehabilitation. Quality of life 
assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI-specific screening tests, 
including fecal occult blood testing and colonoscopy/sigmoidoscopy, which are commonly part 
of the routine care of these subjects, will be performed to ensure safety. This study captures long-
term safety data on polyps and other colonic mucosal changes in teduglutide-exposed subjects 
using the surveillance strategy proposed in Section 7.2.2.10.
Figure 3-1 Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide 
at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey 
lines). If an escape criterion is met during the follow-up period, subjects may proceed directly to another pretreatment visit.
For non-commercial use only

Shire
CONFIDENTIAL
Page 34
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
3.2
Duration and Study Completion Definition
A subject will be considered enrolled in the study once the subject has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility 
Criteria. The study will continue for at least 1 year, and until each subject has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
3 years. The study will be completed in approximately 40 months. A subject will be considered 
as having completed the study if the subject has not withdrawn early from the study for any 
reason prior to completing the EOS visit.
The study completion date is defined as the date the final subject, across all sites, completes their 
final protocol-defined assessment. Please note that this includes the follow-up visit or contact 
(last safety contact), whichever is later. The study completion date will be used to ascertain 
timing for study results posting and reporting.
For non-commercial use only

Shire
CONFIDENTIAL
Page 35
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
4
STUDY POPULATION
Each subject and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any study-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility does not impact study eligibility.
4.1
Study Inclusion Eligibility Criteria
The subject will not be considered eligible for the study without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing any 
study-related procedures. 
2. Subject completed the TED-C13-003 study (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully adhere to study requirements as 
defined in this protocol.
4.2
Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study.
4.3
Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria 
and none of the teduglutide treatment exclusion criteria are met. In addition, the investigator and 
the subject (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.4
Teduglutide Treatment Inclusion Criteria
1. Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and
during the teduglutide pretreatment visit, as assessed by the investigator. Transient 
instability for events such as interruption of central access or treatment for sepsis is 
allowed if the PS returns to within 10% of baseline prior to the event.
2. Subject was previously treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b. Decreased PS requirement during prior teduglutide treatment, followed by 
cessation of improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite 
maximal tolerated enteral nutrition following teduglutide discontinuation
d. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid 
and electrolyte intake following teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 36
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
e.
Severe diarrhea related to teduglutide discontinuation
4.5
Teduglutide Treatment Exclusion Criteria
1. Body weight <10 kg at the pretreatment visit
2. Unresected GI polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3. History of cancer in the previous 5 years except surgically curative skin cancers
4. Serial transverse enteroplasty or other major intestinal surgery within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5. Intestinal or other major surgery planned or scheduled to occur during the 28-week 
cycle
6. Clinically significant intestinal stricture or obstruction
7. Clinically significant, active or recurrent pancreatic or biliary disease
8. Active, severe, or unstable, clinically significant hepatic impairment or injury, 
including the following laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9. Renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) 
below 50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the 
exception of subjects who had undergone ventricular or atrial septal defect repair, or 
patent ductus arteriosus (PDA) ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, 
Omegaven, Smoflipid, or teduglutide) within 3 months or 5.5 half-lives of the 
experimental drug, whichever is longer, prior to the pretreatment visit and for the 
duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 
(GLP-2) (not including teduglutide), insulin-like growth factor-1 (IGF-1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months 
prior to the pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, 
closely-related compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the 
pretreatment visit
For non-commercial use only

Shire
CONFIDENTIAL
Page 37
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
16. Pregnant or lactating female subjects 
17. Sexually active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 days after the treatment period 
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts 
the subject at any undue risk, prevents completion of the study, or interferes with 
analysis of the study results
4.6
Follow-up Period Escape Criteria
At the discretion of the investigator, the follow-up period may be interrupted and the subject may 
proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1. Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal 
tolerated enteral nutrition following teduglutide discontinuation
3. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and 
electrolyte intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
4.7
Reproductive Potential
4.7.1
Female Contraception
To be eligible for treatment with teduglutide, sexually active females of child-bearing potential 
must use an acceptable form of contraception throughout the study period and for 30 days 
following the last dose of investigational product. If hormonal contraceptives are used, they 
should be administered according to the package insert. Females of child-bearing potential who 
are not currently sexually active must agree to use acceptable contraception, as defined below, if 
they become sexually active during the period of the study and 30 days following the last dose of 
investigational product. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:

Premenarchal and either Tanner Stage 1 or less than age 9 years, or

Females of child-bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin (-HCG) pregnancy test at the teduglutide pretreatment visit. Females of 
child-bearing potential must agree to abstain from sexual activity that could result in 
pregnancy or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
For non-commercial use only

Shire
CONFIDENTIAL
Page 38
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017

True abstinence: Abstention of sexual activity that is in line with the preferred and usual 
lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception). 

Intrauterine devices plus condoms

Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)

Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 days prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually active during the study, they should use 1 of the other acceptable methods noted 
above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
4.8
Discontinuation of Subjects 
4.8.1
Teduglutide Discontinuation
If the investigational product is discontinued prematurely during a teduglutide treatment cycle 
and the subject wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow-up period will ensue, consisting of weekly telephone visits 
(CxW25-27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility according to the study 
schedules. 
Comments (spontaneous or elicited) or complaints made by the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.3. The investigator is encouraged to discuss withdrawal of a subject 
from investigational product with the medical monitor, when possible.
4.8.2
Study Withdrawal
At any time during the study, the investigator or sponsor may withdraw a subject, or a subject 
may withdraw from the study, for any reason, without prejudice to their future medical care by 
the physician or at the institution.
If a subject withdraws from the study during a teduglutide cycle, the evaluations listed for the 
EOT visit are to be performed as completely as possible. Whenever possible, the subject will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contacted 
weekly by phone during the interim period between EOT and ET for safety follow-up.
If a subject withdraws from the study during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completely as possible. 
Subjects who withdraw from the study will not be replaced.
For non-commercial use only

Shire
CONFIDENTIAL
Page 39
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
4.8.3
Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study must
be determined by the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than 1 reason, each reason should be documented in the source 
document, and the most clinically relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:

Adverse event

Protocol deviation

Lack of efficacy

Physician decision

Withdrawal by subject

Withdrawal by parent/guardian

Lost to follow-up

Pregnancy (Discontinuation of treatment only)

Death

Other
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations, and return any unused investigational product.
For non-commercial use only

Shire
CONFIDENTIAL
Page 40
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
5
CONCOMITANT TREATMENT
5.1
Concomitant Medications and GI Procedures
Concomitant treatment will be collected for the prospective period only and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study. Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medication changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may increase absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, and digoxin). Accordingly, due consideration should be given to 
modifying concomitant medication regimens. Down-titration of concomitant medications should 
be considered when drugs, especially those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.1
Permitted Treatment
Standard medical therapy for SBS should be continued.
5.1.2
Prohibited Treatment
At the time of screening, any teduglutide treatment being received through any mechanism other 
than participation in this study (eg, by off-label prescription, participation in an investigator-
initiated trial, compassionate access program, etc) must be discontinued. In such cases, there is 
no minimum duration of interruption of teduglutide treatment before pretreatment evaluations 
can be performed.
The mechanism of action of teduglutide may increase enteral absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, digoxin), so consideration should be given to modifying 
concomitant enteral medication regimens. Down-titration of concomitant enteral medications 
should be considered when drugs, especially those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
For non-commercial use only

Shire
CONFIDENTIAL
Page 41
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Table 5-1 Prohibited Treatment
Prior Therapy
Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon-like peptide-2 (not-including teduglutide)
Any
Glucagon-like peptide-1 analog or human growth hormone
3 months
Octreotide or dipeptidyl peptidase 4 inhibitors
3 months
Biological therapy (eg, antitumor necrosis factor)
6 months
For non-commercial use only

Shire
CONFIDENTIAL
Page 42
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
6
INVESTIGATIONAL PRODUCT
6.1
Identity of Investigational Product
The test product is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L-histidine, mannitol, monobasic sodium 
phosphate monohydrate, and dibasic sodium phosphate as excipients. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.1
Blinding the Treatment Assignment
Not applicable for this open-label study.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology for Investigational Product Management
An interactive web-based response system (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory management and supply ordering, investigational product expiration tracking and 
management, and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The IWRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.2
Allocation of Subjects to Treatment
This is an open-label study. Subjects will retain their assigned subject number from the 
TED-C13-003 study. Assessment of need for teduglutide treatment should be guided by the 
teduglutide treatment inclusion criteria. If the investigator, subject, and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit (Table 1-4).
6.2.3
Dosing
If teduglutide treatment eligibility is established at the pretreatment visit and again, confirmed at 
the CxD1 visit, the subject will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered by SC injection once daily (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 43
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than 3 hours 
later.
The subject should be dosed at approximately the same time each day. Consecutive doses should 
be separated by at least 12 hours. Each day, the injection site should be rotated.
The first SC injection in teduglutide-naïve subjects should be administered under the supervision 
of the investigator or designee and the subject observed for hypersensitivity reactions for at least 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the Instructions for Use. 
Following each 24-week teduglutide treatment period, subjects will enter a 4-week follow-up 
period. During the follow-up, the investigator will assess the subject via weekly telephone visits. 
At any time during the follow-up period, if escape criteria are met, the subject may proceed 
directly to another Pretreatment visit to assess treatment eligibility for another cycle 
(Section 4.6). Following the completion of the 4-week follow-up, the subject will continue in the 
study off teduglutide. Additional 28-week cycles may be repeated if treatment eligibility is 
established each time. 
6.2.4
Unblinding the Treatment Assignment
Not applicable for this open-label study.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification will be applied to the investigational 
product(s) container.
The study drug will be packaged, labeled, and shipped to the study site by the sponsor or 
designee. Kits containing 7 vials of study drug will be supplied and these will be labeled in 
accordance with applicable regulatory requirements. Sterile water for injection syringes and 
other ancillary components will also be provided separately and will be labeled in accordance 
with the applicable regulatory requirements.
All study drug used in this study will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2
Packaging
Teduglutide will be provided in a 3 mL sterile, single-use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL) will be provided in a prefilled syringe.
For non-commercial use only

Shire
CONFIDENTIAL
Page 44
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the sponsor.
6.3.3
Storage and Handling
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Limited responsibility may be delegated to the pharmacy or 
member of the study team, but this delegation must be documented.
Study drug must be kept in a locked area with access restricted to specific study personnel. Study 
drug will be stored refrigerated at a temperature between 2-8°C (35.6-46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2-25°C, or 35.6-77°F). Parent/legal guardian 
will be instructed to keep the subject’s study drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study drug may be refrigerated. The study drug is for single use only, and should be used within 
3 hours following reconstitution.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed by the pharmacy or nominated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed number of subjects. The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. The 
For non-commercial use only

Shire
CONFIDENTIAL
Page 45
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
investigator is to keep a current record of the inventory and dispensation of all clinical supplies. 
This record will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any discrepancy or deficiency will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any unauthorized situation.
The investigator has overall responsibility for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study protocol. All dispensed 
study medication will be documented in the interactive response technology system and/or other 
investigational product record (eg, investigation product accountability form). The investigator is 
responsible for assuring the retrieval of all study supplies from subjects.
All used and unused study drug vials must be returned by the subjects and/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unused study drug vials to the same subject. All original containers, whether empty 
or containing study drug will be returned to the pharmacy. Returned study drugs will NOT be 
relabeled or reassigned for use by other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may be destroyed on site without approval by the sponsor.
Please see the Pharmacy Manual for additional information.
6.5
Subject Compliance
Subjects will be instructed to bring their unused investigational product and empty/used 
investigational product packaging to every visit. Drug accountability will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper-evident sealed container (eg, bottles, trays, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 46
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
7
STUDY PROCEDURES
7.1
Study Schedule
Detailed study procedures and assessments to be performed for subjects throughout the study are 
outlined in the Schedule of Assessments (Table 1-1, Table 1-2, Table 1-3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing any study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject (Table 1-1).
7.1.1
Retrospective Data Collection
Retrospective data are defined as specific safety and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. Retrospective PS and growth data will be 
captured in 12-week intervals, with the first 12-week interval beginning at the TED-C13-003 
EOS visit. All available retrospective data should be captured in the corresponding eCRFs. 
Failure to collect retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent only to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study:

Informed consent, and informed assent (if applicable)

Study eligibility is determined

A screen failure is a subject who has given informed consent and failed to meet 
the study inclusion eligibility criteria. Subjects cannot be rescreened once they 
have been designated as a screen failure.

Prior teduglutide use (as prescribed)

Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, compassionate 
use, and named-patient access programs.

Collect start and end dates when a subject’s teduglutide use was interrupted. 

Parenteral support (as prescribed)

The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide treatment 
will be collected. Usually, the prescription at the end of the interval will represent 
For non-commercial use only

Shire
CONFIDENTIAL
Page 47
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
the status of intestinal adaptation. However, transient alterations in PS related to 
loss of central venous access or acute illness are not representative of intestinal 
adaptation. When such events occur at the end of a 12-week interval, earlier, more 
representative PS prescription data should be recorded.
Data collected should include weekly prescribed volume, calories, average hours 
per day, and days per week of prescribed PS. Hours per day should be averaged 
over the days where PS is prescribed. 

Growth (height, head circumference, and weight)

The last representative value for height, during each 12-week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and younger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.

Adverse events

All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study. The details of data collection and safety reporting for these events 
can be found in Section 8.

End dates for AEs ongoing at the end of TED-C13-003 will be collected.
7.1.2
Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:

Informed consent, and informed assent (if applicable)

Study eligibility is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study inclusion eligibility criteria. Subjects cannot be 
rescreened once they have been designated as a screen failure.

Demographics, updates to medical history and SBS history

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference
For non-commercial use only

Shire
CONFIDENTIAL
Page 48
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017

Record PS prescription and adjust as needed
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3
Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide-treatment cycle, subjects will be followed 
approximately every 12 weeks for safety and efficacy assessments. No-teduglutide treatment 
visits are numbered sequentially (NT1, NT2, etc.), even if interrupted by the treatment cycles. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1-3 and described below.

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS  prescription and adjust as needed

Safety laboratory tests (ie, clinical chemistry, hematology, and urinalysis)

PedsQL Generic Core Scale/PedsQL Family Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub-Scales

Antibodies to teduglutide, if and when required

Fecal occult blood testing, as indicated (see Section 7.2.2.10)

Colonoscopy/sigmoidoscopy, as indicated (see Section 7.2.2.10)

Serum sample, as indicated
Teduglutide treatment may be considered at any time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may proceed to the pretreatment visit immediately to determine 
eligibility. 
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
7.1.4.1
Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may proceed to the pretreatment visit immediately. Similarly, 
subjects who meet escape criteria during the teduglutide follow-up period may proceed to the 
pretreatment visit immediately. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 49
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
In general, pretreatment assessments may occur over a period of up to 21 days. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:

Evaluate teduglutide eligibility (treatment inclusion/exclusion criteria)

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Fecal occult blood testing

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy as indicated

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries 

Record PS prescription and adjust as needed.

Safety laboratory tests
(In addition to clinical chemistry, hematology, and urinalysis, labs at this visit include 
prothrombin time [PT] international normalized ratio [INR]. Subsequent prothrombin 
time/international normalized ratio (PT/INR) measurement is only required to evaluate 
for suspected drug-induced liver injury [DILI]).

Pregnancy testing (serum)

Serum sample
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24)
The open-label teduglutide treatment period will comprise 24 weeks, during which all 
assessments and procedures listed for Visits CxD1-CxW24 in Table 1-4 shall be completed. 
Cycles are numbered sequentially, such that the first visit of the first cycle is C1D1, and the first 
visit of the second cycle is C2D1, etc. Visit windows are calculated relative to the date of first 
investigational product administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1-4 and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.

Confirm teduglutide treatment eligibility

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight
For non-commercial use only

Shire
CONFIDENTIAL
Page 50
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing (urine)

Dispense study drug
SITE VISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects will return for clinic visits on cycle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:

Dispense and review intake and output diaries (every effort should be made to complete 2 
weeks of intake diary entries prior to each clinic visit and to complete 48 hours of output 
diary entries during a period of nutritional stability prior to each clinic visit)

Physical examination and vital signs, including weight

Record PS prescription and adjust as needed

Safety laboratory tests

Urine pregnancy testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)

Study drug dispensation (except for CxW24)

Adverse events, concomitant medications and concomitant GI procedures
In addition, at CxW12 and CxW24 Visits ONLY, the following procedures will be performed:

Height and head circumference

Antibodies to teduglutide

Fecal occult blood testing (FOBT)

GI-specific testing, including colonoscopy or sigmoidoscopy as indicated

Quality of life measurements
At CxW24 ONLY, a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 51
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
PHONE VISITS
Phone visits are required approximately 1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-4 and described 
below:

Review intake and output diaries

Safety laboratory tests (clinical chemistry and urinalysis)

Record PS prescription and adjust as needed

Obtain AEs, concomitant medications, and concomitant GI procedures

Evaluate escape criteria
7.1.5
Teduglutide Follow-up Period
The safety follow-up period for this protocol is 4 weeks (Weeks 25-28 of the cycle). Phone visits 
will occur on cycle Weeks 25, 26, and 27 for all subjects. Phone visit assessments and 
procedures at Weeks 25-27 will be the same as for telephone visits performed during the 
teduglutide treatment period. In addition, subjects will be evaluated for follow-up period escape 
criteria. If escape criteria are met at any time during the follow-up period, the subject may 
proceed directly to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pretreatment assessments occur within 7 days of the CxW28 
visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Section 7.1.6) 
will take place in lieu of the CxW28 visit. Otherwise, following completion of the 28-week 
treatment cycle, the subject will proceed to an NTT visit within approximately 12 weeks.
At Cycle Week 28 (CxW28), subjects will return to the study site. In addition to the assessments 
performed at Weeks 25-27, the following procedures will be performed at CxW28 only:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Antibodies to teduglutide

Pregnancy testing (urine)

Evaluate escape criteria
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study site for the end of study/early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-2 and as 
For non-commercial use only

Shire
CONFIDENTIAL
Page 52
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
described here. If a subject discontinues the study prematurely, the assessments for the EOS/ET 
visit are to be performed as completely as possible (see Section 4.8.2).

Adverse events, concomitant medications, and concomitant GI procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries (the intake diary should be completed daily for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily over a 48-hour period of nutritional stability before the EOS/ET visit)

Record PS prescription and adjust as needed

Safety laboratory tests

Fecal occult blood testing, as indicated

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy, as indicated

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing, as needed
7.2
Study Evaluations and Procedures
7.2.1
Retrospective Data Collection
Retrospective data are being collected to evaluate the safety, tolerability, and efficacy of 
teduglutide during the interval between a subject's completion of the TED-C13-003 study and the 
date the ICF (and if applicable, assent) is signed for the SHP633-303 study.
7.2.1.1
Growth (Height, Weight, and Head Circumference)
Retrospective body height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z-score, weight z-score, body mass index (BMI), and BMI z-score will be calculated by 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analysis plan (SAP).
7.2.1.2
Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency will be 
recorded on the appropriate eCRF page.
For non-commercial use only

Shire
CONFIDENTIAL
Page 53
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
7.2.1.3
Parenteral Support Prescribed
Retrospective parenteral support entries consist of 1 prescription per 12-week interval during the 
retrospective period. If the subject has multiple PS prescriptions in a 12-week interval, the last 
representative prescription from the interval should be used (see Section 7.1.1). In addition, PS 
prescriptions at the beginning and end of any retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekly volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
7.2.1.4
Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESIs) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide, 
that occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safety reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED-C13-003 will be collected.
7.2.2
Prospective Data Collection
7.2.2.1
Demographics, Medical History, and SBS History
Demographics, updates to medical history, and updates to SBS history will be obtained at 
screening. Medical history for purposes of this extension study will consist of updates to the 
medical history collected at the start of the TED-C13-003 core study. If the subject has any 
changes to the SBS history since the baseline visit of the TED-C13-003 study, that information 
(updated SBS history) will also be collected.
7.2.2.2
Physical Examination
Physical examinations will be performed according to the study schedules. Any new clinically 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF.
7.2.2.3
Adverse Event Collection
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body temperature 
For non-commercial use only

Shire
CONFIDENTIAL
Page 54
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
(°C/°F). Blood pressure should be determined by cuff (using the same method, the same arm, 
and in the same position throughout the study).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each study visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z-score, weight z-score, BMI, and BMI z-score will be 
calculated by the sponsor using the site-provided height and weight data collected at each site 
visit.
New clinically significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.2.5
Clinical Laboratory Tests
Safety laboratory tests to be performed at site visits consist of clinical chemistry, hematology, 
and urinalysis and will be performed as outlined in the study plan (Table 1-2, Table 1-3, and 
Table 1-4). Scheduled laboratory testing will be processed by a central lab. All laboratory assays 
will be performed according to the central laboratory’s normal procedures. Reference ranges are 
to be supplied by the laboratory. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Abnormal clinical laboratory values, which are unexpected or not 
explained by the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safety labs within approximately 
5-7 days after a PS adjustment. Safety labs performed after PS adjustment and between site visits 
will consist of clinical chemistry and urinalysis and may be processed by the central laboratory 
or a local laboratory. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate any new clinically significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safety labs, but lack of urinalysis will not constitute a protocol deviation.
New clinically significant labs should be reported as AEs.
The following clinical laboratory assessments will be performed according to the study 
schedules:
For non-commercial use only

Shire
CONFIDENTIAL
Page 55
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Table 7-1 List of Laboratory Tests 
Hematology:

Hematocrit

Hemoglobin

Platelet count

Red blood cell count

Red blood cell morphology, if needed

White blood cell count with differential
Coagulation:
Prothrombin time/International normalized ratio
Urinalysis:

Blood

Glucose

Leukocytes

Microscopic analysis

pH

Protein

Specific gravity
Pregnancy tests (females of childbearing potential):

Serum β-HCG (screening)

Urine β-HCG (all other visits)
Biochemistry:

Albumin

Alkaline phosphatase

Alanine aminotransferase

Amylase

Aspartate aminotransferase

Bicarbonate

Bilirubin (total and indirect)

Blood urea nitrogen

Calcium (total)

Chloride

Cholesterol

C-reactive protein

Creatinine

Estimated Glomerular Filtration Rate 
(Schwartz formula)

Gamma-glutamyl transferase

Glucose

Lipase

Magnesium

Phosphorus

Potassium

Sodium

Triglycerides

Uric acid
For non-commercial use only

Shire
CONFIDENTIAL
Page 56
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
7.2.2.6
Serum Sampling
Serum samples will be collected and stored for future analysis at the following times:

At the pretreatment visit. If the subject met a follow-up period escape criterion, the serum 
sample will not be collected at the pretreatment visit

At the CxW24 (EOT) visit

During NTT: Approximately every 24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and any specialty laboratories will be 
blinded to the subject’s identity. The sample and/or extracted material will otherwise be stored 
for up to 15 years from the end of the study after which time it will be destroyed. Upon written 
request, subjects will be permitted to withdraw their sample from the analysis and have their 
sample and/or extracted material destroyed. Any results already generated from the samples will 
not be removed from any analyses that have already been performed.
7.2.2.7
Pregnancy Testing
A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy tests will be administered at all other visits according to the study schedules, or if 
pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the 
study.
7.2.2.8
Antibody Testing
Blood samples will be drawn for the analysis of antibodies to teduglutide according to the 
Schedule of Assessments (Table 1-2, Table 1-3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least 14 hours after dosing. Subjects who test 
positive for antibodies to teduglutide will also be tested for neutralizing antibody. Subjects who 
have been previously treated with teduglutide, and who test positive for antibodies to 
teduglutide, will have follow-up blood draws for antibodies to teduglutide every 12 weeks while 
on study until a negative result is obtained.
7.2.2.9
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study. The volumes of blood to be drawn from each subject will vary depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annually are shown 
in Table 7-2.
For non-commercial use only

Shire
CONFIDENTIAL
Page 57
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Table 7-2 Approximate Volume of Blood to be Drawn from Each Subject Annually 
Assessment
Sample 
Volume (mL)
No. Samples per two 28-week 
Teduglutide Cycles
Total 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety
Biochemistry and -hCGa
2.5
24
60
Hematology
2
24
48
Coagulation Parameters
1
2
2
Antibodies
2
8
16
Serum storage samples
3
4
12
Total mL per 2, 28-week Treatment Cycles (Approximate Annual Volume):
138
Subjects Not Receiving Teduglutide Treatmentb
Assessment
Sample 
Volume (mL)
No. Samples per 4 NTT Visits
Total 
Volume (mL)
Safety
Biochemistry
2.5
4
10
Hematology
2
4
8
Serum storage samples
3
2
6
Total mL per 4 “No Teduglutide Treatment” Visits 48-week period:
24
β-hCG=beta-human chorionic gonadotropin; NTT=no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
b Subjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti-teduglutide 
antibodies will require blood samples for antibody testing every 12 weeks until they test negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by the manufacturer or laboratory 
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they require the same type of tube, the assessments should be combined. Blood 
volume estimates do not include safety labs performed after PS adjustment, and anti-teduglutide 
antibody testing during no-teduglutide treatment.
7.2.2.10
Gastrointestinal-specific Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week 24 of the teduglutide cycle. During NTT periods, FOBT must be performed on 
teduglutide-exposed subjects (subjects who have received teduglutide any time in the past and 
are therefore not teduglutide-naïve) on a roughly annual basis (approximately every 48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY OR SIGMOIDOSCOPY
Teduglutide-naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pretreatment visit if one has not been performed within 1 year.
For non-commercial use only

Shire
CONFIDENTIAL
Page 58
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Subjects of any age with newly positive FOBT results at the pretreatment visit for which a 
readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy or 
sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a 
readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
colonoscopy or sigmoidoscopy in response to positive FOBTs at any other point during the 
study, or to reevaluate persistently positive FOBTs is at the discretion of the investigator.
Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks 
of study drug exposure) will undergo colonoscopy or sigmoidoscopy. While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 year intervals or 
more often as needed.
Upper endoscopy may be performed along with any colonoscopy or sigmoidoscopy at the 
investigator’s discretion. If a polyp is found, adherence to current polyp follow-up guidelines is 
recommended. Subjects with unresected GI polyps, polyposis conditions, premalignant change 
or malignancy in the GI tract will be excluded from teduglutide treatment.
7.2.2.11
Nutritional Support
Nutritional support includes PS, enteral nutrition, and other food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety laboratory results. Intake and output diaries will include data to be 
considered in the adjustment of each subject’s nutritional support. Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2.
7.2.2.12
Diaries
STUDY DRUG ADMINISTRATION DIARY
A study drug administration diary will record administration of teduglutide. This diary should be 
completed by the subject (or parent/legally authorized representative, as applicable) daily during 
the teduglutide treatment period (between visits CxD1 and CxW24).
INTAKE DIARY
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary 
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week teduglutide treatment period, the intake diary will also be completed for 1 week 
following PS adjustments. The intake diary will also be completed daily during the 4-week 
follow-up period. The following data will be captured in the intake diaries:

Parenteral support volume and infusion duration

Site personnel will determine the actual PS daily calories based on diary entries
For non-commercial use only

Shire
CONFIDENTIAL
Page 59
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
OUTPUT DIARY
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional 
stability before every clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cycle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:

Toilet-trained subjects (who do not wear diapers)
Measure and record all urine output in mL or cc 

Nontoilet-trained subjects (who wear diapers)
Measure and record the weight of all urine-only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL or 1 cc

At the discretion of the investigator, the parent or legal guardian may be asked to collect 
the first void after the daily PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):

Toilet-trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency using the 
Bristol Stool Form Scale (see Output diary)

Nontoilet-trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency using the Bristol Stool Form Scale 
(see Output diary). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mL or 1 cc
All ostomy output volume should be recorded. Ostomy output will not be scored using the 
Bristol scale.
All available diary data will be reviewed by the investigator or their designee at each clinic and 
telephone visit to assess clinical status and opportunity for PS reduction and advance in feeds.
7.2.2.13
Health-related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes less than 4 minutes to 
complete. The scales include self-reports for pediatric subjects and adolescents aged 5 to 
18 years and proxy-reports from parents of pediatric subjects aged 2 to 18 years.
Field trials have shown that the internal consistency reliability of the PedsQL was excellent, with 
alphas for the generic core scales in both self- and proxy-report greater than the 0.70 standard, 
and alphas for the full 23-item scale approaching 0.90 for self- and proxy-report. Missing data 
For non-commercial use only

Shire
CONFIDENTIAL
Page 60
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
were minimal. Item response distributions were across the full scale range, with no floor effects, 
and minimal ceiling effects.
The validity of the PedsQL Generic Core Scales was demonstrated through known group 
comparisons, and correlations with other measures of disease burden. The PedsQL self- and 
proxy-report distinguished between pediatric subjects with and without a chronic health 
condition, and within the group of pediatric subjects with a chronic condition, between those 
who did or did not have an overnight hospital visit in the last 12 months. Further, both child 
self-report and parent proxy-report correlated significantly with the number of days the child was 
too ill to pursue normal activities, needed someone to care for him or her, missed school in the 
last month, the number of days the parent missed from work in the last month, and parent-report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (PEDSQL™), ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health-related quality of life (HRQoL) 
in pediatric subjects and adolescents (2-18 years of age). The developmentally appropriate 
PedsQL Generic Core Scale will be completed by either the parent or legal guardian and subject 
as indicated in Table 7-3 at the time points as outlined in Table 1-2, Table 1-3, and Table 1-4.
Table 7-3 Developmentally Appropriate PedsQL™Generic Core Scales
Report
Completed by
Parent Report for Toddlers (ages 2-4)
Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Young Pediatric subjects 
(ages 5-7)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Pediatric subjects 
(ages 8-12)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Teens (ages 13-18)a
Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy-Report for Teens (ages 13-18) will also be completed for subjects older 
than 18 years of age
The Parent Report for Toddlers (ages 2-4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8-12), and Teens (ages 13-18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
For non-commercial use only

Shire
CONFIDENTIAL
Page 61
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Family Impact Module is a parent-report multidimensional instrument that will be 
completed by the parent or legal guardian, as outlined in Table 1-2, Table 1-3, and Table 1-4.
The PedsQL Family Impact Module is a specific module of the PedsQL that is used to measure 
the impact of pediatric chronic health conditions on parents and the family (Varni et al., 2004).
The 36-item PedsQL Family Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry (5 items). Two additional scales measure parent-
reported family functioning as follows: 1) Daily Activities (3 items), and 2) Family Relationships 
(5 items). The PedsQL Family Impact Module should take the parent or legal guardian 
approximately 5-10 minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Gastrointestinal Symptom Module is a disease-specific 58-item module, comprised 
of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Symptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink Limits (6 items) and Diarrhea (7 items) were identified as 
clinically relevant and appropriate for the symptoms experienced in this pediatric study 
population, and therefore, are the only scales used in this study. The scales will be completed by 
either the parent or legal guardian and subject as indicated in Table 7-3 at the time points 
outlined in Table 1-2, Table 1-3, and Table 1-4.
For non-commercial use only

Shire
CONFIDENTIAL
Page 62
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD OF OBSERVATION
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any nonserious AEs related to teduglutide that occurred during this 
time and any AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment-related event:

The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.

The event cannot be explained by the subject’s medical condition, other therapies, or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this study 
in the eCRF.
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow-up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the study, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of symptoms should be 
recorded. If a diagnosis has not been made, then each symptom should be listed individually. All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. Closure indicates that an outcome is reached, stabilization achieved 
For non-commercial use only

Shire
CONFIDENTIAL
Page 63
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
(the investigator does not expect any further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
8.1.1
Severity Categorization
The severity of all AEs must be recorded during the course of the event including the start and 
stop dates for each change in severity. An event that changes in severity should be captured as a 
new event. Worsening of pretreatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
In consideration of whether a treatment-emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early termination of the study (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) severity grading criteria (US Department of Health and Human 
Services et al., 2010).
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause-and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
The following additional guidance may be helpful:
For non-commercial use only

Shire
CONFIDENTIAL
Page 64
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
Not Related
The event can be readily explained by other factors such as the 
subject’s underlying medical condition, concomitant therapy, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled physical examinations must 
be reported as AEs if the investigator considers the finding to be a clinically significant change 
from the baseline.
8.1.3
Outcome Categorization
The outcome of all AEs must be recorded during the course of the study in the eCRF. Outcomes 
are as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae

Recovering/Resolving

Unknown
8.1.4
Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the disease and are part of the efficacy 
data to be collected in the study; however, significant worsening of the symptoms should be 
recorded as an AE.
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory or vital sign can represent an AE if the change is 
clinically relevant or if, during the study, a shift of a parameter is observed from a normal value 
For non-commercial use only

Shire
CONFIDENTIAL
Page 65
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
to an abnormal value, or a further worsening of an already abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study, further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign is clinically significant and 
therefore represents an AE.
8.1.6
Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core study until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633-303 study until the defined follow-up 
period stated in Section 7.1.5.
Any report of pregnancy for any female study participant must be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigational and Marketed Products 
Pregnancy Report Form. A copy of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and any applicable follow-up reports) must also be sent to the Shire Medical 
Monitor using the details specified in the emergency contact information section of the protocol. 
In the event a subject becomes pregnant after signing the ICF (and, if applicable, assent), 
teduglutide administration must be discontinued immediately.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. For pregnancy reports during the prospective period of observation, it is 
the responsibility of the investigator to obtain this information within 30 calendar days after the 
initial notification and approximately 30 calendar days post partum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633-303), the initial notification date will be the date the pregnancy is recorded for this 
study and outcome and infant condition information may be collected anytime post partum.
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire Clinical Study Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required by the Protocol. Note: An 
elective abortion is not considered an SAE.
For non-commercial use only

Shire
CONFIDENTIAL
Page 66
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Nonserious AEs as required by the Protocol as well as the Shire Investigational and Marketed 
Products Pregnancy Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy onset date.
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may be detrimental to the individual and/or society

Misuse – Intentional use of investigational product other than as directed or indicated 
at any dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed by the protocol)

Overdose – Administration of a dose greater than the allocated dose of the study 
medication or at a frequency greater than the dosing interval specified by the protocol

Medication Error – An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors

Medication errors should be collected/reported for all products under 
investigation

The administration and/or use of an expired investigational product should 
be considered as a reportable medication error
All investigational product provided to pediatric subjects should be supervised by the 
parent/legally-authorized representative/caregiver.
For non-commercial use only

Shire
CONFIDENTIAL
Page 67
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference for safety information for this study is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
8.2.2
Reporting Procedures
All SAEs experienced during the retrospective period of observation for the protocol must be 
reported by the investigator to the Shire Global Drug Safety Department and the Shire Medical 
Monitor within 24 hours of first awareness of the event.
All initial and follow-up SAE reports for SAEs experienced during the prospective period of 
observation must be reported by the investigator to the Shire Global Drug Safety Department and 
the Shire Medical Monitor within 24 hours of the first awareness of the event. Note: The 24-hour 
reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by the investigator to the Shire Global Drug 
Safety Department and the Shire Medical Monitor within 24 hours of the first awareness of the 
event even if the event does not fulfill seriousness criterion.
The investigator must complete, sign, and date the Shire Clinical Study Adverse Event Form for 
SAEs and Nonserious AEs as Required by Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e-mail the completed form to the Shire Global Drug Safety
Department. A copy of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Nonserious AEs as Required by Protocol (and any applicable 
follow-up reports) must also be sent to the Shire Medical Monitor or designee using the details 
specified in the emergency contact information section of the protocol.
8.2.3
Serious Adverse Event Definition
A SAE is any untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 

Results in death

Is life-threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it was more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
For non-commercial use only

Shire
CONFIDENTIAL
Page 68
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospitalization for an elective or previously scheduled surgery that meet(s) serious 
criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity

Is a congenital abnormality/birth defect

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency or 
drug abuse.
8.2.4
Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Drug Safety Department and the Shire Medical Monitor within 24 hours of first 
awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow-up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Drug Safety Department and the Shire Medical Monitor within 24 hours of the first 
awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Drug Safety Department within 24 hours of the first awareness of the event.
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
For non-commercial use only

Shire
CONFIDENTIAL
Page 69
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notifying the 
relevant regulatory authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notifying active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
8.3
Adverse Events of Special Interest
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
the investigator to the sponsor is required.
The AEs of special interest that require expedited regulatory reporting include the following:

Growth of pre-existing polyps of the colon

Benign neoplasia of the GI tract including the hepatobiliary system

Tumor-promoting ability (eg, benign and/or malignant neoplasia of any kind, not limited 
to those of the GI or hepatobiliary system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within 24 hours of first awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
For non-commercial use only

Shire
CONFIDENTIAL
Page 70
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5 apply only to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contacting the sponsor/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may include but are 
not limited to hospitalization, AEs, a lapse in investigational product delivery, etc.
Study drug must be discontinued if any of the following events occur:

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to be related 
to study drug. This does not include the presence of anti-teduglutide antibodies, mild 
injection site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.

An AE that is of NCI CTCAE severity Grade 3 or 4 and considered to be related to study 
drug administration

Confirmed drug-induced liver injury (DILI) related to teduglutide (see Section 8.4.2)
8.4.1
Dose Interruption Criteria Based on Adverse Event Severity and 
Relationship to Investigational Product (Prospective Period of Observation 
Only)
The investigational product must be discontinued if the subject experienced an AE that is of 
severity ≥Grade 3 per the NCI CTCAE and is reported as related to the investigational product. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI CTCAE severity grading criteria (US Department of Health and 
Human Services et al., 2010). All such TEAEs should be discussed with the Shire Medical 
Monitor or designee as soon as possible. The length of the dose interruption, and whether 
teduglutide administration resumes or is permanently discontinued, depends on the clinical 
situation.
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may need to be interrupted if the subject has 
clinical and laboratory evidence of potential DILI, in the absence of an alternative explanation, 
as identified by the following criteria:

ALT or AST >8x ULN

ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
For non-commercial use only

Shire
CONFIDENTIAL
Page 71
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017

(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)

ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory values suggestive of potentially new DILI should be repeated and verified within 
3 days. International normalized ratio should be measured with this set of verification laboratory 
assessments and an inquiry should be made as to the presence of clinical symptoms consistent 
with new liver injury. The subject should be followed closely to determine the trajectory of the 
laboratory abnormalities and to evaluate the cause of liver injury. This evaluation may include, 
as clinically indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cytomegalovirus IgM, 
Epstein-Barr virus antibody panel), hepatobiliary obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti-actin, or anti-liver kidney microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permanently discontinued if DILI is confirmed and deemed 
related to study drug.
8.5
Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may recommend stopping the study if any of the following conditions are met:

≥2 subjects develop the same event of CTCAE severity Grade 3 that is reported as related 
to the investigational product
or

1 subject develops an event of CTCAE severity Grade 4 that is reported as related to the 
investigational product
For non-commercial use only

Shire
CONFIDENTIAL
Page 72
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
9
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
in the eCRF. A study monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safety follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality control and data validation procedures are applied to ensure the validity and 
accuracy of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed 
using SAS® (SAS Institute, Cary, NC, USA) version 9.3 or higher.
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4
Planned Interim Analysis, and Data Monitoring Committee
An interim analysis of all retrospective data will be conducted. Other interim analyses may also 
be conducted if needed.
A DMC will be involved in the management of this study. The DMC members will review the 
data approximately every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety data (ie, AEs, laboratory assessments, physical examinations, etc.) 
from study assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only

Shire
CONFIDENTIAL
Page 73
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
The DMC will be an external, independent board comprised of physicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory in nature. The DMC will be governed by a 
Charter agreed to by members of the Board and the sponsor. Members of the Board may not be 
study investigators or be employed at the same institution as a study investigator, individuals 
employed by the sponsor, independent contractors hired by the sponsor, or members of 
regulatory agencies. The DMC may make recommendations to the sponsor regarding study 
aspects including stopping, modifying or continuing the study; however, the sponsor will have 
the final responsibility to determine whether the study should be modified or temporarily or 
permanently stopped.
9.5
Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects was determined by enrollment in 
TED-C13-003.
9.6
Study Population
The safety population includes all enrolled subjects in the study. The safety population will be 
used for both safety and efficacy analyses.
9.7
Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or 
first exposure to teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
9.8
Safety Analyses
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
For non-commercial use only

Shire
CONFIDENTIAL
Page 74
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
for quantitative safety data as well as for the difference from baseline, if applicable. Frequency 
counts will be compiled for classification of qualitative safety data.
9.8.1
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study 
period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing including fetal occult blood testing and colonoscopy or 
sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) 
to the beginning of the prospective study period:

Adverse events related to teduglutide

All SAEs

All AESIs (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study 
(TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
body mass index
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by System Organ Class and by preferred term. Serious adverse events will be further 
summarized by severity and relationship to investigational product. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization-Drug 
Dictionary (WHO-DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history (including 
For non-commercial use only

Shire
CONFIDENTIAL
Page 75
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
surgical/procedural history) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by system organ class and preferred term. 
For clinical laboratory tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional safety parameters and measures will include change in body weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z-score, BMI, and BMI z-score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9
Other Analyses
9.9.1
Health-related Quality of Life Analyses
Health economics and outcomes research endpoints will be analyzed at approximately 12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study period. The beginning of 
each treatment cycle (CxD1) will be an additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:

Food and drink limits

Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 76
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
10
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH Good Clinical Practice (GCP) Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO as necessary. 
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
For non-commercial use only

Shire
CONFIDENTIAL
Page 77
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an EOS declaration to the relevant competent authority as required by 
Article 10 (c) of Directive 2001/20/EC.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by the signed and dated signature of the 
principal investigator (single-site study) or coordinating principal investigator (multicenter 
study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH 
Guidance E3 (1995). 
For non-commercial use only

Shire
CONFIDENTIAL
Page 78
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by international regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly into the 
eCRF.
Electronic case report forms should be approved by the investigator per study specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory reports, and histology and 
pathology reports.
All key data must be recorded in the subject’s medical records.
For non-commercial use only

Shire
CONFIDENTIAL
Page 79
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the eCRF 
entries against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory authorities, or the IRB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X-rays etc.). Nonstudy site personnel will not 
disclose any personal information or personal medical information.
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA, 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Agency) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory authorities), the 
European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory 
Agency, other regulatory authorities, the sponsor or its representatives, and the IRB/EC for each 
site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, where 
applicable, from all study subjects prior to any study-related procedures including screening 
assessments. All consent and assent documentation must be in accordance with applicable 
regulations and GCP. Each subject or the subject’s legally-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
For non-commercial use only

Shire
CONFIDENTIAL
Page 80
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully executed signature pages) must be given to the subject or the 
subject’s legally-authorized representative, as applicable. This document may require translation 
into the local language. Signed consent forms must remain in each subject’s study file and must 
be available for verification at any time.
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legally-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study subject.
The principal investigator provides the sponsor with a copy of the consent form, and assent form 
where applicable, which was reviewed by the IRB/EC and which received their favorable 
opinion/approval. A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study unless it is agreed to 
and documented (abiding by regulatory guidelines and national provisions) prior to study start 
that another party (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally, if the IRB/EC requires modification of the sample subject information and 
consent document provided by the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
For non-commercial use only

Shire
CONFIDENTIAL
Page 81
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity as defined by HIPAA must provide documentation of 
this fact to the sponsor (or designee).
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representatives 
review their medical records and data collected during the study. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP633; national or local regulatory authorities; and the IRBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subject).
The results of studies – containing subjects’ unique identifying number, relevant medical 
records, and possibly initials and dates of birth – will be recorded. They may be transferred to, 
and used in, other countries which may not afford the same level of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities.
10.5
Study Results / Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the 
publication steering committee is to act as a noncommercial body that advises or decides on 
dissemination of scientific study data in accordance with the scope of this policy.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
For non-commercial use only

Shire
CONFIDENTIAL
Page 82
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any rights to authorship of 
publications.
For non-commercial use only

Shire
CONFIDENTIAL
Page 83
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
11
REFERENCES
Drucker, D. J. & Yusta, B. 2014. Physiology and pharmacology of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonomy in Children with Intestinal Failure: A Multicenter Cohort Study. J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 
analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy, K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs-Lasky, M. & Belle, S. H. 2012. Natural 
history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon-like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
US Department of Health and Human Services, National Institutes of Health & National Cancer 
Institute 2010. Common Terminology Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL 
Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg, 39, 690-5.
For non-commercial use only

Shire
CONFIDENTIAL
Page 84
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
12
APPENDICES
For non-commercial use only

Shire
CONFIDENTIAL
Page 85
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
APPENDIX 1
PROTOCOL HISTORY
Document
Date
Global/Country/Site Specific
Original Protocol
11 May 2016
Global
Amendment 1
22 Nov 2016
Global
Amendment 1.1
09 Jan 2017
UK Specific
Amendment 2
17 Mar 2017
Global
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Title of the Shire medical monitor has been changed to Medical 
Director for clarity.
Protocol Signature Page
Emergency Contact Information
Clarification has been made that during the no-teduglutide treatment 
period, visits will take place approximately every 12 weeks.
Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3-1
The study design flow chart has been edited for clarity.
Synopsis
Figure 3-1
The collection of all actual and prescribed enteral nutrition data has 
been removed to reduce the burden on the subjects and investigators. 
Enteral nutrition data are not required as the efficacy endpoints are 
limited to parenteral support parameters.
Synopsis
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.2, 7.1.3, 7.1.4.1, 
7.1.4.2, 7.1.6, 7.2.2.11, 7.2.2.12
Exclusion criterion 11 has been revised to add Smoflipid as other 
experimental drugs that are allowed prior and during the study. Like 
glutamine and Omegaven, Smoflipid is not expected to interfere with 
the assessments of safety and efficacy of teduglutide and many subjects 
may already be receiving the treatments off-label as part of standard 
medical therapy.  
Synopsis
Section 4.5
Exclusion criterion 12 and prohibited treatment have been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to 3 months for consistency with other teduglutide studies. 
Synopsis
Section 4.5
Table 5-1
Retrospective data collection has been removed from the duration of the 
study for clarity.
Synopsis
Language in efficacy and safety endpoints has been clarified.
Synopsis
Sections 9.7.1, 9.8.1
Instructions on recording retrospective data for teduglutide and PS 
usage, and growth parameters have been refined.
Table 1-1
Sections 7.1.1, 7.2.1.2, 7.2.1.3
For non-commercial use only

Shire
CONFIDENTIAL
Page 86
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Completion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.
Table 1-2, Table 1-3, Table 1-4
Sections 7.1.2, 7.1.4.1, 7.1.4.2, 7.1.6, 
7.2.2.12
The requirement for urine specimen collection has been revised so that 
a lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects wearing diapers).
Table 1-2, Table 1-3, Table 1-4
Section 7.2.2.5
Clarification has been made that the first no-teduglutide treatment visit 
after the screening visit will occur within 2 to 12 weeks of the screening 
(formerly within 12 weeks of screening). 
Synopsis
Table 1-3
Sections  3.1.3, 7.1.2
Windows have been clarified for visits during the no-teduglutide and 
teduglutide treatment periods.
Table 1-3, Table 1-4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. By definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. 
Table 1-3 
Sections 7.2.2.8, 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. 
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.3, 7.2.2.10
Removal of former footnote j on fecal occult blood test for clarity.
Table 1-4
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit.  
Table 1-4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects 
with SBS has been clarified, and text on intestinal adaptation has been 
refined.
Section 1.1
Status of current teduglutide approvals for use has been updated.
Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced with ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency with other 
studies.
Synopsis
Sections 3.1, 3.1.3
Evaluations to be performed when a subject discontinues teduglutide or 
when withdraws from the study have been clarified.
Sections 4.8.1, 4.8.2
Withdrawal by parent/guardian has been added as reason for 
discontinuation.
Section 4.8.3
COUMADIN has been changed to warfarin for clarity.
Sections 5.1,  5.1.2
Clarification has been made on handling of study drug, which is for 
single use only and should be used within 3 hours following 
reconstitution.  
Section 6.3.3
The investigator or designee may now dispense the unused study drug 
vials to the same subject if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
drug has been clarified.
Section 6.4
For non-commercial use only

Shire
CONFIDENTIAL
Page 87
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Paragraph on the purpose of prospective data collection has been 
deleted for clarity.
Section 7.2.2
Clarification has been made on the collection of medical history and 
SBS history.
Synopsis
Sections 3.1.3, 7.1.2, 7.2.2.1
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. 
Section 7.2.2.3
Clarification has been made that local laboratory results are not 
required to be entered in the eCRFs. (formerly Section 7.2.2.4)
Section 7.2.2.5
Collection of urine sodium and urine osmolality has been removed.
Section 7.2.2.5
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow-up period escape 
criterion. (formerly Section 7.2.2.5)
Section 7.2.2.6
Nutritional support and diaries (formerly in Section 7.2.2.9) have been 
moved under separate sections (Sections 7.2.2.11 and 7.2.2.12, 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be reviewed at each clinic and telephone 
visit.
Sections 7.2.2.11, 7.2.2.12 
Performance of dipstick specific gravity tests by the subject at home on 
the first urine produced after the daily infusions of PS has been 
removed. It is now at the discretion of the investigator for all subjects, 
not just those in diapers. This change is to align with standard medical 
practice.
Section 7.2.2.12
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related) to teduglutide need 
to be reported. No changes to the protocol were made for the reporting 
of all AEs of special interest or any serious adverse events, regardless 
of relationship to teduglutide, that occurred during the retrospective 
period.
Section 8.1
The timeframe for collecting and reporting AESIs and SAEs occurring 
during the retrospective period of the study has been clarified.
Sections 8.2.2, 8.2.4, 8.3
Minor clarifications have been made to the language on dose 
interruption.
Sections 8.4, 8.4.1
Unscheduled safety follow up assessments (including visits conducted 
after EOS) are not to be recorded. However, clarification has been made 
that they are to be collected where requested.
Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.
Section 9.4
For non-commercial use only

Shire
CONFIDENTIAL
Page 88
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
The protocol now refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.
Section 9.4
Minor corrections have been made to the guidelines for nutritional 
support management during the study.
Appendix 2
Amendment Number 1.1
Amendment Date
09 Jan 2017
United-Kingdom-Specific
Description of Change and Rationale
Section(s) Affected by Change
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.
Section 4.7.1
For non-commercial use only

Shire
CONFIDENTIAL
Page 89
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
APPENDIX 2
GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 

Growth trajectory, including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)

Other clinical evaluations

Serum electrolytes

Blood urea nitrogen /creatinine levels

Changes in stool frequency or volume, including mixed output

Stool consistency (ie, Bristol Stool Scale)

Urine specific gravity

General consideration to possible clinical deterioration in SBS

Inability to maintain weight and growth velocity

Diarrhea (≥10 bowel movements per day, ≥80 mL/kg/day from an ostomy, or 
≥75 mL/kg/day mixed output)

Colic/vomiting frequency increased

Electrolyte changes or imbalance

Skin breakdown 

Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the study.

Nutritional support constituents may be adjusted at the discretion of the investigator.

During the 48-hour output measurement period prior to the subject’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.

If there is a change in enteral nutrition (EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only

Shire
CONFIDENTIAL
Page 90
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Figure A-1
Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 91
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Figure A-2
Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 92
SHP633-303 Protocol Amendment 2
Teduglutide 
17 Mar 2017
Figure A-3
Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only

PROTOCOL: SHP633-303
TITLE:
A Retrospective and Prospective, Open-label, Long-term Safety and 
Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED-C13-003
DRUG:
Teduglutide
IND:
IND# 058213
EUDRACT NO.:
2016-000863-17
SPONSOR:
Shire Human Genetic Therapies, Inc.
300 Shire Way, Lexington, MA 02421 USA
PROTOCOL 
HISTORY:
Amendment 3: 16 May 2018
Amendment 2: 17 Mar 2017
Amendment 1.1: 09 Jan 2017 (United Kingdom-Specific)
Amendment 1: 22 Nov 2016
Original Protocol: 11 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only

Shire 
CONFIDENTIAL 
Page2 
SHP633-303 Protocol Amendment 3 
Teduglutide 
16May2018 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Shire) Approval 
Signature: 
, MD PhD 
 
I Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
I Date: ·
1 
I 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-003 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however; permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
For non-commercial use only

Shire
CONFIDENTIAL
Page 3
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
SUMMARY OF CHANGES FROM PREVIOUS VERSION
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3
Amendment Date
16 May 2018
Global
Description of Change and Rationale
Section(s) Affected by Change
The primary contact for EU and backup contact for NA was updated to 
.
Emergency Contact Information
To minimize risk to subjects, a new escape criterion was added, allowing 
those who had escaped during the follow-up period of a previous 
teduglutide treatment to omit the follow-up period during subsequent 
teduglutide treatment cycles.
For subjects who previously escaped the follow-up period, CxW24 
assessments can be combined with the next pretreatment visit assessments.
Study Synopsis; Table 1-4, Figure 
3-1; Section 3.1; Section 4.6; 
Section 6.2.3; Section 7.1.4.1; 
Section 7.1.4.2; Section 7.1.5; 
Section 7.2.2.6
Clarified language that all concomitant procedures are to be captured, not 
just gastrointestinal procedures.
Table 1-2; Table 1-3; Table 1-4, 
Section 5.1; Section 7.1.2; 
Section7.1.3; Section 7.1.4.1; 
Section 7.1.4.2; Section 7.1.6
Updated the information on the clinical studies with teduglutide in pediatric 
subjects to include the results of TED-C14-006. 
Section 1.3
Added new PK simulation data to further support dosing. 
Section 3.1
Deleted text that was duplicated in other sentences of sections.
Section 5.1
Deleted biological therapy (eg, antitumor necrosis factor) from the table of 
prohibited treatments as it was included in error.
Table 5-1
Clarified that compliance with study drug is calculated from subject diaries
Section 6.5
Added direct bilirubin to the list of laboratory tests.
Table 7-1
Clarified that if a child is unable to complete a quality of life questionnaire 
(due to developmental delay or other illness) it will not constitute a 
protocol deviation.
Section 7.2.2.13
Minor editorial changes and corrections to typographical errors (which do 
not modify content and/or intent of the original document) were made.
Throughout protocol
See Appendix 1 for protocol history, including all amendments.
For non-commercial use only

Shire
CONFIDENTIAL
Page 4
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required by Protocol within 24 hours to the Shire Global Drug Safety Department. Applicable 
fax numbers and e-mail address can be found on the form (sent under separate cover). A copy of 
this form must also be sent to the Shire Medical Monitor by fax or e-mail using the details 
below.
, MD PhD
Email: 
Fax: 
For protocol- or safety-related issues, the investigator must contact Quintiles Medical 
Support:
Primary contact for United States and backup contact for United Kingdom
, MD, 
Mobile: 
US Toll Free number: 
Phone: 
 (medical emergencies – US)
Email: 
Primary contact for United Kingdom and backup contact for United States
, MD, 
Mobile: 
Phone: 
Phone: 
 (medical emergencies – EU)
Email: 
In addition, the investigator may also contact the Shire Medical Monitor:
, MD PhD, 
Phone: 
Mobile: 
3
Email: 
 non
mmercial use only

Shire
CONFIDENTIAL
Page 5
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints to Shire within 
24 hours. This includes any instances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint
E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire (USA)
For non-commercial u
 only

Shire
CONFIDENTIAL
Page 6
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSION........................................................3
EMERGENCY CONTACT INFORMATION................................................................................4
PRODUCT QUALITY COMPLAINTS..........................................................................................5
TABLE OF CONTENTS.................................................................................................................6
LIST OF TABLES.........................................................................................................................11
LIST OF FIGURES .......................................................................................................................11
LIST OF APPENDICES................................................................................................................11
ABBREVIATIONS .......................................................................................................................12
STUDY SYNOPSIS ......................................................................................................................14
STUDY SCHEDULES..................................................................................................................20
1
BACKGROUND INFORMATION.......................................................................................26
1.1
Indication and Current Treatment Options...............................................................26
1.2
Product Background.................................................................................................26
1.3
Clinical Studies with Teduglutide in Pediatric Subjects ..........................................27
2
STUDY OBJECTIVES AND PURPOSE ..............................................................................28
2.1
Rationale for the Study.............................................................................................28
2.2
Study Objectives ......................................................................................................28
2.2.1
Primary Objectives .........................................................................................28
2.2.2
Secondary Objectives .....................................................................................28
3
STUDY DESIGN ...................................................................................................................29
3.1
Study Design and Flow Chart ..................................................................................29
3.1.1
Informed Consent/Assent and Eligibility .......................................................31
3.1.2
Retrospective Data Collection........................................................................31
3.1.3
Prospective Data Collection and Treatment ...................................................31
3.2
Duration and Study Completion Definition .............................................................33
4
STUDY POPULATION.........................................................................................................34
4.1
Study Inclusion Eligibility Criteria ..........................................................................34
4.2
Study Exclusion Eligibility Criteria .........................................................................34
4.3
Teduglutide Eligibility Criteria ................................................................................34
4.4
Teduglutide Treatment Inclusion Criteria................................................................34
4.5
Teduglutide Treatment Exclusion Criteria...............................................................35
4.6
Follow-up Period Escape Criteria ............................................................................36
4.7
Reproductive Potential .............................................................................................36
4.7.1
Female Contraception.....................................................................................36
4.8
Discontinuation of Subjects .....................................................................................37
For non-commercial use only

Shire
CONFIDENTIAL
Page 7
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
4.8.1
Teduglutide Discontinuation ..........................................................................37
4.8.2
Study Withdrawal ...........................................................................................37
4.8.3
Reasons for Discontinuation...........................................................................38
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit ..................38
5
CONCOMITANT TREATMENT..........................................................................................39
5.1
Concomitant Medications and Procedures...............................................................39
5.1.1
Permitted Treatment .......................................................................................39
5.1.2
Prohibited Treatment ......................................................................................39
6
INVESTIGATIONAL PRODUCT ........................................................................................40
6.1
Identity of Investigational Product...........................................................................40
6.1.1
Blinding the Treatment Assignment...............................................................40
6.2
Administration of Investigational Product(s)...........................................................40
6.2.1
Interactive Response Technology for Investigational Product 
Management ...................................................................................................40
6.2.2
Allocation of Subjects to Treatment...............................................................40
6.2.3
Dosing.............................................................................................................40
6.2.4
Unblinding the Treatment Assignment...........................................................41
6.3
Labeling, Packaging, Storage, and Handling ...........................................................41
6.3.1
Labeling..........................................................................................................41
6.3.2
Packaging........................................................................................................42
6.3.3
Storage and Handling .....................................................................................42
6.4
Drug Accountability.................................................................................................43
6.5
Subject Compliance..................................................................................................43
7
STUDY PROCEDURES........................................................................................................44
7.1
Study Schedule.........................................................................................................44
7.1.1
Retrospective Data Collection........................................................................44
7.1.2
Screening ........................................................................................................45
7.1.3
Visits for Subjects Not Receiving Teduglutide ..............................................46
7.1.4
Visits for Subjects Receiving Teduglutide Treatment....................................46
7.1.4.1
Pretreatment Visit...................................................................................46
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24).....................................47
7.1.5
Teduglutide Follow-up Period........................................................................49
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)..........................50
7.2
Study Evaluations and Procedures ...........................................................................50
7.2.1
Retrospective Data Collection........................................................................50
7.2.1.1
Growth (Height, Weight, and Head Circumference) .............................50
7.2.1.2
Prior Teduglutide Treatment Prescribed ................................................51
For non-commercial use only

Shire
CONFIDENTIAL
Page 8
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
7.2.1.3
Parenteral Support Prescribed ................................................................51
7.2.1.4
Adverse Events.......................................................................................51
7.2.2
Prospective Data Collection ...........................................................................51
7.2.2.1
Demographics, Medical History, and SBS History................................51
7.2.2.2
Physical Examination.............................................................................51
7.2.2.3
Adverse Event Collection.......................................................................51
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body 
Mass Index .............................................................................................52
7.2.2.5
Clinical Laboratory Tests.......................................................................52
7.2.2.6
Serum Sampling.....................................................................................53
7.2.2.7
Pregnancy Testing..................................................................................54
7.2.2.8
Antibody Testing....................................................................................54
7.2.2.9
Volume of Blood....................................................................................54
7.2.2.10
Gastrointestinal-specific Testing............................................................55
7.2.2.11
Nutritional Support.................................................................................56
7.2.2.12
Diaries ....................................................................................................56
7.2.2.13
Health-related Quality of Life Assessments...........................................57
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................60
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................60
8.1.1
Severity Categorization ..................................................................................61
8.1.2
Relationship Categorization............................................................................61
8.1.3
Outcome Categorization.................................................................................62
8.1.4
Symptoms of the Disease under Study...........................................................62
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period 
of Observation Only) ......................................................................................63
8.1.6
Pregnancy .......................................................................................................63
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only) ..........................................................................................64
8.2
Serious Adverse Event Procedures ..........................................................................65
8.2.1
Reference Safety Information.........................................................................65
8.2.2
Reporting Procedures......................................................................................65
8.2.3
Serious Adverse Event Definition ..................................................................65
8.2.4
Serious Adverse Event Collection Time Frame .............................................66
8.2.5
Serious Adverse Event Onset and Resolution Dates......................................66
8.2.6
Fatal Outcome.................................................................................................67
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and 
Site Reporting.................................................................................................67
For non-commercial use only

Shire
CONFIDENTIAL
Page 9
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
8.3
Adverse Events of Special Interest...........................................................................67
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only).........................................................................................................................68
8.4.1
Dose Interruption Criteria Based on Adverse Event Severity and 
Relationship to Investigational Product (Prospective Period of 
Observation Only) ..........................................................................................68
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)......................................................69
8.5
Early Termination of the Clinical Study (Prospective Period of Observation 
Only).........................................................................................................................69
9
DATA MANAGEMENT AND STATISTICAL METHODS...............................................70
9.1
Data Collection.........................................................................................................70
9.2
Clinical Data Management.......................................................................................70
9.3
Statistical Analysis Process......................................................................................70
9.4
Planned Interim Analysis, and Data Monitoring Committee...................................70
9.5
Sample Size Calculation and Power Considerations................................................71
9.6
Study Population ......................................................................................................71
9.7
Efficacy Analyses.....................................................................................................71
9.7.1
Efficacy Endpoints..........................................................................................71
9.8
Safety Analyses........................................................................................................72
9.8.1
Safety Endpoints.............................................................................................72
9.9
Other Analyses .........................................................................................................73
9.9.1
Health-related Quality of Life Analyses.........................................................73
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES...........................................74
10.1
Sponsor’s Responsibilities .......................................................................................74
10.1.1
Good Clinical Practice Compliance................................................................74
10.1.2
Indemnity/Liability and Insurance..................................................................74
10.1.3
Public Posting of Study Information ..............................................................74
10.1.4
Submission of Summary of Clinical Study Report to Competent 
Authorities of Member States Concerned and Ethics Committees ................75
10.1.5
Study Suspension, Termination, and Completion ..........................................75
10.2
Investigator’s Responsibilities .................................................................................75
10.2.1
Good Clinical Practice Compliance................................................................75
10.2.2
Protocol Adherence and Investigator Agreement...........................................76
10.2.3
Documentation and Retention of Records......................................................76
10.2.3.1
Case Report Forms.................................................................................76
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents..............................................................................................76
10.2.3.3
Audit/Inspection.....................................................................................77
For non-commercial use only

Shire
CONFIDENTIAL
Page 10
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
10.2.3.4
Financial Disclosure...............................................................................77
10.3
Ethical Considerations..............................................................................................77
10.3.1
Informed Consent ...........................................................................................77
10.3.2
Institutional Review Board or Ethics Committee...........................................78
10.4
Privacy and Confidentiality......................................................................................79
10.5
Study Results / Publication Policy ...........................................................................79
11 REFERENCES .......................................................................................................................81
12 APPENDICES ........................................................................................................................82
For non-commercial use only

Shire
CONFIDENTIAL
Page 11
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
LIST OF TABLES
Table 1-1
Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................20
Table 1-2
Schedule of Events for Screening and End of Study or Early 
Termination ...................................................................................................21
Table 1-3
Schedule of Events for No Teduglutide Treatment Period ...........................22
Table 1-4
Schedule of Events for Teduglutide Treatment Period .................................23
Table 5-1
Prohibited Treatment.....................................................................................39
Table 7-1
List of Laboratory Tests ................................................................................53
Table 7-2
Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................55
Table 7-3
Developmentally Appropriate PedsQL™Generic Core Scales .....................58
LIST OF FIGURES
Figure 3-1
Study Design Flow Chart .............................................................................33
LIST OF APPENDICES
Appendix 1
Protocol History.............................................................................................83
Appendix 2
Guidelines for Nutritional Support Management During the Study .............88
For non-commercial use only

Shire
CONFIDENTIAL
Page 12
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
-HCG
beta-human chorionic gonadotropin
BMI
body mass index
CRA
clinical research associate
CRO
contract research organization
CSR
clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
drug-induced livery injury
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase 4
EC
ethics committee
eCRF
electronic case report form
EMA
European Medicines Agency
EN
enteral nutrition
EOS
end of study
EOT
end of treatment
ET
early termination
EU
European Union
FDA
Food and Drug Administration
FOBT
fecal occult blood test
FOCBP
female of child-bearing potential
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide 1
GLP-2
glucagon-like peptide 2
HIPAA
Health Insurance Portability and Accountability Act
ICF
informed consent form
ICH
International Conference on Harmonization
IGF-1
insulin-like growth factor 1
IRB
institutional review board
IV
intravenous
IWRS
interactive web-based response system
MedDRA
Medical Dictionary for Regulatory Activities
NCI
National Cancer Institute
NDA
new drug application
NTT
no-teduglutide treatment
For non-commercial use only

Shire
CONFIDENTIAL
Page 13
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
PedsQL
Pediatric Quality of Life Inventory
PS
parenteral support
PT/INR
prothrombin time/international normalized ratio
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SBS
short bowel syndrome
SC
subcutaneous
SOC
standard of care
t1/2
elimination half-life
TEAE
treatment-emergent adverse event
TESAE
treatment-emergent serious adverse event
UK
United Kingdom
ULN
upper limit of normal
US
United States
WHO-DD
World Health Organization-Drug Dictionary
For non-commercial use only

Shire
CONFIDENTIAL
Page 14
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
STUDY SYNOPSIS
Protocol number: SHP633-303
Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003
Number of subjects (total and for each treatment arm):
Approximately 40 subjects who completed the TED-C13-003 study, including subjects in the standard of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED-C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the United States (US) and the United Kingdom (UK) will participate in 
this extension study.
Study period (planned):
October 2016-September 2019
Clinical phase:
3 Extension
Objectives:
Primary: To evaluate the long-term safety and tolerability of teduglutide treatment in pediatric subjects with short 
bowel syndrome (SBS) who completed TED-C13-003.
Secondary: To evaluate long-term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED-C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED-C13-003 study. In addition to 
evaluating the long-term safety and durability of efficacy after 12 weeks of treatment in TED-C13-003, this 
extension study will evaluate the need for additional teduglutide treatment in these subjects, and will allow for the 
first-time treatment of teduglutide-naïve subjects who participated in the standard of care (SOC) treatment arm in 
TED-C13-003.
Investigational product, dose, and mode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED-C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
between the date of the TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only

Shire
CONFIDENTIAL
Page 15
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and Section 7.1.1. For subjects 
that only consent to retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were completed in the course 
of the subject’s standard medical care between the date of the TED-C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide treatment

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1-2. These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. The parenteral support prescription will also be collected at screening.
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section 7.2.2.12). Diary data for PS volume will be collected for at least 2 weeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no-teduglutide treatment [NTT] period), will be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed immediately to the pretreatment visit if 
the investigator, subject, and parent or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none of 
the teduglutide treatment exclusion criteria, will start a 28-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4-week follow-up (no treatment) period (Figure 3-1). During 
the 28-week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and weekly during the follow-up period (between Weeks 24 and 28). Safety and PS requirements will be evaluated 
at every visit, and quality of life assessments will be made approximately every 12 weeks. If a subject meets 1 of 
the follow-up period escape criteria between cycle week 24 and 28, the subject may "escape" the follow-up period 
early and proceed immediately to another pretreatment visit. Following completion of the 28-week treatment cycle, 
the subject will proceed to an NTT visit or another pretreatment visit within approximately 12 weeks.
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 weeks. To maintain 
consistency across centers, all attempts should be made to follow the nutritional support adjustment guidelines 
(developed with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only

Shire
CONFIDENTIAL
Page 16
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 
1 week after adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects 
discontinue teduglutide at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be 
performed weekly (solid grey lines). If an escape criterion is met at Week 24 or during the follow-up period, subjects may 
proceed directly to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet all of the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.
Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study-related procedures.
2.
Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
3.
Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria, and none of the 
teduglutide treatment exclusion criteria, are met. In addition, the investigator and the subject (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria:
1.
Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds (eg, 10% or less 
change in PS or advance in feeds) for at least 3 months prior to and during the teduglutide pretreatment 
visit, as assessed by the investigator. Transient instability for events such as interruption of central access 
or treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the event.
2.
Subject was previously treated with teduglutide and at least 1 of the following criteria is satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 17
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
b.
Decreased PS requirement during prior teduglutide treatment, followed by cessation of 
improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition (EN) following teduglutide discontinuation
d.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.
Body weight <10 kg at the pretreatment visit
2.
Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.
History of cancer in the previous 5 years except surgically curative skin cancers
4.
Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10 cm, and endoscopic procedures are allowed.
5.
Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6.
Clinically significant intestinal stricture or obstruction
7.
Clinically significant, active or recurrent pancreatic or biliary disease
8.
Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b.
Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9.
Renal dysfunction shown by results of an estimated glomerular filtration rate below 50 mL/min/1.73 m2
at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects 
who had undergone ventricular or atrial septal defect repair, or patent ductus arteriosus ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, Smoflipid, 
or teduglutide) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to 
the pretreatment visit and for the duration of the 28-week cycle 
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) (not 
including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, within 3 months 
preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior to the 
pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related 
compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16. Pregnant or lactating female subjects
17. Sexually active female subjects of child-bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the subject at any 
undue risk, prevents completion of the study, or interferes with analysis of the study results
For non-commercial use only

Shire
CONFIDENTIAL
Page 18
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow-up period may be interrupted 
or omitted and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.
Increasing PS requirements following teduglutide discontinuation
2.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated EN
following teduglutide discontinuation
3.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake 
following teduglutide discontinuation
4.
Severe diarrhea related to teduglutide discontinuation
5.
The subject escaped during the follow-up period of a previous teduglutide treatment cycle within 
SHP633-303.
Maximum duration of subject involvement in the study:
A subject will be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple 28-week treatment cycles. The study will continue for at least 1 year, and until each 
subject has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately 3 years. A subject will be considered as having completed the study if the subject has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.

Planned duration of no-teduglutide treatment periods: variable, depending on disease course

Planned duration of the teduglutide pretreatment visit: 1-21 days

Planned teduglutide treatment cycle duration: 28 weeks. Each cycle consists of 24 weeks of 
teduglutide treatment followed by a 4-week follow-up period (no treatment)
Endpoints and statistical analysis:

The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
Health Economics and Outcomes Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an 
additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:
o
Food and drink limits
o
Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 19
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) to the beginning of 
the prospective study period:

Adverse events related to teduglutide

All SAEs

All Adverse Events of Special Interest (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study (TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compiled for classification of 
qualitative safety data.
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by enrollment in TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 20
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
STUDY SCHEDULES
Table 1-1 Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment
Note
Informed consent/assent
Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study-related 
procedures, including retrospective data collection.
Study eligibility
Weighta
The last representative value for weight during each 12-week interval 
throughout the retrospective data collection period will be captured.
Height and head circumferencea
The last representative value for height during each 12-week interval 
throughout the retrospective data collection period will be captured. Head 
circumference should be provided for subjects 36 months of age and younger at 
the time the data were collected, if available.
Prior teduglutide treatment
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, 
compassionate use, and named-patient access programs.
Parenteral support (PS) 
prescribeda
The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per week of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED-C13-003
Teduglutide-related AEs
Teduglutide-related AEs must be deemed by the investigator to be related to 
teduglutide treatment.
AEs of special interest
Serious adverse events (SAEs)
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a The first 12-week interval begins at TED-C13-003 EOS visit.
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED-C13-003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
For non-commercial use only

Shire
CONFIDENTIAL
Page 21
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Table 1-2 Schedule of Events for Screening and End of Study or Early Termination
Screening
End of Study or Early 
Termination
Visit Type
Site
Site
Informed consent/assent
X
Study eligibility
X
Demographics, medical history, SBS historya
X
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriab
X
Adverse events
X
X
Concomitant medications and procedures
X
X
Physical examination and vital signs, including weight
X
X
Height and head circumferencec
X
X
Review intake and output diariesd
X
Record PS prescription and adjust as needede
X
X
Safety laboratory testsf
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-Scales
X
Antibodies to teduglutideg
X
Fecal occult blood testingh
(X)
Colonoscopy or sigmoidoscopyi
(X)
Pregnancy testingj
(X)
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
a If the subject has any changes to the medical history and SBS history that had been collected at the baseline of the 
TED-C13-003 study, then the updated medical history and SBS history will be collected.
b Subjects who meet ≥1 teduglutide treatment inclusion criteria may proceed to the pretreatment visit if the investigator, subject, 
and parent or legal guardian agrees to proceed with teduglutide therapy (Table 1-4).
c Head circumference will be measured in subjects 36 months of age and younger.
d The intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48-hour period of nutritional stability before the EOS/ET visit.
e Parenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after 
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix 2.
f Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
g Required for all teduglutide-exposed subjects.
h Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
i The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no-teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section 7.2.2.10 for details.
j Pregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 22
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Table 1-3 Schedule of Events for No Teduglutide Treatment Period
Visit Number
NTx
Visit Type
Site
Visit Frequencya
Every 12 weeks
Window (days)b
±7
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriac
X
Adverse events
X
Concomitant medications and procedures
X
Physical examination and vital signs, including weight
X
Height and head circumferenced
X
Review intake and output diariese 
X
Record PS prescription and adjust as neededf
X
Safety laboratory testsg
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-Scales
X
Antibodies to teduglutideh
(X)
Fecal occult blood testingi
Annually
Colonoscopy or sigmoidoscopyj
(X)
Serum samplek
Every 24 weeks
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
a The first NTx visit after the screening visit must occur within 2 to 12 weeks of screening.
b Window is relative to the first NTx visit in the current no-teduglutide treatment period.
c Subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed to the pretreatment visit if the investigator, subject, 
and parent or legal guardian agree to proceed with teduglutide therapy (Table 1-4).
d Head circumference will be measured in subjects 36 months of age and younger.
e Intake diaries will collect actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section 7.2.2.10 for more detail.
f Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix 2.
g Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
h Subjects who have been treated previously and test positive for teduglutide antibodies should have follow-up samples collected 
every 12 weeks during the study until a negative result is obtained.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive fecal occult blood test during a no-teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy/sigmoidoscopy at 5-year intervals or more often as needed. See Section 7.2.2.10 for 
details.
k Lack of collection of serum samples will not constitute a protocol deviation.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 23
SHP633-303 Protocol Amendment 3
Teduglutide
16 May 2018
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Cx
W4
Cx 
W6
Cx 
W9
Cx 
W12
Cx 
W16
Cx W20
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window 
(days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteria
X
Xe
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Dispense intake 
and output 
diaries
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant 
medications and 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examination 
and vital signs, 
including 
weight
X
X
X
X
X
X
X
X
X
X
X
X
Height and head 
circumferencef
X
X
X
X
Review intake 
and output 
diariesg
X
X
X
X
X
X
X
X
X
X
X
X
X
Record PS Rx 
and adjust as 
neededh
X
X
X
X
X
X
X
X
X
X
X
X
X
Safety 
laboratory testsi
Xj
X
X
X
X
X
X
X
X
X
X
(X)
X
For non-commercial use only

Shire
CONFIDENTIAL
Page 24
SHP633-303 Protocol Amendment 3
Teduglutide
16 May 2018
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Cx
W4
Cx 
W6
Cx 
W9
Cx 
W12
Cx 
W16
Cx W20
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window 
(days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
PedsQL 
Generic Core 
Scale/ Family 
Impact Module/ 
GI Symptoms 
Module Sub-
Scales
X
X
X
Antibodies to 
teduglutidej
X
X
X
X
Fecal occult 
blood testing
X
X
X
Colonoscopy/
Sigmoidoscopyk
(X)
(X)
(X)
Pregnancy 
testingl
X
X
X
X
X
X
X
X
X
Serum samplem
X
X
Evaluate escape 
criterian
Xp
X
X
Dispense study 
drugo
X
X
X
X
X
X
X
X
X
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; FU=follow-up; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio; SBS=short bowel syndrome; SC=subcutaneous; 
Scr=screening; TED=teduglutide; Tx=treatment
a If the first pretreatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening. 
b Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except for evaluation of escape 
criteria).
c The investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur within 7 days of the 
CxW28 visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-2) will take place in lieu of the CxW28 visit.
d Visit windows are relative to the CxD1 visit.
e Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs obtained at the CxD1 
visit are not required to determine teduglutide treatment eligibility.
For non-commercial use only

Shire
CONFIDENTIAL
Page 25
SHP633-303 Protocol Amendment 3
Teduglutide
16 May 2018
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Cx
W4
Cx 
W6
Cx 
W9
Cx 
W12
Cx 
W16
Cx W20
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window 
(days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
f Head circumference will be measured in subjects 36 months of age and younger.
g Intake diaries will collect actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except at pretreatment visit), 
for 1 week following PS adjustment, and daily during the 4-week follow-up period. Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before 
every clinic visit, and within 1 week of implementing a change in the PS prescription. See Section 7.2.2.12 for more detail.
h Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment provided in Appendix 2.
i Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed by a central laboratory. Clinical chemistry and urinalysis must also be 
performed within approximately 5-7 days of any adjustment to the PS prescription. Safety labs performed between clinic visits may be performed locally. Unscheduled lab results will not be captured in 
the eCRFs. If abnormal results are considered an adverse event, an AE form will be completed. Collect PT/INR at the pretreatment visit. Additional collection will occur if a potential drug-induced liver 
injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not constitute a protocol deviation.
j Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be drawn at least 14 hours 
after dosing.
k The teduglutide-naïve subjects age 12 and older will undergo colonoscopy/sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any age with newly positive 
FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy/sigmoidoscopy prior to receiving teduglutide. If newly 
positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment cycle (CxW24/EOT), colonoscopy/sigmoidoscopy will be performed. 
The need for colonoscopy/sigmoidoscopy in response to positive FOBT results at CxW12 is at the discretion of the investigator. Teduglutide-exposed subjects who have received the equivalent of 2 
treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy/sigmoidoscopy. See Section 7.2.2.10 for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all other visits according to the study schedules, or if pregnancy is 
suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.
n If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed for hypersensitivity 
reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See Section 6.2.3 for dose adjustment.
p Escape criteria will be assessed for subjects who escaped during the follow-up period of a previous teduglutide treatment cycle at CxW24. The investigator may combine the CxW24 visit with the next 
pretreatment visit if at least 1 escape criterion is met at the CxW24 visit. In order to combine assessments, the pretreatment assessments must occur within 7 days of the CxW24 visit.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 26
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
1
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options
Short bowel syndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. It is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with SBS (Khan et al., 
2015; Wales et al., 2004). Unlike the adult population, the majority of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy. 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 years of the initial diagnosis (Khan et al., 2015). 
Nevertheless, despite optimal medical management, many pediatric subjects remain dependent 
on PS. Complications of long-term PS include liver disease, catheter-related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality of life is poor (Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al., 2015; Squires et al., 2012).
Intestinal adaptation is driven by hormonal cues in response to nutrient malabsorption (Drucker 
and Yusta, 2014). Chief among these is hormones glucagon-like peptide 2 (GLP-2), which is 
secreted from L-type enteroendocrine cells that reside in the intestinal epithelium in the ileum 
and colon. Resection of these regions may impair the adaptive response by limiting endogenous 
production of GLP-2.
1.2
Product Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP-2 that 
regulates the functional and structural integrity of the cells lining the gastrointestinal (GI) 
tract. Teduglutide is a 33-amino acid peptide that differs from native GLP-2 in the substitution 
of glycine for alanine at the second position at the N-terminus. As a result, teduglutide 
demonstrates resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and therefore 
maintains a longer elimination half-life (t1/2) in adults of approximately 2 hours compared to 
the native peptide, which has a t1/2 of approximately 7 minutes. Teduglutide has been shown 
in animal studies and previous human clinical trials to increase villus height and crypt depth in 
the intestinal epithelium, thereby increasing the absorptive surface area of the intestines 
(Tappenden et al., 2013; Thymann et al., 2014). The European Commission granted a 
centralized marketing authorization valid throughout the European Union (EU) for teduglutide 
(REVESTIVE™) on 30 August 2012 and a New Drug Application (NDA) for teduglutide 
(GATTEX®) was approved by the United States (US) Food and Drug Administration (FDA) on 
21 December 2012 for the treatment of adult patients with SBS who are dependent on PS. 
Teduglutide has also been approved for use in adult patients with SBS in Canada and 
Switzerland. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 27
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
On 29 Jun 2016, the European Commission granted an extension of the Market Authorization for 
teduglutide (REVESTIVE™) for the treatment of patients aged 1 year and above with SBS; patients 
should be stable following a period of intestinal adaptation.
1.3
Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 study, TED-C13-003, was completed in pediatric SBS subjects in the US and 
United Kingdom (UK). In this study, teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1-17. Thirty-seven pediatric subjects received teduglutide at doses of 
0.0125, 0.025, or 0.05 mg/kg/day for 12 weeks. Five additional pediatric subjects were 
enrolled in an observational standard of care (SOC) cohort. There were clear dose-dependent 
effects of teduglutide seen at the 0.025 and 0.05 mg/kg/day doses compared to SOC and the 
0.0125 mg/kg/day dose. In the 0.025 mg/kg/day cohort there was a reduction in PS volume at 
Week 12 of 37%, including complete independence from PS support in 1 subject, and a 
reduction of 3.94 hours per day infusion time. In the 0.05 mg/kg/day cohort there was a 
reduction in PS volume at Week 12 of 39%, including complete independence from PS support 
in 3 subjects, and a reduction of 4.18 hours per day infusion time. Teduglutide was generally safe 
and well tolerated by pediatric subjects in all dosing cohorts. There were no deaths during the 
study and no treatment-emergent serious adverse events (TESAEs) related to teduglutide were 
reported. No discontinuations from study were due to adverse events (AEs).
TED-C14-006 is a recently completed study of pediatric subjects through 17 years which 
included 2 treatment arms: a teduglutide treatment arm and a SOC treatment arm. Subjects in 
both arms participated in a 2-week minimum screening period, a 24-week treatment period, and a 
4-week follow-up period. During the screening period, subjects chose into which arm to enroll. 
During the 24-week treatment period, subjects in the SOC treatment arm received standard 
medical therapy for SBS; while those in the teduglutide treatment arm received daily 
subcutaneous (SC) injections of teduglutide (study drug) in addition to standard medical therapy. 
The subjects enrolling in the teduglutide treatment arm were randomized 1:1 in a double-blinded 
manner into 2 parallel dose groups: 0.025 mg/kg/day or 0.05 mg/kg/day of teduglutide 
administered subcutaneously for 24 weeks. Compared to the SOC, treatment of pediatric subjects 
with SBS with teduglutide resulted in clinically meaningful reductions in PN/IV volume, 
calories, days per week, and hours per day. A total 10% of subjects who received teduglutide 
achieved enteral autonomy within 24 weeks despite prior dependence on PN/IV for several 
years. Teduglutide treatment also resulted in increases in EN volume and caloric intake as well 
as plasma citrulline. Although the differences in efficacy between the 0.025 and 0.05 mg/kg dose 
groups were small, a consistently greater effect was seen in the 0.05 mg/kg dose in all efficacy 
parameters. The PK properties were well characterized in this population and were consistent 
with the prior 12 week pediatric study. Teduglutide was generally well tolerated by pediatric 
subjects with SBS. The safety profile was favorable and consistent with the prior pediatric study, 
the underlying disease, and previous experience with teduglutide in adult subjects with SBS.
Always refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy and safety of teduglutide (SHP633).
For non-commercial use only

Shire
CONFIDENTIAL
Page 28
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
2
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to 
evaluate the safety and efficacy of teduglutide in pediatric subjects with SBS who completed the 
TED-C13-003 study. In addition to evaluating the long-term safety and durability of efficacy 
after 12 weeks of treatment in TED-C13-003, this extension study will evaluate the need for 
additional teduglutide treatment in these subjects, and will allow for the first-time treatment of 
teduglutide-naïve subjects who participated in the SOC treatment arm in TED-C13-003.
2.2
Study Objectives
2.2.1
Primary Objectives
The primary objective of the study is to evaluate the long-term safety and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED-C13-003.
2.2.2
Secondary Objectives
The secondary objective of this study is to evaluate the long-term efficacy of teduglutide 
treatment in pediatric subjects with SBS who completed TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 29
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
3
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects who completed the TED-C13-003 study (the core 
study). At the time of entry into the TED-C13-003 study, subjects were less than 18 years of age, 
were dependent on parenteral nutrition to provide at least 30% of their caloric or fluid needs, and 
had not been able to significantly reduce PS for at least 3 months prior to enrollment. During the 
core study, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day, 0.025 mg/kg/day, or 0.05 mg/kg/day dose cohort based on the timing of their 
enrollment in the study. The cohorts were filled in a sequential manner.
Approximately 40 subjects who completed the core study are expected to enroll in this extension 
study. Subjects who previously received teduglutide during the core study, as well as subjects 
who were in the SOC treatment group, may be eligible to receive teduglutide treatment in this 
extension study. To be eligible for treatment with teduglutide in this extension study, subjects 
must meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately every 12 weeks for safety, parenteral support (PS) requirements, and 
quality of life. At any point during an NTT period, subjects who meet ≥1 teduglutide treatment 
inclusion criteria may proceed directly to the pretreatment visit if the investigator, subject, and 
parent or legal guardian agrees to proceed with teduglutide therapy.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long-term follow-up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analysis suggested that pediatric patients, ages 1-17 years-old, are likely to require the same 
dose as used in adults, namely 0.05 mg/kg/day (Mouksassi et al., 2009). In this extension study,
all subjects who enter a teduglutide treatment cycle will receive 0.05 mg/kg SC QD.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed pediatric studies (TED-C13-003 and 
TED-C14-006) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day 
was associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
For non-commercial use only

Shire
CONFIDENTIAL
Page 30
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
studies as well as the pediatric (core) study (TED-C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults (O'Keefe et al., 2006).
Further PK simulation was conducted based on the population PK model previously established 
and a virtual population of 1000 pediatric patients created based on Centers for Disease Control 
(CDC) growth charts in the target age group (4 to 12 months) and taking into consideration 
body weights of pediatric patients with SBS enrolled in study TED-C13-003 (approximately 15% 
lower than healthy subjects in the same age group). Monte Carlo simulations for all age groups 
were performed according to the SC dosing regimens of 0.0125, 0.025 and 0.05 mg/kg every 
24 hours. Rich concentration-time profiles were simulated with the customized population PK 
model to derive the exposure metrics area under the concentration curve at steady state (AUCss) 
and maximum concentration at steady state (Cmax,ss). Following 0.05 mg/kg daily SC 
administration, the median Cmax,ss of teduglutide in infants (24.9 ng/mL) was within 20% of that 
observed in the 2 to 4 and 4 to 6 years age groups (26.9 and 29.4 ng/mL, respectively); and 
approximately ~28% lower than that in adult patients with SBS. The clinical package in 
conjunction with Cmax was considered to support teduglutide dose selection since AUCss was 
previously shown not to correlate with efficacy. Thus, the 0.05 mg/kg dose is proposed for testing 
in all age groups.
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED-C14-006 study, 
consisting of 24 weeks of teduglutide treatment, followed by a 4-week follow-up period. The 
follow-up period is a mechanism to evaluate whether continued teduglutide is needed. If a 
subject deteriorates during the follow-up period, the subject may be evaluated immediately for 
additional teduglutide treatment. Subjects who clinically deteriorate or stop improving at any 
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED-C13-003 and TED-C14-006, to ensure sufficient safety monitoring and 
weaning of PS. During the NTT period, visits occur every 12 weeks, a frequency that is 
consistent with standard medical practices. To minimize risk to subjects, those who have 
deteriorated quickly after treatment interruption (ie, escaped from a prior follow-up period) may 
be evaluated immediately for eligibility for additional treatment when they reach the Week 24 
visit of subsequent treatment cycles.
Measures and Parameters
To evaluate efficacy and safety from the time subjects completed the core study to the time they 
enter this extension study, retrospective data collection is planned for this study. The 
retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. In addition to this retrospective data 
collection, prospective study assessments of safety and efficacy will be completed as a part of 
this study.
For non-commercial use only

Shire
CONFIDENTIAL
Page 31
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
3.1.1
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be 
completed before any other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study; however subjects may 
consent to retrospective data collection only. Subjects may not consent to the prospective data 
collection only. After informed consent/assent is obtained, study eligibility will be assessed for 
all subjects.
3.1.2
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and 
Section 7.1.1. For subjects that only consent to retrospective data collection, these procedures are 
all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study. Retrospective data collection may begin any time after informed consent/assent is 
obtained for this study. The following data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
3.1.3
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history and short bowel syndrome history. The parenteral support prescription will 
also be collected at screening. Additionally, intake diaries will be dispensed at the screening visit 
for collection of actual PS volume and hours per day (Section 7.2.2.12). Diary data for PS 
volume will be collected for at least 2 weeks after the ICF (and if applicable, the informed 
assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately 
every 12 weeks for safety, PS requirements, and quality of life. Diary data for PS volume will be 
collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 32
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
At any point after screening, including during an NTT period, subjects who meet ≥1 teduglutide 
treatment inclusion criteria, may proceed immediately to the pretreatment visit if the investigator, 
subject, and parent or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, 
and meet none of the teduglutide treatment exclusion criteria, will start a 28-week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily, followed by a 
4-week follow-up (no treatment) period (Figure 3-1). During the 28-week cycle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality of life assessments will be made approximately every 
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation (Appendix 2).
Rationale: Measures of long-term safety will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
by reduction in PS and improvement in pediatric quality of life measures (Pediatric Quality of 
Life Inventory [PedsQL], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pivotal Phase 3 adult clinical 
trials and the completed Phase 3 pediatric study (TED-C13-003), and will be used as an endpoint 
in this extension study. In previous clinical studies, a reduction of this magnitude was associated 
with a reduction in the number of days per week of PS, and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may provide a pediatric subject 
with opportunities for more age-appropriate activities including oral rehabilitation. Quality of life 
assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI-specific screening tests, 
including fecal occult blood testing and colonoscopy/sigmoidoscopy, which are commonly part 
of the routine care of these subjects, will be performed to ensure safety. This study captures 
long-term safety data on polyps and other colonic mucosal changes in teduglutide-exposed 
subjects using the surveillance strategy proposed in Section 7.2.2.10.
For non-commercial use only

Shire
CONFIDENTIAL
Page 33
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Figure 3-1
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide 
at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey 
lines). If an escape criterion is met at Week 24 or during the follow-up period, subjects may proceed directly to another 
pretreatment visit.
3.2
Duration and Study Completion Definition
A subject will be considered enrolled in the study once the subject has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility 
Criteria. The study will continue for at least 1 year, and until each subject has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
3 years. The study will be completed in approximately 40 months. A subject will be considered 
as having completed the study if the subject has not withdrawn early from the study for any 
reason prior to completing the EOS visit.
The study completion date is defined as the date the final subject, across all sites, completes their 
final protocol-defined assessment. Please note that this includes the follow-up visit or contact 
(last safety contact), whichever is later. The study completion date will be used to ascertain 
timing for study results posting and reporting.
For non-commercial use only

Shire
CONFIDENTIAL
Page 34
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
4
STUDY POPULATION
Each subject and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any study-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility does not impact study eligibility.
4.1
Study Inclusion Eligibility Criteria
The subject will not be considered eligible for the study without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing any 
study-related procedures. 
2. Subject completed the TED-C13-003 study (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully adhere to study requirements as 
defined in this protocol.
4.2
Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study.
4.3
Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria 
and none of the teduglutide treatment exclusion criteria are met. In addition, the investigator and 
the subject (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.4
Teduglutide Treatment Inclusion Criteria
1. Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and 
during the teduglutide pretreatment visit, as assessed by the investigator. Transient 
instability for events such as interruption of central access or treatment for sepsis is 
allowed if the PS returns to within 10% of baseline prior to the event.
2. Subject was previously treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b. Decreased PS requirement during prior teduglutide treatment, followed by 
cessation of improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite 
maximal tolerated enteral nutrition (EN) following teduglutide discontinuation
d. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid 
and electrolyte intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 35
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
4.5
Teduglutide Treatment Exclusion Criteria
1. Body weight <10 kg at the pretreatment visit
2. Unresected GI polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3. History of cancer in the previous 5 years except surgically curative skin cancers
4. Serial transverse enteroplasty or other major intestinal surgery within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5. Intestinal or other major surgery planned or scheduled to occur during the 28-week 
cycle
6. Clinically significant intestinal stricture or obstruction
7. Clinically significant, active or recurrent pancreatic or biliary disease
8. Active, severe, or unstable, clinically significant hepatic impairment or injury, 
including the following laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9. Renal dysfunction shown by results of an estimated glomerular filtration rate below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the 
exception of subjects who had undergone ventricular or atrial septal defect repair, or 
patent ductus arteriosus ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, 
Omegaven, Smoflipid, or teduglutide) within 3 months or 5.5 half-lives of the 
experimental drug, whichever is longer, prior to the pretreatment visit and for the 
duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 
(GLP-2) (not including teduglutide), insulin-like growth factor-1 (IGF-1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months 
prior to the pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, 
closely-related compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
For non-commercial use only

Shire
CONFIDENTIAL
Page 36
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
17. Sexually active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 days after the treatment period 
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts 
the subject at any undue risk, prevents completion of the study, or interferes with 
analysis of the study results
4.6
Follow-up Period Escape Criteria
At the discretion of the investigator, the follow-up period may be interrupted or omitted and the 
subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1. Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal 
tolerated EN following teduglutide discontinuation
3. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and 
electrolyte intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
5. The subject escaped during the follow-up period of a previous teduglutide treatment 
cycle within SHP633-303.
4.7
Reproductive Potential
4.7.1
Female Contraception
To be eligible for treatment with teduglutide, sexually active females of child-bearing potential 
must use an acceptable form of contraception throughout the study period and for 30 days 
following the last dose of investigational product. If hormonal contraceptives are used, they 
should be administered according to the package insert. Females of child-bearing potential who 
are not currently sexually active must agree to use acceptable contraception, as defined below, if 
they become sexually active during the period of the study and 30 days following the last dose of 
investigational product. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:

Premenarchal and either Tanner Stage 1 or less than age 9 years, or

Females of child-bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin (-HCG) pregnancy test at the teduglutide pretreatment visit. Females of 
child-bearing potential must agree to abstain from sexual activity that could result in 
pregnancy or agree to use acceptable methods of contraception.
For non-commercial use only

Shire
CONFIDENTIAL
Page 37
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Acceptable methods of contraception are:

True abstinence: Abstention of sexual activity that is in line with the preferred and usual 
lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception). 

Intrauterine devices plus condoms

Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)

Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 days prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually active during the study, they should use 1 of the other acceptable methods noted 
above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
4.8
Discontinuation of Subjects 
4.8.1
Teduglutide Discontinuation
If the investigational product is discontinued prematurely during a teduglutide treatment cycle 
and the subject wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow-up period will ensue, consisting of weekly telephone visits 
(CxW25-27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility according to the study 
schedules. 
Comments (spontaneous or elicited) or complaints made by the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.3. The investigator is encouraged to discuss withdrawal of a subject 
from investigational product with the medical monitor, when possible.
4.8.2
Study Withdrawal
At any time during the study, the investigator or sponsor may withdraw a subject, or a subject 
may withdraw from the study, for any reason, without prejudice to their future medical care by 
the physician or at the institution.
If a subject withdraws from the study during a teduglutide cycle, the evaluations listed for the 
EOT visit are to be performed as completely as possible. Whenever possible, the subject will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contacted 
weekly by phone during the interim period between EOT and ET for safety follow-up.
If a subject withdraws from the study during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completely as possible. 
Subjects who withdraw from the study will not be replaced.
For non-commercial use only

Shire
CONFIDENTIAL
Page 38
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
4.8.3
Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study must 
be determined by the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than 1 reason, each reason should be documented in the source 
document, and the most clinically relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:

Adverse event

Protocol deviation

Lack of efficacy

Physician decision

Withdrawal by subject

Withdrawal by parent/guardian

Lost to follow-up

Pregnancy (Discontinuation of treatment only)

Death

Other
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations, and return any unused investigational product.
For non-commercial use only

Shire
CONFIDENTIAL
Page 39
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
5
CONCOMITANT TREATMENT
5.1
Concomitant Medications and Procedures
Concomitant treatment will be collected for the prospective period only and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study. Concomitant medications and procedures will be assessed at each site visit, and include all 
nonstudy treatments (medications, herbal treatments, vitamins, invasive and diagnostic 
procedures). Concomitant treatment information must be recorded on the appropriate eCRF 
page. Details of medication changes and/or dosages will be recorded on the eCRF.
5.1.1
Permitted Treatment
Standard medical therapy for SBS should be continued.
5.1.2
Prohibited Treatment
At the time of screening, any teduglutide treatment being received through any mechanism 
other than participation in this study (eg, by off-label prescription, participation in an 
investigator-initiated trial, compassionate access program, etc) must be discontinued. In such 
cases, there is no minimum duration of interruption of teduglutide treatment before pretreatment 
evaluations can be performed.
The mechanism of action of teduglutide may increase enteral absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, digoxin), so consideration should be given to modifying 
concomitant enteral medication regimens. Down-titration of concomitant enteral medications 
should be considered when drugs, especially those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1 Prohibited Treatment
Prior Therapy
Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon-like peptide-2 (not-including teduglutide)
Any
Glucagon-like peptide-1 analog or human growth hormone
3 months
Octreotide or dipeptidyl peptidase 4 inhibitors
3 months
For non-commercial use only

Shire
CONFIDENTIAL
Page 40
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
6
INVESTIGATIONAL PRODUCT
6.1
Identity of Investigational Product
The test product is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L-histidine, mannitol, monobasic sodium 
phosphate monohydrate, and dibasic sodium phosphate as excipients. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.1
Blinding the Treatment Assignment
Not applicable for this open-label study.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology for Investigational Product Management
An interactive web-based response system (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory management and supply ordering, investigational product expiration tracking and 
management, and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The IWRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.2
Allocation of Subjects to Treatment
This is an open-label study. Subjects will retain their assigned subject number from the 
TED-C13-003 study. Assessment of need for teduglutide treatment should be guided by the 
teduglutide treatment inclusion criteria. If the investigator, subject, and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit (Table 1-4).
6.2.3
Dosing
If teduglutide treatment eligibility is established at the pretreatment visit and again, confirmed at 
the CxD1 visit, the subject will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered by SC injection once daily (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 41
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than 3 hours 
later.
The subject should be dosed at approximately the same time each day. Consecutive doses should 
be separated by at least 12 hours. Each day, the injection site should be rotated.
The first SC injection in teduglutide-naïve subjects should be administered under the supervision 
of the investigator or designee and the subject observed for hypersensitivity reactions for at least 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the Instructions for Use. 
At the end of each 24-week teduglutide treatment period, subjects will be evaluated for the need 
for additional teduglutide treatment. During the 4-week follow-up period, the investigator will 
assess the subject via weekly telephone visits. At any time during the follow-up period, if escape 
criteria are met, the subject may proceed directly to another Pretreatment visit to assess treatment 
eligibility for another cycle (Section 4.6). Following the completion of the 4-week follow-up, the 
subject will continue in the study off teduglutide until teduglutide treatment eligibility criteria are 
again met. Additional 28-week cycles may be repeated if treatment eligibility is established each 
time.
6.2.4
Unblinding the Treatment Assignment
Not applicable for this open-label study.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification will be applied to the investigational 
product(s) container.
The study drug will be packaged, labeled, and shipped to the study site by the sponsor or 
designee. Kits containing 7 vials of study drug will be supplied and these will be labeled in 
accordance with applicable regulatory requirements. Sterile water for injection syringes and 
other ancillary components will also be provided separately and will be labeled in accordance 
with the applicable regulatory requirements.
All study drug used in this study will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
For non-commercial use only

Shire
CONFIDENTIAL
Page 42
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
6.3.2
Packaging
Teduglutide will be provided in a 3 mL sterile, single-use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL) will be provided in a prefilled syringe.
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the sponsor.
6.3.3
Storage and Handling
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Limited responsibility may be delegated to the pharmacy or 
member of the study team, but this delegation must be documented.
Study drug must be kept in a locked area with access restricted to specific study personnel. Study 
drug will be stored refrigerated at a temperature between 2-8°C (35.6-46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2-25°C, or 35.6-77°F). Parent/legal guardian 
will be instructed to keep the subject’s study drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study drug may be refrigerated. The study drug is for single use only, and should be used within 
3 hours following reconstitution.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed by the pharmacy or nominated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
For non-commercial use only

Shire
CONFIDENTIAL
Page 43
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed number of subjects. The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. The 
investigator is to keep a current record of the inventory and dispensation of all clinical supplies. 
This record will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any discrepancy or deficiency will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any unauthorized situation.
The investigator has overall responsibility for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study protocol. All dispensed 
study medication will be documented in the interactive response technology system and/or other 
investigational product record (eg, investigation product accountability form). The investigator is 
responsible for assuring the retrieval of all study supplies from subjects.
All used and unused study drug vials must be returned by the subjects and/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unused study drug vials to the same subject. All original containers, whether empty 
or containing study drug will be returned to the pharmacy. Returned study drugs will NOT be 
relabeled or reassigned for use by other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may be destroyed on site without approval by the sponsor.
Please see the Pharmacy Manual for additional information.
6.5
Subject Compliance
Subjects will be instructed to bring their unused investigational product and empty/used 
investigational product packaging to every visit. Drug accountability will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper-evident sealed container (eg, bottles, trays, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability form.
Compliance with study drug is calculated from subject diaries. Of those subjects eligible for 
teduglutide treatment, subjects who have received 80% of the planned doses administered will be 
assessed as being compliant with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 44
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
7
STUDY PROCEDURES
7.1
Study Schedule
Detailed study procedures and assessments to be performed for subjects throughout the study are 
outlined in the Schedule of Assessments (Table 1-1, Table 1-2, Table 1-3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing any study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject (Table 1-1).
7.1.1
Retrospective Data Collection
Retrospective data are defined as specific safety and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. Retrospective PS and growth data will be 
captured in 12-week intervals, with the first 12-week interval beginning at the TED-C13-003 
EOS visit. All available retrospective data should be captured in the corresponding eCRFs. 
Failure to collect retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent only to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study:

Informed consent, and informed assent (if applicable)

Study eligibility is determined

A screen failure is a subject who has given informed consent and failed to meet 
the study inclusion eligibility criteria. Subjects cannot be rescreened once they 
have been designated as a screen failure.

Prior teduglutide use (as prescribed)

Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, compassionate 
use, and named-patient access programs.

Collect start and end dates when a subject’s teduglutide use was interrupted.

Parenteral support (as prescribed)

The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide treatment 
will be collected. Usually, the prescription at the end of the interval will represent 
the status of intestinal adaptation. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 45
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
However, transient alterations in PS related to loss of central venous access or 
acute illness are not representative of intestinal adaptation. When such events 
occur at the end of a 12-week interval, earlier, more representative PS prescription 
data should be recorded.
Data collected should include weekly prescribed volume, calories, average hours 
per day, and days per week of prescribed PS. Hours per day should be averaged 
over the days where PS is prescribed.

Growth (height, head circumference, and weight)

The last representative value for height, during each 12-week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and younger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.

Adverse events

All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study. The details of data collection and safety reporting for these events 
can be found in Section 8.

End dates for AEs ongoing at the end of TED-C13-003 will be collected.
7.1.2
Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:

Informed consent, and informed assent (if applicable)

Study eligibility is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study inclusion eligibility criteria. Subjects cannot be 
rescreened once they have been designated as a screen failure.

Demographics, updates to medical history and SBS history

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications and concomitant procedures

Physical examination and vital signs, including weight

Height and head circumference

Record PS prescription and adjust as needed
For non-commercial use only

Shire
CONFIDENTIAL
Page 46
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3
Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide-treatment cycle, subjects will be followed 
approximately every 12 weeks for safety and efficacy assessments. No-teduglutide treatment 
visits are numbered sequentially (NT1, NT2, etc.), even if interrupted by the treatment cycles. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1-3 and described below.

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications, and concomitant procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests (ie, clinical chemistry, hematology, and urinalysis)

PedsQL Generic Core Scale/PedsQL Family Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub-Scales

Antibodies to teduglutide, if and when required

Fecal occult blood testing, as indicated (see Section 7.2.2.10)

Colonoscopy/sigmoidoscopy, as indicated (see Section 7.2.2.10)

Serum sample, as indicated
Teduglutide treatment may be considered at any time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may proceed to the pretreatment visit immediately to determine 
eligibility.
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
7.1.4.1
Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may proceed to the pretreatment visit immediately. Similarly, 
subjects who meet escape criteria at cycle Week 24 or during the teduglutide follow-up period 
may proceed to the pretreatment visit immediately.
For non-commercial use only

Shire
CONFIDENTIAL
Page 47
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
In general, pretreatment assessments may occur over a period of up to 21 days. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:

Evaluate teduglutide eligibility (treatment inclusion/exclusion criteria)

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant procedures

Fecal occult blood testing

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy as indicated

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries 

Record PS prescription and adjust as needed.

Safety laboratory tests
(In addition to clinical chemistry, hematology, and urinalysis, labs at this visit include 
prothrombin time [PT] international normalized ratio [INR]. Subsequent prothrombin 
time/international normalized ratio [PT/INR] measurement is only required to evaluate 
for suspected drug-induced liver injury [DILI]).

Pregnancy testing (serum), if applicable

Serum sample
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24)
The open-label teduglutide treatment period will comprise 24 weeks, during which all 
assessments and procedures listed for Visits CxD1-CxW24 in Table 1-4 shall be completed. 
Cycles are numbered sequentially, such that the first visit of the first cycle is C1D1, and the first 
visit of the second cycle is C2D1, etc. Visit windows are calculated relative to the date of first 
investigational product administration (Visit CxD1).
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1-4 and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.

Confirm teduglutide treatment eligibility

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant procedures
For non-commercial use only

Shire
CONFIDENTIAL
Page 48
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing (urine), if applicable

Dispense study drug
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cycle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:

Dispense and review intake and output diaries (every effort should be made to complete 
2 weeks of intake diary entries prior to each clinic visit and to complete 48 hours of 
output diary entries during a period of nutritional stability prior to each clinic visit)

Physical examination and vital signs, including weight

Record PS prescription and adjust as needed

Safety laboratory tests

Urine pregnancy testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)

Study drug dispensation (except for CxW24)

Adverse events, concomitant medications and concomitant procedures
In addition, at CxW12 and CxW24 Visits ONLY, the following procedures will be performed:

Height and head circumference

Antibodies to teduglutide

Fecal occult blood testing (FOBT)

GI-specific testing, including colonoscopy or sigmoidoscopy as indicated

Quality of life measurements
At CxW24 ONLY, a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 49
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Escape criteria are also evaluated at CxW24. The investigator may combine the CxW24 
assessments with the next pretreatment visit assessments if at least 1 escape criterion is met at the 
CxW24 visit and the pretreatment assessments occur within 7 days of the CxW24 visit.
Phone Visits
Phone visits are required approximately 1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-4 and described 
below:

Review intake and output diaries

Safety laboratory tests (clinical chemistry and urinalysis)

Record PS prescription and adjust as needed

Obtain AEs, concomitant medications, and concomitant procedures

Evaluate escape criteria
7.1.5
Teduglutide Follow-up Period
The safety follow-up period for this protocol is 4 weeks (Weeks 25-28 of the cycle). Phone visits 
will occur on cycle Weeks 25, 26, and 27 for all subjects. Phone visit assessments and 
procedures at Weeks 25-27 will be the same as for telephone visits performed during the 
teduglutide treatment period. In addition, subjects will be evaluated for follow-up period escape 
criteria. If escape criteria are met at any time during the follow-up period, the subject may
proceed directly to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW24 or CxW28 visits with the next pretreatment visit if at least 1 escape 
criterion is met at the CxW24 or CxW28 visits, and the pretreatment assessments occur within 
7 days of the CxW24 or CxW28 visit. If a subject is completing the study at the CxW28 visit, the 
EOS/ET visit (Section 7.1.6) will take place in lieu of the CxW28 visit. Otherwise, following 
completion of the 28-week treatment cycle, the subject will proceed to an NTT visit within 
approximately 12 weeks.
At Cycle Week 28 (CxW28), subjects will return to the study site. In addition to the assessments 
performed at Weeks 25-27, the following procedures will be performed at CxW28 only:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Antibodies to teduglutide

Pregnancy testing (urine), if applicable

Evaluate escape criteria
For non-commercial use only

Shire
CONFIDENTIAL
Page 50
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study site for the end of study/early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-2 and as 
described here. If a subject discontinues the study prematurely, the assessments for the EOS/ET 
visit are to be performed as completely as possible (see Section 4.8.2).

Adverse events, concomitant medications, and concomitant procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries (the intake diary should be completed daily for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily over a 48-hour period of nutritional stability before the EOS/ET visit)

Record PS prescription and adjust as needed

Safety laboratory tests

Fecal occult blood testing, as indicated

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy, as indicated

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing, as needed
7.2
Study Evaluations and Procedures
7.2.1
Retrospective Data Collection
Retrospective data are being collected to evaluate the safety, tolerability, and efficacy of 
teduglutide during the interval between a subject's completion of the TED-C13-003 study and the 
date the ICF (and if applicable, assent) is signed for the SHP633-303 study.
7.2.1.1
Growth (Height, Weight, and Head Circumference)
Retrospective body height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z-score, weight z-score, body mass index (BMI), and BMI z-score will be calculated by 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analysis plan (SAP).
For non-commercial use only

Shire
CONFIDENTIAL
Page 51
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
7.2.1.2
Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency will be 
recorded on the appropriate eCRF page.
7.2.1.3
Parenteral Support Prescribed
Retrospective parenteral support entries consist of 1 prescription per 12-week interval during the 
retrospective period. If the subject has multiple PS prescriptions in a 12-week interval, the last 
representative prescription from the interval should be used (see Section 7.1.1). In addition, PS 
prescriptions at the beginning and end of any retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekly volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
7.2.1.4
Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESIs) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide that 
occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safety reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED-C13-003 will be collected.
7.2.2
Prospective Data Collection
7.2.2.1
Demographics, Medical History, and SBS History
Demographics, updates to medical history, and updates to SBS history will be obtained at 
screening. Medical history for purposes of this extension study will consist of updates to the 
medical history collected at the start of the TED-C13-003 core study. If the subject has any 
changes to the SBS history since the baseline visit of the TED-C13-003 study, that information 
(updated SBS history) will also be collected.
7.2.2.2
Physical Examination
Physical examinations will be performed according to the study schedules. Any new clinically 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF.
7.2.2.3
Adverse Event Collection
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
For non-commercial use only

Shire
CONFIDENTIAL
Page 52
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body temperature 
(°C/°F). Blood pressure should be determined by cuff (using the same method, the same arm, 
and in the same position throughout the study).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each study visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z-score, weight z-score, BMI, and BMI z-score will be 
calculated by the sponsor using the site-provided height and weight data collected at each site 
visit.
New clinically significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.2.5
Clinical Laboratory Tests
Safety laboratory tests to be performed at site visits consist of clinical chemistry, hematology, 
and urinalysis and will be performed as outlined in the study plan (Table 1-2, Table 1-3, and 
Table 1-4). Scheduled laboratory testing will be processed by a central lab. All laboratory assays 
will be performed according to the central laboratory’s normal procedures. Reference ranges are 
to be supplied by the laboratory. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Abnormal clinical laboratory values, which are unexpected or not 
explained by the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safety labs within approximately 
5-7 days after a PS adjustment. Safety labs performed after PS adjustment and between site visits 
will consist of clinical chemistry and urinalysis and may be processed by the central laboratory 
or a local laboratory. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate any new clinically significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safety labs, but lack of urinalysis will not constitute a protocol deviation.
New clinically significant labs should be reported as AEs.
For non-commercial use only

Shire
CONFIDENTIAL
Page 53
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
The following clinical laboratory assessments will be performed according to the study 
schedules:
Table 7-1 List of Laboratory Tests 
Hematology:

Hematocrit

Hemoglobin

Platelet count

Red blood cell count

Red blood cell morphology, if needed

White blood cell count with differential
Coagulation:
Prothrombin time/International normalized ratio
Urinalysis:

Blood

Glucose

Leukocytes

Microscopic analysis

pH

Protein

Specific gravity
Pregnancy tests (females of childbearing potential):

Serum β-HCG (screening)

Urine β-HCG (all other visits)
Biochemistry:

Albumin

Alkaline phosphatase

Alanine aminotransferase

Amylase

Aspartate aminotransferase

Bicarbonate

Bilirubin (total, direct, and indirect)

Blood urea nitrogen

Calcium (total)

Chloride

Cholesterol

C-reactive protein

Creatinine

Estimated Glomerular Filtration Rate 
(Schwartz formula)

Gamma-glutamyl transferase

Glucose

Lipase

Magnesium

Phosphorus

Potassium

Sodium

Triglycerides

Uric acid
7.2.2.6
Serum Sampling
Serum samples will be collected and stored for future analysis at the following times:

At the pretreatment visit. If the subject arrived at the pretreatment visit by meeting an 
escape criterion, the serum sample will not be repeated at the pretreatment visit, because 
it will have been collected recently at the CxW24 visit.

At the CxW24 (EOT) visit

During NTT: Approximately every 24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 54
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
The sponsor, sponsor’s representatives, biorepositories, and any specialty laboratories will be 
blinded to the subject’s identity. The sample and/or extracted material will otherwise be stored 
for up to 15 years from the end of the study after which time it will be destroyed. Upon written 
request, subjects will be permitted to withdraw their sample from the analysis and have their 
sample and/or extracted material destroyed. Any results already generated from the samples will 
not be removed from any analyses that have already been performed.
7.2.2.7
Pregnancy Testing
A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy tests will be administered at all other visits according to the study schedules, or if 
pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the 
study.
7.2.2.8
Antibody Testing
Blood samples will be drawn for the analysis of antibodies to teduglutide according to the 
Schedule of Assessments (Table 1-2, Table 1-3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least 14 hours after dosing. Subjects who test 
positive for antibodies to teduglutide will also be tested for neutralizing antibody. Subjects who 
have been previously treated with teduglutide, and who test positive for antibodies to 
teduglutide, will have follow-up blood draws for antibodies to teduglutide every 12 weeks while 
on study until a negative result is obtained.
7.2.2.9
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study. The volumes of blood to be drawn from each subject will vary depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annually are shown 
in Table 7-2.
For non-commercial use only

Shire
CONFIDENTIAL
Page 55
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Table 7-2 Approximate Volume of Blood to be Drawn from Each Subject Annually 
Assessment
Sample 
Volume (mL)
No. Samples per two 28-week 
Teduglutide Cycles
Total 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety
Biochemistry and -hCGa
2.5
24
60
Hematology
2
24
48
Coagulation Parameters
1
2
2
Antibodies
2
8
16
Serum storage samples
3
4
12
Total mL per 2, 28-week Treatment Cycles (Approximate Annual Volume):
138
Subjects Not Receiving Teduglutide Treatmentb
Assessment
Sample 
Volume (mL)
No. Samples per 4 NTT Visits
Total 
Volume (mL)
Safety
Biochemistry
2.5
4
10
Hematology
2
4
8
Serum storage samples
3
2
6
Total mL per 4 “No Teduglutide Treatment” Visits 48-week period:
24
β-hCG=beta-human chorionic gonadotropin; NTT=no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
b Subjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti-teduglutide 
antibodies will require blood samples for antibody testing every 12 weeks until they test negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by the manufacturer or laboratory 
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they require the same type of tube, the assessments should be combined. Blood 
volume estimates do not include safety labs performed after PS adjustment, and anti-teduglutide 
antibody testing during no-teduglutide treatment.
7.2.2.10
Gastrointestinal-specific Testing
Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week 24 of the teduglutide cycle. During NTT periods, FOBT must be performed on 
teduglutide-exposed subjects (subjects who have received teduglutide any time in the past and 
are therefore not teduglutide-naïve) on a roughly annual basis (approximately every 48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
Colonoscopy or Sigmoidoscopy
Teduglutide-naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pretreatment visit if one has not been performed within 1 year.
For non-commercial use only

Shire
CONFIDENTIAL
Page 56
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Subjects of any age with newly positive FOBT results at the pretreatment visit for which a 
readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy or 
sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a 
readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
colonoscopy or sigmoidoscopy in response to positive FOBTs at any other point during the 
study, or to reevaluate persistently positive FOBTs is at the discretion of the investigator.
Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks 
of study drug exposure) will undergo colonoscopy or sigmoidoscopy. While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 year intervals or 
more often as needed.
Upper endoscopy may be performed along with any colonoscopy or sigmoidoscopy at the 
investigator’s discretion. If a polyp is found, adherence to current polyp follow-up guidelines is 
recommended. Subjects with unresected GI polyps, polyposis conditions, premalignant change 
or malignancy in the GI tract will be excluded from teduglutide treatment.
7.2.2.11
Nutritional Support
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hydration 
status, and safety laboratory results. Intake and output diaries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 2.
7.2.2.12
Diaries
Study drug administration diary
A study drug administration diary will record administration of teduglutide. This diary should be 
completed by the subject (or parent/legally authorized representative, as applicable) daily during 
the teduglutide treatment periods (between visits CxD1 and CxW24).
Intake Diary
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary 
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week teduglutide treatment period, the intake diary will also be completed for 1 week 
following PS adjustments. The intake diary will also be completed daily during the 4-week 
follow-up period. The following data will be captured in the intake diaries:

Parenteral support volume and infusion duration

Site personnel will determine the actual PS daily calories based on diary entries
For non-commercial use only

Shire
CONFIDENTIAL
Page 57
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Output Diary
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional 
stability before every clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cycle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:

Toilet-trained subjects (who do not wear diapers)
Measure and record all urine output in mL or cc 

Nontoilet-trained subjects (who wear diapers)
Measure and record the weight of all urine-only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL or 1 cc

At the discretion of the investigator, the parent or legal guardian may be asked to collect 
the first void after the daily PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):

Toilet-trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency using the 
Bristol Stool Form Scale (see Output diary)

Nontoilet-trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency using the Bristol Stool Form Scale 
(see Output diary). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mL or 1 cc
All ostomy output volume should be recorded. Ostomy output will not be scored using the 
Bristol scale.
All available diary data will be reviewed by the investigator or their designee at each clinic and 
telephone visit to assess clinical status and opportunity for PS reduction and advance in feeds.
7.2.2.13
Health-related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes less than 4 minutes to 
complete. The scales include self-reports for pediatric subjects and adolescents aged 5to 18 years 
and proxy-reports from parents of pediatric subjects aged 2 to 18 years. If a child is unable to 
complete the age-appropriate questionnaire (eg, due to developmental delay or other illness) it 
will not constitute a protocol deviation, but the parent should continue to complete the 
appropriate parent-specific forms.
For non-commercial use only

Shire
CONFIDENTIAL
Page 58
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Field trials have shown that the internal consistency reliability of the PedsQL was excellent, with 
alphas for the generic core scales in both self- and proxy-report greater than the 0.70 standard, 
and alphas for the full 23-item scale approaching 0.90 for self- and proxy-report. Missing data 
were minimal. Item response distributions were across the full scale range, with no floor effects, 
and minimal ceiling effects.
The validity of the PedsQL Generic Core Scales was demonstrated through known group 
comparisons, and correlations with other measures of disease burden. The PedsQL self- and 
proxy-report distinguished between pediatric subjects with and without a chronic health 
condition, and within the group of pediatric subjects with a chronic condition, between those 
who did or did not have an overnight hospital visit in the last 12 months. Further, both child 
self-report and parent proxy-report correlated significantly with the number of days the child was 
too ill to pursue normal activities, needed someone to care for him or her, missed school in the 
last month, the number of days the parent missed from work in the last month, and parent-report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
Pediatric Quality of Life Generic Core Scale (PedsQL™), Acute version
The PedsQL Generic Core Scale is designed to measures health-related quality of life (HRQoL) 
in pediatric subjects and adolescents (2-18 years of age). The developmentally appropriate 
PedsQL Generic Core Scale will be completed by either the parent or legal guardian and subject 
as indicated in Table 7-3 at the time points as outlined in Table 1-2, Table 1-3, and Table 1-4.
Table 7-3 Developmentally Appropriate PedsQL™Generic Core Scales
Report
Completed by
Parent Report for Toddlers (ages 2-4)
Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Young Pediatric subjects 
(ages 5-7)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Pediatric subjects 
(ages 8-12)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Teens (ages 13-18)a
Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy-Report for Teens (ages 13-18) will also be completed for subjects older 
than 18 years of age
The Parent Report for Toddlers (ages 2-4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8-12), and Teens (ages 13-18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
For non-commercial use only

Shire
CONFIDENTIAL
Page 59
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Pediatric Quality of Life Family Impact Module (PedsQL™), Acute version
The PedsQL Family Impact Module is a parent-report multidimensional instrument that will be 
completed by the parent or legal guardian, as outlined in Table 1-2, Table 1-3, and Table 1-4.
The PedsQL Family Impact Module is a specific module of the PedsQL that is used to measure 
the impact of pediatric chronic health conditions on parents and the family (Varni et al., 2004). 
The 36-item PedsQL Family Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry (5 items). Two additional scales measure parent-
reported family functioning as follows: 1) Daily Activities (3 items), and 2) Family Relationships 
(5 items). The PedsQL Family Impact Module should take the parent or legal guardian 
approximately 5-10 minutes to complete.
PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute version
The PedsQL Gastrointestinal Symptom Module is a disease-specific 58-item module, comprised 
of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Symptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink Limits (6 items) and Diarrhea (7 items) were identified as 
clinically relevant and appropriate for the symptoms experienced in this pediatric study 
population, and therefore, are the only scales used in this study. The scales will be completed by 
either the parent or legal guardian and subject as indicated in Table 7-3 at the time points 
outlined in Table 1-2, Table 1-3, and Table 1-4.
For non-commercial use only

Shire
CONFIDENTIAL
Page 60
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
Retrospective period of observation
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any nonserious AEs related to teduglutide that occurred during this 
time and any AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment-related event:

The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.

The event cannot be explained by the subject’s medical condition, other therapies, or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this study 
in the eCRF.
Prospective period of observation
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow-up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the study, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of symptoms should be 
recorded. If a diagnosis has not been made, then each symptom should be listed individually. All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 61
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Closure indicates that an outcome is reached, stabilization achieved (the investigator does not 
expect any further improvement or worsening of the event), or the event is otherwise explained. 
When appropriate, medical tests and examinations are performed so that resolution of event(s) 
can be documented.
8.1.1
Severity Categorization
The severity of all AEs must be recorded during the course of the event including the start and 
stop dates for each change in severity. An event that changes in severity should be captured as a 
new event. Worsening of pretreatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
In consideration of whether a treatment-emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early termination of the study (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) severity grading criteria (US Department of Health and Human 
Services et al., 2010).
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause-and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
For non-commercial use only

Shire
CONFIDENTIAL
Page 62
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
The following additional guidance may be helpful:
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
Not Related
The event can be readily explained by other factors such as the 
subject’s underlying medical condition, concomitant therapy, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled physical examinations must 
be reported as AEs if the investigator considers the finding to be a clinically significant change 
from the baseline.
8.1.3
Outcome Categorization
The outcome of all AEs must be recorded during the course of the study in the eCRF. Outcomes 
are as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae

Recovering/Resolving

Unknown
8.1.4
Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the disease and are part of the efficacy 
data to be collected in the study; however, significant worsening of the symptoms should be 
recorded as an AE.
For non-commercial use only

Shire
CONFIDENTIAL
Page 63
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory or vital sign can represent an AE if the change is 
clinically relevant or if, during the study, a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an already abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study, further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign is clinically significant and 
therefore represents an AE.
8.1.6
Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core study until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633-303 study until the defined follow-up 
period stated in Section 7.1.5.
Any report of pregnancy for any female study participant must be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigational and Marketed Products 
Pregnancy Report Form. A copy of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and any applicable follow-up reports) must also be sent to the Shire Medical 
Monitor using the details specified in the emergency contact information section of the protocol. 
In the event a subject becomes pregnant after signing the ICF and assent (if applicable), 
teduglutide administration must be discontinued immediately.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. For pregnancy reports during the prospective period of observation, it is 
the responsibility of the investigator to obtain this information within 30 calendar days after the 
initial notification and approximately 30 calendar days postpartum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633-303), the initial notification date will be the date the pregnancy is recorded for this 
study and outcome and infant condition information may be collected anytime postpartum.
For non-commercial use only

Shire
CONFIDENTIAL
Page 64
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire Clinical Study Adverse Event Form 
for Serious Adverse Events and Non-serious AEs as Required by the Protocol. Note: An elective 
abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Non-serious AEs as required by the Protocol as well as the Shire Investigational and Marketed 
Products Pregnancy Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy onset date.
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a non-medical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may be detrimental to the individual and/or society

Misuse – Intentional use of investigational product other than as directed or indicated 
at any dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed by the protocol)

Overdose – Administration of a dose greater than the allocated dose of the study 
medication or at a frequency greater than the dosing interval specified by the protocol

Medication Error – An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors

Medication errors should be collected/reported for all products under 
investigation

The administration and/or use of an expired investigational product should 
be considered as a reportable medication error
For non-commercial use only

Shire
CONFIDENTIAL
Page 65
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
All investigational product provided to pediatric subjects should be supervised by the 
parent/legally-authorized representative/caregiver.
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference for safety information for this study is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
8.2.2
Reporting Procedures
All SAEs experienced during the retrospective period of observation for the protocol must be 
reported by the investigator to the Shire Global Drug Safety Department and the Shire Medical 
Monitor within 24 hours of first awareness of the event.
All initial and follow-up SAE reports for SAEs experienced during the prospective period of 
observation must be reported by the investigator to the Shire Global Drug Safety Department and 
the Shire Medical Monitor within 24 hours of the first awareness of the event. Note: The 24-hour 
reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by the investigator to the Shire Global Drug 
Safety Department and the Shire Medical Monitor within 24 hours of the first awareness of the 
event even if the event does not fulfill seriousness criterion.
The investigator must complete, sign, and date the Shire Clinical Study Adverse Event Form for 
SAEs and Nonserious AEs as Required by Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e-mail the completed form to the Shire Global Drug Safety
Department. A copy of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Nonserious AEs as Required by Protocol (and any applicable 
follow-up reports) must also be sent to the Shire Medical Monitor or designee using the details 
specified in the emergency contact information section of the protocol.
8.2.3
Serious Adverse Event Definition
A serious adverse event (SAE) is any untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose: 

Results in death

Is life-threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it was more severe.
For non-commercial use only

Shire
CONFIDENTIAL
Page 66
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018

Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospitalization for an elective or previously scheduled surgery that meet(s) serious 
criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity

Is a congenital abnormality/birth defect

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency or 
drug abuse.
8.2.4
Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Drug Safety Department and the Shire Medical Monitor within 24 hours of first 
awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow-up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Drug Safety Department and the Shire Medical Monitor within 24 hours of the first 
awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Drug Safety Department within 24 hours of the first awareness of the event.
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
For non-commercial use only

Shire
CONFIDENTIAL
Page 67
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notifying the 
relevant regulatory authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notifying active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
8.3
Adverse Events of Special Interest
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
the investigator to the sponsor is required.
The AEs of special interest that require expedited regulatory reporting include the following:

Growth of pre-existing polyps of the colon

Benign neoplasia of the GI tract including the hepatobiliary system

Tumor-promoting ability (eg, benign and/or malignant neoplasia of any kind, not limited 
to those of the GI or hepatobiliary system)
For non-commercial use only

Shire
CONFIDENTIAL
Page 68
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within 24 hours of first awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5 apply only to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contacting the sponsor/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may include but are 
not limited to hospitalization, AEs, a lapse in investigational product delivery, etc.
Study drug must be discontinued if any of the following events occur:

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to be related 
to study drug. This does not include the presence of anti-teduglutide antibodies, mild 
injection site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.

An AE that is of NCI CTCAE severity Grade 3 or 4 and considered to be related to study 
drug administration

Confirmed DILI related to teduglutide (see Section 8.4.2)
8.4.1
Dose Interruption Criteria Based on Adverse Event Severity and 
Relationship to Investigational Product (Prospective Period of Observation 
Only)
The investigational product must be discontinued if the subject experienced an AE that is of 
severity ≥Grade 3 per the NCI CTCAE and is reported as related to the investigational product. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI CTCAE severity grading criteria (US Department of Health and 
Human Services et al., 2010). All such TEAEs should be discussed with the Shire Medical 
Monitor or designee as soon as possible. The length of the dose interruption, and whether 
teduglutide administration resumes or is permanently discontinued, depends on the clinical 
situation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 69
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may need to be interrupted if the subject has 
clinical and laboratory evidence of potential DILI, in the absence of an alternative explanation, 
as identified by the following criteria:

ALT or AST >8x ULN

ALT or AST >5x ULN and >2x baseline value for more than 2 weeks

(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)

ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory values suggestive of potentially new DILI should be repeated and verified within 
3 days. International normalized ratio should be measured with this set of verification laboratory 
assessments and an inquiry should be made as to the presence of clinical symptoms consistent 
with new liver injury. The subject should be followed closely to determine the trajectory of the 
laboratory abnormalities and to evaluate the cause of liver injury. This evaluation may include, 
as clinically indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cytomegalovirus IgM, 
Epstein-Barr virus antibody panel), hepatobiliary obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti-actin, or anti-liver kidney microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permanently discontinued if DILI is confirmed and deemed 
related to study drug.
8.5
Early Termination of the Clinical Study (Prospective Period of Observation Only)
The data monitoring committee (DMC) may recommend stopping the study if any of the 
following conditions are met:

≥2 subjects develop the same event of CTCAE severity Grade 3 that is reported as related 
to the investigational product
or

1 subject develops an event of CTCAE severity Grade 4 that is reported as related to the 
investigational product
For non-commercial use only

Shire
CONFIDENTIAL
Page 70
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
9
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
in the eCRF. A study monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safety follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality control and data validation procedures are applied to ensure the validity and 
accuracy of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed 
using SAS® (SAS Institute, Cary, NC, USA) version 9.3 or higher.
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4
Planned Interim Analysis, and Data Monitoring Committee
An interim analysis of all retrospective data will be conducted. Other interim analyses may also 
be conducted if needed.
A DMC will be involved in the management of this study. The DMC members will review the 
data approximately every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety data (ie, AEs, laboratory assessments, physical examinations, etc.) 
from study assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product.
The DMC for this study will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only

Shire
CONFIDENTIAL
Page 71
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
The DMC will be an external, independent board comprised of physicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory in nature. The DMC will be governed by a 
Charter agreed to by members of the Board and the sponsor. Members of the Board may not be 
study investigators or be employed at the same institution as a study investigator, individuals 
employed by the sponsor, independent contractors hired by the sponsor, or members of 
regulatory agencies. The DMC may make recommendations to the sponsor regarding study 
aspects including stopping, modifying or continuing the study; however, the sponsor will have 
the final responsibility to determine whether the study should be modified or temporarily or 
permanently stopped.
9.5
Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects was determined by enrollment in 
TED-C13-003.
9.6
Study Population
The safety population includes all enrolled subjects in the study. The safety population will be 
used for both safety and efficacy analyses.
9.7
Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or 
first exposure to teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
For non-commercial use only

Shire
CONFIDENTIAL
Page 72
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
9.8
Safety Analyses
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safety data as well as for the difference from baseline, if applicable. Frequency 
counts will be compiled for classification of qualitative safety data.
9.8.1
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study 
period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing including fetal occult blood testing and colonoscopy or 
sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) 
to the beginning of the prospective study period:

Adverse events related to teduglutide

All SAEs

All AESIs (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study 
(TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
BMI
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by System Organ Class and by preferred term. Serious adverse events will be further 
summarized by severity and relationship to investigational product. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
For non-commercial use only

Shire
CONFIDENTIAL
Page 73
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Prior and concomitant medications will be coded using the World Health Organization-Drug 
Dictionary (WHO-DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history (including 
surgical/procedural history) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by system organ class and preferred term.
For clinical laboratory tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies.
Additional safety parameters and measures will include change in body weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z-score, BMI, and BMI z-score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9
Other Analyses
9.9.1
Health-related Quality of Life Analyses
Health economics and outcomes research endpoints will be analyzed at approximately 12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study period. The beginning of 
each treatment cycle (CxD1) will be an additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:

Food and drink limits

Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 74
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
10
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO as necessary. 
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
For non-commercial use only

Shire
CONFIDENTIAL
Page 75
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
10.1.4
Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an EOS declaration to the relevant competent authority as required by 
Article 10 (c) of Directive 2001/20/EC.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by the signed and dated signature of the 
principal investigator (single-site study) or coordinating principal investigator (multicenter 
study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH 
Guidance E3 (1995). 
For non-commercial use only

Shire
CONFIDENTIAL
Page 76
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by (inter)national regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly into the 
eCRF.
Electronic case report forms should be approved by the investigator per study specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory reports, and histology and 
pathology reports.
All key data must be recorded in the subject’s medical records.
For non-commercial use only

Shire
CONFIDENTIAL
Page 77
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
The investigator must permit authorized representatives of the sponsor, the respective national,
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the 
eCRF entries against the source documents. The consent form includes a statement by 
which the subject agrees to the monitor/auditor from the sponsor or its representatives, 
national or local regulatory authorities, or the IRB/EC, having access to source data 
(eg, subject’s medical file, appointment books, original laboratory reports, X-rays etc.). 
Nonstudy site personnel will not disclose any personal information or personal medical 
information.
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA, 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Agency) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory authorities), the European Medicines Agency (EMA), the 
Medicines and Healthcare products Regulatory Agency, other regulatory authorities, the sponsor 
or its representatives, and the IRB/EC for each site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, 
retainer for ongoing consultation or honoraria; any proprietary interest in investigational 
product; any significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 
2(b) (1998).
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, 
where applicable, from all study subjects prior to any study-related procedures 
including screening assessments. All consent and assent documentation must be in 
accordance with applicable regulations and GCP. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 78
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Each subject or the subject’s legally-authorized representative, as applicable, is requested to sign 
and date the subject informed consent form or a certified translation if applicable, after the 
subject has received and read (or been read) the written subject information and received an 
explanation of what the study involves, including but not limited to: the objectives, potential 
benefits and risk, inconveniences, and the subject’s rights and responsibilities. A copy of the 
informed consent and assent documentation (ie, a complete set of subject information sheets and 
fully executed signature pages) must be given to the subject or the subject’s legally-authorized 
representative, as applicable. This document may require translation into the local language. 
Signed consent forms must remain in each subject’s study file and must be available for 
verification at any time.
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legally-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study subject.
The principal investigator provides the sponsor with a copy of the consent form, and assent form 
where applicable, that was reviewed by the IRB/EC and which received their favorable 
opinion/approval. A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study unless it is agreed to 
and documented (abiding by regulatory guidelines and national provisions) prior to study start 
that another party (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally, if the IRB/EC requires modification of the sample subject information and 
consent document provided by the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written IRB/EC approval of and copies of revised documents.
For non-commercial use only

Shire
CONFIDENTIAL
Page 79
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity as defined by HIPAA must provide documentation of 
this fact to the sponsor (or designee).
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representatives
review their medical records and data collected during the study. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP633; national or local regulatory authorities; and the IRBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subject).
The results of studies – containing subjects’ unique identifying number, relevant medical 
records, and possibly initials and dates of birth – will be recorded. They may be transferred to, 
and used in, other countries which may not afford the same level of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities.
10.5
Study Results / Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the 
publication steering committee is to act as a noncommercial body that advises or decides on 
dissemination of scientific study data in accordance with the scope of this policy.
For non-commercial use only

Shire
CONFIDENTIAL
Page 80
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements,
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any rights to authorship of 
publications.
For non-commercial use only

Shire
CONFIDENTIAL
Page 81
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
11
REFERENCES
Drucker, D. J.and Yusta, B. 2014. Physiology and pharmacology of the enteroendocrine 
hormone glucagon-like peptide-2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W.and Duggan, C. 
2015. Predictors of Enteral Autonomy in Children with Intestinal Failure: A Multicenter 
Cohort Study. J Pediatr, 167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J.and Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like 
peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol 
Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy, K. N., Jeppesen, P. B.and Shaffer, 
J. 2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs-Lasky, M.and Belle, S. H. 
2012. Natural history of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J.and Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin 
Gastroenterol, 47, 602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B.and Sangild, P. T. 2014. Acute effects of the glucagon-like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr 
Gastroenterol Nutr, 58, 694-702.
US Department of Health and Human Services, National Institutes of Healthand National Cancer 
Institute 2010. Common Terminology Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E.and Dixon, P. 2004. The 
PedsQL Family Impact Module: preliminary reliability and validity. Health Qual Life 
Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T.and Moore, A. 2004. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg,
39, 690-5.
For non-commercial use only

Shire
CONFIDENTIAL
Page 82
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
12
APPENDICES
For non-commercial use only

Shire
CONFIDENTIAL
Page 83
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
APPENDIX 1
PROTOCOL HISTORY
Document
Date
Global/Country/Site Specific
Original Protocol
11 May 2016
Global
Amendment 1
22 Nov 2016
Global
Amendment 1.1
09 Jan 2017
UK Specific
Amendment 2
17 Mar 2017
Global
Amendment 3
16 May 2018
Global
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2
Amendment Date
17 Mar 2017
Global
Description of Change and Rationale
Section(s) Affected by Change
Updated emergency contact information.
Emergency Contact Information; 
Section 8.1.6; Section 8.2.2; Section 
8.2.4
Revised teduglutide treatment inclusion criterion #1 to ensure that 
subjects whose prior exposure to teduglutide in Study TED-C13-003 
may not have been enough to assess efficacy are eligible to receive 
treatment in Study SHP633-303. 
Study Synopsis; Section 4.4
Revised teduglutide treatment exclusion criterion #11 to add 
teduglutide to the list of experimental drugs exempt of a washout period 
before initiating teduglutide treatment in Study SHP633-303. 
Study Synopsis; Section 4.5; Section 
5.1.2
A footnote was added at the pretreatment visit in the Schedule of 
Events for Subjects While Receiving Teduglutide to underscore that, 
when the first pretreatment visit (P1) follows the screening visit, it must 
occur within 12 weeks of screening.
Table 1-4
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.
Section 4.7.1
Clarification that ancillary components, in addition to sterile water for 
injection syringes, will also be provided and labeled in accordance with 
the applicable regulatory requirements.
Section 6.3.1
A footnote was added in Table 7-3 to clarify that subjects older than 
18 years of age will continue to use the Child Self Report and Parent 
Proxy-Report for Teens (ages 13-18) when completing the Pediatric 
Quality of Life Generic Core Scale (PEDSQL™).
Section 7.2.2.13 (Table 7-3)
For non-commercial use only

Shire
CONFIDENTIAL
Page 84
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2
Amendment Date
17 Mar 2017
Global
Description of Change and Rationale
Section(s) Affected by Change
Revised the text on severity categorization to specify that a severe 
treatment-emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study 
(Section 8.5) will also be graded according to the National Cancer 
Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) severity grading criteria, in addition to the standard severity 
categorization. These events are no longer limited to only the events 
described in Table 8-1, entitled “CTCAE Criteria for Adverse Events 
that May Lead to Dose Interruption (Prospective Period of Observation 
Only). Therefore, Table 8-1 has been deleted.
Section 8.1.1; Section 8.4; Section 
8.4.1; Table 8-1 (deleted)
Revised the criteria for early termination of the study as requested by 
the US FDA in their letter dated 06 Jan 2017: stopping criteria were 
extended to all NCI CTCAE Grade 3 and 4 severity events reported as 
related to the investigational product, and no longer limited to the 
events described in Table 8-1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of 
Observation Only).
Section 8.5
Amendment Number 1.1
Amendment Date
09 Jan 2017
United-Kingdom-Specific
Description of Change and Rationale
Section(s) Affected by Change
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.
Section 4.7.1
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Title of the Shire medical monitor has been changed to Medical 
Director for clarity.
Protocol Signature Page
Emergency Contact Information
Clarification has been made that during the no-teduglutide treatment 
period, visits will take place approximately every 12 weeks.
Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3-1
For non-commercial use only

Shire
CONFIDENTIAL
Page 85
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
The study design flow chart has been edited for clarity.
Synopsis
Figure 3-1
The collection of all actual and prescribed enteral nutrition data has 
been removed to reduce the burden on the subjects and investigators. 
Enteral nutrition data are not required as the efficacy endpoints are 
limited to parenteral support parameters.
Synopsis
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.2, 7.1.3, 7.1.4.1, 
7.1.4.2, 7.1.6, 7.2.2.11, 7.2.2.12
Exclusion criterion 11 has been revised to add Smoflipid as other 
experimental drugs that are allowed prior and during the study. Like 
glutamine and Omegaven, Smoflipid is not expected to interfere with 
the assessments of safety and efficacy of teduglutide and many subjects 
may already be receiving the treatments off-label as part of standard 
medical therapy.
Synopsis
Section 4.5
Exclusion criterion 12 and prohibited treatment have been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to 3 months for consistency with other teduglutide studies. 
Synopsis
Section 4.5
Table 5-1
Retrospective data collection has been removed from the duration of the 
study for clarity.
Synopsis
Language in efficacy and safety endpoints has been clarified.
Synopsis
Sections 9.7.1, 9.8.1
Instructions on recording retrospective data for teduglutide and PS 
usage, and growth parameters have been refined.
Table 1-1
Sections 7.1.1, 7.2.1.2, 7.2.1.3
Completion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.
Table 1-2, Table 1-3, Table 1-4
Sections 7.1.2, 7.1.4.1, 7.1.4.2, 7.1.6, 
7.2.2.12
The requirement for urine specimen collection has been revised so that 
a lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects wearing diapers).
Table 1-2, Table 1-3, Table 1-4
Section 7.2.2.5
Clarification has been made that the first no-teduglutide treatment visit 
after the screening visit will occur within 2 to 12 weeks of the screening 
(formerly within 12 weeks of screening). 
Synopsis
Table 1-3
Sections 3.1.3, 7.1.2
Windows have been clarified for visits during the no-teduglutide and 
teduglutide treatment periods.
Table 1-3, Table 1-4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. By definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. 
Table 1-3 
Sections 7.2.2.8, 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. 
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.3, 7.2.2.10
Removal of former footnote j on fecal occult blood test for clarity.
Table 1-4
For non-commercial use only

Shire
CONFIDENTIAL
Page 86
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit.
Table 1-4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects 
with SBS has been clarified, and text on intestinal adaptation has been 
refined.
Section 1.1
Status of current teduglutide approvals for use has been updated.
Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced with ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency with other 
studies.
Synopsis
Sections 3.1, 3.1.3
Evaluations to be performed when a subject discontinues teduglutide or 
when withdraws from the study have been clarified.
Sections 4.8.1, 4.8.2
Withdrawal by parent/guardian has been added as reason for 
discontinuation.
Section 4.8.3
COUMADIN has been changed to warfarin for clarity.
Sections 5.1, 5.1.2
Clarification has been made on handling of study drug, which is for 
single use only and should be used within 3 hours following 
reconstitution.
Section 6.3.3
The investigator or designee may now dispense the unused study drug 
vials to the same subject if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
drug has been clarified.
Section 6.4
Paragraph on the purpose of prospective data collection has been 
deleted for clarity.
Section 7.2.2
Clarification has been made on the collection of medical history and 
SBS history.
Synopsis
Sections 3.1.3, 7.1.2, 7.2.2.1
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. 
Section 7.2.2.3
Clarification has been made that local laboratory results are not 
required to be entered in the eCRFs. (formerly Section 7.2.2.4)
Section 7.2.2.5
Collection of urine sodium and urine osmolality has been removed.
Section 7.2.2.5
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow-up period escape 
criterion. (formerly Section 7.2.2.5)
Section 7.2.2.6
Nutritional support and diaries (formerly in Section 7.2.2.9) have been 
moved under separate sections (Sections 7.2.2.11 and 7.2.2.12, 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be reviewed at each clinic and telephone 
visit.
Sections 7.2.2.11, 7.2.2.12 
For non-commercial use only

Shire
CONFIDENTIAL
Page 87
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Performance of dipstick specific gravity tests by the subject at home on 
the first urine produced after the daily infusions of PS has been 
removed. It is now at the discretion of the investigator for all subjects, 
not just those in diapers. This change is to align with standard medical 
practice.
Section 7.2.2.12 
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related) to teduglutide need 
to be reported. No changes to the protocol were made for the reporting 
of all AEs of special interest or any serious adverse events, regardless 
of relationship to teduglutide, that occurred during the retrospective 
period.
Section 8.1
The timeframe for collecting and reporting AESIs and SAEs occurring 
during the retrospective period of the study has been clarified.
Sections 8.2.2, 8.2.4, 8.3
Minor clarifications have been made to the language on dose 
interruption.
Sections 8.4, 8.4.1
Unscheduled safety follow up assessments (including visits conducted 
after EOS) are not to be recorded. However, clarification has been made 
that they are to be collected where requested.
Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.
Section 9.4
The protocol now refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.
Section 9.4
Minor corrections have been made to the guidelines for nutritional 
support management during the study.
Appendix 2
For non-commercial use only

Shire
CONFIDENTIAL
Page 88
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
APPENDIX 2
GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period.

Growth trajectory, including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)

Other clinical evaluations

Serum electrolytes

Blood urea nitrogen /creatinine levels

Changes in stool frequency or volume, including mixed output

Stool consistency (ie, Bristol Stool Scale)

Urine specific gravity

General consideration to possible clinical deterioration in SBS

Inability to maintain weight and growth velocity

Diarrhea (≥10 bowel movements per day, ≥80 mL/kg/day from an ostomy, or 
≥75 mL/kg/day mixed output)

Colic/vomiting frequency increased

Electrolyte changes or imbalance

Skin breakdown 

Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the study.

Nutritional support constituents may be adjusted at the discretion of the investigator.

During the 48-hour output measurement period prior to the subject’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.

If there is a change in EN or other food or fluid intake, the investigator should consider this 
when adjusting the PS/EN support in volume and calories.
For non-commercial use only

Shire
CONFIDENTIAL
Page 89
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Figure A-1
Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 90
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Figure A-2
Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 91
SHP633-303 Protocol Amendment 3
Teduglutide 
16 May 2018
Figure A-3
Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only

PROTOCOL: SHP633-303
TITLE:
A Retrospective and Prospective, Open-label, Long-term Safety and 
Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED-C13-003
DRUG:
Teduglutide
IND:
IND# 058213
EUDRACT NO.:
2016-000863-17
SPONSOR:
Shire Human Genetic Therapies, Inc.
300 Shire Way, Lexington, MA 02421 USA
PROTOCOL 
HISTORY:
Amendment 4: 01 Oct 2019
Amendment 3: 16 May 2018
Amendment 2: 17 Mar 2017
Amendment 1.1: 09 Jan 2017 (United Kingdom-Specific)
Amendment 1: 22 Nov 2016
Original Protocol: 11 May 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only

Shire 
CONFIDENTIAL 
Page2 
SHP633-303 Protocol Amendment 4 
Teduglutide 
01Oct2019 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Shire) Approval 
Signature: 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
• Date: 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-C13-003 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the 
study, without written authorization from the sponsor. It is, however, permissible to provide 
the information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good 
Clinical Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at 
any time for whatever reason; such a decision will be communicated to me in writing. 
Conversely, should I decide to withdraw from execution of the study I will communicate my 
intention immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
For non-commercial use only

Shire
CONFIDENTIAL
Page 3
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
SUMMARY OF CHANGES FROM PREVIOUS VERSION  
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 4
Amendment Date
01 Oct 2019
Global
Description of Change and Rationale
Section(s) Affected by 
Change
The name and contact information of the Sponsor Medical Monitor was updated to 
. 
(Administrative letter dated 22 Oct 2018)
The fax number of the Sponsor Medical Monitor was removed. 
(Administrative letter dated 15 Jan 2019)
Emergency Contact 
Information
The contact for medical support was updated to reflect Quintiles’ current name,
IQVIA, and 
 email address as 
Emergency Contact 
Information
Updated the Product Quality Complaints to match the current Sponsor standard
Product Quality 
Complaints
Extended the planned study period to December 2020. 
Study Synopsis
Clarification of the follow-up period escape criteria and their use in combining the 
CxW24 and pretreatment visits was added.
(Clarification Memo dated 09 Apr 2019)
Study Synopsis, 
Section 4.6
Clarified that AEs during the prospective period will be collected for 4 weeks after the 
last dose of teduglutide in the study even if the EOS/ET occurs within that timeframe.
Table 1-2, Section 7.1.6,
Section 8.1
An optional qualitative interview to be conducted by phone and within 14 days after 
completion of the end of study/early termination visit was added. A single individual 
telephone interview will be conducted with English-speaking parents (or legal 
guardians) of subjects and subjects aged 12 years or older who provide informed 
consent (and if applicable, informed assent) to participate in the interview. These 
interviews will be performed in selected countries participating in this trial.
Table 1-2, Section 7.1.7, 
Section 7.2.2.14, 
Section 9.9.2, Appendix 3, 
Appendix 4
Noted that stored serum samples should be omitted for subjects weighing less than 
15 kg and whenever local blood volume limitations are exceeded.
Table 1-3, Table 1-4, 
Section 7.2.2.9, Table 7-2
Clarified that serum pregnancy tests will be collected at the teduglutide pretreatment 
visits.
Table 7-1
Clarified that adverse events during the prospective period would include events that 
were reported during the qualitative interviews.
Section 8.1
The definition of an overdose was clarified as the administration of the investigational 
product at a dose or frequency greater than 0.05 mg/kg subcutaneous once daily. An 
overdose occurs if any of the following criteria are met: 

More than 0.05 mg/kg is given at any one time

Consecutive doses are spaced less than 12 hours apart

Any more than 0.05 mg/kg given in one day (a day is defined as beginning at 
12:00 AM and ending at 11:59 PM)
Section 8.1.7
For non-commercial use only

Shire
CONFIDENTIAL
Page 4
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 4
Amendment Date
01 Oct 2019
Global
Description of Change and Rationale
Section(s) Affected by 
Change
The teduglutide dose interruption criteria were updated to specify events leading to an 
interruption of teduglutide treatment and events leading to a permanent 
discontinuation of teduglutide treatment. 
Investigational product must be interrupted if any of the following events occur:

An AE of special interest

An AE that is of NCI CTCAE severity Grade 3 or 4 and related to teduglutide

Intestinal obstruction

Biliary obstruction related to teduglutide

Pancreatic duct obstruction related to teduglutide

Heart failure with severe fluid overload related to teduglutide 
Investigational product must be permanently discontinued if any of the following 
events occur:

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to be 
related to study drug. This does not include the presence of anti-teduglutide 
antibodies, mild injection site reactions or mild symptoms that according to the 
investigator do not pose a significant risk to the subject.

Confirmed drug-induced liver injury (DILI) related to teduglutide 

Any malignancy
These clarifications were made for consistency with other teduglutide studies. 
Section 8.4, Section 8.4.1
Minor editorial changes and corrections to typographical errors (which do not modify 
content and/or intent of the original document) were made.
Throughout the protocol
See Appendix 1 for protocol history, including all amendments.
For non-commercial use only

Shire
CONFIDENTIAL
Page 5
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required by Protocol within 24 hours to the Shire Global Drug Safety Department. Applicable 
fax numbers and e-mail address can be found on the form (sent under separate cover). A copy of 
this form must also be sent to the Sponsor Medical Monitor by e-mail using the details below.
, MD
Email: 
For protocol- or safety-related issues, the investigator must contact IQVIA Medical Support:
Primary contact for United States and backup contact for United Kingdom
, MD, 
Mobile: 
US Toll Free number: 
Phone: 
 (medical emergencies – US)
Email: 
Primary contact for United Kingdom and backup contact for United States
, MD, 
Mobile: 
Phone: 
Phone: 
 (medical emergencies – EU)
Email: 
In addition, the investigator may also contact the Sponsor Medical Monitor (8:00 to 20:00 US 
Eastern Standard Time):
, MD, 
Mobile: 
Email: 
r n
ommercial use only

Shire
CONFIDENTIAL
Page 6
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints or non-medical 
complaints to Shire within 24 hours. If requested, defective product(s) will be returned to the 
sponsor for inspection and analysis.
A product quality complaint includes any instances where there is an allegation or report relating 
to Shire licensed or investigational products, received in writing, electronically, or orally, which 
indicates an impact to a product’s strength, identity, safety, purity, or quality, or which suggests 
that the product did not meet the criteria defined in the regulatory applications, licenses, or 
marketing authorizations for the product. Examples of investigational product quality complaints 
include, but are not limited to, the following:
Unit issues

Capsule fill empty or overage

Bottle/vial fill shortage or overage

Capsule/tablet damaged/broken

Syringe/vial cracked/broken

Syringe leakage

Missing components

Product discoloration

Device malfunction
Labeling

Label missing

Leaflet or Instructions For Use 
(IFU) missing 

Label illegible

Incomplete, inaccurate, or 
misleading labeling

Lot number or serial number missing
Packaging

Damaged packaging (eg, secondary, 
primary, bag/pouch)

Tampered seals

Inadequate or faulty closure

Missing components within package
Foreign 
material

Contaminated product

Particulate in bottle/vial

Particulate in packaging
Please report the product quality complaint using the “Product Quality Complaint Data 
Collection Form” via the email address:
Telephone number (provided for reference if needed):
Shire, Lexington, MA (USA)
For instruction on reporting AEs related to product complaints see Section 8.
For non-commercial use only

Shire
CONFIDENTIAL
Page 7
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSION........................................................3
EMERGENCY CONTACT INFORMATION................................................................................5
PRODUCT QUALITY COMPLAINTS..........................................................................................6
TABLE OF CONTENTS.................................................................................................................7
LIST OF TABLES.........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
LIST OF APPENDICES................................................................................................................12
ABBREVIATIONS .......................................................................................................................13
STUDY SYNOPSIS ......................................................................................................................15
STUDY SCHEDULES..................................................................................................................21
1
BACKGROUND INFORMATION.......................................................................................27
1.1
Indication and Current Treatment Options...............................................................27
1.2
Product Background.................................................................................................27
1.3
Clinical Studies with Teduglutide in Pediatric Subjects ..........................................28
2
STUDY OBJECTIVES AND PURPOSE ..............................................................................29
2.1
Rationale for the Study.............................................................................................29
2.2
Study Objectives ......................................................................................................29
2.2.1
Primary Objectives .........................................................................................29
2.2.2
Secondary Objectives .....................................................................................29
3
STUDY DESIGN ...................................................................................................................30
3.1
Study Design and Flow Chart ..................................................................................30
3.1.1
Informed Consent/Assent and Eligibility .......................................................32
3.1.2
Retrospective Data Collection........................................................................32
3.1.3
Prospective Data Collection and Treatment ...................................................32
3.2
Duration and Study Completion Definition .............................................................34
4
STUDY POPULATION.........................................................................................................35
4.1
Study Inclusion Eligibility Criteria ..........................................................................35
4.2
Study Exclusion Eligibility Criteria .........................................................................35
4.3
Teduglutide Eligibility Criteria ................................................................................35
4.4
Teduglutide Treatment Inclusion Criteria................................................................35
4.5
Teduglutide Treatment Exclusion Criteria...............................................................36
4.6
Follow-up Period Escape Criteria ............................................................................37
4.7
Reproductive Potential .............................................................................................37
4.7.1
Female Contraception.....................................................................................37
4.8
Discontinuation of Subjects .....................................................................................38
For non-commercial use only

Shire
CONFIDENTIAL
Page 8
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
4.8.1
Teduglutide Discontinuation ..........................................................................38
4.8.2
Study Withdrawal ...........................................................................................38
4.8.3
Reasons for Discontinuation...........................................................................39
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit ..................39
5
CONCOMITANT TREATMENT..........................................................................................40
5.1
Concomitant Medications and Procedures...............................................................40
5.1.1
Permitted Treatment .......................................................................................40
5.1.2
Prohibited Treatment ......................................................................................40
6
INVESTIGATIONAL PRODUCT ........................................................................................41
6.1
Identity of Investigational Product...........................................................................41
6.1.1
Blinding the Treatment Assignment...............................................................41
6.2
Administration of Investigational Product(s)...........................................................41
6.2.1
Interactive Response Technology for Investigational Product 
Management ...................................................................................................41
6.2.2
Allocation of Subjects to Treatment...............................................................41
6.2.3
Dosing.............................................................................................................41
6.2.4
Unblinding the Treatment Assignment...........................................................42
6.3
Labeling, Packaging, Storage, and Handling ...........................................................42
6.3.1
Labeling..........................................................................................................42
6.3.2
Packaging........................................................................................................43
6.3.3
Storage and Handling .....................................................................................43
6.4
Drug Accountability.................................................................................................44
6.5
Subject Compliance..................................................................................................44
7
STUDY PROCEDURES........................................................................................................45
7.1
Study Schedule.........................................................................................................45
7.1.1
Retrospective Data Collection........................................................................45
7.1.2
Screening ........................................................................................................46
7.1.3
Visits for Subjects Not Receiving Teduglutide ..............................................47
7.1.4
Visits for Subjects Receiving Teduglutide Treatment....................................47
7.1.4.1
Pretreatment Visit...................................................................................47
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24).....................................48
7.1.5
Teduglutide Follow-up Period........................................................................50
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)..........................51
7.1.7
Qualitative Interview ......................................................................................51
7.2
Study Evaluations and Procedures ...........................................................................51
7.2.1
Retrospective Data Collection........................................................................51
7.2.1.1
Growth (Height, Weight, and Head Circumference) .............................52
For non-commercial use only

Shire
CONFIDENTIAL
Page 9
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
7.2.1.2
Prior Teduglutide Treatment Prescribed ................................................52
7.2.1.3
Parenteral Support Prescribed ................................................................52
7.2.1.4
Adverse Events.......................................................................................52
7.2.2
Prospective Data Collection ...........................................................................52
7.2.2.1
Demographics, Medical History, and SBS History................................52
7.2.2.2
Physical Examination.............................................................................52
7.2.2.3
Adverse Event Collection.......................................................................53
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body 
Mass Index .............................................................................................53
7.2.2.5
Clinical Laboratory Tests.......................................................................53
7.2.2.6
Serum Sampling.....................................................................................54
7.2.2.7
Pregnancy Testing..................................................................................55
7.2.2.8
Antibody Testing....................................................................................55
7.2.2.9
Volume of Blood....................................................................................55
7.2.2.10
Gastrointestinal-specific Testing............................................................56
7.2.2.11
Nutritional Support.................................................................................57
7.2.2.12
Diaries ....................................................................................................57
7.2.2.13
Health-related Quality of Life Assessments...........................................59
7.2.2.14
Qualitative Interviews ............................................................................60
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................64
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................64
8.1.1
Severity Categorization ..................................................................................65
8.1.2
Relationship Categorization............................................................................65
8.1.3
Outcome Categorization.................................................................................66
8.1.4
Symptoms of the Disease under Study...........................................................66
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period 
of Observation Only) ......................................................................................67
8.1.6
Pregnancy .......................................................................................................67
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only) ..........................................................................................68
8.2
Serious Adverse Event Procedures ..........................................................................69
8.2.1
Reference Safety Information.........................................................................69
8.2.2
Reporting Procedures......................................................................................69
8.2.3
Serious Adverse Event Definition ..................................................................69
8.2.4
Serious Adverse Event Collection Time Frame .............................................70
8.2.5
Serious Adverse Event Onset and Resolution Dates......................................71
8.2.6
Fatal Outcome.................................................................................................71
For non-commercial use only

Shire
CONFIDENTIAL
Page 10
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and 
Site Reporting.................................................................................................71
8.3
Adverse Events of Special Interest...........................................................................71
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only).........................................................................................................................72
8.4.1
Dose Interruption Criteria Based on Adverse Event Severity and 
Relationship to Investigational Product (Prospective Period of 
Observation Only) ..........................................................................................73
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)......................................................73
8.5
Early Termination of the Clinical Study (Prospective Period of Observation 
Only).........................................................................................................................74
9
DATA MANAGEMENT AND STATISTICAL METHODS...............................................75
9.1
Data Collection.........................................................................................................75
9.2
Clinical Data Management.......................................................................................75
9.3
Statistical Analysis Process......................................................................................75
9.4
Planned Interim Analysis, and Data Monitoring Committee...................................75
9.5
Sample Size Calculation and Power Considerations................................................76
9.6
Study Population ......................................................................................................76
9.7
Efficacy Analyses.....................................................................................................76
9.7.1
Efficacy Endpoints..........................................................................................76
9.8
Safety Analyses........................................................................................................77
9.8.1
Safety Endpoints.............................................................................................77
9.9
Other Analyses .........................................................................................................78
9.9.1
Health-related Quality of Life Analyses.........................................................78
9.9.2
Qualitative Interviews.....................................................................................78
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES...........................................79
10.1
Sponsor’s Responsibilities .......................................................................................79
10.1.1
Good Clinical Practice Compliance................................................................79
10.1.2
Indemnity/Liability and Insurance..................................................................79
10.1.3
Public Posting of Study Information ..............................................................79
10.1.4
Submission of Summary of Clinical Study Report to Competent 
Authorities of Member States Concerned and Ethics Committees ................80
10.1.5
Study Suspension, Termination, and Completion ..........................................80
10.2
Investigator’s Responsibilities .................................................................................80
10.2.1
Good Clinical Practice Compliance................................................................80
10.2.2
Protocol Adherence and Investigator Agreement...........................................81
10.2.3
Documentation and Retention of Records......................................................81
10.2.3.1
Case Report Forms.................................................................................81
For non-commercial use only

Shire
CONFIDENTIAL
Page 11
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents..............................................................................................81
10.2.3.3
Audit/Inspection.....................................................................................82
10.2.3.4
Financial Disclosure...............................................................................82
10.3
Ethical Considerations..............................................................................................82
10.3.1
Informed Consent ...........................................................................................82
10.3.2
Institutional Review Board or Ethics Committee...........................................83
10.4
Privacy and Confidentiality......................................................................................84
10.5
Study Results / Publication Policy ...........................................................................84
11 REFERENCES .......................................................................................................................86
For non-commercial use only

Shire
CONFIDENTIAL
Page 12
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
LIST OF TABLES
Table 1-1
Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................21
Table 1-2
Schedule of Events for Screening and End of Study or Early 
Termination ...................................................................................................22
Table 1-3
Schedule of Events for No Teduglutide Treatment Period ...........................23
Table 1-4
Schedule of Events for Teduglutide Treatment Period .................................24
Table 5-1
Prohibited Treatment.....................................................................................40
Table 7-1
List of Laboratory Tests ................................................................................54
Table 7-2
Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................56
Table 7-3
Developmentally Appropriate PedsQL™Generic Core Scales .....................59
LIST OF FIGURES
Figure 3-1
Study Design Flow Chart .............................................................................34
LIST OF APPENDICES
Appendix 1
Protocol History.............................................................................................88
Appendix 2
Guidelines for Nutritional Support Management During the Study .............93
Appendix 3
Caregiver Interview Guide ............................................................................97
Appendix 4
Pediatric Subject Interview Guide...............................................................102
For non-commercial use only

Shire
CONFIDENTIAL
Page 13
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
ABBREVIATIONS
Abbreviations
Definitions
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
-HCG
beta-human chorionic gonadotropin
BMI
body mass index
CRA
clinical research associate
CRO
contract research organization
CSR
clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
drug-induced livery injury
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase 4
EC
ethics committee
eCRF
electronic case report form
EMA
European Medicines Agency
EN
enteral nutrition
EOS
end of study
EOT
end of treatment
ET
early termination
EU
European Union
FDA
Food and Drug Administration
FOBT
fecal occult blood test
FOCBP
female of child-bearing potential
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide 1
GLP-2
glucagon-like peptide 2
HIPAA
Health Insurance Portability and Accountability Act
ICF
informed consent form
ICH
International Conference on Harmonization
IGF-1
insulin-like growth factor 1
IRB
institutional review board
IV
intravenous
IWRS
interactive web-based response system
MedDRA
Medical Dictionary for Regulatory Activities
NCI
National Cancer Institute
NDA
new drug application
For non-commercial use only

Shire
CONFIDENTIAL
Page 14
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Abbreviations
Definitions
NTT
no-teduglutide treatment
PedsQL
Pediatric Quality of Life Inventory
PS
parenteral support
PT/INR
prothrombin time/international normalized ratio
QD
once daily
SAE
serious adverse event
SAP
statistical analysis plan
SBS
short bowel syndrome
SC
subcutaneous
SOC
standard of care
t1/2
elimination half-life
TEAE
treatment-emergent adverse event
TESAE
treatment-emergent serious adverse event
UK
United Kingdom
ULN
upper limit of normal
US
United States
WHO-DD
World Health Organization-Drug Dictionary
For non-commercial use only

Shire
CONFIDENTIAL
Page 15
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
STUDY SYNOPSIS
Protocol number: SHP633-303
Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003
Number of subjects (total and for each treatment arm):
Approximately 40 subjects who completed the TED-C13-003 study, including subjects in the standard of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED-C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the United States (US) and the United Kingdom (UK) will participate in 
this extension study.
Study period (planned):
October 2016-December 2020
Clinical phase:
3 Extension
Objectives:
Primary: To evaluate the long-term safety and tolerability of teduglutide treatment in pediatric subjects with short 
bowel syndrome (SBS) who completed TED-C13-003.
Secondary: To evaluate long-term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED-C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED-C13-003 study. In addition to 
evaluating the long-term safety and durability of efficacy after 12 weeks of treatment in TED-C13-003, this 
extension study will evaluate the need for additional teduglutide treatment in these subjects, and will allow for the 
first-time treatment of teduglutide-naïve subjects who participated in the standard of care (SOC) treatment arm in 
TED-C13-003.
Investigational product, dose, and mode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED-C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of 
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
between the date of the TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only

Shire
CONFIDENTIAL
Page 16
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and Section 7.1.1. For subjects 
that only consent to retrospective data collection, these procedures are all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were completed in the course 
of the subject’s standard medical care between the date of the TED-C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide treatment

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1-2. These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. The parenteral support prescription will also be collected at screening.
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section 7.2.2.12). Diary data for PS volume will be collected for at least 2 weeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no-teduglutide treatment [NTT] period), will be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed immediately to the pretreatment visit if 
the investigator, subject, and parent or legal guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none of 
the teduglutide treatment exclusion criteria, will start a 28-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4-week follow-up (no treatment) period (Figure 3-1). During 
the 28-week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and weekly during the follow-up period (between Weeks 24 and 28). Safety and PS requirements will be evaluated 
at every visit, and quality of life assessments will be made approximately every 12 weeks. If a subject meets 1 of 
the follow-up period escape criteria between cycle week 24 and 28, the subject may "escape" the follow-up period 
early and proceed immediately to another pretreatment visit. Following completion of the 28-week treatment cycle, 
the subject will proceed to an NTT visit or another pretreatment visit within approximately 12 weeks.
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 weeks. To maintain 
consistency across centers, all attempts should be made to follow the nutritional support adjustment guidelines 
(developed with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only

Shire
CONFIDENTIAL
Page 17
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 
1 week after adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects 
discontinue teduglutide at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be 
performed weekly (solid grey lines). If an escape criterion is met at Week 24 or during the follow-up period, subjects may 
proceed directly to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet all of the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.
Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study-related procedures.
2.
Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
3.
Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria, and none of the 
teduglutide treatment exclusion criteria, are met. In addition, the investigator and the subject (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria:
1.
Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds (eg, 10% or less 
change in PS or advance in feeds) for at least 3 months prior to and during the teduglutide pretreatment 
visit, as assessed by the investigator. Transient instability for events such as interruption of central access 
or treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the event.
2.
Subject was previously treated with teduglutide and at least 1 of the following criteria is satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 18
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
b.
Decreased PS requirement during prior teduglutide treatment, followed by cessation of 
improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated 
enteral nutrition (EN) following teduglutide discontinuation
d.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte 
intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.
Body weight <10 kg at the pretreatment visit
2.
Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.
History of cancer in the previous 5 years except surgically curative skin cancers
4.
Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10 cm, and endoscopic procedures are allowed.
5.
Intestinal or other major surgery planned or scheduled to occur during the 28-week cycle
6.
Clinically significant intestinal stricture or obstruction
7.
Clinically significant, active or recurrent pancreatic or biliary disease
8.
Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b.
Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9.
Renal dysfunction shown by results of an estimated glomerular filtration rate below 50 mL/min/1.73 m2
at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects 
who had undergone ventricular or atrial septal defect repair, or patent ductus arteriosus ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, Smoflipid, 
or teduglutide) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to 
the pretreatment visit and for the duration of the 28-week cycle 
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) (not 
including teduglutide), insulin-like growth factor-1 (IGF-1), or growth hormone, within 3 months 
preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months prior to the 
pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related 
compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16. Pregnant or lactating female subjects
17. Sexually active female subjects of child-bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts the subject at any 
undue risk, prevents completion of the study, or interferes with analysis of the study results
For non-commercial use only

Shire
CONFIDENTIAL
Page 19
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow-up period may be interrupted 
(if the subject meets 1 or more of escape criteria 1 to 4 during the follow-up period) or omitted (if the subject 
meets escape criterion 5 at the CxW24 visit) and the subject may proceed directly to the pretreatment visit, if 
≥1 of the following criteria is met:
1.
Increasing PS requirements following teduglutide discontinuation
2.
Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal tolerated EN 
following teduglutide discontinuation
3.
Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake 
following teduglutide discontinuation
4.
Severe diarrhea related to teduglutide discontinuation
5.
The subject escaped during the follow-up period of a previous teduglutide treatment cycle within 
SHP633-303. In this case, the CxW24 visit may be combined with the next cycle pretreatment visit.
Maximum duration of subject involvement in the study:
A subject will be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple 28-week treatment cycles. The study will continue for at least 1 year, and until each 
subject has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately 3 years. A subject will be considered as having completed the study if the subject has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.

Planned duration of no-teduglutide treatment periods: variable, depending on disease course

Planned duration of the teduglutide pretreatment visit: 1-21 days

Planned teduglutide treatment cycle duration: 28 weeks. Each cycle consists of 24 weeks of 
teduglutide treatment followed by a 4-week follow-up period (no treatment)
Endpoints and statistical analysis:

The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
Health Economics and Outcomes Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an 
additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:
o
Food and drink limits
o
Diarrhea
For non-commercial use only

Shire
CONFIDENTIAL
Page 20
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) to the beginning of 
the prospective study period:

Adverse events related to teduglutide

All SAEs

All Adverse Events of Special Interest (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study (TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compiled for classification of 
qualitative safety data.
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by enrollment in TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 21
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
STUDY SCHEDULES
Table 1-1 Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment
Note
Informed consent/assent
Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study-related 
procedures, including retrospective data collection.
Study eligibility
Weighta
The last representative value for weight during each 12-week interval 
throughout the retrospective data collection period will be captured.
Height and head circumferencea
The last representative value for height during each 12-week interval 
throughout the retrospective data collection period will be captured. Head 
circumference should be provided for subjects 36 months of age and younger at 
the time the data were collected, if available.
Prior teduglutide treatment
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, 
compassionate use, and named-patient access programs.
Parenteral support (PS) 
prescribeda
The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per week of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED-C13-003
Teduglutide-related AEs
Teduglutide-related AEs must be deemed by the investigator to be related to 
teduglutide treatment.
AEs of special interest
Serious adverse events (SAEs)
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a The first 12-week interval begins at TED-C13-003 EOS visit.
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED-C13-003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
For non-commercial use only

Shire
CONFIDENTIAL
Page 22
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Table 1-2 Schedule of Events for Screening and End of Study or Early Termination
Screening
End of Study or Early 
Termination
Visit Type
Site
Site
Informed consent/assent
X
Study eligibility
X
Demographics, medical history, SBS historya
X
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriab
X
Adverse events
X
Xl
Concomitant medications and procedures
X
X
Physical examination and vital signs, including weight
X
X
Height and head circumferencec
X
X
Review intake and output diariesd
X
Record PS prescription and adjust as needede
X
X
Safety laboratory testsf
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-Scales
X
Antibodies to teduglutideg
X
Fecal occult blood testingh
(X)
Colonoscopy or sigmoidoscopyi
(X)
Pregnancy testingj
(X)
Qualitative interviewk
X
EOS=end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
a If the subject has any changes to the medical history and SBS history that had been collected at the baseline of the 
TED-C13-003 study, then the updated medical history and SBS history will be collected.
b Subjects who meet ≥1 teduglutide treatment inclusion criteria may proceed to the pretreatment visit if the investigator, subject, 
and parent or legal guardian agrees to proceed with teduglutide therapy (Table 1-4).
c Head circumference will be measured in subjects 36 months of age and younger.
d The intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48-hour period of nutritional stability before the EOS/ET visit.
e Parenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after 
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix 2.
f Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
g Required for all teduglutide-exposed subjects.
h Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
i The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no-teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section 7.2.2.10 for details.
j Pregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
k Optional interview to be conducted by phone within 14 days after completion of the EOS/ET visit (see Section 7.2.2.14). 
l AEs will be collected for 4 weeks after the last dose of teduglutide in the study even if the EOS/ET occurs within that 
timeframe.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 23
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Table 1-3 Schedule of Events for No Teduglutide Treatment Period
Visit Number
NTx
Visit Type
Site
Visit Frequencya
Every 12 weeks
Window (days)b
±7
Dispense intake and output diaries
X
Evaluate teduglutide treatment inclusion criteriac
X
Adverse events
X
Concomitant medications and procedures
X
Physical examination and vital signs, including weight
X
Height and head circumferenced
X
Review intake and output diariese 
X
Record PS prescription and adjust as neededf
X
Safety laboratory testsg
X
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-Scales
X
Antibodies to teduglutideh
(X)
Fecal occult blood testingi
Annually
Colonoscopy or sigmoidoscopyj
(X)
Serum samplek
Every 24 weeks
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
a The first NTx visit after the screening visit must occur within 2 to 12 weeks of screening.
b Window is relative to the first NTx visit in the current no-teduglutide treatment period.
c Subjects who meet ≥1 teduglutide treatment inclusion criteria, may proceed to the pretreatment visit if the investigator, subject, 
and parent or legal guardian agree to proceed with teduglutide therapy (Table 1-4).
d Head circumference will be measured in subjects 36 months of age and younger.
e Intake diaries will collect actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section 7.2.2.10 for more detail.
f Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix 2.
g Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
h Subjects who have been treated previously and test positive for teduglutide antibodies should have follow-up samples collected 
every 12 weeks during the study until a negative result is obtained.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 
48-60 weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive fecal occult blood test during a no-teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy/sigmoidoscopy at 5-year intervals or more often as needed. See Section 7.2.2.10 for 
details.
k Lack of collection of serum samples will not constitute a protocol deviation.  Stored serum samples should be omitted for 
subjects weighing less than 15 kg and whenever local blood volume limitations are exceeded.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 24
SHP633-303 Protocol Amendment 4
Teduglutide
01 Oct 2019
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Cx
W4
Cx 
W6
Cx 
W9
Cx 
W12
Cx 
W16
Cx W20
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window 
(days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteria
X
Xe
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Phone contact is required approximately 1 week after PS adjustment
Dispense intake 
and output 
diaries
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant 
medications and 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examination 
and vital signs, 
including 
weight
X
X
X
X
X
X
X
X
X
X
X
X
Height and head 
circumferencef
X
X
X
X
Review intake 
and output 
diariesg
X
X
X
X
X
X
X
X
X
X
X
X
X
Record PS Rx 
and adjust as 
neededh
X
X
X
X
X
X
X
X
X
X
X
X
X
Safety 
laboratory testsi
Xj
X
X
X
X
X
X
X
X
X
X
(X)
X
For non-commercial use only

Shire
CONFIDENTIAL
Page 25
SHP633-303 Protocol Amendment 4
Teduglutide
01 Oct 2019
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Cx
W4
Cx 
W6
Cx 
W9
Cx 
W12
Cx 
W16
Cx W20
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window 
(days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
PedsQL 
Generic Core 
Scale/ Family 
Impact Module/ 
GI Symptoms 
Module Sub-
Scales
X
X
X
Antibodies to 
teduglutidej
X
X
X
X
Fecal occult 
blood testing
X
X
X
Colonoscopy/
Sigmoidoscopyk
(X)
(X)
(X)
Pregnancy 
testingl
X
X
X
X
X
X
X
X
X
Serum samplem
X
X
Evaluate escape 
criterian
Xp
X
X
Dispense study 
drugo
X
X
X
X
X
X
X
X
X
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; FU=follow-up; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio; SBS=short bowel syndrome; SC=subcutaneous; 
Scr=screening; TED=teduglutide; Tx=treatment
a If the first pretreatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening. 
b Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except for evaluation of escape 
criteria).
c The investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur within 7 days of the 
CxW28 visit. If a subject is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-2) will take place in lieu of the CxW28 visit.
d Visit windows are relative to the CxD1 visit.
e Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs obtained at the CxD1 
visit are not required to determine teduglutide treatment eligibility.
For non-commercial use only

Shire
CONFIDENTIAL
Page 26
SHP633-303 Protocol Amendment 4
Teduglutide
01 Oct 2019
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period
Pretreatment
Teduglutide Treatment
Follow-up
Visit Number
Pxa
Cx
D1
Cx
W1
Cx
W2
Cx
W4
Cx 
W6
Cx 
W9
Cx 
W12
Cx 
W16
Cx W20
CxW24 
(EOT)
CxW25 
CxW26 
CxW27
CxW28c
Visit Type
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Site
Phoneb
Site
Cycle Day
-21 to 0
1
8
15
29
43
64
85
113
141
169
176
197
183
190
Window 
(days)d
-21 to 0
±2
±2
±2
±2
±4
±4
±4
±4
±4
±2
±2
f Head circumference will be measured in subjects 36 months of age and younger.
g Intake diaries will collect actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except at pretreatment visit), 
for 1 week following PS adjustment, and daily during the 4-week follow-up period. Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before 
every clinic visit, and within 1 week of implementing a change in the PS prescription. See Section 7.2.2.12 for more detail.
h Parenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment provided in Appendix 2.
i Safety laboratory assessments at site visits will consist of clinical chemistry, hematology, and urinalysis, with results processed by a central laboratory. Clinical chemistry and urinalysis must also be 
performed within approximately 5-7 days of any adjustment to the PS prescription. Safety labs performed between clinic visits may be performed locally. Unscheduled lab results will not be captured in 
the eCRFs. If abnormal results are considered an adverse event, an AE form will be completed. Collect PT/INR at the pretreatment visit. Additional collection will occur if a potential drug-induced liver 
injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not constitute a protocol deviation.
j Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be drawn at least 14 hours 
after dosing.
k The teduglutide-naïve subjects age 12 and older will undergo colonoscopy/sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any age with newly positive 
FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy/sigmoidoscopy prior to receiving teduglutide. If newly 
positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment cycle (CxW24/EOT), colonoscopy/sigmoidoscopy will be performed. 
The need for colonoscopy/sigmoidoscopy in response to positive FOBT results at CxW12 is at the discretion of the investigator. Teduglutide-exposed subjects who have received the equivalent of 2 
treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy/sigmoidoscopy. See Section 7.2.2.10 for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all other visits according to the study schedules, or if pregnancy is 
suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.  Stored serum samples should be omitted for subjects weighing less than 15 kg and whenever local blood volume 
limitations are exceeded.
n If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed for hypersensitivity 
reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See Section 6.2.3 for dose adjustment.
p Escape criteria will be assessed for subjects who escaped during the follow-up period of a previous teduglutide treatment cycle at CxW24. The investigator may combine the CxW24 visit with the next 
pretreatment visit if at least 1 escape criterion is met at the CxW24 visit. In order to combine assessments, the pretreatment assessments must occur within 7 days of the CxW24 visit.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 27
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
1
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options
Short bowel syndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. It is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with SBS (Khan et al., 
2015; Wales et al., 2004). Unlike the adult population, the majority of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy. 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 years of the initial diagnosis (Khan et al., 2015). 
Nevertheless, despite optimal medical management, many pediatric subjects remain dependent 
on PS. Complications of long-term PS include liver disease, catheter-related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality of life is poor (Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al., 2015; Squires et al., 2012).
Intestinal adaptation is driven by hormonal cues in response to nutrient malabsorption (Drucker 
and Yusta, 2014). Chief among these is hormones glucagon-like peptide 2 (GLP-2), which is 
secreted from L-type enteroendocrine cells that reside in the intestinal epithelium in the ileum 
and colon. Resection of these regions may impair the adaptive response by limiting endogenous 
production of GLP-2.
1.2
Product Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP-2 that 
regulates the functional and structural integrity of the cells lining the gastrointestinal (GI) 
tract. Teduglutide is a 33-amino acid peptide that differs from native GLP-2 in the substitution 
of glycine for alanine at the second position at the N-terminus. As a result, teduglutide 
demonstrates resistance to degradation by dipeptidyl peptidase 4 (DPP-4) and therefore 
maintains a longer elimination half-life (t1/2) in adults of approximately 2 hours compared to 
the native peptide, which has a t1/2 of approximately 7 minutes. Teduglutide has been shown 
in animal studies and previous human clinical trials to increase villus height and crypt depth in 
the intestinal epithelium, thereby increasing the absorptive surface area of the intestines 
(Tappenden et al., 2013; Thymann et al., 2014). The European Commission granted a 
centralized marketing authorization valid throughout the European Union (EU) for teduglutide 
(REVESTIVE™) on 30 August 2012 and a New Drug Application (NDA) for teduglutide 
(GATTEX®) was approved by the United States (US) Food and Drug Administration (FDA) on 
21 Dec 2012 for the treatment of adult patients with SBS who are dependent on PS. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 28
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Teduglutide has also been approved for use in adult patients with SBS in Canada and 
Switzerland. On 29 Jun 2016, the European Commission granted an extension of the Market
Authorization for teduglutide (REVESTIVE) for the treatment of patients aged 1 year and above 
with SBS; patients should be stable following a period of intestinal adaptation.
1.3
Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 study, TED-C13-003, was completed in pediatric SBS subjects in the US and 
United Kingdom (UK). In this study, teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1-17. Thirty-seven pediatric subjects received teduglutide at doses of 
0.0125, 0.025, or 0.05 mg/kg/day for 12 weeks. Five additional pediatric subjects were 
enrolled in an observational standard of care (SOC) cohort. There were clear dose-dependent 
effects of teduglutide seen at the 0.025 and 0.05 mg/kg/day doses compared to SOC and the 
0.0125 mg/kg/day dose. In the 0.025 mg/kg/day cohort there was a reduction in PS volume at 
Week 12 of 37%, including complete independence from PS support in 1 subject, and a 
reduction of 3.94 hours per day infusion time. In the 0.05 mg/kg/day cohort there was a 
reduction in PS volume at Week 12 of 39%, including complete independence from PS support 
in 3 subjects, and a reduction of 4.18 hours per day infusion time. Teduglutide was generally safe 
and well tolerated by pediatric subjects in all dosing cohorts. There were no deaths during the 
study and no treatment-emergent serious adverse events (TESAEs) related to teduglutide were 
reported. No discontinuations from study were due to adverse events (AEs).
TED-C14-006 is a recently completed study of pediatric subjects through 17 years which 
included 2 treatment arms: a teduglutide treatment arm and a SOC treatment arm. Subjects in 
both arms participated in a 2-week minimum screening period, a 24-week treatment period, and a 
4-week follow-up period. During the screening period, subjects chose into which arm to enroll. 
During the 24-week treatment period, subjects in the SOC treatment arm received standard 
medical therapy for SBS; while those in the teduglutide treatment arm received daily 
subcutaneous (SC) injections of teduglutide (study drug) in addition to standard medical therapy. 
The subjects enrolling in the teduglutide treatment arm were randomized 1:1 in a double-blinded 
manner into 2 parallel dose groups: 0.025 mg/kg/day or 0.05 mg/kg/day of teduglutide 
administered subcutaneously for 24 weeks. Compared to the SOC, treatment of pediatric subjects 
with SBS with teduglutide resulted in clinically meaningful reductions in PN/IV volume, 
calories, days per week, and hours per day. A total 10% of subjects who received teduglutide 
achieved enteral autonomy within 24 weeks despite prior dependence on PN/IV for several 
years. Teduglutide treatment also resulted in increases in EN volume and caloric intake as well 
as plasma citrulline. Although the differences in efficacy between the 0.025 and 0.05 mg/kg dose 
groups were small, a consistently greater effect was seen in the 0.05 mg/kg dose in all efficacy 
parameters. The PK properties were well characterized in this population and were consistent 
with the prior 12 week pediatric study. Teduglutide was generally well tolerated by pediatric 
subjects with SBS. The safety profile was favorable and consistent with the prior pediatric study, 
the underlying disease, and previous experience with teduglutide in adult subjects with SBS.
Always refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy and safety of teduglutide (SHP633).
For non-commercial use only

Shire
CONFIDENTIAL
Page 29
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
2
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
This is a Phase 3, retrospective and prospective, open-label, long-term extension study to 
evaluate the safety and efficacy of teduglutide in pediatric subjects with SBS who completed the 
TED-C13-003 study. In addition to evaluating the long-term safety and durability of efficacy 
after 12 weeks of treatment in TED-C13-003, this extension study will evaluate the need for 
additional teduglutide treatment in these subjects, and will allow for the first-time treatment of 
teduglutide-naïve subjects who participated in the SOC treatment arm in TED-C13-003.
2.2
Study Objectives
2.2.1
Primary Objectives
The primary objective of the study is to evaluate the long-term safety and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED-C13-003.
2.2.2
Secondary Objectives
The secondary objective of this study is to evaluate the long-term efficacy of teduglutide 
treatment in pediatric subjects with SBS who completed TED-C13-003.
For non-commercial use only

Shire
CONFIDENTIAL
Page 30
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
3
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a Phase 3, prospective, open-label, long-term extension study to evaluate the safety 
and efficacy of teduglutide in pediatric subjects who completed the TED-C13-003 study 
(the core study). At the time of entry into the TED-C13-003 study, subjects were less than 
18 years of age, were dependent on parenteral nutrition to provide at least 30% of their 
caloric or fluid needs and had not been able to significantly reduce PS for at least 3 months 
prior to enrollment. During the core study, pediatric subjects in the teduglutide treatment 
arm were entered into a 0.0125 mg/kg/day, 0.025 mg/kg/day, or 0.05 mg/kg/day dose cohort 
based on the timing of their enrollment in the study. The cohorts were filled in a sequential 
manner.
Approximately 40 subjects who completed the core study are expected to enroll in this extension 
study. Subjects who previously received teduglutide during the core study, as well as subjects 
who were in the SOC treatment group, may be eligible to receive teduglutide treatment in this 
extension study. To be eligible for treatment with teduglutide in this extension study, subjects 
must meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately every 12 weeks for safety, parenteral support (PS) requirements, and 
quality of life. At any point during an NTT period, subjects who meet ≥1 teduglutide treatment 
inclusion criteria may proceed directly to the pretreatment visit if the investigator, subject, and 
parent or legal guardian agrees to proceed with teduglutide therapy.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long-term follow-up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analysis suggested that pediatric patients, ages 1-17 years-old, are likely to require the same 
dose as used in adults, namely 0.05 mg/kg/day (Mouksassi et al., 2009). In this extension study, 
all subjects who enter a teduglutide treatment cycle will receive 0.05 mg/kg SC QD.
For non-commercial use only

Shire
CONFIDENTIAL
Page 31
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed pediatric studies (TED-C13-003 and 
TED-C14-006) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day 
was associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
studies as well as the pediatric (core) study (TED-C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults (O'Keefe et al., 2006).
Further PK simulation was conducted based on the population PK model previously established 
and a virtual population of 1000 pediatric patients created based on Centers for Disease Control 
(CDC) growth charts in the target age group (4 to 12 months) and taking into consideration 
body weights of pediatric patients with SBS enrolled in study TED-C13-003 (approximately 
15% lower than healthy subjects in the same age group). Monte Carlo simulations for all age 
groups were performed according to the SC dosing regimens of 0.0125, 0.025 and 0.05 mg/kg 
every 24 hours. Rich concentration-time profiles were simulated with the customized population 
PK model to derive the exposure metrics area under the concentration curve at steady state 
(AUCss) and maximum concentration at steady state (Cmax,ss). Following 0.05 mg/kg daily SC 
administration, the median Cmax,ss of teduglutide in infants (24.9 ng/mL) was within 20% of that 
observed in the 2 to 4 and 4 to 6 years age groups (26.9 and 29.4 ng/mL, respectively); and 
approximately ~28% lower than that in adult patients with SBS. The clinical package in 
conjunction with Cmax was considered to support teduglutide dose selection since AUCss was 
previously shown not to correlate with efficacy. Thus, the 0.05 mg/kg dose is proposed for testing 
in all age groups.
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED-C14-006 study, 
consisting of 24 weeks of teduglutide treatment, followed by a 4-week follow-up period. The 
follow-up period is a mechanism to evaluate whether continued teduglutide is needed. If a 
subject deteriorates during the follow-up period, the subject may be evaluated immediately for 
additional teduglutide treatment. Subjects who clinically deteriorate or stop improving at any 
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED-C13-003 and TED-C14-006, to ensure sufficient safety monitoring and 
weaning of PS. During the NTT period, visits occur every 12 weeks, a frequency that is 
consistent with standard medical practices. To minimize risk to subjects, those who have 
deteriorated quickly after treatment interruption (ie, escaped from a prior follow-up period) may 
be evaluated immediately for eligibility for additional treatment when they reach the Week 24 
visit of subsequent treatment cycles.
Measures and Parameters
To evaluate efficacy and safety from the time subjects completed the core study to the time they 
enter this extension study, retrospective data collection is planned for this study. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 32
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. In addition to this retrospective data 
collection, prospective study assessments of safety and efficacy will be completed as a part of 
this study.
3.1.1
Informed Consent/Assent and Eligibility
The review and signing of the ICF (and if applicable, informed assent) for this study, must be 
completed before any other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study; however, subjects may 
consent to retrospective data collection only. Subjects may not consent to the prospective data 
collection only. After informed consent/assent is obtained, study eligibility will be assessed for 
all subjects.
3.1.2
Retrospective Data Collection
Procedures for retrospective data collection assessments can be found in Table 1-1 and 
Section 7.1.1. For subjects that only consent to retrospective data collection, these procedures are 
all that will be completed.
Retrospective data collection will consist of specific safety and efficacy measures that were 
completed in the course of the subject’s standard medical care between the date of the 
TED-C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study. Retrospective data collection may begin any time after informed consent/assent is 
obtained for this study. The following data will be collected:

Teduglutide use (as prescribed)

Parenteral support (as prescribed)

Growth (height, head circumference [up to 36 months of age], weight)

End dates for adverse events (AEs) ongoing at the time of TED-C13-003

All nonserious AEs related to teduglutide

All adverse events of special interest (AESIs)

All serious adverse events (SAEs)
3.1.3
Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history and short bowel syndrome history. The parenteral support prescription will 
also be collected at screening. Additionally, intake diaries will be dispensed at the screening visit 
for collection of actual PS volume and hours per day (Section 7.2.2.12). 
For non-commercial use only

Shire
CONFIDENTIAL
Page 33
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Diary data for PS volume will be collected for at least 2 weeks after the ICF (and if applicable, 
the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately 
every 12 weeks for safety, PS requirements, and quality of life. Diary data for PS volume will be 
collected for at least 2 weeks prior to any NTT visit. The first NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any point after screening, including
during an NTT period, subjects who meet ≥1 teduglutide treatment inclusion criteria, may 
proceed immediately to the pretreatment visit if the investigator, subject, and parent or legal 
guardian agrees to proceed with teduglutide therapy.
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, 
and meet none of the teduglutide treatment exclusion criteria, will start a 28-week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily, followed by a 
4-week follow-up (no treatment) period (Figure 3-1). During the 28-week cycle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekly during the follow-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored, and nutritional support will be 
reviewed and adjusted as needed. Quality of life assessments will be made approximately every 
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation (Appendix 2).
Rationale: Measures of long-term safety will include AEs, growth parameters, and anti-drug 
antibodies. Measure of long-term efficacy will include durability of effect as measured by 
reduction in PS and improvement in pediatric quality of life measures (Pediatric Quality of Life 
Inventory [PedsQL], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pivotal Phase 3 adult clinical 
trials and the completed Phase 3 pediatric study (TED-C13-003) and will be used as an endpoint 
in this extension study. In previous clinical studies, a reduction of this magnitude was associated 
with a reduction in the number of days per week of PS and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may provide a pediatric subject 
with opportunities for more age-appropriate activities including oral rehabilitation. Quality of life 
assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI-specific screening tests, 
including fecal occult blood testing and colonoscopy/sigmoidoscopy, which are commonly part 
of the routine care of these subjects, will be performed to ensure safety. This study captures 
long-term safety data on polyps and other colonic mucosal changes in teduglutide-exposed 
subjects using the surveillance strategy proposed in Section 7.2.2.10.
For non-commercial use only

Shire
CONFIDENTIAL
Page 34
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Figure 3-1
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 (dashed grey lines). Subjects discontinue teduglutide 
at Week 24 and enter a 4-week follow-up (no-treatment) period, during which phone visits will be performed weekly (solid grey 
lines). If an escape criterion is met at Week 24 or during the follow-up period, subjects may proceed directly to another 
pretreatment visit.
3.2
Duration and Study Completion Definition
A subject will be considered enrolled in the study once the subject has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility 
Criteria. The study will continue for at least 1 year, and until each subject has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
3 years. The study will be completed in approximately 40 months. A subject will be considered 
as having completed the study if the subject has not withdrawn early from the study for any 
reason prior to completing the EOS visit.
The study completion date is defined as the date the final subject, across all sites, completes their 
final protocol-defined assessment. Please note that this includes the follow-up visit or contact 
(last safety contact), whichever is later. The study completion date will be used to ascertain 
timing for study results posting and reporting.
For non-commercial use only

Shire
CONFIDENTIAL
Page 35
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
4
STUDY POPULATION
Each subject and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any study-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility does not impact study eligibility.
4.1
Study Inclusion Eligibility Criteria
The subject will not be considered eligible for the study without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing any 
study-related procedures. 
2. Subject completed the TED-C13-003 study (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully adhere to study requirements as 
defined in this protocol.
4.2
Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study.
4.3
Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥1 of the teduglutide treatment inclusion criteria 
and none of the teduglutide treatment exclusion criteria are met. In addition, the investigator and 
the subject (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.4
Teduglutide Treatment Inclusion Criteria
1. Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and 
during the teduglutide pretreatment visit, as assessed by the investigator. Transient 
instability for events such as interruption of central access or treatment for sepsis is 
allowed if the PS returns to within 10% of baseline prior to the event.
2. Subject was previously treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.
Increasing PS requirements following teduglutide discontinuation
b. Decreased PS requirement during prior teduglutide treatment, followed by 
cessation of improvement after teduglutide discontinuation
c.
Deteriorating nutritional status (eg, weight loss or growth failure) despite 
maximal tolerated enteral nutrition (EN) following teduglutide discontinuation
d. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid 
and electrolyte intake following teduglutide discontinuation
e.
Severe diarrhea related to teduglutide discontinuation
For non-commercial use only

Shire
CONFIDENTIAL
Page 36
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
4.5
Teduglutide Treatment Exclusion Criteria
1. Body weight <10 kg at the pretreatment visit
2. Unresected GI polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3. History of cancer in the previous 5 years except surgically curative skin cancers
4. Serial transverse enteroplasty or other major intestinal surgery within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5. Intestinal or other major surgery planned or scheduled to occur during the 28-week 
cycle
6. Clinically significant intestinal stricture or obstruction
7. Clinically significant, active or recurrent pancreatic or biliary disease
8. Active, severe, or unstable, clinically significant hepatic impairment or injury, 
including the following laboratory values at the pretreatment visit:
a.
Total bilirubin ≥2 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) ≥7 × ULN
c.
Alanine aminotransferase (ALT) ≥7 × ULN
9. Renal dysfunction shown by results of an estimated glomerular filtration rate below 
50 mL/min/1.73 m2 at the pretreatment visit
10. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the 
exception of subjects who had undergone ventricular or atrial septal defect repair, or 
patent ductus arteriosus ligation
11. Participation in a clinical study using an experimental drug (other than glutamine, 
Omegaven, Smoflipid, or teduglutide) within 3 months or 5.5 half-lives of the 
experimental drug, whichever is longer, prior to the pretreatment visit and for the 
duration of the 28-week cycle
12. Treatment with analogs of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 
(GLP-2) (not including teduglutide), insulin-like growth factor-1 (IGF-1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit
13. Treatment with octreotide or dipeptidyl peptidase 4 (DPP-4) inhibitors within 3 months 
prior to the pretreatment visit
14. Known or suspected intolerance or hypersensitivity to the investigational product, 
closely-related compounds, or any of the stated ingredients
15. Known history of alcohol or other substance abuse within 1 year prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
For non-commercial use only

Shire
CONFIDENTIAL
Page 37
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
17. Sexually active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 days after the treatment period 
18. Any condition, disease, illness, or circumstance that in the investigator’s opinion puts 
the subject at any undue risk, prevents completion of the study, or interferes with 
analysis of the study results
4.6
Follow-up Period Escape Criteria
At the discretion of the investigator, the follow-up period may be interrupted (if the subject 
meets 1 or more of escape criteria 1 to 4 during the follow-up period) or omitted (if the subject 
meets escape criterion 5 at the CxW24 visit) and the subject may proceed directly to the 
pretreatment visit, if ≥1 of the following criteria is met:
1. Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) despite maximal 
tolerated EN following teduglutide discontinuation
3. Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and 
electrolyte intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
5. The subject escaped during the follow-up period of a previous teduglutide treatment 
cycle within SHP633-303. In this case, the CxW24 visit may be combined with the next 
cycle pretreatment visit.
4.7
Reproductive Potential
4.7.1
Female Contraception
To be eligible for treatment with teduglutide, sexually active females of child-bearing potential 
must use an acceptable form of contraception throughout the study period and for 30 days 
following the last dose of investigational product. If hormonal contraceptives are used, they 
should be administered according to the package insert. Females of child-bearing potential who 
are not currently sexually active must agree to use acceptable contraception, as defined below, if 
they become sexually active during the period of the study and 30 days following the last dose of 
investigational product. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:

Premenarchal and either Tanner Stage 1 or less than age 9 years, or

Females of child-bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin (-HCG) pregnancy test at the teduglutide pretreatment visit. Females
of child-bearing potential must agree to abstain from sexual activity that could result in 
pregnancy or agree to use acceptable methods of contraception.
For non-commercial use only

Shire
CONFIDENTIAL
Page 38
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Acceptable methods of contraception are:

True abstinence: Abstention of sexual activity that is in line with the preferred and usual 
lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception). 

Intrauterine devices plus condoms

Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)

Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 days prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually active during the study, they should use 1 of the other acceptable methods noted 
above in addition to the hormonal contraceptive until it has been stabilized for 30 days.
4.8
Discontinuation of Subjects 
4.8.1
Teduglutide Discontinuation
If the investigational product is discontinued prematurely during a teduglutide treatment cycle 
and the subject wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow-up period will ensue, consisting of weekly telephone visits 
(CxW25-27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility according to the study 
schedules. 
Comments (spontaneous or elicited) or complaints made by the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.3. The investigator is encouraged to discuss withdrawal of a subject 
from investigational product with the medical monitor, when possible.
4.8.2
Study Withdrawal
At any time during the study, the investigator or sponsor may withdraw a subject, or a subject 
may withdraw from the study, for any reason, without prejudice to their future medical care by 
the physician or at the institution.
If a subject withdraws from the study during a teduglutide cycle, the evaluations listed for the 
EOT visit are to be performed as completely as possible. Whenever possible, the subject will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contacted 
weekly by phone during the interim period between EOT and ET for safety follow-up.
If a subject withdraws from the study during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completely as possible. 
Subjects who withdraw from the study will not be replaced.
For non-commercial use only

Shire
CONFIDENTIAL
Page 39
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
4.8.3
Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study must 
be determined by the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than 1 reason, each reason should be documented in the source 
document, and the most clinically relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:

Adverse event

Protocol deviation

Lack of efficacy

Physician decision

Withdrawal by subject

Withdrawal by parent/guardian

Lost to follow-up

Pregnancy (Discontinuation of treatment only)

Death

Other
4.8.3.1
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations, and return any unused investigational product.
For non-commercial use only

Shire
CONFIDENTIAL
Page 40
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
5
CONCOMITANT TREATMENT
5.1
Concomitant Medications and Procedures
Concomitant treatment will be collected for the prospective period only and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study. Concomitant medications and procedures will be assessed at each site visit, and include all 
nonstudy treatments (medications, herbal treatments, vitamins, invasive and diagnostic 
procedures). Concomitant treatment information must be recorded on the appropriate eCRF 
page. Details of medication changes and/or dosages will be recorded on the eCRF.
5.1.1
Permitted Treatment
Standard medical therapy for SBS should be continued.
5.1.2
Prohibited Treatment
At the time of screening, any teduglutide treatment being received through any mechanism 
other than participation in this study (eg, by off-label prescription, participation in an 
investigator-initiated trial, compassionate access program, etc) must be discontinued. In such 
cases, there is no minimum duration of interruption of teduglutide treatment before pretreatment 
evaluations can be performed.
The mechanism of action of teduglutide may increase enteral absorption of drugs (eg, motility 
medication including narcotics and opioids used for the management of SBS, warfarin, 
psychotropics, metronidazole, digoxin), so consideration should be given to modifying 
concomitant enteral medication regimens. Down-titration of concomitant enteral medications 
should be considered when drugs, especially those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1 Prohibited Treatment
Prior Therapy
Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon-like peptide-2 (not-including teduglutide)
Any
Glucagon-like peptide-1 analog or human growth hormone
3 months
Octreotide or dipeptidyl peptidase 4 inhibitors
3 months
For non-commercial use only

Shire
CONFIDENTIAL
Page 41
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
6
INVESTIGATIONAL PRODUCT
6.1
Identity of Investigational Product
The test product is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L-histidine, mannitol, monobasic sodium 
phosphate monohydrate, and dibasic sodium phosphate as excipients. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.1
Blinding the Treatment Assignment
Not applicable for this open-label study.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology for Investigational Product Management
An interactive web-based response system (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory management and supply ordering, investigational product expiration tracking and 
management, and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The IWRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.2
Allocation of Subjects to Treatment
This is an open-label study. Subjects will retain their assigned subject number from the 
TED-C13-003 study. Assessment of need for teduglutide treatment should be guided by the 
teduglutide treatment inclusion criteria. If the investigator, subject, and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit (Table 1-4).
6.2.3
Dosing
If teduglutide treatment eligibility is established at the pretreatment visit and again, confirmed at 
the CxD1 visit, the subject will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered by SC injection once daily (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 42
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than 3 hours 
later.
The subject should be dosed at approximately the same time each day. Consecutive doses should 
be separated by at least 12 hours. Each day, the injection site should be rotated.
The first SC injection in teduglutide-naïve subjects should be administered under the supervision 
of the investigator or designee and the subject observed for hypersensitivity reactions for at least 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the Instructions for Use. 
At the end of each 24-week teduglutide treatment period, subjects will be evaluated for the need 
for additional teduglutide treatment. During the 4-week follow-up period, the investigator will 
assess the subject via weekly telephone visits. At any time during the follow-up period, if escape 
criteria are met, the subject may proceed directly to another Pretreatment visit to assess treatment 
eligibility for another cycle (Section 4.6). Following the completion of the 4-week follow-up, the 
subject will continue in the study off teduglutide until teduglutide treatment eligibility criteria are 
again met. Additional 28-week cycles may be repeated if treatment eligibility is established each 
time.
6.2.4
Unblinding the Treatment Assignment
Not applicable for this open-label study.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification will be applied to the investigational 
product(s) container.
The study drug will be packaged, labeled, and shipped to the study site by the sponsor or 
designee. Kits containing 7 vials of study drug will be supplied and these will be labeled in 
accordance with applicable regulatory requirements. Sterile water for injection syringes and 
other ancillary components will also be provided separately and will be labeled in accordance 
with the applicable regulatory requirements.
All study drug used in this study will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
For non-commercial use only

Shire
CONFIDENTIAL
Page 43
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
6.3.2
Packaging
Teduglutide will be provided in a 3 mL sterile, single-use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL) will be provided in a prefilled syringe.
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in
advance by the sponsor.
6.3.3
Storage and Handling
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Limited responsibility may be delegated to the pharmacy or 
member of the study team, but this delegation must be documented.
Study drug must be kept in a locked area with access restricted to specific study personnel. Study 
drug will be stored refrigerated at a temperature between 2-8°C (35.6-46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2-25°C, or 35.6-77°F). Parent/legal guardian 
will be instructed to keep the subject’s study drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study drug may be refrigerated. The study drug is for single use only, and should be used within 
3 hours following reconstitution.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed by the pharmacy or nominated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
For non-commercial use only

Shire
CONFIDENTIAL
Page 44
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed number of subjects. The investigator or designee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. The 
investigator is to keep a current record of the inventory and dispensation of all clinical supplies. 
This record will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any discrepancy or deficiency will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any unauthorized situation.
The investigator has overall responsibility for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study protocol. All dispensed 
study medication will be documented in the interactive response technology system and/or other 
investigational product record (eg, investigation product accountability form). The investigator is 
responsible for assuring the retrieval of all study supplies from subjects.
All used and unused study drug vials must be returned by the subjects and/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unused study drug vials to the same subject. All original containers, whether empty 
or containing study drug will be returned to the pharmacy. Returned study drugs will NOT be 
relabeled or reassigned for use by other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may be destroyed on site without approval by the sponsor.
Please see the Pharmacy Manual for additional information.
6.5
Subject Compliance
Subjects will be instructed to bring their unused investigational product and empty/used 
investigational product packaging to every visit. Drug accountability will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper-evident sealed container (eg, bottles, trays, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability form.
Compliance with study drug is calculated from subject diaries. Of those subjects eligible for 
teduglutide treatment, subjects who have received 80% of the planned doses administered will be 
assessed as being compliant with the study protocol.
For non-commercial use only

Shire
CONFIDENTIAL
Page 45
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
7
STUDY PROCEDURES
7.1
Study Schedule
Detailed study procedures and assessments to be performed for subjects throughout the study are 
outlined in the Schedule of Assessments (Table 1-1, Table 1-2, Table 1-3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing any study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject (Table 1-1).
7.1.1
Retrospective Data Collection
Retrospective data are defined as specific safety and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED-C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if 
applicable, informed assent) is signed for this study. Retrospective PS and growth data will be 
captured in 12-week intervals, with the first 12-week interval beginning at the TED-C13-003 
EOS visit. All available retrospective data should be captured in the corresponding eCRFs. 
Failure to collect retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent only to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study:

Informed consent, and informed assent (if applicable)

Study eligibility is determined

A screen failure is a subject who has given informed consent and failed to meet 
the study inclusion eligibility criteria. Subjects cannot be rescreened once they 
have been designated as a screen failure.

Prior teduglutide use (as prescribed)

Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator-initiated trials, compassionate 
use, and named-patient access programs.

Collect start and end dates when a subject’s teduglutide use was interrupted.

Parenteral support (as prescribed)

The last representative PS prescription during each 12-week interval throughout 
the retrospective period and at the beginning and end of any teduglutide treatment 
will be collected. Usually, the prescription at the end of the interval will represent 
the status of intestinal adaptation. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 46
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
However, transient alterations in PS related to loss of central venous access or 
acute illness are not representative of intestinal adaptation. When such events 
occur at the end of a 12-week interval, earlier, more representative PS prescription 
data should be recorded.
Data collected should include weekly prescribed volume, calories, average hours 
per day, and days per week of prescribed PS. Hours per day should be averaged 
over the days where PS is prescribed.

Growth (height, head circumference, and weight)

The last representative value for height, during each 12-week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and younger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.

Adverse events

All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study. The details of data collection and safety reporting for these events 
can be found in Section 8.

End dates for AEs ongoing at the end of TED-C13-003 will be collected.
7.1.2
Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:

Informed consent, and informed assent (if applicable)

Study eligibility is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study inclusion eligibility criteria. Subjects cannot be 
rescreened once they have been designated as a screen failure.

Demographics, updates to medical history and SBS history

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications and concomitant procedures

Physical examination and vital signs, including weight

Height and head circumference

Record PS prescription and adjust as needed
For non-commercial use only

Shire
CONFIDENTIAL
Page 47
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3
Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide-treatment cycle, subjects will be followed 
approximately every 12 weeks for safety and efficacy assessments. No-teduglutide treatment 
visits are numbered sequentially (NT1, NT2, etc.), even if interrupted by the treatment cycles. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1-3 and described below.

Intake and output diaries are dispensed

Evaluate teduglutide treatment inclusion criteria

Adverse events, concomitant medications, and concomitant procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests (ie, clinical chemistry, hematology, and urinalysis)

PedsQL Generic Core Scale/PedsQL Family Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub-Scales

Antibodies to teduglutide, if and when required

Fecal occult blood testing, as indicated (see Section 7.2.2.10)

Colonoscopy/sigmoidoscopy, as indicated (see Section 7.2.2.10)

Serum sample, as indicated
Teduglutide treatment may be considered at any time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may proceed to the pretreatment visit immediately to determine 
eligibility.
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
7.1.4.1
Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may proceed to the pretreatment visit immediately. Similarly, 
subjects who meet escape criteria at cycle Week 24 or during the teduglutide follow-up period 
may proceed to the pretreatment visit immediately.
For non-commercial use only

Shire
CONFIDENTIAL
Page 48
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
In general, pretreatment assessments may occur over a period of up to 21 days. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:

Evaluate teduglutide eligibility (treatment inclusion/exclusion criteria)

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant procedures

Fecal occult blood testing

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy as indicated

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries 

Record PS prescription and adjust as needed.

Safety laboratory tests
(In addition to clinical chemistry, hematology, and urinalysis, labs at this visit include 
prothrombin time [PT] international normalized ratio [INR]. Subsequent prothrombin 
time/international normalized ratio [PT/INR] measurement is only required to evaluate 
for suspected drug-induced liver injury [DILI]).

Pregnancy testing (serum), if applicable

Serum sample
7.1.4.2
Teduglutide Treatment Period (CxD1-CxW24)
The open-label teduglutide treatment period will comprise 24 weeks, during which all 
assessments and procedures listed for Visits CxD1-CxW24 in Table 1-4 shall be completed. 
Cycles are numbered sequentially, such that the first visit of the first cycle is C1D1, and the first 
visit of the second cycle is C2D1, etc. Visit windows are calculated relative to the date of first 
investigational product administration (Visit CxD1).
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1-4 and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.

Confirm teduglutide treatment eligibility

Dispense intake and output diaries

Adverse events, concomitant medications, and concomitant procedures
For non-commercial use only

Shire
CONFIDENTIAL
Page 49
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries

Record PS prescription and adjust as needed

Safety laboratory tests

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing (urine), if applicable

Dispense study drug
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cycle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:

Dispense and review intake and output diaries (every effort should be made to complete 
2 weeks of intake diary entries prior to each clinic visit and to complete 48 hours of 
output diary entries during a period of nutritional stability prior to each clinic visit)

Physical examination and vital signs, including weight

Record PS prescription and adjust as needed

Safety laboratory tests

Urine pregnancy testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)

Study drug dispensation (except for CxW24)

Adverse events, concomitant medications and concomitant procedures
In addition, at CxW12 and CxW24 Visits ONLY, the following procedures will be performed:

Height and head circumference

Antibodies to teduglutide

Fecal occult blood testing (FOBT)

GI-specific testing, including colonoscopy or sigmoidoscopy as indicated

Quality of life measurements
At CxW24 ONLY, a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only

Shire
CONFIDENTIAL
Page 50
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Escape criteria are also evaluated at CxW24. The investigator may combine the CxW24 
assessments with the next pretreatment visit assessments if at least 1 escape criterion is met at the 
CxW24 visit and the pretreatment assessments occur within 7 days of the CxW24 visit.
Phone Visits
Phone visits are required approximately 1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-4 and described 
below:

Review intake and output diaries

Safety laboratory tests (clinical chemistry and urinalysis)

Record PS prescription and adjust as needed

Obtain AEs, concomitant medications, and concomitant procedures

Evaluate escape criteria
7.1.5
Teduglutide Follow-up Period
The safety follow-up period for this protocol is 4 weeks (Weeks 25-28 of the cycle). Phone visits 
will occur on cycle Weeks 25, 26, and 27 for all subjects. Phone visit assessments and 
procedures at Weeks 25-27 will be the same as for telephone visits performed during the 
teduglutide treatment period. In addition, subjects will be evaluated for follow-up period escape 
criteria. If escape criteria are met at any time during the follow-up period, the subject may 
proceed directly to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW24 or CxW28 visits with the next pretreatment visit if at least 1 escape 
criterion is met at the CxW24 or CxW28 visits, and the pretreatment assessments occur within 
7 days of the CxW24 or CxW28 visit. If a subject is completing the study at the CxW28 visit, the 
EOS/ET visit (Section 7.1.6) will take place in lieu of the CxW28 visit. Otherwise, following 
completion of the 28-week treatment cycle, the subject will proceed to an NTT visit within 
approximately 12 weeks.
At Cycle Week 28 (CxW28), subjects will return to the study site. In addition to the assessments 
performed at Weeks 25-27, the following procedures will be performed at CxW28 only:

Dispense and review intake and output diaries

Physical examination and vital signs, including weight

Antibodies to teduglutide

Pregnancy testing (urine), if applicable

Evaluate escape criteria
For non-commercial use only

Shire
CONFIDENTIAL
Page 51
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
7.1.6
Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study site for the end of study/early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-2 and as 
described here. If a subject discontinues the study prematurely, the assessments for the EOS/ET 
visit are to be performed as completely as possible (see Section 4.8.2).

Adverse events - AEs will be collected for 4 weeks after the last dose of teduglutide in 
the study even if the EOS/ET occurs within that timeframe

Concomitant medications and concomitant procedures

Physical examination and vital signs, including weight

Height and head circumference

Review intake and output diaries (the intake diary should be completed daily for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily over a 48-hour period of nutritional stability before the EOS/ET visit)

Record PS prescription and adjust as needed

Safety laboratory tests

Fecal occult blood testing, as indicated

Gastrointestinal-specific testing, including colonoscopy or sigmoidoscopy, as indicated

Quality of life measurements

Antibodies to teduglutide

Pregnancy testing, as needed
7.1.7
Qualitative Interview
An optional qualitative interview will be conducted by phone and within 14 days after 
completion of the EOS/ET visit (see Section 7.2.2.14). A single individual telephone interview 
will be conducted with English-speaking parents (or legal guardians) of subjects and subjects 
aged 12 years or older and who provide informed consent (and if applicable, informed assent) to 
participate in the interview. These interviews will be performed in selected countries.
7.2
Study Evaluations and Procedures
7.2.1
Retrospective Data Collection
Retrospective data are being collected to evaluate the safety, tolerability, and efficacy of 
teduglutide during the interval between a subject's completion of the TED-C13-003 study and the 
date the ICF (and if applicable, assent) is signed for the SHP633-303 study.
For non-commercial use only

Shire
CONFIDENTIAL
Page 52
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
7.2.1.1
Growth (Height, Weight, and Head Circumference)
Retrospective body height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z-score, weight z-score, body mass index (BMI), and BMI z-score will be calculated by 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analysis plan (SAP).
7.2.1.2
Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency will be 
recorded on the appropriate eCRF page.
7.2.1.3
Parenteral Support Prescribed
Retrospective parenteral support entries consist of 1 prescription per 12-week interval during the 
retrospective period. If the subject has multiple PS prescriptions in a 12-week interval, the last 
representative prescription from the interval should be used (see Section 7.1.1). In addition, PS 
prescriptions at the beginning and end of any retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekly volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
7.2.1.4
Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESIs) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide that 
occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safety reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED-C13-003 will be collected.
7.2.2
Prospective Data Collection
7.2.2.1
Demographics, Medical History, and SBS History
Demographics, updates to medical history, and updates to SBS history will be obtained at 
screening. Medical history for purposes of this extension study will consist of updates to the
medical history collected at the start of the TED-C13-003 core study. If the subject has any 
changes to the SBS history since the baseline visit of the TED-C13-003 study, that information 
(updated SBS history) will also be collected.
7.2.2.2
Physical Examination
Physical examinations will be performed according to the study schedules. Any new clinically 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF.
For non-commercial use only

Shire
CONFIDENTIAL
Page 53
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
7.2.2.3
Adverse Event Collection
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
7.2.2.4
Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body temperature 
(°C/°F). Blood pressure should be determined by cuff (using the same method, the same arm, 
and in the same position throughout the study).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each study visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z-score, weight z-score, BMI, and BMI z-score will be 
calculated by the sponsor using the site-provided height and weight data collected at each site 
visit.
New clinically significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.2.5
Clinical Laboratory Tests
Safety laboratory tests to be performed at site visits consist of clinical chemistry, hematology, 
and urinalysis and will be performed as outlined in the study plan (Table 1-2, Table 1-3, and 
Table 1-4). Scheduled laboratory testing will be processed by a central lab. All laboratory assays 
will be performed according to the central laboratory’s normal procedures. Reference ranges are 
to be supplied by the laboratory. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Abnormal clinical laboratory values, which are unexpected or not 
explained by the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safety labs within approximately 
5-7 days after a PS adjustment. Safety labs performed after PS adjustment and between site visits 
will consist of clinical chemistry and urinalysis and may be processed by the central laboratory 
or a local laboratory. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate any new clinically significant changes, they must be reported as an
AE (see Section 8.1). Urine specimen collection should be attempted as part of the safety labs, 
but lack of urinalysis will not constitute a protocol deviation.
New clinically significant labs should be reported as AEs.
For non-commercial use only

Shire
CONFIDENTIAL
Page 54
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The following clinical laboratory assessments will be performed according to the study 
schedules:
Table 7-1 List of Laboratory Tests 
Hematology:

Hematocrit

Hemoglobin

Platelet count

Red blood cell count

Red blood cell morphology, if needed

White blood cell count with differential
Coagulation:
Prothrombin time/International normalized ratio
Urinalysis:

Blood

Glucose

Leukocytes

Microscopic analysis

pH

Protein

Specific gravity
Pregnancy tests (females of childbearing potential):

Serum β-HCG (teduglutide pretreatment visit)

Urine β-HCG (all other visits)
Biochemistry:

Albumin

Alkaline phosphatase

Alanine aminotransferase

Amylase

Aspartate aminotransferase

Bicarbonate

Bilirubin (total, direct, and indirect)

Blood urea nitrogen

Calcium (total)

Chloride

Cholesterol

C-reactive protein

Creatinine

Estimated Glomerular Filtration Rate 
(Schwartz formula)

Gamma-glutamyl transferase

Glucose

Lipase

Magnesium

Phosphorus

Potassium

Sodium

Triglycerides

Uric acid
7.2.2.6
Serum Sampling
Serum samples will be collected and stored for future analysis at the following times:

At the pretreatment visit. If the subject arrived at the pretreatment visit by meeting an 
escape criterion, the serum sample will not be repeated at the pretreatment visit, because 
it will have been collected recently at the CxW24 visit.

At the CxW24 (EOT) visit

During NTT: Approximately every 24 weeks
Stored serum samples should be omitted for subjects weighing less than 15 kg and whenever 
local blood volume limitations are exceeded.
For non-commercial use only

Shire
CONFIDENTIAL
Page 55
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and any specialty laboratories will be 
blinded to the subject’s identity. The sample and/or extracted material will otherwise be stored 
for up to 15 years from the end of the study after which time it will be destroyed. Upon written 
request, subjects will be permitted to withdraw their sample from the analysis and have their 
sample and/or extracted material destroyed. Any results already generated from the samples will 
not be removed from any analyses that have already been performed.
7.2.2.7
Pregnancy Testing
A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy tests will be administered at all other visits according to the study schedules, or if 
pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the 
study.
7.2.2.8
Antibody Testing
Blood samples will be drawn for the analysis of antibodies to teduglutide according to the 
Schedule of Assessments (Table 1-2, Table 1-3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least 14 hours after dosing. Subjects who test 
positive for antibodies to teduglutide will also be tested for neutralizing antibody. Subjects who 
have been previously treated with teduglutide, and who test positive for antibodies to 
teduglutide, will have follow-up blood draws for antibodies to teduglutide every 12 weeks while 
on study until a negative result is obtained.
7.2.2.9
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study. The volumes of blood to be drawn from each subject will vary depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annually are shown 
in Table 7-2.
For non-commercial use only

Shire
CONFIDENTIAL
Page 56
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Table 7-2 Approximate Volume of Blood to be Drawn from Each Subject Annually 
Assessment
Sample 
Volume (mL)
No. Samples per two 28-week 
Teduglutide Cycles
Total 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety
Biochemistry and -hCGa
2.5
24
60
Hematology
2
24
48
Coagulation Parameters
2
2
4
Antibodies
2
8
16
Serum storage samplesb
3
4
12
Total mL per 2, 28-week Treatment Cycles (Approximate Annual Volume):
140
Subjects Not Receiving Teduglutide Treatmentc
Assessment
Sample 
Volume (mL)
No. Samples per 4 NTT Visits
Total 
Volume (mL)
Safety
Biochemistry
2.5
4
10
Hematology
2
4
8
Serum storage samplesb
3
2
6
Total mL per 4 “No Teduglutide Treatment” Visits 48-week period:
24
β-hCG=beta-human chorionic gonadotropin; NTT=no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
b Stored serum samples should be omitted for subjects weighing less than 15 kg and whenever local blood volume limitations are 
exceeded
c Subjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti-teduglutide 
antibodies will require blood samples for antibody testing every 12 weeks until they test negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by the manufacturer or laboratory 
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they require the same type of tube, the assessments should be combined. Blood 
volume estimates do not include safety labs performed after PS adjustment, and anti-teduglutide 
antibody testing during no-teduglutide treatment.  Stored serum samples should be omitted for 
subjects weighing less than 15 kg and whenever local blood volume limitations are exceeded.  
Maximum blood volume at any given visit occurs when the pretreatment and Week 24 visits are 
combined (8.5 mL).  
7.2.2.10
Gastrointestinal-specific Testing
Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week 24 of the teduglutide cycle. During NTT periods, FOBT must be performed on 
teduglutide-exposed subjects (subjects who have received teduglutide any time in the past 
and are therefore not teduglutide-naïve) on a roughly annual basis (approximately every 
48-60 weeks). Actions to be taken in response to a positive FOBT are described below.
For non-commercial use only

Shire
CONFIDENTIAL
Page 57
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Colonoscopy or Sigmoidoscopy
Teduglutide-naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pretreatment visit if one has not been performed within 1 year.
Subjects of any age with newly positive FOBT results at the pretreatment visit for which 
a readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy 
or sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which 
a readily detectable cause cannot be identified) are obtained at the end of a teduglutide 
treatment cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The 
need for colonoscopy or sigmoidoscopy in response to positive FOBTs at any other point 
during the study, or to reevaluate persistently positive FOBTs is at the discretion of the 
investigator.
Teduglutide-exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks 
of study drug exposure) will undergo colonoscopy or sigmoidoscopy. While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 year intervals or 
more often as needed.
Upper endoscopy may be performed along with any colonoscopy or sigmoidoscopy
at the investigator’s discretion. If a polyp is found, adherence to current polyp 
follow-up guidelines is recommended. Subjects with unresected GI polyps, polyposis 
conditions, premalignant change or malignancy in the GI tract will be excluded from 
teduglutide treatment.
7.2.2.11
Nutritional Support
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hydration 
status, and safety laboratory results. Intake and output diaries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 2.
7.2.2.12
Diaries
Study Drug Administration Diary
A study drug administration diary will record administration of teduglutide. This diary should be 
completed by the subject (or parent/legally authorized representative, as applicable) daily during 
the teduglutide treatment periods (between visits CxD1 and CxW24).
Intake Diary
Intake diaries will be used to collect and evaluate each subject’s nutritional support. 
The subject/parent/guardian will complete the appropriate fields of the PS section of 
the intake diary 2 weeks prior to ALL scheduled prospective site visits (except at pretreatment 
visit). 
For non-commercial use only

Shire
CONFIDENTIAL
Page 58
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
During the 24-week teduglutide treatment period, the intake diary will also be completed for
1 week following PS adjustments. The intake diary will also be completed daily during the 
4-week follow-up period. The following data will be captured in the intake diaries:

Parenteral support volume and infusion duration

Site personnel will determine the actual PS daily calories based on diary entries
Output Diary
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional 
stability before every clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cycle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:

Toilet-trained subjects (who do not wear diapers)
Measure and record all urine output in mL or cc 

Nontoilet-trained subjects (who wear diapers)
Measure and record the weight of all urine-only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL or 1 cc

At the discretion of the investigator, the parent or legal guardian may be asked to collect 
the first void after the daily PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):

Toilet-trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency using the 
Bristol Stool Form Scale (see Output diary)

Nontoilet-trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency using the Bristol Stool Form Scale 
(see Output diary). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mL or 1 cc
All ostomy output volume should be recorded. Ostomy output will not be scored using the 
Bristol scale.
All available diary data will be reviewed by the investigator or their designee at each clinic and 
telephone visit to assess clinical status and opportunity for PS reduction and advance in feeds.
For non-commercial use only

Shire
CONFIDENTIAL
Page 59
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
7.2.2.13
Health-related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes less than 4 minutes to 
complete. The scales include self-reports for pediatric subjects and adolescents aged 5 to 18 years 
and proxy-reports from parents of pediatric subjects aged 2 to 18 years. If a child is unable to 
complete the age-appropriate questionnaire (eg, due to developmental delay or other illness) it 
will not constitute a protocol deviation, but the parent should continue to complete the 
appropriate parent-specific forms.
Field trials have shown that the internal consistency reliability of the PedsQL was excellent, with 
alphas for the generic core scales in both self- and proxy-report greater than the 0.70 standard, 
and alphas for the full 23-item scale approaching 0.90 for self- and proxy-report. Missing data 
were minimal. Item response distributions were across the full-scale range, with no floor effects, 
and minimal ceiling effects.
The validity of the PedsQL Generic Core Scales was demonstrated through known group 
comparisons, and correlations with other measures of disease burden. The PedsQL self- and 
proxy-report distinguished between pediatric subjects with and without a chronic health 
condition, and within the group of pediatric subjects with a chronic condition, between those 
who did or did not have an overnight hospital visit in the last 12 months. Further, both child 
self-report and parent proxy-report correlated significantly with the number of days the child was 
too ill to pursue normal activities, needed someone to care for him or her, missed school in the 
last month, the number of days the parent missed from work in the last month, and parent-report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
Pediatric Quality of Life Generic Core Scale (PedsQL™), Acute Version
The PedsQL Generic Core Scale is designed to measures health-related quality of life (HRQoL) 
in pediatric subjects and adolescents (2-18 years of age). The developmentally appropriate 
PedsQL Generic Core Scale will be completed by either the parent or legal guardian and subject 
as indicated in Table 7-3 at the time points as outlined in Table 1-2, Table 1-3, and Table 1-4.
Table 7-3 Developmentally Appropriate PedsQL™Generic Core Scales
Report
Completed by
Parent Report for Toddlers (ages 2-4)
Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Young Pediatric subjects 
(ages 5-7)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Pediatric subjects 
(ages 8-12)
Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy-Report for Teens (ages 13-18)a
Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy-Report for Teens (ages 13-18) will also be completed for subjects older than 18 years of 
age.
For non-commercial use only

Shire
CONFIDENTIAL
Page 60
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The Parent Report for Toddlers (ages 2-4) of the PedsQL Generic Core Scale is composed of 
21 items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8-12), and Teens (ages 13-18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
Pediatric Quality of Life Family Impact Module (PedsQL™), Acute Version
The PedsQL Family Impact Module is a parent-report multidimensional instrument that will be 
completed by the parent or legal guardian, as outlined in Table 1-2, Table 1-3, and Table 1-4.
The PedsQL Family Impact Module is a specific module of the PedsQL that is used to measure 
the impact of pediatric chronic health conditions on parents and the family (Varni et al., 2004). 
The 36-item PedsQL Family Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 
3) Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry (5 items). Two additional scales measure 
parent-reported family functioning as follows: 1) Daily Activities (3 items), and 2) Family 
Relationships (5 items). The PedsQL Family Impact Module should take the parent or legal 
guardian approximately 5-10 minutes to complete.
PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute Version
The PedsQL Gastrointestinal Symptom Module is a disease-specific 58-item module, comprised 
of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Symptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink Limits (6 items) and Diarrhea (7 items) were identified as 
clinically relevant and appropriate for the symptoms experienced in this pediatric study 
population, and therefore, are the only scales used in this study. The scales will be completed by 
either the parent or legal guardian and subject as indicated in Table 7-3 at the time points 
outlined in Table 1-2, Table 1-3, and Table 1-4.
7.2.2.14
Qualitative Interviews
The objective of the qualitative interviews is to elicit the key symptoms and impacts of 
importance associated with SBS as well as the effect of teduglutide in relation to symptoms and 
impact experienced during the clinical study as described by subjects and caregivers in their own 
words.  In addition, the interviews with caregivers will elicit concepts on aspects of caregiver 
burden associated with caring for their children with SBS requiring PS and the impact of 
teduglutide on the caregiver burden experienced during the study.  
For non-commercial use only

Shire
CONFIDENTIAL
Page 61
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The interviews will be offered to English-speaking parents or legal guardians of subjects and 
subjects aged 12 years or older in selected countries. At the qualified subjects’ clinic sites, 
subjects and caregivers will be provided with a description of the qualitative interview and be 
offered the opportunity to participate. Subjects and caregivers who agree to participate will be 
asked to provide written informed consent (for caregiver interviews) and written assent and 
parental permission (for subject interviews) using forms developed specifically for the 
interviews.
The format will be a single individual telephone interview using a semistructured interview 
guide. Each interview will be approximately 45 minutes and will be completed within 14 days 
after completion of the EOS/ET visit. Subjects and caregivers will be interviewed individually 
and separately, will be instructed to take the interview at a private setting.
Two interview guides have been developed, one for the caregiver interviews (Appendix 3) and 
one for the subject interviews (Appendix 4). Interview guides for UK sites will be reviewed by a 
native speaker of the local dialect. The guides will begin with a brief overview of the interview 
process and very general questions intended to get the participants talking about their 
experiences (and the impacts of these experiences) associated with SBS prior to entering the 
study. These questions will then be followed by a thorough probing of subject and caregiver 
experience during the study and the importance of the treatment outcomes. Topics included in 
the interview are listed below:

Subjects: SBS-related symptoms and impacts 
o
Symptoms due to SBS
o
Symptoms due to parenteral support
o
Impact of SBS on daily activities, physical functioning, and social functioning
o
Impact of parenteral support on daily activities, physical functioning, and social 
functioning

Subjects: experience of teduglutide treatment in relation to SBS symptoms and impacts 
during the study
o
Changes of SBS-related symptoms relating to teduglutide
o
Changes of parenteral support-related symptoms relating to teduglutide
o
Changes of daily activities, physical functioning, and social functioning relating 
to teduglutide

Caregivers: 
o
SBS-related symptoms and impacts described as an observer
For non-commercial use only

Shire
CONFIDENTIAL
Page 62
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

Symptoms due to SBS 

Symptoms due to parenteral support

Impact of SBS on daily activities, physical functioning, and social 
functioning

Impact of parenteral support on daily activities, physical functioning, and 
social functioning
o
Changes in SBS-related symptoms and impacts in relation to teduglutide 
treatment during the study described as an observer

Changes of SBS-related symptoms relating to teduglutide 

Changes of parenteral support-related symptoms relating to teduglutide

Changes of daily activities, physical functioning, and social functioning 
relating to teduglutide
o
Description of care provided and impacts on caregivers of pediatric patients with 
SBS requiring parenteral support

Impact on ability to complete activities of daily living

Impact on emotional and social functioning

Financial impact
o
Changes of caregiver impact in relation to teduglutide treatment during the study

Impact on ability to complete activities of daily living

Impact on emotional and social functioning

Financial impact
To limit bias, the interviewer will begin by asking open-ended questions designed to identify the 
symptoms associated with SBS and their impact, as well as any perceived treatment benefits in 
these areas and the meaningfulness of these changes from the perspective of the parent/legal 
guardian and/or subject. Site personnel will obtain consent, assent, and permission for those 
individuals that agree to participate in the qualitative interviews.
All interviews will be conducted by experienced moderators and will be audio recorded. 
Interviews with subjects and caregivers from UK sites will be conducted by a moderator 
who is a native speaker. The content of the interview will be transcribed, and the audio 
recording will be destroyed to protect patient privacy. All personal information will be removed 
from the transcripts. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 63
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Using the interview transcripts, dominant trends will be identified in each interview and then 
compared across the results of the other interviews to generate themes or patterns in the way 
subjects and caregivers describe their/their child’s treatment experiences and observations during 
the clinical trial as well as their perceptions of treatment benefit over the trial period. 
Should an interviewer become aware of any potential AE during the telephone interview, the 
interviewer will share the relevant information with the subject’s clinical site staff within 1 day. 
The clinical site will be responsible for follow-up with the subject. The investigator will be 
responsible for determining the clinical significance of the event and the reporting of the event as 
outlined in Section 8.
For non-commercial use only

Shire
CONFIDENTIAL
Page 64
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
8
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
Retrospective Period of Observation
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any nonserious AEs related to teduglutide that occurred during this 
time and any AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment-related event:

The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.

The event cannot be explained by the subject’s medical condition, other therapies, or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this study 
in the eCRF.
Prospective Period of Observation
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until 4 weeks following the last dose of teduglutide in the study. This includes events 
occurring during the screening phase of the study and the qualitative interviews, regardless of 
whether or not investigational product is administered. Where possible, a diagnosis rather than a 
list of symptoms should be recorded. If a diagnosis has not been made, then each symptom 
should be listed individually. All AEs should be captured on the appropriate AE pages in the 
eCRF and in source documents. In addition to untoward AEs, unexpected benefits outside the 
investigational product indication should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 65
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Closure indicates that an outcome is reached, stabilization achieved (the investigator does not 
expect any further improvement or worsening of the event), or the event is otherwise explained. 
When appropriate, medical tests and examinations are performed so that resolution of event(s) 
can be documented.
8.1.1
Severity Categorization
The severity of all AEs must be recorded during the course of the event including the start and 
stop dates for each change in severity. An event that changes in severity should be captured as a 
new event. Worsening of pretreatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
In consideration of whether a treatment-emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early termination of the study (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) severity grading criteria (US Department of Health and Human 
Services et al., 2010).
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause-and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
For non-commercial use only

Shire
CONFIDENTIAL
Page 66
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The following additional guidance may be helpful:
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
Not Related
The event can be readily explained by other factors such as the 
subject’s underlying medical condition, concomitant therapy, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled physical examinations must 
be reported as AEs if the investigator considers the finding to be a clinically significant change 
from the baseline.
8.1.3
Outcome Categorization
The outcome of all AEs must be recorded during the course of the study in the eCRF. Outcomes 
are as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae

Recovering/Resolving

Unknown
8.1.4
Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the disease and are part of the efficacy 
data to be collected in the study; however, significant worsening of the symptoms should be 
recorded as an AE.
For non-commercial use only

Shire
CONFIDENTIAL
Page 67
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
8.1.5
Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory or vital sign can represent an AE if the change is 
clinically relevant or if, during the study, a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an already abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study, further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign is clinically significant and 
therefore represents an AE.
8.1.6
Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core study until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633-303 study until the defined follow-up 
period stated in Section 7.1.5.
Any report of pregnancy for any female study participant must be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigational and Marketed Products 
Pregnancy Report Form. A copy of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and any applicable follow-up reports) must also be sent to the Sponsor Medical 
Monitor using the details specified in the emergency contact information section of the protocol. 
In the event a subject becomes pregnant after signing the ICF and assent (if applicable), 
teduglutide administration must be discontinued immediately.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. For pregnancy reports during the prospective period of observation, it is 
the responsibility of the investigator to obtain this information within 30 calendar days after the 
initial notification and approximately 30 calendar days postpartum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633-303), the initial notification date will be the date the pregnancy is recorded for this 
study and outcome and infant condition information may be collected anytime postpartum.
For non-commercial use only

Shire
CONFIDENTIAL
Page 68
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire Clinical Study Adverse Event Form 
for Serious Adverse Events and Non-serious AEs as Required by the Protocol. Note: An elective 
abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Non-serious AEs as required by the Protocol as well as the Shire Investigational and Marketed 
Products Pregnancy Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy onset date.
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a non-medical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may be detrimental to the individual and/or society

Misuse – Intentional use of investigational product other than as directed or indicated 
at any dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed by the protocol)

Overdose – Administration of the investigational product at a dose or frequency 
greater than 0.05 mg/kg subcutaneous once daily. An overdose occurs if any of the 
following criteria are met: 

More than 0.05 mg/kg is given at any one time

Consecutive doses are spaced less than 12 hours apart

Any more than 0.05 mg/kg given in one day (a day is defined as beginning at 
12:00 AM and ending at 11:59 PM)

Medication Error – An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not considered 
reportable as medication errors
For non-commercial use only

Shire
CONFIDENTIAL
Page 69
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

Medication errors should be collected/reported for all products under 
investigation

The administration and/or use of an expired investigational product should be 
considered as a reportable medication error
All investigational product provided to pediatric subjects should be supervised by the 
parent/legally-authorized representative/caregiver.
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference for safety information for this study is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
8.2.2
Reporting Procedures
All SAEs experienced during the retrospective period of observation for the protocol must be 
reported by the investigator to the Shire Global Drug Safety Department and the Sponsor
Medical Monitor within 24 hours of first awareness of the event.
All initial and follow-up SAE reports for SAEs experienced during the prospective period of 
observation must be reported by the investigator to the Shire Global Drug Safety Department 
and the Sponsor Medical Monitor within 24 hours of the first awareness of the event. Note: The 
24-hour reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by the investigator to the Shire Global Drug 
Safety Department and the Sponsor Medical Monitor within 24 hours of the first awareness of 
the event even if the event does not fulfill seriousness criterion.
The investigator must complete, sign, and date the Shire Clinical Study Adverse Event Form for 
SAEs and Nonserious AEs as Required by Protocol and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e-mail the completed form to the Shire Global Drug Safety
Department. A copy of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Nonserious AEs as Required by Protocol (and any applicable 
follow-up reports) must also be sent to the Sponsor Medical Monitor or designee using the 
details specified in the emergency contact information section of the protocol.
8.2.3
Serious Adverse Event Definition
A serious adverse event (SAE) is any untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose: 

Results in death
For non-commercial use only

Shire
CONFIDENTIAL
Page 70
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

Is life-threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it was more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization. 
Note: Hospitalizations, which are the result of elective or previously scheduled surgery 
for pre-existing conditions, which have not worsened after initiation of treatment, should 
not be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospitalization for an elective or previously scheduled surgery that meet(s) serious 
criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity

Is a congenital abnormality/birth defect

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency or 
drug abuse.
8.2.4
Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study 
until signing the ICF [and informed assent, if applicable] for SHP633-303), investigators will be 
asked if they are aware of any SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Drug Safety Department and the Sponsor Medical Monitor within 24 hours of first 
awareness of the event and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow-up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Drug Safety Department and the Sponsor Medical Monitor within 24 hours of the first 
awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Drug Safety Department within 24 hours of the first awareness of the event.
For non-commercial use only

Shire
CONFIDENTIAL
Page 71
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notifying the 
relevant regulatory authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notifying active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
8.3
Adverse Events of Special Interest
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
the investigator to the sponsor is required.
The AEs of special interest that require expedited regulatory reporting include the following:

Growth of pre-existing polyps of the colon
For non-commercial use only

Shire
CONFIDENTIAL
Page 72
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

Benign neoplasia of the GI tract including the hepatobiliary system

Tumor-promoting ability (eg, benign and/or malignant neoplasia of any kind, not limited 
to those of the GI or hepatobiliary system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within 24 hours of first awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5 apply only to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contacting the sponsor/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may include but are 
not limited to hospitalization, AEs, a lapse in investigational product delivery, etc. The length of 
dose interruption, and whether teduglutide administration resumes or is permanently 
discontinued, depends on the clinical situation.
Investigational product must be interrupted if any of the following events occur:

An AE of special interest (see Section 8.3)

An AE that is of NCI CTCAE severity Grade 3 or 4 and related to teduglutide

Intestinal obstruction

Biliary obstruction related to teduglutide

Pancreatic duct obstruction related to teduglutide

Heart failure with severe fluid overload related to teduglutide
Investigational product must be permanently discontinued if any of the following events occur:

Pregnancy

Severe hypersensitivity, such as anaphylaxis determined by the investigator to be related 
to study drug. This does not include the presence of anti-teduglutide antibodies, mild 
injection site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.

Confirmed DILI related to teduglutide (see Section 8.4.2)

Any malignancy
For non-commercial use only

Shire
CONFIDENTIAL
Page 73
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
8.4.1
Dose Interruption Criteria Based on Adverse Event Severity and 
Relationship to Investigational Product (Prospective Period of Observation 
Only)
The investigational product must be interrupted if the subject experienced an AE that is of 
severity ≥Grade 3 per the NCI CTCAE and is reported as related to the investigational product. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI CTCAE severity grading criteria (US Department of Health and 
Human Services et al., 2010). All such TEAEs should be discussed with the Sponsor Medical 
Monitor or designee as soon as possible. The length of the dose interruption, and whether 
teduglutide administration resumes or is permanently discontinued, depends on the clinical 
situation.
8.4.2
Dose Interruption Criteria Based on Drug-Induced Liver Injury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may need to be interrupted if the subject has 
clinical and laboratory evidence of potential DILI, in the absence of an alternative explanation, 
as identified by the following criteria:

ALT or AST >8x ULN

ALT or AST >5x ULN and >2x baseline value for more than 2 weeks

(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)

ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory values suggestive of potentially new DILI should be repeated and verified within 
3 days. International normalized ratio should be measured with this set of verification laboratory 
assessments and an inquiry should be made as to the presence of clinical symptoms consistent 
with new liver injury. The subject should be followed closely to determine the trajectory of the 
laboratory abnormalities and to evaluate the cause of liver injury. This evaluation may include, 
as clinically indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cytomegalovirus IgM, 
Epstein-Barr virus antibody panel), hepatobiliary obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti-actin, or anti-liver kidney microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may be performed at the discretion of the investigator in consultation 
with the Sponsor Medical Monitor.
For non-commercial use only

Shire
CONFIDENTIAL
Page 74
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Teduglutide administration must be permanently discontinued if DILI is confirmed and deemed 
related to study drug.
8.5
Early Termination of the Clinical Study (Prospective Period of Observation Only)
The data monitoring committee (DMC) may recommend stopping the study if any of the 
following conditions are met:

≥2 subjects develop the same event of CTCAE severity Grade 3 that is reported as related 
to the investigational product
or

1 subject develops an event of CTCAE severity Grade 4 that is reported as related to the 
investigational product
For non-commercial use only

Shire
CONFIDENTIAL
Page 75
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
9
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
in the eCRF. A study monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safety follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality control and data validation procedures are applied to ensure the validity and 
accuracy of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed 
using SAS® (SAS Institute, Cary, NC, USA) version 9.3 or higher.
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4
Planned Interim Analysis, and Data Monitoring Committee
An interim analysis of all retrospective data will be conducted. Other interim analyses may also 
be conducted if needed.
A DMC will be involved in the management of this study. The DMC members will review the 
data approximately every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety data (ie, AEs, laboratory assessments, physical examinations, etc.) 
from study assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product.
The DMC for this study will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only

Shire
CONFIDENTIAL
Page 76
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The DMC will be an external, independent board comprised of physicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory in nature. The DMC will be governed by a 
Charter agreed to by members of the Board and the sponsor. Members of the Board may not be 
study investigators or be employed at the same institution as a study investigator, individuals 
employed by the sponsor, independent contractors hired by the sponsor, or members of 
regulatory agencies. The DMC may make recommendations to the sponsor regarding study 
aspects including stopping, modifying or continuing the study; however, the sponsor will have 
the final responsibility to determine whether the study should be modified or temporarily or 
permanently stopped.
9.5
Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects was determined by enrollment in 
TED-C13-003.
9.6
Study Population
The safety population includes all enrolled subjects in the study. The safety population will be 
used for both safety and efficacy analyses.
9.7
Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each study visit, relative to the baseline of the core study (TED-C13-003) and/or 
first exposure to teduglutide. The following efficacy endpoints will be analyzed:

Reduction in PS volume of at least 20%

Absolute and relative change in PS volume

Complete weaning off PS

Change in days per week of PS
For non-commercial use only

Shire
CONFIDENTIAL
Page 77
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
9.8
Safety Analyses
Safety data, including laboratory tests and vital signs assessments, will be summarized by visit. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safety data as well as for the difference from baseline, if applicable. Frequency 
counts will be compiled for classification of qualitative safety data.
9.8.1
Safety Endpoints
The following safety endpoints will be analyzed from the beginning of the prospective study 
period:

Adverse events

Vital signs, including body temperature, heart rate, and blood pressure

Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)

Urine output

Stool output

Antibodies to teduglutide

Gastrointestinal-specific testing including fetal occult blood testing and colonoscopy or 
sigmoidoscopy
The following safety endpoints will be analyzed from the end of the core study (TED-C13-003) 
to the beginning of the prospective study period:

Adverse events related to teduglutide

All SAEs

All AESIs (Section 8.3)
The following safety endpoints will be analyzed relative to the baseline of the core study 
(TED-C13-003):

Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
BMI
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by System Organ Class and by preferred term. Serious adverse events will be further 
summarized by severity and relationship to investigational product. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
For non-commercial use only

Shire
CONFIDENTIAL
Page 78
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Prior and concomitant medications will be coded using the World Health Organization-Drug 
Dictionary (WHO-DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history (including 
surgical/procedural history) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by system organ class and preferred term.
For clinical laboratory tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies.
Additional safety parameters and measures will include change in body weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z-score, BMI, and BMI z-score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9
Other Analyses
9.9.1
Health-related Quality of Life Analyses
Health economics and outcomes research endpoints will be analyzed at approximately 12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study period. The beginning of 
each treatment cycle (CxD1) will be an additional baseline.

Change in Pediatric Quality of Life Inventory (PedsQL) score

Change in PedsQL Family Impact Module score

Change in PedsQL Gastrointestinal Symptoms Module Sub-Scales scores:

Food and drink limits

Diarrhea
9.9.2
Qualitative Interviews
A final report will be developed for the qualitative interviews and will be included the CSR of 
the study.
For non-commercial use only

Shire
CONFIDENTIAL
Page 79
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
10
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO as necessary. 
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
For non-commercial use only

Shire
CONFIDENTIAL
Page 80
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
10.1.4
Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an EOS declaration to the relevant competent authority as required by 
Article 10 (c) of Directive 2001/20/EC.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by the signed and dated signature of the 
principal investigator (single-site study) or coordinating principal investigator (multicenter 
study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH 
Guidance E3 (1995). 
For non-commercial use only

Shire
CONFIDENTIAL
Page 81
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by (inter)national regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly into the 
eCRF.
Electronic case report forms should be approved by the investigator per study specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory reports, and histology and 
pathology reports.
All key data must be recorded in the subject’s medical records.
For non-commercial use only

Shire
CONFIDENTIAL
Page 82
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the 
eCRF entries against the source documents. The consent form includes a statement by 
which the subject agrees to the monitor/auditor from the sponsor or its representatives, 
national or local regulatory authorities, or the IRB/EC, having access to source data 
(eg, subject’s medical file, appointment books, original laboratory reports, X-rays etc.). 
Nonstudy site personnel will not disclose any personal information or personal medical 
information.
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA, 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Agency) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory authorities), the European Medicines Agency (EMA), the 
Medicines and Healthcare products Regulatory Agency, other regulatory authorities, the sponsor 
or its representatives, and the IRB/EC for each site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, 
retainer for ongoing consultation or honoraria; any proprietary interest in investigational 
product; any significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 
2(b) (1998).
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, 
where applicable, from all study subjects prior to any study-related procedures 
including screening assessments. All consent and assent documentation must be in 
accordance with applicable regulations and GCP. 
For non-commercial use only

Shire
CONFIDENTIAL
Page 83
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Each subject or the subject’s legally-authorized representative, as applicable, is requested to sign 
and date the subject informed consent form or a certified translation if applicable, after the 
subject has received and read (or been read) the written subject information and received an 
explanation of what the study involves, including but not limited to: the objectives, potential 
benefits and risk, inconveniences, and the subject’s rights and responsibilities. A copy of the 
informed consent and assent documentation (ie, a complete set of subject information sheets and 
fully executed signature pages) must be given to the subject or the subject’s legally-authorized 
representative, as applicable. This document may require translation into the local language. 
Signed consent forms must remain in each subject’s study file and must be available for 
verification at any time.
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legally-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study subject.
The principal investigator provides the sponsor with a copy of the consent form, and assent form 
where applicable, that was reviewed by the IRB/EC and which received their favorable 
opinion/approval. A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor, prior to the start of the study unless it is agreed to 
and documented (abiding by regulatory guidelines and national provisions) prior to study start 
that another party (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally, if the IRB/EC requires modification of the sample subject information and 
consent document provided by the sponsor, the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written IRB/EC approval of and copies of revised documents.
For non-commercial use only

Shire
CONFIDENTIAL
Page 84
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 
1996. A site that is not a covered entity as defined by HIPAA must provide documentation of 
this fact to the sponsor (or designee).
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representatives 
review their medical records and data collected during the study. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP633; national or local regulatory authorities; and the IRBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subject).
The results of studies – containing subjects’ unique identifying number, relevant medical 
records, and possibly initials and dates of birth – will be recorded. They may be transferred to, 
and used in, other countries which may not afford the same level of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities.
10.5
Study Results / Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines 
(eg, Good Publication Practices 2) when forming a publication steering committee, which is 
done for large, multicenter Phase 2-4 and certain other studies as determined by Shire. The 
purpose of the publication steering committee is to act as a noncommercial body that advises or 
decides on dissemination of scientific study data in accordance with the scope of this policy.
For non-commercial use only

Shire
CONFIDENTIAL
Page 85
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any rights to authorship of 
publications.
For non-commercial use only

Shire
CONFIDENTIAL
Page 86
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
11
REFERENCES
Drucker, D. J. and Yusta, B. 2014. Physiology and pharmacology of the enteroendocrine 
hormone glucagon-like peptide-2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. and Duggan, C. 
2015. Predictors of Enteral Autonomy in Children with Intestinal Failure: A Multicenter 
Cohort Study. J Pediatr, 167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J.and Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like 
peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol 
Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy, K. N., Jeppesen, P. B. and Shaffer, 
J. 2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs-Lasky, M. and Belle, S. H. 
2012. Natural history of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J.and Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin 
Gastroenterol, 47, 602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. and Sangild, P. T. 2014. Acute effects of the glucagon-like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr 
Gastroenterol Nutr, 58, 694-702.
US Department of Health and Human Services, National Institutes of Health and National 
Cancer Institute 2010. Common Terminology Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. and Dixon, P. 2004. The 
PedsQL Family Impact Module: preliminary reliability and validity. Health Qual Life 
Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. and Moore, A. 2004. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg,
39, 690-5.
For non-commercial use only

Shire
CONFIDENTIAL
Page 87
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
APPENDIX 1
PROTOCOL HISTORY
Document
Date
Global/Country/Site Specific
Original Protocol
11 May 2016
Global
Amendment 1
22 Nov 2016
Global
Amendment 1.1
09 Jan 2017
UK Specific
Amendment 2
17 Mar 2017
Global
Amendment 3
16 May 2018
Global
Amendment 4
01 Oct 2019
Global
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3
Amendment Date
16 May 2018
Global
Description of Change and Rationale
Section(s) Affected by Change
The primary contact for EU and backup contact for NA was updated to 
.
Emergency Contact Information
To minimize risk to subjects, a new escape criterion was added, allowing 
those who had escaped during the follow-up period of a previous teduglutide 
treatment to omit the follow-up period during subsequent teduglutide 
treatment cycles. 
For subjects who previously escaped the follow-up period, CxW24 
assessments can be combined with the next pretreatment visit assessments.
Study Synopsis; Table 1-4, 
Figure 3-1; Section 3.1; Section 4.6; 
Section 6.2.3; Section 7.1.4.1; 
Section 7.1.4.2; Section 7.1.5; 
Section 7.2.2.6
Clarified language that all concomitant procedures are to be captured, not 
just gastrointestinal procedures.
Table 1-2; Table 1-3; Table 1-4, 
Section 5.1; Section 7.1.2; 
Section7.1.3; Section 7.1.4.1; 
Section 7.1.4.2; Section 7.1.6
Updated the information on the clinical studies with teduglutide in pediatric 
subjects to include the results of TED-C14-006. 
Section 1.3
Added new PK simulation data to further support dosing. 
Section 3.1
Deleted text that was duplicated in other sentences of sections.
Section 5.1
Deleted biological therapy (eg, antitumor necrosis factor) from the table of 
prohibited treatments as it was included in error.
Table 5-1
Clarified that compliance with study drug is calculated from subject diaries
Section 6.5
Added direct bilirubin to the list of laboratory tests.
Table 7-1
Clarified that if a child is unable to complete a quality of life questionnaire 
(due to developmental delay or other illness) it will not constitute a protocol 
deviation.
Section 7.2.2.13
Minor editorial changes and corrections to typographical errors (which do 
not modify content and/or intent of the original document) were made.
Throughout protocol
For non-commercial use only

Shire
CONFIDENTIAL
Page 88
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2
Amendment Date
17 Mar 2017
Global
Description of Change and Rationale
Section(s) Affected by Change
Updated emergency contact information.
Emergency Contact Information; 
Section 8.1.6; Section 8.2.2; 
Section 8.2.4
Revised teduglutide treatment inclusion criterion #1 to ensure that 
subjects whose prior exposure to teduglutide in Study TED-C13-003 may 
not have been enough to assess efficacy are eligible to receive treatment 
in Study SHP633-303. 
Study Synopsis; Section 4.4
Revised teduglutide treatment exclusion criterion #11 to add teduglutide 
to the list of experimental drugs exempt of a washout period before 
initiating teduglutide treatment in Study SHP633-303. 
Study Synopsis; Section 4.5; 
Section 5.1.2
A footnote was added at the pretreatment visit in the Schedule of Events 
for Subjects While Receiving Teduglutide to underscore that, when the 
first pretreatment visit (P1) follows the screening visit, it must occur 
within 12 weeks of screening.
Table 1-4
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines and 
Healthcare products Regulatory Authority (MHRA) in their letter dated 
29th December 2016.
Section 4.7.1
Clarification that ancillary components, in addition to sterile water for 
injection syringes, will also be provided and labeled in accordance with 
the applicable regulatory requirements.
Section 6.3.1
A footnote was added in Table 7-3 to clarify that subjects older than 
18 years of age will continue to use the Child Self Report and Parent 
Proxy-Report for Teens (ages 13-18) when completing the Pediatric 
Quality of Life Generic Core Scale (PEDSQL™).
Section 7.2.2.13 (Table 7-3)
Revised the text on severity categorization to specify that a severe 
treatment-emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study (Section 8.5) 
will also be graded according to the National Cancer Institute’s (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) severity 
grading criteria, in addition to the standard severity categorization. These 
events are no longer limited to only the events described in Table 8-1, 
entitled “CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only). Therefore, Table 
8-1 has been deleted.
Section 8.1.1; Section 8.4; 
Section 8.4.1; Table 8-1 (deleted)
Revised the criteria for early termination of the study as requested by the 
US FDA in their letter dated 06 Jan 2017: stopping criteria were extended 
to all NCI CTCAE Grade 3 and 4 severity events reported as related to 
the investigational product, and no longer limited to the events described 
in Table 8-1, entitled “CTCAE Criteria for Adverse Events that May 
Lead to Dose Interruption (Prospective Period of Observation Only).
Section 8.5
For non-commercial use only

Shire
CONFIDENTIAL
Page 89
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Amendment Number 1.1
Amendment Date
09 Jan 2017
United-Kingdom-Specific
Description of Change and Rationale
Section(s) Affected by Change
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by the United Kingdom (UK) Medicines and 
Healthcare products Regulatory Authority (MHRA) in their letter dated 
29th December 2016.
Section 4.7.1
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
Title of the Sponsor medical monitor has been changed to Medical 
Director for clarity.
Protocol Signature Page
Emergency Contact Information
Clarification has been made that during the no-teduglutide treatment 
period, visits will take place approximately every 12 weeks.
Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3-1
The study design flow chart has been edited for clarity.
Synopsis
Figure 3-1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.
Synopsis
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.2, 7.1.3, 7.1.4.1, 
7.1.4.2, 7.1.6, 7.2.2.11, 7.2.2.12
Exclusion criterion 11 has been revised to add Smoflipid as other 
experimental drugs that are allowed prior and during the study. Like 
glutamine and Omegaven, Smoflipid is not expected to interfere with the 
assessments of safety and efficacy of teduglutide and many subjects may 
already be receiving the treatments off-label as part of standard medical 
therapy. 
Synopsis
Section 4.5
Exclusion criterion 12 and prohibited treatment have been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to 3 months for consistency with other teduglutide studies. 
Synopsis
Section 4.5
Table 5-1
Retrospective data collection has been removed from the duration of the 
study for clarity.
Synopsis
Language in efficacy and safety endpoints has been clarified.
Synopsis
Sections 9.7.1, 9.8.1
Instructions on recording retrospective data for teduglutide and PS usage, 
and growth parameters have been refined.
Table 1-1
Sections 7.1.1, 7.2.1.2, 7.2.1.3
Completion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.
Table 1-2, Table 1-3, Table 1-4
Sections 7.1.2, 7.1.4.1, 7.1.4.2, 7.1.6, 
7.2.2.12
For non-commercial use only

Shire
CONFIDENTIAL
Page 90
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
The requirement for urine specimen collection has been revised so that a 
lack of urinalysis will not constitute a protocol deviation for any pediatric 
subjects (not only for subjects wearing diapers).
Table 1-2, Table 1-3, Table 1-4
Section 7.2.2.5
Clarification has been made that the first no-teduglutide treatment visit 
after the screening visit will occur within 2 to 12 weeks of the screening 
(formerly within 12 weeks of screening). 
Synopsis
Table 1-3
Sections 3.1.3, 7.1.2
Windows have been clarified for visits during the no-teduglutide and 
teduglutide treatment periods.
Table 1-3, Table 1-4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. By definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. 
Table 1-3 
Sections 7.2.2.8, 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. 
Table 1-2, Table 1-3, Table 1-4
Sections 3.1.3, 7.1.3, 7.2.2.10
Removal of former footnote j on fecal occult blood test for clarity.
Table 1-4
Clarification has been made on circumstances when the CxW28 visit may 
be combined with the next pretreatment or EOS/ET visit. 
Table 1-4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects with 
SBS has been clarified, and text on intestinal adaptation has been refined.
Section 1.1
Status of current teduglutide approvals for use has been updated.
Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced with ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency with other 
studies.
Synopsis
Sections 3.1, 3.1.3
Evaluations to be performed when a subject discontinues teduglutide or 
when withdraws from the study have been clarified.
Sections 4.8.1, 4.8.2
Withdrawal by parent/guardian has been added as reason for 
discontinuation.
Section 4.8.3
COUMADIN has been changed to warfarin for clarity.
Sections 5.1, 5.1.2
Clarification has been made on handling of study drug, which is for 
single use only and should be used within 3 hours following 
reconstitution. 
Section 6.3.3
The investigator or designee may now dispense the unused study drug 
vials to the same subject if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study drug 
has been clarified.
Section 6.4
Paragraph on the purpose of prospective data collection has been deleted 
for clarity.
Section 7.2.2
Clarification has been made on the collection of medical history and SBS 
history.
Synopsis
Sections 3.1.3, 7.1.2, 7.2.2.1
For non-commercial use only

Shire
CONFIDENTIAL
Page 91
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1
Amendment Date
22 Nov 2016
Global
Description of Change and Rationale
Section(s) Affected by Change
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. 
Section 7.2.2.3
Clarification has been made that local laboratory results are not required 
to be entered in the eCRFs. (formerly Section 7.2.2.4)
Section 7.2.2.5
Collection of urine sodium and urine osmolality has been removed.
Section 7.2.2.5
Clarification has been made that the serum sample will not be collected at 
the pretreatment visit if the subject met a follow-up period escape 
criterion. (formerly Section 7.2.2.5)
Section 7.2.2.6
Nutritional support and diaries (formerly in Section 7.2.2.9) have been 
moved under separate sections (Sections 7.2.2.11 and 7.2.2.12, 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that only 
available diary data will be reviewed at each clinic and telephone visit.
Sections 7.2.2.11, 7.2.2.12 
Performance of dipstick specific gravity tests by the subject at home on 
the first urine produced after the daily infusions of PS has been removed. 
It is now at the discretion of the investigator for all subjects, not just 
those in diapers. This change is to align with standard medical practice.
Section 7.2.2.12 
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related) to teduglutide need 
to be reported. No changes to the protocol were made for the reporting of 
all AEs of special interest or any serious adverse events, regardless of 
relationship to teduglutide, that occurred during the retrospective period.
Section 8.1
The timeframe for collecting and reporting AESIs and SAEs occurring 
during the retrospective period of the study has been clarified.
Sections 8.2.2, 8.2.4, 8.3
Minor clarifications have been made to the language on dose interruption.
Sections 8.4, 8.4.1
Unscheduled safety follow up assessments (including visits conducted 
after EOS) are not to be recorded. However, clarification has been made 
that they are to be collected where requested.
Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.
Section 9.4
The protocol now refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.
Section 9.4
Minor corrections have been made to the guidelines for nutritional 
support management during the study.
Appendix 2
For non-commercial use only

Shire
CONFIDENTIAL
Page 92
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
APPENDIX 2
GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period.

Growth trajectory, including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)

Other clinical evaluations

Serum electrolytes

Blood urea nitrogen /creatinine levels

Changes in stool frequency or volume, including mixed output

Stool consistency (ie, Bristol Stool Scale)

Urine specific gravity

General consideration to possible clinical deterioration in SBS

Inability to maintain weight and growth velocity

Diarrhea (≥10 bowel movements per day, ≥80 mL/kg/day from an ostomy, or 
≥75 mL/kg/day mixed output)

Colic/vomiting frequency increased

Electrolyte changes or imbalance

Skin breakdown 

Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the study.

Nutritional support constituents may be adjusted at the discretion of the investigator.

During the 48-hour output measurement period prior to the subject’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.

If there is a change in EN or other food or fluid intake, the investigator should consider this 
when adjusting the PS/EN support in volume and calories.
For non-commercial use only

Shire
CONFIDENTIAL
Page 93
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Figure A-1
Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 94
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Figure A-2
Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only

Shire
CONFIDENTIAL
Page 95
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Figure A-3
Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only

Shire
CONFIDENTIAL
Page 96
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
APPENDIX 3
CAREGIVER INTERVIEW GUIDE
Exit Interviews With Caregivers
Following Participation in a
Short Bowel Syndrome Clinical Trial
1. Introduction
(5 Minutes)
Introduce interviewers
Confirm caregiver’s first name and study ID
Review consent form and obtain consent
Remind participants of the purpose and format of the interview
We are interested in learning more about your child’s symptoms and impacts due to short 
bowel syndrome and parenteral support. We would also like to understand your experiences 
caring for your child as well as you and your child’s experiences with regard to treatment 
during the clinical trial.
The information you share with us will help the study sponsors learn more about potential 
treatment benefits of the clinical trial drug.
As we go along, please feel comfortable to speak openly and share your opinions freely. 
There are no wrong answers. You are the expert.
Unless you report a side effect potentially related to a medication that our study sponsors 
produce during today’s call, your name will never be associated with anything you share 
with us.

If you do report a side effect during today’s call, I have to let the study sponsors know. I 
may ask you some follow-up questions to fully understand the nature of the experience 
so I can fully communicate information to the study sponsor.
**REMEMBER TO TURN ON THE AUDIO RECORDER ONCE CONSENT IS PROVIDED. 
INTERVIEWER WILL VERBALLY NOTE STUDY ID AND INTERVIEW DATE**
2. History and Symptoms 
(10 minutes)
Just briefly, please tell us about your child’s history with SBS.

How old is your child?

How long has your child had SBS?

How long has your child received parenteral support?
For non-commercial use only

Shire
CONFIDENTIAL
Page 97
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

What symptoms of SBS does your child experience? What symptoms due to parenteral 
support does your child experience? Are there other symptoms your child experienced in the 
past but doesn’t experience currently? What are those? [Probe for complete list and write 
down each symptom provided by the participant; for each symptom, probe to understand 
whether due to SBS, parenteral support, or both]

Symptom 1: ________________________________

Symptom 2: ________________________________

Symptom 3: ________________________________

Symptom 4: ________________________________

Symptom 5: ________________________________
[If not provided spontaneously by the participant, specific symptoms will be probed.]
Now we would like to discuss other symptoms that some patients or caregivers have described 
to see whether or not they are things your child has experienced as well.

As I read each symptom, please let me know if your child has experienced this symptom in 
relation to his or her SBS or parenteral support. [Only read those symptoms not already 
provided by the participant; probe to understand whether due to SBS, parenteral support, or 
both]

Pain/discomfort

Fatigue

Frequent need to empty bowels/bag

Diarrhea

Of the symptoms you have described which would you say is the most bothersome for your 
child? Why?
3. Impacts
(10 minutes)

How does your child’s SBS and parenteral support affect his or her life? [Probe for complete 
list and write down each impact provided by the caregiver; probe to understand whether 
impact of SBS, parenteral support, or both]

Impact 1: ________________________________

Impact 2: ________________________________

Impact 3: ________________________________

Impact 4: ________________________________

Impact 5: ________________________________
[If not provided spontaneously by the participant, specific impacts will be probed.]
For non-commercial use only

Shire
CONFIDENTIAL
Page 98
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Now we would like to now discuss other impacts that some patients and caregivers have 
described to see whether or not they are things your child has experienced as well.

As I read each impact, please let me know if you have experienced this in relation to your 
child’s SBS and parenteral support. [Only read those impacts not already provided by the 
participant. For endorsed impacts, ask the participant to describe their experiences with the 
impact and whether they feel it is due to SBS or parenteral therapy or both]

Daily activities, including school if applicable
-
Need to know/plan for bathroom facilities when leaving home

Physical functioning

Social functioning

Emotional functioning

Sleep

Of the impacts you have described, which would you say is the most bothersome to your 
child? Why?
4. Clinical Trial Experiences 
(10 minutes)
Now we would like to talk about your experience during the clinical trial.

What were your expectations of treatment prior to entering the clinical trial?

Thinking back to before you started the clinical trial, what were some of the reasons you 
decided to enroll your child in the trial?

Were there specific symptoms/issues which you most wanted treatment to help? Which 
ones? Why?

How frequently was your child receiving parenteral therapy at the beginning of the trial? 
[Probe on how many times a week, for how many hours, and when administered].

What improvements, if any, have you noticed in your child since starting the study? [Have 
caregivers describe each improvement reported]

Improvement 1: ________________________________

Improvement 2: ________________________________

Improvement 3: ________________________________

Improvement 4: ________________________________

Improvement 5: ________________________________
For non-commercial use only

Shire
CONFIDENTIAL
Page 99
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

What were the biggest improvements you noticed? How important, if at all, were these 
improvements to you?

Were there smaller or other improvements that you noticed that were also meaningful to 
you? If so, please describe these improvements. [Add these improvements to the list above]

I would like to review each of the improvements that you noticed. Thinking about [a 
symptom from the list], how would you describe them before the study? [Probe mild, 
moderate, or severe, as applicable]

How would you describe them after the study? [Probe none, mild, moderate, or severe, as 
applicable]

[If not reported] Were there any improvements in your child’s parenteral therapy during the 
study? How important, if at all, was this change to you? [Probe to capture current parenteral 
frequency]

Of all of the improvements we have talked about, which do you think was the most important 
to your child? Why? Which was the most important to you? Why?

How would you describe the change in your child’s SBS overall after participating in the 
study? [Probe: very much better, much better, a little better, no change, a little worse, much 
worse, or very much worse]
5. Caregiver Experiences 
(10 minutes)
Now we would like to talk about your experience as a caregiver of a child with SBS.

How has having a child with SBS impacted your life? [Probe for complete list and write down 
each impact provided by the caregiver; probe to understand whether impact of SBS, 
parenteral support, or both]

Impact 1: ________________________________

Impact 2: ________________________________

Impact 3: ________________________________

Impact 4: ________________________________

Impact 5: ________________________________
[If not provided spontaneously by the participant, specific impacts will be probed.]
For non-commercial use only

Shire
CONFIDENTIAL
Page 100
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Now we would like to now discuss other impacts that some caregivers have described to see 
whether or not they are things you have experienced as well.

As I read each impact, please let me know if you have experienced this in relation to caring 
for your child with SBS [Only read those impacts not already provided by the participant. For 
endorsed impacts, ask participants to describe their experiences with the impact and 
whether they feel it is due to their child’s SBS, parenteral therapy for the SBS, or both.]

Caregiver’s daily activities
-
Need to know/plan for bathroom facilities when leaving home with child

Caregiver’s physical functioning

Caregiver’s emotional functioning

Caregiver’s social functioning

Caregiver’s sleep

Financial impact

Of the impacts you have described which would you say is the most bothersome for you? 
Why?

Which, if any, of the above do you feel was improved during your child’s participation in the 
clinical trial? How important, if at all, was this improvement?
6. Closing
Is there anything else you would like to add about your child’s SBS?
Thank you for taking the time to meet with us today. Your input has been very helpful and will 
also be helpful for the patients that will participate in further research on SBS. Thank you again.
For non-commercial use only

Shire
CONFIDENTIAL
Page 101
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
APPENDIX 4
PEDIATRIC SUBJECT INTERVIEW GUIDE
Exit Interviews With Pediatric Subjects
Following Participation in a
Short Bowel Syndrome Clinical Trial
7. Introduction
(5 Minutes)
Introduce interviewers
Confirm subject’s first name and study ID with caregiver
Review parental consent form and confirm consent
Confirm pediatric subject assent 
Remind participants of the purpose and format of the interview
We are interested in learning more about your symptoms and impacts due to short bowel 
syndrome and parenteral support (the nutrition and fluids you get because of your short 
bowel). We would also like to understand your experiences during the study you were in. 
The information you share with us will help the study sponsors learn more about potential 
treatment benefits of the clinical trial drug.
As we go along, please feel free to speak openly and share your opinions freely. There are 
no wrong answers. You are the expert.
Unless you report a side effect that might be related to a medication that our study sponsors 
produce during today’s call, your name will never be associated with anything you share 
with us.

If you do report a side effect during today’s call, I have to let the study sponsors know. I 
may ask you some follow-up questions to fully understand what happened so I can fully 
share this with the study sponsor.
**REMEMBER TO TURN ON THE AUDIO RECORDER ONCE CONSENT IS PROVIDED. 
INTERVIEWER WILL VERBALLY NOTE STUDY ID AND INTERVIEW DATE**
8. History and Symptoms 
(15 minutes)
Just briefly, please tell us about history with SBS.

How old are you? 

How long have you had SBS?

How long have you been getting parenteral support? [Confirm participant understanding 
of term and use term if understood/used or use the participant preferred term throughout 
the interview]
For non-commercial use only

Shire
CONFIDENTIAL
Page 102
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

What symptoms of SBS do you experience? What symptoms due to parenteral support do 
you experience? Are there other symptoms you have had in the past but do not experience 
today? What are those? [Probe for complete list and write down each symptom provided by 
the participant; for each symptom, probe to understand whether due to SBS, parenteral 
support, or both]

Symptom 1: ________________________________

Symptom 2: ________________________________

Symptom 3: ________________________________

Symptom 4: ________________________________

Symptom 5: ________________________________
[If not provided spontaneously by the participant, specific symptoms will be probed.]
Now we would like to discuss other symptoms that some patients have described to see 
whether or not they are things you have experienced as well.

As I read each symptom, please let me know if you have experienced this symptom in 
relation to your SBS or parenteral support. [Only read those symptoms not already provided 
by the participant; probe to understand whether due to SBS, parenteral support, or both]

Pain/discomfort

Fatigue

Frequent need to empty bowels/bag

Diarrhea

Of the symptoms you have described which would you say is the most bothersome for you? 
Why?
9. Impacts
(15 minutes)

How does your SBS and parenteral support affect your life? [Probe for complete list and 
write down each impact provided by the participant; probe to understand whether impact of 
SBS, parenteral support, or both]

Impact 1: ________________________________

Impact 2: ________________________________

Impact 3: ________________________________

Impact 4: ________________________________

Impact 5: ________________________________
[If not provided spontaneously by the participant, specific impacts will be probed.]
For non-commercial use only

Shire
CONFIDENTIAL
Page 103
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019
Now we would like to now discuss other impacts that some patients have described to see 
whether or not they are things you have experienced as well.

As I read each impact, please let me know if you have experienced this in relation to your 
SBS and parenteral support. [Only read those impacts not already provided by the 
participant. For endorsed impacts, ask the participant to describe their experiences with the 
impact and whether they feel it is due to SBS or parenteral therapy or both]

Daily activities, including school if applicable
-
Need to know/plan for bathroom facilities when leaving home

Physical functioning

Social functioning

Emotional functioning

Sleep

Of the impacts you have described, which would you say is the most bothersome to? Why?
10.
Clinical Trial Experiences 
(10 
minutes)
Now we would like to talk about your experience during the clinical trial.

What did you think the study would be like before you started it? 

Thinking back to before you started the study, what were some of the reasons you decided 
to be a part of the study? 

Were there specific symptoms/issues which you most wanted treatment to help? Which 
ones? Why?

How frequently were you child receiving parenteral therapy at the beginning of the trial? 
[Probe on how many times a week, for how many hours, and when administered].

What improvements, if any, have you noticed since you started the study? [Have 
participants describe each improvement reported]

Improvement 1: ________________________________

Improvement 2: ________________________________

Improvement 3: ________________________________

Improvement 4: ________________________________

Improvement 5: ________________________________
For non-commercial use only

Shire
CONFIDENTIAL
Page 104
SHP633-303 Protocol Amendment 4
Teduglutide 
01 Oct 2019

What were the biggest improvements you noticed? How important, if at all, were these 
improvements to you?

Were there smaller or other improvements that you noticed that were also meaningful to 
you? If so, please describe these improvements. [Add these improvements to the list above]

I would like to review each of the improvements that you noticed. Thinking about [a 
symptom from the list], how would you describe them before the study? [Probe mild, 
moderate, or severe, as applicable]

How would you describe them after the study? [Probe none, mild, moderate, or severe, as 
applicable]

[If not reported] Were there any improvements in your parenteral therapy during the study? 
How important, if at all, was this change to you? [Probe to capture current parenteral 
frequency]

Of all of the improvements we have talked about, which do you think was the most important 
to you? Why? 

How would you describe the change in your SBS overall after being in the study? [Probe: 
very much better, much better, a little better, no change, a little worse, much worse, or very 
much worse]
11.
Closing
Is there anything else you would like to add about your SBS?
Thank you for taking the time to meet with us today. Your input has been very helpful and will 
also be helpful for the patients that will participate in further research on SBS. Thank you again.
For non-commercial use only